PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19840943-3 2009 A search for signaling mediators of Tyr(P)-845 revealed that mitochondrial cytochrome c oxidase subunit II (CoxII) binds EGFR in a Tyr(P)-845- and EGF-dependent manner. Tyrosine 36-39 epidermal growth factor receptor Homo sapiens 121-125 19828124-4 2010 A13 efficiently inhibited both EGF-dependant EGFR tyrosine phosphorylation in cervical and breast tumor cells and also in vitro colony formation of EGFR-overexpressing lung tumors. Tyrosine 50-58 epidermal growth factor receptor Homo sapiens 45-49 19864455-6 2010 Induction of RPTP-kappa by TGF-beta significantly decreases basal and EGF-stimulated EGFR tyrosine phosphorylation. Tyrosine 90-98 epidermal growth factor receptor Homo sapiens 85-89 19840943-3 2009 A search for signaling mediators of Tyr(P)-845 revealed that mitochondrial cytochrome c oxidase subunit II (CoxII) binds EGFR in a Tyr(P)-845- and EGF-dependent manner. Tyrosine 131-134 epidermal growth factor receptor Homo sapiens 121-125 19836242-1 2009 BACKGROUND: The epidermal growth factor (EGF) stimulates rapid tyrosine phosphorylation of the EGF receptor (EGFR). Tyrosine 63-71 epidermal growth factor receptor Homo sapiens 95-107 19716804-4 2009 PLC-gamma-1 was used as a substrate immobilized on a ProteoChip and incubated with an EGFR kinase to phosphorylate tyrosine residues of the substrate, followed by a fluorescence detection of the substrate recognized by a phospho-specific monoclonal antibody. Tyrosine 115-123 epidermal growth factor receptor Homo sapiens 86-90 20029029-5 2009 A negative feedback loop consisting of EGFR-mediated phosphorylation of HDAC6 Tyr(570) resulted in reduced deacetylase activity and increased acetylation of alpha-tubulin. Tyrosine 78-81 epidermal growth factor receptor Homo sapiens 39-43 19804359-4 2009 Treatment of pancreatic carcinoma cells with purified EFEMP1 activates autophosphorylation of EGFR at the positions Tyr-992 and Tyr-1068, but not at the position Tyr-1048. Tyrosine 116-119 epidermal growth factor receptor Homo sapiens 94-98 19804359-4 2009 Treatment of pancreatic carcinoma cells with purified EFEMP1 activates autophosphorylation of EGFR at the positions Tyr-992 and Tyr-1068, but not at the position Tyr-1048. Tyrosine 128-131 epidermal growth factor receptor Homo sapiens 94-98 19804359-4 2009 Treatment of pancreatic carcinoma cells with purified EFEMP1 activates autophosphorylation of EGFR at the positions Tyr-992 and Tyr-1068, but not at the position Tyr-1048. Tyrosine 128-131 epidermal growth factor receptor Homo sapiens 94-98 19798056-2 2009 We show here that EGF stimulates transient tyrosine phosphorylation of Tom1L1 by the Src family kinases, resulting in transient interaction of Tom1L1 with the activated EGFR bridged by Grb2 and Shc. Tyrosine 43-51 epidermal growth factor receptor Homo sapiens 169-173 19798056-8 2009 These results suggest that EGF triggers a transient Grb2/Shc-mediated association of EGFR with Tyr-phosphorylated Tom1L1 to engage the endocytic machinery for endocytosis of the ligand-receptor complex. Tyrosine 95-98 epidermal growth factor receptor Homo sapiens 85-89 19836242-1 2009 BACKGROUND: The epidermal growth factor (EGF) stimulates rapid tyrosine phosphorylation of the EGF receptor (EGFR). Tyrosine 63-71 epidermal growth factor receptor Homo sapiens 109-113 19807095-5 2009 Activation of EGFR by Cu(II)(gtsm) involved phosphorylation of multiple tyrosine residues and was mediated by a cognate ligand-independent process involving M(II)(btsc) inhibition of protein tyrosine phosphatase (PTP) activity. Tyrosine 72-80 epidermal growth factor receptor Homo sapiens 14-18 19749156-3 2009 These effects exerted by EGF and TGF alpha were dependent on EGF receptor (EGFR) expression and activation and involved phosphorylation of the Tyr(1045) and Tyr(1173) EGFR sites. Tyrosine 143-146 epidermal growth factor receptor Homo sapiens 75-79 19704002-3 2009 Here, we demonstrate that retention of a conserved amino acid motif surrounding tyrosine 877 (referred to here as EGFR(YHAD)) is sufficient to confer binding to c-Src. Tyrosine 80-88 epidermal growth factor receptor Homo sapiens 114-118 19749156-3 2009 These effects exerted by EGF and TGF alpha were dependent on EGF receptor (EGFR) expression and activation and involved phosphorylation of the Tyr(1045) and Tyr(1173) EGFR sites. Tyrosine 157-160 epidermal growth factor receptor Homo sapiens 167-171 19415674-2 2009 EGFR activation results from increased phosphorylation on specific tyrosine residues in the C-terminal intracellular domain. Tyrosine 67-75 epidermal growth factor receptor Homo sapiens 0-4 19531499-13 2009 These results suggest that coordinated phosphorylation of EGFR involving sites Tyr(998), Ser(991), Ser(1039), and Thr(1041) governs the trafficking of EGF receptors. Tyrosine 79-82 epidermal growth factor receptor Homo sapiens 58-62 19415674-11 2009 In addition, over-expression of receptor type protein tyrosine phosphatase-kappa (RPTP-kappa), which specifically dephosphorylates EGFR tyrosines, decreased UV irradiation-induced EGFR nuclear translocation in human keratinocytes. Tyrosine 136-145 epidermal growth factor receptor Homo sapiens 131-135 19415674-11 2009 In addition, over-expression of receptor type protein tyrosine phosphatase-kappa (RPTP-kappa), which specifically dephosphorylates EGFR tyrosines, decreased UV irradiation-induced EGFR nuclear translocation in human keratinocytes. Tyrosine 136-145 epidermal growth factor receptor Homo sapiens 180-184 19415674-12 2009 These data demonstrate that UV irradiation stimulates rapid EGFR nuclear translocation, which is dependent on phosphorylation of specific EGFR tyrosine residues. Tyrosine 143-151 epidermal growth factor receptor Homo sapiens 60-64 19415674-12 2009 These data demonstrate that UV irradiation stimulates rapid EGFR nuclear translocation, which is dependent on phosphorylation of specific EGFR tyrosine residues. Tyrosine 143-151 epidermal growth factor receptor Homo sapiens 138-142 19518076-7 2009 We show that EGFR is capable of direct autophosphorylation of tyrosine 845, which is located on its kinase activation loop, and that the kinase activity of EGFR is approximately 500-fold higher in the presence of EGF vs the inhibitory anti-EGFR antibody cetuximab. Tyrosine 62-70 epidermal growth factor receptor Homo sapiens 13-17 19483730-9 2009 Immunoblotting shows that HKa significantly decreases the bFGF-transactivated phosphorylation of EGFR at Tyr 1173 between 30 min and 4 h. The phosphorylation of extracellular signal-regulated kinase (ERK) and AKT, which are downstream effectors of EGFR, is also inhibited by HKa. Tyrosine 105-108 epidermal growth factor receptor Homo sapiens 97-101 19518076-7 2009 We show that EGFR is capable of direct autophosphorylation of tyrosine 845, which is located on its kinase activation loop, and that the kinase activity of EGFR is approximately 500-fold higher in the presence of EGF vs the inhibitory anti-EGFR antibody cetuximab. Tyrosine 62-70 epidermal growth factor receptor Homo sapiens 156-160 19518076-7 2009 We show that EGFR is capable of direct autophosphorylation of tyrosine 845, which is located on its kinase activation loop, and that the kinase activity of EGFR is approximately 500-fold higher in the presence of EGF vs the inhibitory anti-EGFR antibody cetuximab. Tyrosine 62-70 epidermal growth factor receptor Homo sapiens 156-160 19254954-0 2009 Tyrosine phosphorylation of the human glutathione S-transferase P1 by epidermal growth factor receptor. Tyrosine 0-8 epidermal growth factor receptor Homo sapiens 70-102 19766894-5 2009 Nuclear accumulation of EGFR was analyzed by SDS-PAGE followed by Western blotting of nuclear extracts using an anti-EGFR Ab or with a phosphospecific Ab against the Tyr-1068 of EGFR and with anti-Rb Ab as the loading control. Tyrosine 166-169 epidermal growth factor receptor Homo sapiens 24-28 19766894-7 2009 RESULTS: EGF induces the nuclear accumulation of EGFR, an increase in EGFR phosphorylation at Tyr-1068 and the formation of the complex EGFR-DNA in MCF-7 and MDA-MB-231 breast cancer cells. Tyrosine 94-97 epidermal growth factor receptor Homo sapiens 70-74 19766894-7 2009 RESULTS: EGF induces the nuclear accumulation of EGFR, an increase in EGFR phosphorylation at Tyr-1068 and the formation of the complex EGFR-DNA in MCF-7 and MDA-MB-231 breast cancer cells. Tyrosine 94-97 epidermal growth factor receptor Homo sapiens 70-74 19457093-6 2009 This was disclosed by abolishment of micro-opioid-induced ERK phosphorylation with the EGF receptor-specific tyrosine phosphorylation inhibitor, AG1478, and micro-opioid-induced reduction of EGF receptor tyrosine phosphorylation by PTX, and beta-arrestin2 targeting siRNA in the present studies and formerly by CaM antisense. Tyrosine 109-117 epidermal growth factor receptor Homo sapiens 87-99 19457093-6 2009 This was disclosed by abolishment of micro-opioid-induced ERK phosphorylation with the EGF receptor-specific tyrosine phosphorylation inhibitor, AG1478, and micro-opioid-induced reduction of EGF receptor tyrosine phosphorylation by PTX, and beta-arrestin2 targeting siRNA in the present studies and formerly by CaM antisense. Tyrosine 204-212 epidermal growth factor receptor Homo sapiens 87-99 19254954-3 2009 Here, we provide evidence that GSTP1 is a downstream EGFR target and that EGFR binds to and phosphorylates tyrosine residues in the GSTP1 protein in vitro and in vivo. Tyrosine 107-115 epidermal growth factor receptor Homo sapiens 74-78 19254954-4 2009 Mass spectrometry and mutagenesis analyses in a cell-free system and in gliomas cells identified Tyr-7 and Tyr-198 as major EGFR-specific phospho-acceptor residues in the GSTP1 protein. Tyrosine 97-100 epidermal growth factor receptor Homo sapiens 124-128 19254954-4 2009 Mass spectrometry and mutagenesis analyses in a cell-free system and in gliomas cells identified Tyr-7 and Tyr-198 as major EGFR-specific phospho-acceptor residues in the GSTP1 protein. Tyrosine 107-110 epidermal growth factor receptor Homo sapiens 124-128 19190079-11 2009 EGFR-mutant carcinomas exhibited increased phosphorylation of EGFR (Tyr 992) compared with wild-type carcinomas. Tyrosine 68-71 epidermal growth factor receptor Homo sapiens 0-4 20641864-4 2004 As a result, several tyrosine residues in the C-terminal domain of EGFR are autophosphorylated, and its intracellular tyrosine kinase is activated. Tyrosine 21-29 epidermal growth factor receptor Homo sapiens 67-71 19190079-11 2009 EGFR-mutant carcinomas exhibited increased phosphorylation of EGFR (Tyr 992) compared with wild-type carcinomas. Tyrosine 68-71 epidermal growth factor receptor Homo sapiens 62-66 19359598-10 2009 Inhibition of thrombin signaling by recombinant hirudin also blocked balloon injury-induced EGFR tyrosine phosphorylation and PAK1 activity. Tyrosine 97-105 epidermal growth factor receptor Homo sapiens 92-96 19333814-5 2009 sEGFR501.Fc inhibited EGF-stimulated tyrosine phosphorylation of the EGFR of the lung cancer cell lines A549 and H1437, and inhibited and blocked the proliferation of H1437 cells. Tyrosine 37-45 epidermal growth factor receptor Homo sapiens 1-5 19388149-2 2009 In the current study, we showed that TCTP overexpression using adenovirus as vehicle, induced partial inhibition of Na,K-ATPase; phosphorylation of EGFR tyrosine residues 845, 992,1068, and 1148; activation of Ras/Raf/ERK pathway; activation of PI3K/Akt pathway; and phosphorylation of PLC-gamma in HeLa cells. Tyrosine 153-161 epidermal growth factor receptor Homo sapiens 148-152 19002495-5 2009 RESULTS: We show that the phosphorylation of tyrosine residues 922 and 1173, but not 1068, are primarily affected by the activating EGFR mutations. Tyrosine 45-53 epidermal growth factor receptor Homo sapiens 132-136 19154417-1 2009 Constitutively active mutations of epidermal growth factor receptor (EGFR) (delE746_A750) activate downstream signals, such as ERK and Akt, through the phosphorylation of tyrosine residues in the C-terminal region of EGFR. Tyrosine 171-179 epidermal growth factor receptor Homo sapiens 35-67 19336574-3 2009 Herein, we describe for the first time that UVA-mediated EGFR activation results in beta-catenin tyrosine phosphorylation at the Y654 residue responsible for the dissociation of E-cadherin/alpha-catenin/beta-catenin complexes. Tyrosine 97-105 epidermal growth factor receptor Homo sapiens 57-61 18340549-4 2009 In human EGFR, potential phosphorylation sites on Ser, Thr and Tyr residues including five autophosphorylation sites on Tyr were investigated using in silico procedures. Tyrosine 63-66 epidermal growth factor receptor Homo sapiens 9-13 18340549-4 2009 In human EGFR, potential phosphorylation sites on Ser, Thr and Tyr residues including five autophosphorylation sites on Tyr were investigated using in silico procedures. Tyrosine 120-123 epidermal growth factor receptor Homo sapiens 9-13 19166869-4 2009 In the present study we demonstrated that BPQs not only induced EGFR tyrosine autophosphorylation, but also induced EGFR-dependent tyrosine phosphorylation of phospholipase C-gamma1 and several signal transducers and activators of transcription (STATs). Tyrosine 131-139 epidermal growth factor receptor Homo sapiens 116-120 19166869-6 2009 We found that BPQs (1 muM), induced EGFR tyrosine phosphorylation at positions Y845, Y992, Y1068, and Y1086. Tyrosine 41-49 epidermal growth factor receptor Homo sapiens 36-40 19166869-7 2009 PLC-gamma1 phosphorylation correlated with the phosphorylation of tyrosine-Y992, a proposed docking site for PLC-gamma1 on the EGFR. Tyrosine 66-74 epidermal growth factor receptor Homo sapiens 127-131 19129184-5 2009 In A431 cells, TSP1 increased autophosphorylation of Tyr-1068 of EGFR in a dose- and time-dependent manner. Tyrosine 53-56 epidermal growth factor receptor Homo sapiens 65-69 19129184-10 2009 TSP1 and its EGF-like repeats also increased phosphorylation of EGFR Tyr-845, Tyr-992, Tyr-1045, Tyr-1086, and Tyr-1173, activated phospholipase Cgamma, and increased cell migration. Tyrosine 69-72 epidermal growth factor receptor Homo sapiens 64-68 19218870-6 2009 Furthermore, clusterin treatment provoked tyrosine phosphorylation of EGFR (pY(1173)), which was also blocked by AG1478. Tyrosine 42-50 epidermal growth factor receptor Homo sapiens 70-74 19305428-5 2009 Importantly, a tyrosine to phenylalanine mutation of the major Src phosphorylation site on EGFR, Y845, reduced the constitutive phosphorylation of NSCLC-EGFR mutants, as well as that of STAT3, Akt, Erk and Src, and reduced the mutant EGFR-Src association as well as proliferation, migration and anchorage-independent growth. Tyrosine 15-23 epidermal growth factor receptor Homo sapiens 91-95 19305428-5 2009 Importantly, a tyrosine to phenylalanine mutation of the major Src phosphorylation site on EGFR, Y845, reduced the constitutive phosphorylation of NSCLC-EGFR mutants, as well as that of STAT3, Akt, Erk and Src, and reduced the mutant EGFR-Src association as well as proliferation, migration and anchorage-independent growth. Tyrosine 15-23 epidermal growth factor receptor Homo sapiens 153-157 19305428-5 2009 Importantly, a tyrosine to phenylalanine mutation of the major Src phosphorylation site on EGFR, Y845, reduced the constitutive phosphorylation of NSCLC-EGFR mutants, as well as that of STAT3, Akt, Erk and Src, and reduced the mutant EGFR-Src association as well as proliferation, migration and anchorage-independent growth. Tyrosine 15-23 epidermal growth factor receptor Homo sapiens 153-157 19289054-0 2009 Molecular dynamics simulations reveal that Tyr-317 phosphorylation reduces Shc binding affinity for phosphotyrosyl residues of epidermal growth factor receptor. Tyrosine 43-46 epidermal growth factor receptor Homo sapiens 127-159 19289058-2 2009 Although several crystal structures of ErbB kinases have been solved, the precise mechanism of HER2 activation remains unknown, and it has been suggested that HER2 is unique in its requirement for phosphorylation of Y877, a key tyrosine residue located in the activation loop. Tyrosine 228-236 epidermal growth factor receptor Homo sapiens 39-43 19166869-4 2009 In the present study we demonstrated that BPQs not only induced EGFR tyrosine autophosphorylation, but also induced EGFR-dependent tyrosine phosphorylation of phospholipase C-gamma1 and several signal transducers and activators of transcription (STATs). Tyrosine 69-77 epidermal growth factor receptor Homo sapiens 64-68 19151764-7 2009 Rapamycin treatment increases tyrosine phosphorylation of EGFR without the addition of growth factor and this transactivation of receptor involves activation of c-Src. Tyrosine 30-38 epidermal growth factor receptor Homo sapiens 58-62 19154417-1 2009 Constitutively active mutations of epidermal growth factor receptor (EGFR) (delE746_A750) activate downstream signals, such as ERK and Akt, through the phosphorylation of tyrosine residues in the C-terminal region of EGFR. Tyrosine 171-179 epidermal growth factor receptor Homo sapiens 69-73 19154417-1 2009 Constitutively active mutations of epidermal growth factor receptor (EGFR) (delE746_A750) activate downstream signals, such as ERK and Akt, through the phosphorylation of tyrosine residues in the C-terminal region of EGFR. Tyrosine 171-179 epidermal growth factor receptor Homo sapiens 217-221 19154417-3 2009 To examine the correlation between phosphorylation of the tyrosine residues in the C-terminal region of EGFR and cellular sensitivity to EGFR TKI, we used wild-type (wt) EGFR, as well as the following constructs: delE746_A750 EGFR; delE746_A750 EGFR with substitution of seven tyrosine residues to phenylalanine in the C-terminal region; and delE746_A750 EGFR with a C-terminal truncation at amino acid 980. Tyrosine 58-66 epidermal growth factor receptor Homo sapiens 104-108 19154417-3 2009 To examine the correlation between phosphorylation of the tyrosine residues in the C-terminal region of EGFR and cellular sensitivity to EGFR TKI, we used wild-type (wt) EGFR, as well as the following constructs: delE746_A750 EGFR; delE746_A750 EGFR with substitution of seven tyrosine residues to phenylalanine in the C-terminal region; and delE746_A750 EGFR with a C-terminal truncation at amino acid 980. Tyrosine 277-285 epidermal growth factor receptor Homo sapiens 104-108 19154417-9 2009 Our results indicate that tyrosine residues in the C-terminal region of EGFR are not required for cellular sensitivity to EGFR TKI, and that an as-yet-unknown signaling pathway of EGFR may exist that is independent of the C-terminal region of EGFR. Tyrosine 26-34 epidermal growth factor receptor Homo sapiens 72-76 18803307-8 2009 We further show that treatment of human astrocytes with a protein kinase C activator results in rapid tyrosine phosphorylation of erbB receptors that involves cleavage of endogenous membrane bound erbB ligands by metalloproteinases. Tyrosine 102-110 epidermal growth factor receptor Homo sapiens 130-134 18803307-8 2009 We further show that treatment of human astrocytes with a protein kinase C activator results in rapid tyrosine phosphorylation of erbB receptors that involves cleavage of endogenous membrane bound erbB ligands by metalloproteinases. Tyrosine 102-110 epidermal growth factor receptor Homo sapiens 197-201 18951974-6 2009 Consistent with this observation, tyrosine 1045 on the EGFR, the c-cbl binding site, exhibited less phosphorylation following stimulation with AR than following stimulation with EGF. Tyrosine 34-42 epidermal growth factor receptor Homo sapiens 55-59 19133285-8 2009 Furthermore, phosphorylation of tyrosines on the EGFR multiple autophosphorylation sites and the conserved SFK autophosphorylation site occurred during exposure of cells to Pb for 1-5 min and 5-30 min, respectively. Tyrosine 32-41 epidermal growth factor receptor Homo sapiens 49-53 18854960-7 2009 EGFR activation was analyzed by Westerns of phosphorylated EGFR tyrosines. Tyrosine 64-73 epidermal growth factor receptor Homo sapiens 0-4 18854960-10 2009 Each treatment (pH 5, DCA or pH 5 plus DCA) activated the EGFR on all tyrosines tested but in different time courses. Tyrosine 70-79 epidermal growth factor receptor Homo sapiens 58-62 19190119-2 2009 BMS-354825 (dasatinib) is an ATP-competitive small-molecule inhibitor effective in treating drug-resistant tumors with mutant BCR-ABL, KIT, and epidermal growth factor receptor by blocking tyrosine phosphorylation sites that are critical in tumorigenesis. Tyrosine 189-197 epidermal growth factor receptor Homo sapiens 144-176 19148533-2 2009 Proinflammatory cytokines are capable of activating a tumor cell death program by reducing EGFR tyrosine phosphorylation. Tyrosine 96-104 epidermal growth factor receptor Homo sapiens 91-95 19162527-2 2009 Plants lack classic Tyr kinases, such as the epidermal growth factor receptor, that govern Tyr phosphorylation in animals. Tyrosine 20-23 epidermal growth factor receptor Homo sapiens 45-77 19010870-10 2008 Surrogate kinase assays show that the EGFR T854A mutation abrogates the inhibition of tyrosine phosphorylation by erlotinib. Tyrosine 86-94 epidermal growth factor receptor Homo sapiens 38-42 18987342-2 2009 We previously showed that EGFR inhibition results in accumulation of the desmosomal cadherin, desmoglein 2 (Dsg2), at cell-cell interfaces accompanied by inhibition of matrix metalloprotease (MMP)-dependent shedding of the Dsg2 ectodomain and tyrosine phosphorylation of its cytoplasmic domain. Tyrosine 243-251 epidermal growth factor receptor Homo sapiens 26-30 19033391-6 2008 Downregulation of N-cadherin levels in the plasma membrane was accompanied by a direct interaction of the EGFR-HER2 and N-cadherin-beta-catenin complexes, leading to tyrosine phosphorylation of beta-catenin. Tyrosine 166-174 epidermal growth factor receptor Homo sapiens 106-115 18952113-5 2009 The epidermal growth factor (EGF)-repeats of TSP1 activate the (EGF) receptor (EGFR) and ErbB2, and these two receptor protein tyrosine kinases (PTK)s participate in ZA protein tyrosine phosphorylation and barrier disruption in response to the TSP1 stimulus. Tyrosine 127-135 epidermal growth factor receptor Homo sapiens 45-77 18952113-5 2009 The epidermal growth factor (EGF)-repeats of TSP1 activate the (EGF) receptor (EGFR) and ErbB2, and these two receptor protein tyrosine kinases (PTK)s participate in ZA protein tyrosine phosphorylation and barrier disruption in response to the TSP1 stimulus. Tyrosine 127-135 epidermal growth factor receptor Homo sapiens 79-83 18952113-7 2009 Protein tyrosine phosphatase (PTP)mu counter-regulates phosphorylation of selected tyrosine residues within the cytoplasmic domain of EGFR. Tyrosine 8-16 epidermal growth factor receptor Homo sapiens 134-138 19081932-2 2009 In a prior phosphoproteomic study performed in the U87MG glioblastoma cell line, we identified tyrosine phosphorylation events that are regulated as a result of titrating EGFRvIII, a constitutively active mutant of the epidermal growth factor receptor (EGFR) associated with poor prognosis in GBM patients. Tyrosine 95-103 epidermal growth factor receptor Homo sapiens 219-251 19081932-2 2009 In a prior phosphoproteomic study performed in the U87MG glioblastoma cell line, we identified tyrosine phosphorylation events that are regulated as a result of titrating EGFRvIII, a constitutively active mutant of the epidermal growth factor receptor (EGFR) associated with poor prognosis in GBM patients. Tyrosine 95-103 epidermal growth factor receptor Homo sapiens 171-175 19133013-0 2008 Enhanced phosphorylation of the epidermal growth factor receptor at the site of tyrosine 992 in esophageal carcinomas. Tyrosine 80-88 epidermal growth factor receptor Homo sapiens 32-64 19110530-9 2008 In addition, Ang II induces tyrosine phosphorylation of the epidermal growth factor receptor (EGFR) in UB cells. Tyrosine 28-36 epidermal growth factor receptor Homo sapiens 60-92 19110530-9 2008 In addition, Ang II induces tyrosine phosphorylation of the epidermal growth factor receptor (EGFR) in UB cells. Tyrosine 28-36 epidermal growth factor receptor Homo sapiens 94-98 19110530-11 2008 In summary: 1) Ang II, acting via the AT1R, stimulates UB branching; 2) This process depends on tyrosine phosphorylation of the EGFR. Tyrosine 96-104 epidermal growth factor receptor Homo sapiens 128-132 18834608-3 2008 In the present studies, we observed that AAV capsids can indeed be phosphorylated at tyrosine residues by EGFR-PTK in in vitro phosphorylation assays and that phosphorylated AAV capsids retain their structural integrity. Tyrosine 85-93 epidermal growth factor receptor Homo sapiens 106-110 18776048-2 2008 Tyrosine phosphorylation of signaling molecules was greater in HBECs expressing the mutant EGFRs than in cells expressing WT EGFR or mutant KRAS. Tyrosine 0-8 epidermal growth factor receptor Homo sapiens 91-95 18762250-8 2008 Further, pretreatment with the MEK1/ERK inhibitor PD98059 enhanced EGF-induced EGFR loss in cells expressing WT EGFR, but not EGFR T669A, suggesting that the ERK-dependent effects on EGFR downregulation required phosphorylation of (669)T. In signaling experiments, EGFR T669A displayed enhanced acute (15 min) EGFR tyrosine phosphorylation (reflecting EGFR kinase activity) compared to WT EGFR. Tyrosine 315-323 epidermal growth factor receptor Homo sapiens 79-83 18586691-5 2008 As expected, the EGFR protein was phosphorylated at tyrosine residues, ubiquitinated and partially degraded when the cells were treated with EGF, but treatment with EGCG caused none of these effects. Tyrosine 52-60 epidermal growth factor receptor Homo sapiens 17-21 18687633-6 2008 EGFR mutant cell lines (H1975 L858R) displayed a pattern of EGFR Tyr-1045 and HER2 Tyr-1248 phosphorylation similar to that found in tissue. Tyrosine 65-68 epidermal growth factor receptor Homo sapiens 0-4 18687633-6 2008 EGFR mutant cell lines (H1975 L858R) displayed a pattern of EGFR Tyr-1045 and HER2 Tyr-1248 phosphorylation similar to that found in tissue. Tyrosine 65-68 epidermal growth factor receptor Homo sapiens 60-64 18687633-6 2008 EGFR mutant cell lines (H1975 L858R) displayed a pattern of EGFR Tyr-1045 and HER2 Tyr-1248 phosphorylation similar to that found in tissue. Tyrosine 83-86 epidermal growth factor receptor Homo sapiens 0-4 18687633-8 2008 These data suggest that a higher proportion of the EGFR mutant carcinoma cells may exhibit activation of the phosphatidylinositol 3-kinase/protein kinase B (AKT)/mammalian target of rapamycin (MTOR) pathway through Tyr-1148 and Tyr-1068 and suppression of IRS-1 Ser-612, altered heterodimerization with ERBB2, reduced response to transforming growth factor beta suppression, and reduced ubiquitination/degradation of the EGFR through EGFR Tyr-1045, thus providing a survival advantage. Tyrosine 215-218 epidermal growth factor receptor Homo sapiens 51-55 18687633-8 2008 These data suggest that a higher proportion of the EGFR mutant carcinoma cells may exhibit activation of the phosphatidylinositol 3-kinase/protein kinase B (AKT)/mammalian target of rapamycin (MTOR) pathway through Tyr-1148 and Tyr-1068 and suppression of IRS-1 Ser-612, altered heterodimerization with ERBB2, reduced response to transforming growth factor beta suppression, and reduced ubiquitination/degradation of the EGFR through EGFR Tyr-1045, thus providing a survival advantage. Tyrosine 215-218 epidermal growth factor receptor Homo sapiens 421-425 18687633-8 2008 These data suggest that a higher proportion of the EGFR mutant carcinoma cells may exhibit activation of the phosphatidylinositol 3-kinase/protein kinase B (AKT)/mammalian target of rapamycin (MTOR) pathway through Tyr-1148 and Tyr-1068 and suppression of IRS-1 Ser-612, altered heterodimerization with ERBB2, reduced response to transforming growth factor beta suppression, and reduced ubiquitination/degradation of the EGFR through EGFR Tyr-1045, thus providing a survival advantage. Tyrosine 215-218 epidermal growth factor receptor Homo sapiens 421-425 18687633-8 2008 These data suggest that a higher proportion of the EGFR mutant carcinoma cells may exhibit activation of the phosphatidylinositol 3-kinase/protein kinase B (AKT)/mammalian target of rapamycin (MTOR) pathway through Tyr-1148 and Tyr-1068 and suppression of IRS-1 Ser-612, altered heterodimerization with ERBB2, reduced response to transforming growth factor beta suppression, and reduced ubiquitination/degradation of the EGFR through EGFR Tyr-1045, thus providing a survival advantage. Tyrosine 228-231 epidermal growth factor receptor Homo sapiens 51-55 18687633-8 2008 These data suggest that a higher proportion of the EGFR mutant carcinoma cells may exhibit activation of the phosphatidylinositol 3-kinase/protein kinase B (AKT)/mammalian target of rapamycin (MTOR) pathway through Tyr-1148 and Tyr-1068 and suppression of IRS-1 Ser-612, altered heterodimerization with ERBB2, reduced response to transforming growth factor beta suppression, and reduced ubiquitination/degradation of the EGFR through EGFR Tyr-1045, thus providing a survival advantage. Tyrosine 228-231 epidermal growth factor receptor Homo sapiens 51-55 18829495-7 2008 Interestingly, IMC-C225 pretreatment was accompanied by EGFR phosphorylation, as detected using an anti-phosphorylated tyrosine antibody (PY99), which correlated with phosphorylation of Vav2 guanine nucleotide exchange factor and activation of RhoA GTPase irrespective of EGFR level, and Vav2 interacted with EGFR only in IMC-C225-treated cells. Tyrosine 119-127 epidermal growth factor receptor Homo sapiens 56-60 18776048-0 2008 Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS. Tyrosine 15-23 epidermal growth factor receptor Homo sapiens 100-104 18776048-5 2008 There were also differences in degree of phosphorylation at individual tyrosine sites within a protein; for example, a previously uncharacterized phosphorylation site in the nucleotide-binding loop of the kinase domains of EGFR (Y727), ERBB2 (Y735), or ERBB4 (Y733), is phosphorylated significantly more in HBECs expressing the deletion mutant than in cells expressing the wild type or L858R EGFR. Tyrosine 71-79 epidermal growth factor receptor Homo sapiens 223-227 18508924-8 2008 We propose that sustained tyrosine phosphorylation of EGFR facilitates its polyubiquitination in endosomes and counteracts rapid deubiquitination, thereby ensuring Hrs-dependent lysosomal sorting. Tyrosine 26-34 epidermal growth factor receptor Homo sapiens 54-58 18417251-6 2008 The N-terminal IMD, which mediates dimerisation of IRSp53, is required for efficient tyrosine phosphorylation downstream of either the insulin or epidermal growth factor receptor stimulation, yet does not appear to include a tyrosine-phosphorylated site itself. Tyrosine 85-93 epidermal growth factor receptor Homo sapiens 146-178 18719212-2 2008 Treatment of gingival fibroblasts with EMD resulted in tyrosine phosphorylation of the EGFR, as assessed by immunoblotting and ELISA, while EMD-induced ERK activation and thymidine incorporation were markedly inhibited (approximately 40-50%) by a specific EGFR tyrosine kinase inhibitor. Tyrosine 55-63 epidermal growth factor receptor Homo sapiens 87-91 17882547-6 2008 In the EGFR bearing lines, the receptor was phosphorylated at tyrosine 992 under basal conditions, and the addition of 100 nM amphiregulin did not lead to the phosphorylation of other tyrosine residues typically phosphorylated by the prototypical ligand EGF. Tyrosine 62-70 epidermal growth factor receptor Homo sapiens 7-11 18262213-8 2008 Moreover, addition of AG1478, an inhibitor of EGFR tyrosine phosphorylation, or cetuximab, a monoclonal antibody that precludes ligand binding to the same receptor, prevented cell differentiation by nicotine. Tyrosine 51-59 epidermal growth factor receptor Homo sapiens 46-50 18493663-0 2008 A quantitative study of the recruitment potential of all intracellular tyrosine residues on EGFR, FGFR1 and IGF1R. Tyrosine 71-79 epidermal growth factor receptor Homo sapiens 92-96 18451158-5 2008 Conversely, overexpressing wild-type (wt) c-Src in the EGFR TKI-sensitive breast cancer cell line SUM149 increased EGFR kinase-independent EGFR tyrosine phosphorylation. Tyrosine 144-152 epidermal growth factor receptor Homo sapiens 55-59 18451158-5 2008 Conversely, overexpressing wild-type (wt) c-Src in the EGFR TKI-sensitive breast cancer cell line SUM149 increased EGFR kinase-independent EGFR tyrosine phosphorylation. Tyrosine 144-152 epidermal growth factor receptor Homo sapiens 115-119 18451158-5 2008 Conversely, overexpressing wild-type (wt) c-Src in the EGFR TKI-sensitive breast cancer cell line SUM149 increased EGFR kinase-independent EGFR tyrosine phosphorylation. Tyrosine 144-152 epidermal growth factor receptor Homo sapiens 115-119 18451158-9 2008 In addition, inhibiting Met kinase activity in SUM229 cells decreased EGFR tyrosine phosphorylation and growth in the presence of EGFR TKIs. Tyrosine 75-83 epidermal growth factor receptor Homo sapiens 70-74 18451158-10 2008 Stimulating Met kinase activity in SUM149 cells with hepatocyte growth factor increased EGFR tyrosine phosphorylation and cell growth in the presence of EGFR TKIs. Tyrosine 93-101 epidermal growth factor receptor Homo sapiens 88-92 18451158-11 2008 These data suggest a Met/c-Src-mediated signaling pathway as a mediator of EGFR tyrosine phosphorylation and cell growth in the presence of EGFR TKIs. Tyrosine 80-88 epidermal growth factor receptor Homo sapiens 75-79 18451158-11 2008 These data suggest a Met/c-Src-mediated signaling pathway as a mediator of EGFR tyrosine phosphorylation and cell growth in the presence of EGFR TKIs. Tyrosine 80-88 epidermal growth factor receptor Homo sapiens 140-144 18632638-0 2008 Activation of platelet-activating factor receptor and pleiotropic effects on tyrosine phospho-EGFR/Src/FAK/paxillin in ovarian cancer. Tyrosine 77-85 epidermal growth factor receptor Homo sapiens 94-98 18396150-3 2008 A second EGFR actin-binding domain (ABD 2) was identified in the region of the receptor that includes Tyr-1148 by a yeast two-hybrid assay. Tyrosine 102-105 epidermal growth factor receptor Homo sapiens 9-13 18390828-8 2008 IL-8/CXCL8 induction and ERK1/2 activation were preceded by EGF receptor (EGFR) tyrosine phosphorylation, within 2 min, and reduced by selective EGFR tyrosine kinase inhibitors (AG-1478 and PD168393) by a neutralizing EGFR antibody and by small interfering RNA oligonucleotides directed against EGFR, implicating EGFR activation. Tyrosine 80-88 epidermal growth factor receptor Homo sapiens 60-72 18390828-8 2008 IL-8/CXCL8 induction and ERK1/2 activation were preceded by EGF receptor (EGFR) tyrosine phosphorylation, within 2 min, and reduced by selective EGFR tyrosine kinase inhibitors (AG-1478 and PD168393) by a neutralizing EGFR antibody and by small interfering RNA oligonucleotides directed against EGFR, implicating EGFR activation. Tyrosine 80-88 epidermal growth factor receptor Homo sapiens 74-78 18080320-7 2008 Pretreatment with calcitriol, enhanced TNF-induced EGFR-Src dependent ERK activation and tyrosine phosphorylation of the EGFR, but abolished the EGFR-Src independent ERK activation. Tyrosine 89-97 epidermal growth factor receptor Homo sapiens 121-125 18080320-7 2008 Pretreatment with calcitriol, enhanced TNF-induced EGFR-Src dependent ERK activation and tyrosine phosphorylation of the EGFR, but abolished the EGFR-Src independent ERK activation. Tyrosine 89-97 epidermal growth factor receptor Homo sapiens 121-125 18451158-3 2008 Here, we observed that EGFR remains tyrosine phosphorylated in breast cancer cells that proliferate in the presence of EGFR TKIs. Tyrosine 36-44 epidermal growth factor receptor Homo sapiens 23-27 18451158-3 2008 Here, we observed that EGFR remains tyrosine phosphorylated in breast cancer cells that proliferate in the presence of EGFR TKIs. Tyrosine 36-44 epidermal growth factor receptor Homo sapiens 119-123 18451158-4 2008 In one such cell line, SUM229, inhibiting c-Src kinase activity with either a dominant-negative c-Src or a c-Src TKI decreased EGFR phosphorylation on Tyr(845), Tyr(992), and Tyr(1086) in the presence of EGFR TKIs. Tyrosine 151-154 epidermal growth factor receptor Homo sapiens 127-131 18324805-5 2008 The faster diffusion was related to the tyrosine phosphorylation of HER2 or EGFR. Tyrosine 40-48 epidermal growth factor receptor Homo sapiens 76-80 18033688-4 2008 Similar to EGF, matuzumab and cetuximab each induced phosphorylation of EGFR at several tyrosine phosphorylation sites as a result of receptor dimerization and activation of the receptor tyrosine kinase. Tyrosine 88-96 epidermal growth factor receptor Homo sapiens 72-76 18258606-4 2008 MIC-1 induced a significant phosphorylation of Akt and ERK-1/2, and also effected an increase in the levels of tyrosine phosphorylation of ErbB1, ErbB2 and ErbB3 in SK-BR-3 and SNU-216 cells. Tyrosine 111-119 epidermal growth factor receptor Homo sapiens 139-144 18271526-0 2008 Tandem immunoprecipitation of phosphotyrosine-mass spectrometry (TIPY-MS) indicates C19ORF19 becomes tyrosine-phosphorylated and associated with activated epidermal growth factor receptor. Tyrosine 37-45 epidermal growth factor receptor Homo sapiens 155-187 18183397-1 2008 Autophosphorylation of tyrosine residues on the cytoplasmic tail of the epidermal growth factor receptor (EGFR) upon ligand binding leads to recruitment of the Grb2/Sos complex to the activated receptor and to activation of the Ras pathway. Tyrosine 23-31 epidermal growth factor receptor Homo sapiens 106-110 18271526-6 2008 The novel human C19orf19 gene product was found EGFR-associated and phosphorylated at 5 tyrosines in response to EGFR activation and, therefore, represents a new component of the EGFR signaling network. Tyrosine 88-97 epidermal growth factor receptor Homo sapiens 113-117 18271526-6 2008 The novel human C19orf19 gene product was found EGFR-associated and phosphorylated at 5 tyrosines in response to EGFR activation and, therefore, represents a new component of the EGFR signaling network. Tyrosine 88-97 epidermal growth factor receptor Homo sapiens 48-52 18271526-6 2008 The novel human C19orf19 gene product was found EGFR-associated and phosphorylated at 5 tyrosines in response to EGFR activation and, therefore, represents a new component of the EGFR signaling network. Tyrosine 88-97 epidermal growth factor receptor Homo sapiens 113-117 18037521-10 2008 Knockdown of PKCepsilon by siRNA blocked both radiation- and P-Tyr-triggered nuclear EGFR accumulation. Tyrosine 63-66 epidermal growth factor receptor Homo sapiens 85-89 17654528-1 2008 In this study, we demonstrated that tyrosine phosphorylation of EGFR and the autocrine expression of uPA and HB-EGF depend on the activity of c-jun amino-terminal kinase (JNK) in human prostatic DU-145 cells. Tyrosine 36-44 epidermal growth factor receptor Homo sapiens 64-68 17708540-9 2008 In addition, pp60c-src kinase activity and tyrosine phosphorylation of epidermal growth factor receptors (EGFR) are also rapidly enhanced after wounding and pharmacological inhibition of both these activities strongly attenuates basal and TGFalpha-induced migration as well as Akt phosphorylation levels. Tyrosine 43-51 epidermal growth factor receptor Homo sapiens 71-104 17653080-6 2008 Mutation at tyrosine 869 (845) residue, an Src phosphorylation site, decreased the phosphorylation levels of wild-type EGFR and other mutants, but not that of S768I and L861Q mutants, suggesting that S768I and L861Q mutants became Src independent for their activation and biological functions. Tyrosine 12-20 epidermal growth factor receptor Homo sapiens 119-123 18023290-7 2008 Suppressing FUT1/4 expression also blocked EGF-induced tyrosine phosphorylation of EGFR and mitogen-activated protein kinases. Tyrosine 55-63 epidermal growth factor receptor Homo sapiens 83-87 18211286-8 2008 Phosphor-Tyr-specific antibodies recognizing the phosphorylation status of either the 1173 Tyr residue of epidermal growth factor receptor (HER1) or the 1248 Tyr residue of HER2, further revealed that FASN-induced Tyr-phosphorylation at approximately 180 kDa region mainly represented that of these key members of the HER (erbB) network, which remained switched-off in mock-transfected HBL100 cells. Tyrosine 9-12 epidermal growth factor receptor Homo sapiens 106-138 18211286-8 2008 Phosphor-Tyr-specific antibodies recognizing the phosphorylation status of either the 1173 Tyr residue of epidermal growth factor receptor (HER1) or the 1248 Tyr residue of HER2, further revealed that FASN-induced Tyr-phosphorylation at approximately 180 kDa region mainly represented that of these key members of the HER (erbB) network, which remained switched-off in mock-transfected HBL100 cells. Tyrosine 9-12 epidermal growth factor receptor Homo sapiens 140-144 18211286-8 2008 Phosphor-Tyr-specific antibodies recognizing the phosphorylation status of either the 1173 Tyr residue of epidermal growth factor receptor (HER1) or the 1248 Tyr residue of HER2, further revealed that FASN-induced Tyr-phosphorylation at approximately 180 kDa region mainly represented that of these key members of the HER (erbB) network, which remained switched-off in mock-transfected HBL100 cells. Tyrosine 9-12 epidermal growth factor receptor Homo sapiens 323-327 18211286-8 2008 Phosphor-Tyr-specific antibodies recognizing the phosphorylation status of either the 1173 Tyr residue of epidermal growth factor receptor (HER1) or the 1248 Tyr residue of HER2, further revealed that FASN-induced Tyr-phosphorylation at approximately 180 kDa region mainly represented that of these key members of the HER (erbB) network, which remained switched-off in mock-transfected HBL100 cells. Tyrosine 91-94 epidermal growth factor receptor Homo sapiens 106-138 18211286-8 2008 Phosphor-Tyr-specific antibodies recognizing the phosphorylation status of either the 1173 Tyr residue of epidermal growth factor receptor (HER1) or the 1248 Tyr residue of HER2, further revealed that FASN-induced Tyr-phosphorylation at approximately 180 kDa region mainly represented that of these key members of the HER (erbB) network, which remained switched-off in mock-transfected HBL100 cells. Tyrosine 91-94 epidermal growth factor receptor Homo sapiens 140-144 18211286-8 2008 Phosphor-Tyr-specific antibodies recognizing the phosphorylation status of either the 1173 Tyr residue of epidermal growth factor receptor (HER1) or the 1248 Tyr residue of HER2, further revealed that FASN-induced Tyr-phosphorylation at approximately 180 kDa region mainly represented that of these key members of the HER (erbB) network, which remained switched-off in mock-transfected HBL100 cells. Tyrosine 91-94 epidermal growth factor receptor Homo sapiens 106-138 18211286-8 2008 Phosphor-Tyr-specific antibodies recognizing the phosphorylation status of either the 1173 Tyr residue of epidermal growth factor receptor (HER1) or the 1248 Tyr residue of HER2, further revealed that FASN-induced Tyr-phosphorylation at approximately 180 kDa region mainly represented that of these key members of the HER (erbB) network, which remained switched-off in mock-transfected HBL100 cells. Tyrosine 91-94 epidermal growth factor receptor Homo sapiens 140-144 18211286-8 2008 Phosphor-Tyr-specific antibodies recognizing the phosphorylation status of either the 1173 Tyr residue of epidermal growth factor receptor (HER1) or the 1248 Tyr residue of HER2, further revealed that FASN-induced Tyr-phosphorylation at approximately 180 kDa region mainly represented that of these key members of the HER (erbB) network, which remained switched-off in mock-transfected HBL100 cells. Tyrosine 91-94 epidermal growth factor receptor Homo sapiens 106-138 18211286-8 2008 Phosphor-Tyr-specific antibodies recognizing the phosphorylation status of either the 1173 Tyr residue of epidermal growth factor receptor (HER1) or the 1248 Tyr residue of HER2, further revealed that FASN-induced Tyr-phosphorylation at approximately 180 kDa region mainly represented that of these key members of the HER (erbB) network, which remained switched-off in mock-transfected HBL100 cells. Tyrosine 91-94 epidermal growth factor receptor Homo sapiens 140-144 18048348-2 2008 We previously identified a tyrosine phosphorylation event as critical in the plasma membrane translocation and activation of hTRPC4 channels following epidermal growth factor (EGF) receptor activation. Tyrosine 27-35 epidermal growth factor receptor Homo sapiens 151-189 17708540-9 2008 In addition, pp60c-src kinase activity and tyrosine phosphorylation of epidermal growth factor receptors (EGFR) are also rapidly enhanced after wounding and pharmacological inhibition of both these activities strongly attenuates basal and TGFalpha-induced migration as well as Akt phosphorylation levels. Tyrosine 43-51 epidermal growth factor receptor Homo sapiens 106-110 17637750-3 2008 Immunoprecipitation and immunofluorescence staining showed that EGFR was phosphorylated on tyrosine in response to TGF-beta1. Tyrosine 91-99 epidermal growth factor receptor Homo sapiens 64-68 17975007-2 2008 Treatment of human cancer cells with JNJ-28871063 inhibited phosphorylation of functionally important tyrosine residues in both EGFR and ErbB2 and blocked downstream signal transduction pathways responsible for proliferation and survival. Tyrosine 102-110 epidermal growth factor receptor Homo sapiens 128-132 17918158-5 2008 These changes were associated with decreased expression and activation (tyrosine phosphorylation) of EGFR, HER-2, HER-3 (72-100%) and IGF-1R (67%) as well as their downstream effectors such as Akt and cycloxygenase-2 (51-97%). Tyrosine 72-80 epidermal growth factor receptor Homo sapiens 101-105 17923481-8 2008 Similar results were obtained following treatment with Tyr-phostin 23 (Tyr23), a specific inhibitor of epidermal growth factor receptor-protein-tyrosine kinase (EGFR-PTK), which also restored E1beta protein levels to those in cells from healthy subjects or from patients with PDHA1 deficiency. Tyrosine 55-58 epidermal growth factor receptor Homo sapiens 161-165 18180459-4 2008 Here, we investigate dependence on EGFR signaling by comparing non-small-cell lung cancer cell lines driven by EGFR-activating mutations and genomic amplifications using a global proteomic analysis of phospho-tyrosine signaling. Tyrosine 209-217 epidermal growth factor receptor Homo sapiens 35-39 17923481-10 2008 These data indicate that PDH deficiency in our patient involves a post-translational modification in which EGFR-PTK-mediated tyrosine phosphorylation of the E1beta protein leads to enhanced ubiquitination followed by proteasome-mediated degradation. Tyrosine 125-133 epidermal growth factor receptor Homo sapiens 107-111 18986098-9 2008 The MMP inhibitors also abolished leptin-induced proliferation as well as leptin-induced EGFR tyrosine phosphorylation, but did not affect proliferation or EGFR activation induced by TGFalpha. Tyrosine 94-102 epidermal growth factor receptor Homo sapiens 89-93 18696232-2 2008 Here we find that in mesenchymal-like tumor cells both tyrosine phosphorylation of EGFR, ErbB2, and ErbB3 signaling networks and expression of EGFR family ligands were decreased. Tyrosine 55-63 epidermal growth factor receptor Homo sapiens 83-87 18832819-8 2008 DC27 markedly reduced tyrosine phosphorylation of EGFR and inhibited activation of Erk1/2 and AKT, two key downstream effectors of proliferation. Tyrosine 22-30 epidermal growth factor receptor Homo sapiens 50-54 18028876-5 2007 Inhibitors of MAPK activation (PD98059) and EGFR tyrosine kinase activity (AG1478) abrogated PAR-2-induced ERK1/2 and EGFR tyrosine phosphorylation, respectively, and subsequent mucin secretion. Tyrosine 49-57 epidermal growth factor receptor Homo sapiens 44-48 18234969-5 2008 EGFR phosphorylation at Tyr(845) and Tyr(1068) increased 6 to 24 h after cell stimulation with HGF and temporally coincided with the induction of transforming growth factor-alpha (~5-fold) and HB-EGF (~23-fold) expression. Tyrosine 24-27 epidermal growth factor receptor Homo sapiens 0-4 17959712-6 2008 Indeed, both SDF-1 and E2 caused EGFR tyrosine phosphorylation. Tyrosine 38-46 epidermal growth factor receptor Homo sapiens 33-37 18028876-5 2007 Inhibitors of MAPK activation (PD98059) and EGFR tyrosine kinase activity (AG1478) abrogated PAR-2-induced ERK1/2 and EGFR tyrosine phosphorylation, respectively, and subsequent mucin secretion. Tyrosine 49-57 epidermal growth factor receptor Homo sapiens 118-122 17825525-5 2007 DFMO increased EGFR phosphorylation on tyrosine residues 1173 (pY1173) and 845 (pY845) within 5 min. Tyrosine 39-47 epidermal growth factor receptor Homo sapiens 15-19 17715395-9 2007 Epidermal growth factor receptor (EGFR) BRET structure-function studies identify the tyrosine residues 1068, 1114, and 1148 as the main residues mediating the interaction of EGFR with the adapter protein Grb2. Tyrosine 85-93 epidermal growth factor receptor Homo sapiens 34-38 17715395-9 2007 Epidermal growth factor receptor (EGFR) BRET structure-function studies identify the tyrosine residues 1068, 1114, and 1148 as the main residues mediating the interaction of EGFR with the adapter protein Grb2. Tyrosine 85-93 epidermal growth factor receptor Homo sapiens 174-178 17715395-9 2007 Epidermal growth factor receptor (EGFR) BRET structure-function studies identify the tyrosine residues 1068, 1114, and 1148 as the main residues mediating the interaction of EGFR with the adapter protein Grb2. Tyrosine 85-93 epidermal growth factor receptor Homo sapiens 0-32 17991782-1 2007 Phosphorylation of the cytoplasmic tyrosine residues of the epidermal growth factor receptor (EGFR) upon binding of EGF induces recognition of various intracellular signaling molecules, including Grb2. Tyrosine 35-43 epidermal growth factor receptor Homo sapiens 60-92 17991782-1 2007 Phosphorylation of the cytoplasmic tyrosine residues of the epidermal growth factor receptor (EGFR) upon binding of EGF induces recognition of various intracellular signaling molecules, including Grb2. Tyrosine 35-43 epidermal growth factor receptor Homo sapiens 94-98 17726113-1 2007 The nervous system-specific leucine-rich repeat Ig-containing protein LINGO-1 is associated with the Nogo-66 receptor complex and is endowed with a canonical EGF receptor (EGFR)-like tyrosine phosphorylation site. Tyrosine 183-191 epidermal growth factor receptor Homo sapiens 158-170 17880946-4 2007 Here, we demonstrate that the PGM of Sts-1, but not of Sts-2, dephosphorylates the EGFR at multiple tyrosines thereby terminating its signalling and endocytosis. Tyrosine 100-109 epidermal growth factor receptor Homo sapiens 83-87 17705384-2 2007 To define the sensitivity and dynamic range of the response of the LC, we covalently immobilized a tyrosine-containing, 13-residue peptide sequence (Y1173) from the epidermal growth factor receptor/kinase (EGFR) at which autophosphorylation takes place and to which the adapter protein Shc binds. Tyrosine 99-107 epidermal growth factor receptor Homo sapiens 165-204 17705384-2 2007 To define the sensitivity and dynamic range of the response of the LC, we covalently immobilized a tyrosine-containing, 13-residue peptide sequence (Y1173) from the epidermal growth factor receptor/kinase (EGFR) at which autophosphorylation takes place and to which the adapter protein Shc binds. Tyrosine 99-107 epidermal growth factor receptor Homo sapiens 206-210 17726113-1 2007 The nervous system-specific leucine-rich repeat Ig-containing protein LINGO-1 is associated with the Nogo-66 receptor complex and is endowed with a canonical EGF receptor (EGFR)-like tyrosine phosphorylation site. Tyrosine 183-191 epidermal growth factor receptor Homo sapiens 172-176 17551925-5 2007 Inhibition of EGFR blocked the effects of HP on GJIC and HP-induced Cx43 tyrosine phosphorylation. Tyrosine 73-81 epidermal growth factor receptor Homo sapiens 14-18 17671194-0 2007 Epidermal growth factor receptor tyrosine phosphorylation and signaling controlled by a nuclear receptor coactivator, amplified in breast cancer 1. Tyrosine 33-41 epidermal growth factor receptor Homo sapiens 0-32 17671194-5 2007 Further analysis revealed that the depletion of AIB1 reduced tyrosine phosphorylation of EGFR at multiple residues both at autophosphorylation and Src kinase phosphorylation sites. Tyrosine 61-69 epidermal growth factor receptor Homo sapiens 89-93 17671194-10 2007 Vanadate treatment of cells revealed that the reduction in EGFR tyrosine phosphorylation is dependent in part on changes in cellular phosphatase activity. Tyrosine 64-72 epidermal growth factor receptor Homo sapiens 59-63 17561374-1 2007 Phospholipase Cgamma1 (PLCgamma1) represents a major downstream signalling component of the epidermal growth factor (EGF) receptor (EGFR) and is activated by tyrosine phosphorylation. Tyrosine 158-166 epidermal growth factor receptor Homo sapiens 92-130 17561374-1 2007 Phospholipase Cgamma1 (PLCgamma1) represents a major downstream signalling component of the epidermal growth factor (EGF) receptor (EGFR) and is activated by tyrosine phosphorylation. Tyrosine 158-166 epidermal growth factor receptor Homo sapiens 132-136 17561374-2 2007 Here we show for the first time that cellular knockdown of protein kinase Cepsilon (PKCepsilon) leads to decreased activation of PLCgamma1 by EGF and that EGF induces tyrosine phosphorylation of PKCepsilon as well as association of PKCepsilon with both EGFR and PLCgamma1. Tyrosine 167-175 epidermal growth factor receptor Homo sapiens 253-257 17561374-6 2007 Thereby the tyrosine phosphorylation of PLCgamma1 via the EGFR may be facilitated. Tyrosine 12-20 epidermal growth factor receptor Homo sapiens 58-62 17714814-7 2007 At the molecular level P-Tyr mediated a general phosphorylation of EGFR and a pronounced phosphorylation of nuclear EGFR at residue Thr No. Tyrosine 25-28 epidermal growth factor receptor Homo sapiens 67-71 17714814-7 2007 At the molecular level P-Tyr mediated a general phosphorylation of EGFR and a pronounced phosphorylation of nuclear EGFR at residue Thr No. Tyrosine 25-28 epidermal growth factor receptor Homo sapiens 116-120 17551925-7 2007 We conclude that activation of the EGFR pathway in response to HP leads to decrease of GJIC via tyrosine phosphorylation of Cx43 in ONH astrocytes. Tyrosine 96-104 epidermal growth factor receptor Homo sapiens 35-39 17521961-0 2007 Ganglioside GM(3) is stably associated to tyrosine-phosphorylated ErbB2/EGFR receptor complexes and EGFR monomers, but not to ErbB2. Tyrosine 42-50 epidermal growth factor receptor Homo sapiens 72-76 17635937-4 2007 The epidermal growth factor (EGF) receptor directly phosphorylates PIPKIgamma661 at tyrosine 634, and this event is required for EGF-induced migration. Tyrosine 84-92 epidermal growth factor receptor Homo sapiens 4-42 17490650-2 2007 We hypothesize that injury releases ATP, which stimulates purinergic receptors and elicits the phosphorylation of epidermal growth factor receptor (EGFR) tyrosine residues and subsequent cell migration by a MMP and HB-EGF dependent pathway. Tyrosine 154-162 epidermal growth factor receptor Homo sapiens 114-146 17490650-2 2007 We hypothesize that injury releases ATP, which stimulates purinergic receptors and elicits the phosphorylation of epidermal growth factor receptor (EGFR) tyrosine residues and subsequent cell migration by a MMP and HB-EGF dependent pathway. Tyrosine 154-162 epidermal growth factor receptor Homo sapiens 148-152 17440440-1 2007 A 52 kd cellular protein, FK506-binding protein (FKBP52), phosphorylated at tyrosine residues by epidermal growth factor receptor protein tyrosine kinase (EGFR-PTK), inhibits adeno-associated virus 2 (AAV2) second-strand DNA synthesis and transgene expression. Tyrosine 76-84 epidermal growth factor receptor Homo sapiens 155-159 17575160-3 2007 We found that N-formyl-methionyl-leucyl-phenylalanine, an FPR agonist peptide, rapidly induced EGFR phosphorylation at tyrosine residue (Tyr) 992, but not residues 846, 1068, or 1173, in glioblastoma cells, whereas all these residues were phosphorylated after only EGF treatment. Tyrosine 119-127 epidermal growth factor receptor Homo sapiens 95-99 17570516-3 2007 Of these, Endofin, DCBLD2, and KIAA0582 were validated to be novel tyrosine-phosphorylation targets of EGF signaling and Iressa, a highly selective inhibitor of EGFR. Tyrosine 67-75 epidermal growth factor receptor Homo sapiens 161-165 17575160-3 2007 We found that N-formyl-methionyl-leucyl-phenylalanine, an FPR agonist peptide, rapidly induced EGFR phosphorylation at tyrosine residue (Tyr) 992, but not residues 846, 1068, or 1173, in glioblastoma cells, whereas all these residues were phosphorylated after only EGF treatment. Tyrosine 137-140 epidermal growth factor receptor Homo sapiens 95-99 17043637-4 2007 In response to EGF, these cells demonstrated equivalent overall EGFR tyrosine phosphorylation and ERK/MAP kinase activation; however, phosphorylation of Tyr-845 in the EGFR, which has been implicated in cell growth, was substantially decreased in uPAR-/- MEFs. Tyrosine 153-156 epidermal growth factor receptor Homo sapiens 168-172 17273938-2 2007 Through these modeling approaches, we are able to extend the prior modeling of EGF-mediated signal transduction by considering specific EGFR tyrosine kinase (EGFRTK) docking interactions mediated by differential binding and phosphorylation of different C-terminal peptide tyrosines on the RTK tail. Tyrosine 272-281 epidermal growth factor receptor Homo sapiens 136-140 17339316-4 2007 Here we show that direct activation of the EGFR by EGFR ligands produces a different pattern of EGFR tyrosine phosphorylation and downstream phosphatidylinositol 3-kinase recruitment than GPCR-stimulated transactivation of the EGFR occurring via paracrine EGFR ligand release. Tyrosine 101-109 epidermal growth factor receptor Homo sapiens 43-47 17339316-4 2007 Here we show that direct activation of the EGFR by EGFR ligands produces a different pattern of EGFR tyrosine phosphorylation and downstream phosphatidylinositol 3-kinase recruitment than GPCR-stimulated transactivation of the EGFR occurring via paracrine EGFR ligand release. Tyrosine 101-109 epidermal growth factor receptor Homo sapiens 51-55 17339316-4 2007 Here we show that direct activation of the EGFR by EGFR ligands produces a different pattern of EGFR tyrosine phosphorylation and downstream phosphatidylinositol 3-kinase recruitment than GPCR-stimulated transactivation of the EGFR occurring via paracrine EGFR ligand release. Tyrosine 101-109 epidermal growth factor receptor Homo sapiens 51-55 17339316-4 2007 Here we show that direct activation of the EGFR by EGFR ligands produces a different pattern of EGFR tyrosine phosphorylation and downstream phosphatidylinositol 3-kinase recruitment than GPCR-stimulated transactivation of the EGFR occurring via paracrine EGFR ligand release. Tyrosine 101-109 epidermal growth factor receptor Homo sapiens 51-55 17339316-4 2007 Here we show that direct activation of the EGFR by EGFR ligands produces a different pattern of EGFR tyrosine phosphorylation and downstream phosphatidylinositol 3-kinase recruitment than GPCR-stimulated transactivation of the EGFR occurring via paracrine EGFR ligand release. Tyrosine 101-109 epidermal growth factor receptor Homo sapiens 51-55 17460286-10 2007 HGF also induced EGFR tyrosine phosphorylation. Tyrosine 22-30 epidermal growth factor receptor Homo sapiens 17-21 17525275-3 2007 Although total ErbB1 protein and mRNA were similar in cancerous and normal skin, we found that ErbB1 activation (phospho-Tyr(1068)) was greater in bulk SCC versus BCC or normal skin. Tyrosine 121-124 epidermal growth factor receptor Homo sapiens 95-100 17433115-10 2007 PAR4 stimulation increased tyrosine phosphorylated EGFR or tyrosine phosphorylated Src level in A549 cells, and the former response being inhibited by Src inhibitor. Tyrosine 27-35 epidermal growth factor receptor Homo sapiens 51-55 17362940-1 2007 The present report provides evidence that, in A431 cells, interferon gamma (IFNgamma) induces the rapid (within 5 min), and reversible, tyrosine phosphorylation of the epidermal growth factor receptor (EGFR). Tyrosine 136-144 epidermal growth factor receptor Homo sapiens 168-200 17334392-6 2007 Ras activation by NEU3 was abrogated by PP2 (src inhibitor) or AG1478 (epidermal growth factor receptor (EGFR) inhibitor), and NEU3 actually enhanced EGF-stimulated tyrosine-phosphorylation of EGFR, suggesting that the upstream targets might be tyrosine kinases including src and EGFR, and the subsequent stimulation of Ras cascade leads to the inhibition of cell apoptosis. Tyrosine 165-173 epidermal growth factor receptor Homo sapiens 193-197 17334392-6 2007 Ras activation by NEU3 was abrogated by PP2 (src inhibitor) or AG1478 (epidermal growth factor receptor (EGFR) inhibitor), and NEU3 actually enhanced EGF-stimulated tyrosine-phosphorylation of EGFR, suggesting that the upstream targets might be tyrosine kinases including src and EGFR, and the subsequent stimulation of Ras cascade leads to the inhibition of cell apoptosis. Tyrosine 165-173 epidermal growth factor receptor Homo sapiens 193-197 17362940-1 2007 The present report provides evidence that, in A431 cells, interferon gamma (IFNgamma) induces the rapid (within 5 min), and reversible, tyrosine phosphorylation of the epidermal growth factor receptor (EGFR). Tyrosine 136-144 epidermal growth factor receptor Homo sapiens 202-206 17195092-1 2007 Proapoptotic stimuli, such as CD95 ligand and hydrophobic bile acids induce an epidermal growth factor receptor (EGFR)-catalyzed tyrosine phosphorylation of CD95-death receptor in hepatocytes, as a prerequisite for CD95-translocation to the plasma membrane, formation of the death-inducing signalling complex and execution of apoptotic cell death. Tyrosine 129-137 epidermal growth factor receptor Homo sapiens 79-111 17195092-1 2007 Proapoptotic stimuli, such as CD95 ligand and hydrophobic bile acids induce an epidermal growth factor receptor (EGFR)-catalyzed tyrosine phosphorylation of CD95-death receptor in hepatocytes, as a prerequisite for CD95-translocation to the plasma membrane, formation of the death-inducing signalling complex and execution of apoptotic cell death. Tyrosine 129-137 epidermal growth factor receptor Homo sapiens 113-117 17195092-6 2007 CD95/CD95-oligomerization was abolished in presence of AG1478 or a JNK-inhibitory peptide, i.e. maneuvers known to prevent EGFR-catalyzed CD95-tyrosine phosphorylation. Tyrosine 143-151 epidermal growth factor receptor Homo sapiens 123-127 17226785-9 2007 In these situations, heparin inhibits phosphorylation of EGFR on the Src-dependent site Tyr(845), but not the autophosphorylation of Tyr(1173), and decreases Ras activation and Erk phosphorylation. Tyrosine 88-91 epidermal growth factor receptor Homo sapiens 57-61 17195092-9 2007 These findings suggest that EGFR-catalyzed CD95-tyrosine phosphorylation is involved in the CD95/CD95-oligomerization process, which is induced by proapoptotic stimuli and is required for apoptosis induction. Tyrosine 48-56 epidermal growth factor receptor Homo sapiens 28-32 17426253-4 2007 Tyrosine phosphorylation of EGFRs occurred after treatment of PC-14 cells with B4G7 mAb, and it was completely inhibited by AG1478, a specific inhibitor of EGFR tyrosine kinase. Tyrosine 0-8 epidermal growth factor receptor Homo sapiens 28-32 28182936-4 2007 Conversely, treatment with an EGFR function-blocking antibody or inhibition of EGFR tyrosine phosphorylation enhanced gene transfer in a dose-dependent manner. Tyrosine 84-92 epidermal growth factor receptor Homo sapiens 79-83 17235316-4 2007 Conversely, treatment with an EGFR function-blocking antibody or inhibition of EGFR tyrosine phosphorylation enhanced gene transfer in a dose-dependent manner. Tyrosine 84-92 epidermal growth factor receptor Homo sapiens 79-83 17332364-2 2007 Cell-based studies suggest that these mutant EGFRs promote increased autophosphorylating activity on a subset of EGFR COOH-terminal tyrosines and the consequent engagement of a subset of downstream effectors. Tyrosine 132-141 epidermal growth factor receptor Homo sapiens 45-49 17182860-4 2007 The interaction of ACK1 with EGFR was dependent on the kinase activity or tyrosine phosphorylation of EGFR. Tyrosine 74-82 epidermal growth factor receptor Homo sapiens 29-33 17182860-4 2007 The interaction of ACK1 with EGFR was dependent on the kinase activity or tyrosine phosphorylation of EGFR. Tyrosine 74-82 epidermal growth factor receptor Homo sapiens 102-106 17101784-0 2007 Epidermal growth factor receptor fate is controlled by Hrs tyrosine phosphorylation sites that regulate Hrs degradation. Tyrosine 59-67 epidermal growth factor receptor Homo sapiens 0-32 17101784-2 2007 Hrs undergoes ligand-induced tyrosine phosphorylation on residues Y329 and Y334 downstream of epidermal growth factor receptor (EGFR) activation. Tyrosine 29-37 epidermal growth factor receptor Homo sapiens 94-126 17101784-2 2007 Hrs undergoes ligand-induced tyrosine phosphorylation on residues Y329 and Y334 downstream of epidermal growth factor receptor (EGFR) activation. Tyrosine 29-37 epidermal growth factor receptor Homo sapiens 128-132 17085043-4 2006 A mechanism-based bisubstrate analog strategy has given X-ray crystallographic insights into how several topical PTKs, including the insulin receptor, Abl and epidermal growth factor receptor, interact with tyrosine-containing peptide substrates. Tyrosine 207-215 epidermal growth factor receptor Homo sapiens 159-191 16862179-5 2007 NT also induced a time-dependent increase in EGFR Tyr(845) phosphorylation and phosphorylation of c-Src and signal transducer and activator of transcription 5b (Stat5b) (a downstream effector of Tyr(845)), events that were blocked by specific inhibition of c-Src (which mediates Tyr(845) phosphorylation of EGFR) or of EGFR. Tyrosine 50-53 epidermal growth factor receptor Homo sapiens 45-49 16862179-5 2007 NT also induced a time-dependent increase in EGFR Tyr(845) phosphorylation and phosphorylation of c-Src and signal transducer and activator of transcription 5b (Stat5b) (a downstream effector of Tyr(845)), events that were blocked by specific inhibition of c-Src (which mediates Tyr(845) phosphorylation of EGFR) or of EGFR. Tyrosine 195-198 epidermal growth factor receptor Homo sapiens 45-49 16862179-5 2007 NT also induced a time-dependent increase in EGFR Tyr(845) phosphorylation and phosphorylation of c-Src and signal transducer and activator of transcription 5b (Stat5b) (a downstream effector of Tyr(845)), events that were blocked by specific inhibition of c-Src (which mediates Tyr(845) phosphorylation of EGFR) or of EGFR. Tyrosine 195-198 epidermal growth factor receptor Homo sapiens 45-49 16862179-6 2007 Introduction of mutant forms of EGFR (Tyr(845)) or Stat5b in PC3 cells, or treatment with selective, catalytic inhibitors of EGFR, c-Src and matrix metalloproteinases (MMPs) resulted in the loss of NT-induced stimulation of DNA synthesis, relative to wild-type controls. Tyrosine 38-41 epidermal growth factor receptor Homo sapiens 32-36 16862179-7 2007 These data indicate that the mitogenic effect of NT on prostate cancer cells requires transactivation of the EGFR by MMPs and a novel downstream pathway involving c-Src, phosphorylation of EGFR Tyr(845) and activation of Stat5b. Tyrosine 194-197 epidermal growth factor receptor Homo sapiens 189-193 17875416-8 2007 JNK then provides a signal for CD95/EGFR association and subsequent CD95 tyrosine phosphorylation, which is mediated by the EGFR tyrosine kinase activity. Tyrosine 73-81 epidermal growth factor receptor Homo sapiens 36-40 17875416-8 2007 JNK then provides a signal for CD95/EGFR association and subsequent CD95 tyrosine phosphorylation, which is mediated by the EGFR tyrosine kinase activity. Tyrosine 73-81 epidermal growth factor receptor Homo sapiens 124-128 17875416-9 2007 CD95 tyrosine phosphorylation then allows for CD95 receptor oligomerization, translocation of the CD95/EGFR protein complex to the plasma membrane, and formation of the death inducing signaling complex (DISC). Tyrosine 5-13 epidermal growth factor receptor Homo sapiens 103-107 17035230-7 2006 EGFR tyrosine phosphorylation was dramatically decreased in both SUM149 and MCF10A AR cells after inhibition of AR cleavage with the broad spectrum metalloprotease inhibitor GM6001, indicating that an AR autocrine loop is strictly dependent on AR cleavage in culture. Tyrosine 5-13 epidermal growth factor receptor Homo sapiens 0-4 17115032-3 2006 Here, we show that the chromatin-bound PCNA protein is phosphorylated on Tyr 211, which is required for maintaining its function on chromatin and is dependent on the tyrosine kinase activity of EGF receptor (EGFR) in the nucleus. Tyrosine 73-76 epidermal growth factor receptor Homo sapiens 194-206 17115032-3 2006 Here, we show that the chromatin-bound PCNA protein is phosphorylated on Tyr 211, which is required for maintaining its function on chromatin and is dependent on the tyrosine kinase activity of EGF receptor (EGFR) in the nucleus. Tyrosine 73-76 epidermal growth factor receptor Homo sapiens 208-212 17115032-4 2006 Phosphorylation on Tyr 211 by EGFR stabilizes chromatin-bound PCNA protein and associated functions. Tyrosine 19-22 epidermal growth factor receptor Homo sapiens 30-34 17115032-5 2006 Consistently, increased PCNA Tyr 211 phosphorylation coincides with pronounced cell proliferation, and is better correlated with poor survival of breast cancer patients, as well as nuclear EGFR in tumours, than is the total PCNA level. Tyrosine 29-32 epidermal growth factor receptor Homo sapiens 189-193 16495036-6 2006 This EGFR-supported transactivation is strongly dependent on EGFR tyrosine kinase, c-Src, and the c-Src-specific EGFR tyrosine residue 845 and represents a novel paradigm of EGFR transactivation. Tyrosine 66-74 epidermal growth factor receptor Homo sapiens 61-65 17261767-5 2006 The complex assembly triggers Src activity, epidermal growth factor receptor (EGFR) phosphorylation on tyrosine, and the EGF-dependent signaling pathway activation. Tyrosine 103-111 epidermal growth factor receptor Homo sapiens 44-76 17261767-5 2006 The complex assembly triggers Src activity, epidermal growth factor receptor (EGFR) phosphorylation on tyrosine, and the EGF-dependent signaling pathway activation. Tyrosine 103-111 epidermal growth factor receptor Homo sapiens 78-82 17053785-0 2006 Tyrosine phosphorylated Par3 regulates epithelial tight junction assembly promoted by EGFR signaling. Tyrosine 0-8 epidermal growth factor receptor Homo sapiens 86-90 16936701-3 2006 The EGFR can be phosphorylated at different tyrosine sites, leading to subsequent activation of different pathways. Tyrosine 44-52 epidermal growth factor receptor Homo sapiens 4-8 16936701-12 2006 We conclude that EGFR is phosphorylated at tyrosine 845 in most hepatocellular carcinomas and that EGFR expression by immunohistochemistry does not correlate well with STAT-3, STAT-5, MAPK, or AKT immunostaining. Tyrosine 43-51 epidermal growth factor receptor Homo sapiens 17-21 16943190-6 2006 Moreover, we show that activated Abl phosphorylates the EGFR primarily on tyrosine 1173, and that mutation of this site to phenylalanine restores ligand-dependent endocytosis of the EGFR in the presence of activated Abl. Tyrosine 74-82 epidermal growth factor receptor Homo sapiens 56-60 16943190-6 2006 Moreover, we show that activated Abl phosphorylates the EGFR primarily on tyrosine 1173, and that mutation of this site to phenylalanine restores ligand-dependent endocytosis of the EGFR in the presence of activated Abl. Tyrosine 74-82 epidermal growth factor receptor Homo sapiens 182-186 16495036-6 2006 This EGFR-supported transactivation is strongly dependent on EGFR tyrosine kinase, c-Src, and the c-Src-specific EGFR tyrosine residue 845 and represents a novel paradigm of EGFR transactivation. Tyrosine 66-74 epidermal growth factor receptor Homo sapiens 5-9 16495036-6 2006 This EGFR-supported transactivation is strongly dependent on EGFR tyrosine kinase, c-Src, and the c-Src-specific EGFR tyrosine residue 845 and represents a novel paradigm of EGFR transactivation. Tyrosine 66-74 epidermal growth factor receptor Homo sapiens 61-65 16774943-6 2006 A peak in Ca2+ concentration at 20 min was followed by increased phosphorylation of Pyk2 at Tyr881 and increased total tyrosine phosphorylation of the epidermal growth factor receptor (EGFR). Tyrosine 119-127 epidermal growth factor receptor Homo sapiens 151-183 16774943-6 2006 A peak in Ca2+ concentration at 20 min was followed by increased phosphorylation of Pyk2 at Tyr881 and increased total tyrosine phosphorylation of the epidermal growth factor receptor (EGFR). Tyrosine 119-127 epidermal growth factor receptor Homo sapiens 185-189 16969069-3 2006 The interaction between EGFR and c-Cbl has been shown to depend upon receptor phosphorylation at tyrosine residue 1045, the major docking site for c-Cbl. Tyrosine 97-105 epidermal growth factor receptor Homo sapiens 24-28 16969069-7 2006 This is in contrast to other tyrosine residues in EGFRvIII, such as Y1173, which exhibit levels of phosphorylation comparable to those of wild-type EGFR. Tyrosine 29-37 epidermal growth factor receptor Homo sapiens 50-54 16495036-6 2006 This EGFR-supported transactivation is strongly dependent on EGFR tyrosine kinase, c-Src, and the c-Src-specific EGFR tyrosine residue 845 and represents a novel paradigm of EGFR transactivation. Tyrosine 66-74 epidermal growth factor receptor Homo sapiens 61-65 16772534-3 2006 Although phosphorylation of STAT5b on Y699 is required for activation, it was previously shown that in epidermal growth factor receptor (EGFR)-overexpressing cell lines, three tyrosines (Y725, Y740, and Y743) in the STAT5b transactivation domain are also phosphorylated upon epidermal growth factor stimulation. Tyrosine 176-185 epidermal growth factor receptor Homo sapiens 137-141 16671086-6 2006 In vivo labeling and immunoprecipitation assays revealed that NNK phosphorylated the epidermal growth factor receptor (EGFR) at tyrosine residues, 991, 1068 and 1173, an effect inhibited by atenolol. Tyrosine 128-136 epidermal growth factor receptor Homo sapiens 85-117 16671086-6 2006 In vivo labeling and immunoprecipitation assays revealed that NNK phosphorylated the epidermal growth factor receptor (EGFR) at tyrosine residues, 991, 1068 and 1173, an effect inhibited by atenolol. Tyrosine 128-136 epidermal growth factor receptor Homo sapiens 119-123 16687414-3 2006 Treatment of HBEpCs with LPA stimulated tyrosine phosphorylation of EGFR, which was attenuated by matrix metalloproteinase (MMP) inhibitor (GM6001), heparin binding (HB)-EGF inhibitor (CRM 197), and HB-EGF neutralizing antibody. Tyrosine 40-48 epidermal growth factor receptor Homo sapiens 68-72 16849327-1 2006 Ultraviolet (UV) irradiation rapidly increases tyrosine phosphorylation (i.e. activates) of epidermal growth factor receptors (EGFR) in human skin. Tyrosine 47-55 epidermal growth factor receptor Homo sapiens 92-125 16849327-1 2006 Ultraviolet (UV) irradiation rapidly increases tyrosine phosphorylation (i.e. activates) of epidermal growth factor receptors (EGFR) in human skin. Tyrosine 47-55 epidermal growth factor receptor Homo sapiens 127-131 16904111-3 2006 However, treatment of HNSCC cells with cetuximab (Erbitux), a monoclonal antibody designed to block the EGFR ligand binding site, led to paradox EGFR activation due to hyperphosphorylation of tyrosine 1173, however, with a concomitant reduction in Erk1/2 phosphorylation levels. Tyrosine 192-200 epidermal growth factor receptor Homo sapiens 104-108 16895919-1 2006 To decipher the global network of the epidermal growth factor (EGF) receptor-mediated signaling pathway, a large scale proteomic analysis of tyrosine-phosphorylated proteins was conducted. Tyrosine 141-149 epidermal growth factor receptor Homo sapiens 38-76 16904111-0 2006 Treatment of HNSCC cell lines with the EGFR-specific inhibitor cetuximab (Erbitux) results in paradox phosphorylation of tyrosine 1173 in the receptor. Tyrosine 121-129 epidermal growth factor receptor Homo sapiens 39-43 16912177-10 2006 Treatment of HNSCC cells with the epidermal growth factor receptor inhibitor gefitinib inhibits HNSCC motility and down-regulates cortactin tyrosine phosphorylation. Tyrosine 140-148 epidermal growth factor receptor Homo sapiens 34-66 16525676-2 2006 Here, we show that proteinase-activated receptor 1 (PAR1) mediates the tyrosine phosphorylation of EGFR in human renal carcinoma cells expressing PAR1 and PAR3 endogeneously. Tyrosine 71-79 epidermal growth factor receptor Homo sapiens 99-103 16443643-9 2006 Exposure to cigarette smoke causes a significant decrease in PTEN expression and increases dose-dependent EGFR-specific tyrosine phosphorylation, resulting in MUC5AC mucin production in NCI-H292 cells. Tyrosine 120-128 epidermal growth factor receptor Homo sapiens 106-110 16734756-5 2006 This complex process with a NADPH oxidase-derived reactive oxygen species signal as an important upstream event, allows via Yes, JNK and epidermal growth factor-receptor activation for CD95 tyrosine phosphorylation as a prerequisite for CD95 targeting to the plasma membrane and formation of the death inducing signalling complex. Tyrosine 190-198 epidermal growth factor receptor Homo sapiens 137-169 16461772-9 2006 Phosphorylation of EGFR in response to P25 occurred on Tyr-845, an Src-dependent phosphorylation site and was inhibited by PP2, the Src kinase inhibitor, consistent with Src kinase lying upstream of EGFR and integrin activation. Tyrosine 55-58 epidermal growth factor receptor Homo sapiens 19-23 16773209-6 2006 TSA transiently activated EGFR tyrosine phosphorylation and AKT activation in a time- and dose-dependent manner, which had been inhibited by EGFR inhibitor PD153035 and PI3 kinase inhibitor LY294002. Tyrosine 31-39 epidermal growth factor receptor Homo sapiens 26-30 16427093-7 2006 In addition, TNF-alpha stimulated tyrosine phosphorylation of the EGFR within 5 min after stimulation. Tyrosine 34-42 epidermal growth factor receptor Homo sapiens 66-70 16456534-4 2006 These clusters contained high concentrations of activated, tyrosine-phosphorylated EGFR exhibiting greatly reduced mobility in the fluorescence recovery after photobleaching experiments. Tyrosine 59-67 epidermal growth factor receptor Homo sapiens 83-87 16289596-8 2006 RESULTS: Immunoprecipitation analysis revealed that LPA induced a significant level of tyrosine phosphorylation of EGFR in DLD1 cells. Tyrosine 87-95 epidermal growth factor receptor Homo sapiens 115-119 16488447-9 2006 However, in the presence of 1mM ATP, EGF induced phosphorylation of tyrosine residues of EGFR can be revitalized in lysates prepared from MNNG pretreated cells. Tyrosine 68-76 epidermal growth factor receptor Homo sapiens 89-93 16467500-8 2006 At molecular level, in the kidney, Rostafuroxin antagonizes EO triggering of the Src-epidermal growth factor receptor (EGFr)-dependent signaling pathway leading to renal Na+-K+ pump, and ERK tyrosine phosphorylation and activation. Tyrosine 191-199 epidermal growth factor receptor Homo sapiens 119-123 16233948-8 2006 For example, the network model predicts distinct temporal patterns of autophosphorylation for different tyrosine residues of EGFR. Tyrosine 104-112 epidermal growth factor receptor Homo sapiens 125-129 16567414-5 2006 In cultured cells, growth factor-induced tyrosine phosphorylation of growth factor receptors, including EGFr, platelet-derived growth factor receptor, and basic fibroblast growth factor receptor, was inhibited by tannic acid. Tyrosine 41-49 epidermal growth factor receptor Homo sapiens 104-108 16205628-3 2006 In this study, we found that gefitinib could suppress the tyrosine phosphorylation of most EGFR mutants better than the wild-type receptor. Tyrosine 58-66 epidermal growth factor receptor Homo sapiens 91-95 16205628-5 2006 All tested EGFR mutants have high basal phosphorylation at multiple tyrosine residues. Tyrosine 68-76 epidermal growth factor receptor Homo sapiens 11-15 16505275-8 2006 In stage I patients, EGFR phosphorylation at tyrosine residue 845 proved to be an independent prognostic factor. Tyrosine 45-53 epidermal growth factor receptor Homo sapiens 21-25 16321969-2 2006 We constructed a yeast surface-displayed human cDNA library and utilized it to identify protein fragments with affinity for phosphorylated peptides derived from the major tyrosine autophosphorylation sites of the epidermal growth factor receptor or focal adhesion kinase. Tyrosine 171-179 epidermal growth factor receptor Homo sapiens 213-245 16080193-7 2006 Inhibition of EGFR kinase activity in TamR cells reduced beta-catenin tyrosine phosphorylation, increased beta-catenin-E-cadherin association and promoted cell-cell adhesion. Tyrosine 70-78 epidermal growth factor receptor Homo sapiens 14-18 16148030-8 2006 In addition, thrombin stimulated the tyrosine phosphorylation of EGF receptor (EGFR), and inhibition of its kinase activity significantly blocked Akt and S6K1 phosphorylation, Fra-1 and FGF-2 expression, DNA synthesis, and motility induced by thrombin in VSMC. Tyrosine 37-45 epidermal growth factor receptor Homo sapiens 65-77 16148030-8 2006 In addition, thrombin stimulated the tyrosine phosphorylation of EGF receptor (EGFR), and inhibition of its kinase activity significantly blocked Akt and S6K1 phosphorylation, Fra-1 and FGF-2 expression, DNA synthesis, and motility induced by thrombin in VSMC. Tyrosine 37-45 epidermal growth factor receptor Homo sapiens 79-83 16367926-5 2006 In contrast, tyrosine phosphorylation of epidermal growth factor receptor (EGFR) was relatively unaffected by SUCI02. Tyrosine 13-21 epidermal growth factor receptor Homo sapiens 41-73 16367926-5 2006 In contrast, tyrosine phosphorylation of epidermal growth factor receptor (EGFR) was relatively unaffected by SUCI02. Tyrosine 13-21 epidermal growth factor receptor Homo sapiens 75-79 18175225-6 2006 We show that after CXCR4 activation, EGFR becomes tyrosine phosphorylated, and the kinase activity of this receptor, together with the activation of MMPs, Src, and PI3-Kinase, is required for CXCR4-mediated ERK activation. Tyrosine 50-58 epidermal growth factor receptor Homo sapiens 37-41 16613660-3 2006 Genes encoding for epidermal growth factor receptor tyrosine (exons 18, 19, and 21) were amplified by nested polymerase chain reaction, sequenced, and analyzed by chromatograms with manual review. Tyrosine 52-60 epidermal growth factor receptor Homo sapiens 19-51 16275144-5 2006 MG132 treatment resulted in stabilization of EGFR tyrosine phosphorylation and its association with c-Cbl. Tyrosine 50-58 epidermal growth factor receptor Homo sapiens 45-49 16554661-5 2006 ANG2-dependent ERK activation was mediated by both protein kinase C (PKC)- and calcium-dependent mechanisms and was associated with tyrosine phosphorylation of EGFR. Tyrosine 132-140 epidermal growth factor receptor Homo sapiens 160-164 16263724-6 2005 Co-expression of RPTP-kappa, but not other RPTPs, specifically reduced basal EGFR tyrosine phosphorylation. Tyrosine 82-90 epidermal growth factor receptor Homo sapiens 77-81 17044774-6 2006 These changes were associated with decreased activation (tyrosine phosphorylation) of EGFR, ErbB-2, ErbB-3, and/or IGF-1R. Tyrosine 57-65 epidermal growth factor receptor Homo sapiens 86-90 16263724-8 2005 Purified RPTP-kappa preferentially dephosphorylated EGFR tyrosines 1068 and 1173 in vitro. Tyrosine 57-66 epidermal growth factor receptor Homo sapiens 52-56 16263724-3 2005 Protein-tyrosine phosphatase (PTP) inhibitors induced EGFR tyrosine phosphorylation in intact primary human keratinocytes and cell-free membrane preparations. Tyrosine 8-16 epidermal growth factor receptor Homo sapiens 54-58 16263724-5 2005 Full-length human EGFR expressed in CHO cells, which lack endogenous EGFR, displayed high basal (i.e. in the absence of ligand) tyrosine phosphorylation. Tyrosine 128-136 epidermal growth factor receptor Homo sapiens 18-22 16263724-9 2005 Overexpression of wild-type or catalytically inactive RPTP-kappa reduced or enhanced, respectively, basal and EGF-induced EGFR tyrosine phosphorylation in human keratinocytes. Tyrosine 127-135 epidermal growth factor receptor Homo sapiens 122-126 16263724-10 2005 Furthermore, siRNA-mediated knockdown of RPTP-kappa increased basal and EGF-stimulated EGFR tyrosine phosphorylation and augmented downstream Erk activation in human keratinocytes. Tyrosine 92-100 epidermal growth factor receptor Homo sapiens 87-91 16263724-12 2005 Taken together, the above data indicate that RPTP-kappa is a key regulator of EGFR tyrosine phosphorylation and function in human keratinocytes. Tyrosine 83-91 epidermal growth factor receptor Homo sapiens 78-82 16055478-7 2005 Furthermore, in dense cultures, E-cadherin blockade decreased the rate of EGFR tyrosine dephosphorylation, implicating an E-cadherin-dependent protein tyrosine phosphatase in EGFR dephosphorylation. Tyrosine 79-87 epidermal growth factor receptor Homo sapiens 74-78 16122376-1 2005 We previously found that EGF (epidermal growth factor) increases the EGFR (EGF receptor) kinase-binding affinity towards the major tyrosine phosphorylation sites in downstream adaptor proteins such as Gab1 (Grb2-associated binding protein 1) and Shc [Src homology 2 (SH2) domain and collagen containing protein], but not that towards EGFR autophosphorylation sites [Fan, Wong, Deb and Johnson (2004) J. Biol. Tyrosine 131-139 epidermal growth factor receptor Homo sapiens 69-73 16122376-1 2005 We previously found that EGF (epidermal growth factor) increases the EGFR (EGF receptor) kinase-binding affinity towards the major tyrosine phosphorylation sites in downstream adaptor proteins such as Gab1 (Grb2-associated binding protein 1) and Shc [Src homology 2 (SH2) domain and collagen containing protein], but not that towards EGFR autophosphorylation sites [Fan, Wong, Deb and Johnson (2004) J. Biol. Tyrosine 131-139 epidermal growth factor receptor Homo sapiens 75-87 16122376-1 2005 We previously found that EGF (epidermal growth factor) increases the EGFR (EGF receptor) kinase-binding affinity towards the major tyrosine phosphorylation sites in downstream adaptor proteins such as Gab1 (Grb2-associated binding protein 1) and Shc [Src homology 2 (SH2) domain and collagen containing protein], but not that towards EGFR autophosphorylation sites [Fan, Wong, Deb and Johnson (2004) J. Biol. Tyrosine 131-139 epidermal growth factor receptor Homo sapiens 334-338 16122376-4 2005 EGFR activation can also result in transphosphorylation of tyrosine resides in the C-terminal region of the related receptors ErbB2, ErbB3 and ErbB4 in heterodimers which are formed upon ligand stimulation. Tyrosine 59-67 epidermal growth factor receptor Homo sapiens 0-4 16122376-8 2005 Furthermore, peptides containing lysine at position -2 or -3 N-terminal to the target tyrosine were found to be poor EGFR kinase substrates, and substitution of these lysines with glutamine decreased the K(m) and increased the k(cat) for these substrates. Tyrosine 86-94 epidermal growth factor receptor Homo sapiens 117-121 16055478-6 2005 E-cadherin blockade also increased EGFR-dependent cell proliferation and TGF-alpha-induced EGFR tyrosine phosphorylation in dense cultures of NCI-H292 cells, suggesting that E-cadherin promotes EGFR-dependent mucin production and inhibits EGFR-dependent cell proliferation via modulation of EGFR phosphotyrosine levels. Tyrosine 96-104 epidermal growth factor receptor Homo sapiens 91-95 16055478-6 2005 E-cadherin blockade also increased EGFR-dependent cell proliferation and TGF-alpha-induced EGFR tyrosine phosphorylation in dense cultures of NCI-H292 cells, suggesting that E-cadherin promotes EGFR-dependent mucin production and inhibits EGFR-dependent cell proliferation via modulation of EGFR phosphotyrosine levels. Tyrosine 96-104 epidermal growth factor receptor Homo sapiens 91-95 16055478-6 2005 E-cadherin blockade also increased EGFR-dependent cell proliferation and TGF-alpha-induced EGFR tyrosine phosphorylation in dense cultures of NCI-H292 cells, suggesting that E-cadherin promotes EGFR-dependent mucin production and inhibits EGFR-dependent cell proliferation via modulation of EGFR phosphotyrosine levels. Tyrosine 96-104 epidermal growth factor receptor Homo sapiens 91-95 16055478-7 2005 Furthermore, in dense cultures, E-cadherin blockade decreased the rate of EGFR tyrosine dephosphorylation, implicating an E-cadherin-dependent protein tyrosine phosphatase in EGFR dephosphorylation. Tyrosine 79-87 epidermal growth factor receptor Homo sapiens 175-179 16055478-6 2005 E-cadherin blockade also increased EGFR-dependent cell proliferation and TGF-alpha-induced EGFR tyrosine phosphorylation in dense cultures of NCI-H292 cells, suggesting that E-cadherin promotes EGFR-dependent mucin production and inhibits EGFR-dependent cell proliferation via modulation of EGFR phosphotyrosine levels. Tyrosine 96-104 epidermal growth factor receptor Homo sapiens 91-95 16344068-6 2005 Consequences of TLCS-induced oxidative stress were c-Jun-N-terminal kinase activation and Yes-dependent activation of the epidermal growth factor receptor (EGFR), followed by EGFR-catalyzed CD95 tyrosine phosphorylation, formation of the death-inducing signaling complex, and execution of apoptosis. Tyrosine 195-203 epidermal growth factor receptor Homo sapiens 175-179 16144838-3 2005 We report that two tyrosine residues in the C terminus of human TRPC4 (hTRPC4), Tyr-959 and Tyr-972, are phosphorylated following epidermal growth factor (EGF) receptor stimulation of COS-7 cells. Tyrosine 19-27 epidermal growth factor receptor Homo sapiens 130-168 16288052-4 2005 Here, we show that, through EGF receptor (EGFR) and erb-B2, EGF induces tyrosine phosphorylation of ER preassociated with AR, thereby triggering the assembly of ER/AR with Src and EGFR. Tyrosine 72-80 epidermal growth factor receptor Homo sapiens 28-40 16288052-4 2005 Here, we show that, through EGF receptor (EGFR) and erb-B2, EGF induces tyrosine phosphorylation of ER preassociated with AR, thereby triggering the assembly of ER/AR with Src and EGFR. Tyrosine 72-80 epidermal growth factor receptor Homo sapiens 42-46 16288052-4 2005 Here, we show that, through EGF receptor (EGFR) and erb-B2, EGF induces tyrosine phosphorylation of ER preassociated with AR, thereby triggering the assembly of ER/AR with Src and EGFR. Tyrosine 72-80 epidermal growth factor receptor Homo sapiens 180-184 16288052-5 2005 Remarkably, experiments in Cos cells show that this complex stimulates EGF-triggered EGFR tyrosine phosphorylation. Tyrosine 90-98 epidermal growth factor receptor Homo sapiens 85-89 16288052-6 2005 In turn, estradiol and androgen antagonists, through the Src-associated receptors, prevent Src activation by EGF and heavily reduce EGFR tyrosine phosphorylation and the subsequent multiple effects, including DNA synthesis and cytoskeletal changes in MCF-7 cells. Tyrosine 137-145 epidermal growth factor receptor Homo sapiens 132-136 16288052-7 2005 In addition, knockdown of ERalpha or AR gene by small interfering RNA (siRNA) almost abolishes EGFR tyrosine phosphorylation and DNA synthesis in EGF-treated MCF-7 cells. Tyrosine 100-108 epidermal growth factor receptor Homo sapiens 95-99 16287490-9 2005 The present findings suggest that EGFR overexpression was involved in the proliferation and development of UTC and was frequently accompanied by tyrosine phosphorylation. Tyrosine 145-153 epidermal growth factor receptor Homo sapiens 34-38 16399434-2 2005 Activation of EGFR through the autophosphorylation of its tyrosine residues stimulates different signaling downstream pathways and may reflect the level of receptor utilization by the tumor. Tyrosine 58-66 epidermal growth factor receptor Homo sapiens 14-18 16288052-9 2005 EGFR tyrosine phosphorylation, depending on Src, is a part of this mechanism. Tyrosine 5-13 epidermal growth factor receptor Homo sapiens 0-4 16144838-3 2005 We report that two tyrosine residues in the C terminus of human TRPC4 (hTRPC4), Tyr-959 and Tyr-972, are phosphorylated following epidermal growth factor (EGF) receptor stimulation of COS-7 cells. Tyrosine 80-83 epidermal growth factor receptor Homo sapiens 130-168 16144838-3 2005 We report that two tyrosine residues in the C terminus of human TRPC4 (hTRPC4), Tyr-959 and Tyr-972, are phosphorylated following epidermal growth factor (EGF) receptor stimulation of COS-7 cells. Tyrosine 92-95 epidermal growth factor receptor Homo sapiens 130-168 16237757-4 2005 RESULTS: Immunoprecipitation analysis revealed that 10 micromol/L LPA induced tyrosine phosphorylation of c-Met and EGFR in LoVo cells within a few minutes. Tyrosine 78-86 epidermal growth factor receptor Homo sapiens 116-120 16125057-3 2005 We demonstrate here that integrin-dependent EGFR activation is also essential for adhesion-induced formation of actin stress fibers, focal adhesion localization and tyrosine phosphorylation of the adapter protein paxillin, as well as transcriptional activation of the serum response factor. Tyrosine 165-173 epidermal growth factor receptor Homo sapiens 44-48 16230373-4 2005 We found that leptin, even at as low as 0.1 ng/mL, induced significant tyrosine phosphorylation of epidermal growth factor receptor (EGFR). Tyrosine 71-79 epidermal growth factor receptor Homo sapiens 99-131 16230373-4 2005 We found that leptin, even at as low as 0.1 ng/mL, induced significant tyrosine phosphorylation of epidermal growth factor receptor (EGFR). Tyrosine 71-79 epidermal growth factor receptor Homo sapiens 133-137 16230373-6 2005 We also revealed that tyrosine phosphorylation of EGFR induced by leptin was significantly attenuated by two inhibitors, an EGFR tyrosine kinase inhibitor, AG1478, and a broad-spectrum matrix metalloproteinase inhibitor, GM6001. Tyrosine 22-30 epidermal growth factor receptor Homo sapiens 50-54 16230373-6 2005 We also revealed that tyrosine phosphorylation of EGFR induced by leptin was significantly attenuated by two inhibitors, an EGFR tyrosine kinase inhibitor, AG1478, and a broad-spectrum matrix metalloproteinase inhibitor, GM6001. Tyrosine 22-30 epidermal growth factor receptor Homo sapiens 124-128 16037379-6 2005 IGF-II promoted direct association of c-SRC with IGF-IR, phosphorylated c-SRC, and increased EGFR phosphorylation at tyrosine 845, a c-SRC-dependent phosphorylation site. Tyrosine 117-125 epidermal growth factor receptor Homo sapiens 93-97 16111562-8 2005 In these cells, the antimitotic action of NO occurs upon inhibition of the EGFR tyrosine phosphorylation, probably by a direct S-nitrosylation of the receptor. Tyrosine 80-88 epidermal growth factor receptor Homo sapiens 75-79 16164409-4 2005 We present evidence that specific inhibition of ADAM15 or TACE blocks GPCR-induced and proHB-EGF-mediated EGFR tyrosine phosphorylation, downstream mitogenic signalling and cell migration. Tyrosine 111-119 epidermal growth factor receptor Homo sapiens 106-110 15963982-4 2005 The EGFR tyrosine phosphorylation correlates with ERK1,2 activation and the stimulation of urokinase production. Tyrosine 9-17 epidermal growth factor receptor Homo sapiens 4-8 15761868-11 2005 A marked difference in inhibition of site-specific phosphorylation of EGFR was observed at Tyr1068 compared to other tyrosine residues (Tyr845, 992 and 1045). Tyrosine 117-125 epidermal growth factor receptor Homo sapiens 70-74 16116206-10 2005 The results demonstrate that, like the tyrosine sorting motif-dependent endocytosis (for which the transferrin receptor and the epidermal growth factor receptor are the two prototypes), dileucine sorting motif-dependent endocytosis of Nef and CD4 are also AP-2 dependent. Tyrosine 39-47 epidermal growth factor receptor Homo sapiens 128-160 16077934-7 2005 The results showed that BA induced EGFR tyrosine phosphorylation in a time-dependent manner. Tyrosine 40-48 epidermal growth factor receptor Homo sapiens 35-39 15951569-0 2005 Time-resolved mass spectrometry of tyrosine phosphorylation sites in the epidermal growth factor receptor signaling network reveals dynamic modules. Tyrosine 35-43 epidermal growth factor receptor Homo sapiens 73-105 15951569-3 2005 To understand the dynamic operation of signaling cascades, we have developed a method enabling the simultaneous quantification of tyrosine phosphorylation of specific residues on dozens of key proteins in a time-resolved manner, downstream of epidermal growth factor receptor (EGFR) activation. Tyrosine 130-138 epidermal growth factor receptor Homo sapiens 243-275 15951569-3 2005 To understand the dynamic operation of signaling cascades, we have developed a method enabling the simultaneous quantification of tyrosine phosphorylation of specific residues on dozens of key proteins in a time-resolved manner, downstream of epidermal growth factor receptor (EGFR) activation. Tyrosine 130-138 epidermal growth factor receptor Homo sapiens 277-281 15951569-9 2005 The data set of quantitative temporal phosphorylation profiles was further characterized by self-organizing maps, which resulted in identification of several cohorts of tyrosine residues exhibiting self-similar temporal phosphorylation profiles, operationally defining dynamic modules in the EGFR signaling network consistent with particular cellular processes. Tyrosine 169-177 epidermal growth factor receptor Homo sapiens 292-296 15797859-8 2005 In addition, inactivation of Src, MKK3, p38, or the EGF receptor blocked tyrosine phosphorylation of beta-catenin, a key signaling intermediate that is involved in the epithelial-mesenchymal transition and vimentin expression. Tyrosine 73-81 epidermal growth factor receptor Homo sapiens 52-64 15734884-6 2005 We also found that arsenite-stimulated EGF (ErbB1) and ErbB2 receptor transactivation, manifest as receptor tyrosine phosphorylation, appeared to be a proximal signaling event leading to p21Cip1/Waf1 induction, because both pharmacological inhibitors and knockdown of receptors by RNA interference blocked arsenite-induced p21Cip1/Waf1 upregulation. Tyrosine 108-116 epidermal growth factor receptor Homo sapiens 44-49 15723219-2 2005 In the experiments described here using AGS gastric cancer cells, SN38 (the active metabolite of CPT-11) induced tyrosine phosphorylation of EGFR within 5 min, and this was followed by the induction of transcripts and/or proteins of heparin-binding EGF-like growth factor, amphiregulin, transforming growth factor-alpha, and interlukin-8 (IL-8). Tyrosine 113-121 epidermal growth factor receptor Homo sapiens 141-145 15626777-3 2005 Treatment of A549, MET5A, and SAEC cells with asbestos caused a significant reduction of EGFR tyrosine phosphorylation. Tyrosine 94-102 epidermal growth factor receptor Homo sapiens 89-93 15929951-7 2005 Stimulation of bronchial epithelial cells resulted in tyrosine phosphorylation of several proteins, including EGFR, Shc and p42/p44 mitogen-activated protein kinase. Tyrosine 54-62 epidermal growth factor receptor Homo sapiens 110-114 15615697-2 2005 Tyrosine (Tyr) 845 of ErbB1 is phosphorylated by Src and has been implicated in control of malignant behavior. Tyrosine 0-8 epidermal growth factor receptor Homo sapiens 22-27 15723263-2 2005 The findings reported here demonstrate that SN38 (the active metabolite of CPT-11) induces the tyrosine phosphorylation of EGFR within 5 min, followed by the induction of transcripts and/or proteins of the heparin-binding EGF-like growth factor, amphiregulin, transforming growth factor-alpha, and interlukin-8 (IL-8) in AGS gastric cancer cells. Tyrosine 95-103 epidermal growth factor receptor Homo sapiens 123-127 15878750-7 2005 CD40 ligation also induced delayed activation and tyrosine phosphorylation of EGFr. Tyrosine 50-58 epidermal growth factor receptor Homo sapiens 78-82 15657067-4 2005 Diverse sets of known and poorly described functional protein classes were unequivocally identified by affinity selection, comprising either proteins tyrosine phosphorylated or complexed therewith, predominantly through EGF receptor and Src family kinases, principally 1) immediate EGF receptor signaling complexes (18%); 2) complexes involved in adhesion and cell-cell contacts (34%); and 3) receptor internalization and degradation signals. Tyrosine 150-158 epidermal growth factor receptor Homo sapiens 220-232 15657067-4 2005 Diverse sets of known and poorly described functional protein classes were unequivocally identified by affinity selection, comprising either proteins tyrosine phosphorylated or complexed therewith, predominantly through EGF receptor and Src family kinases, principally 1) immediate EGF receptor signaling complexes (18%); 2) complexes involved in adhesion and cell-cell contacts (34%); and 3) receptor internalization and degradation signals. Tyrosine 150-158 epidermal growth factor receptor Homo sapiens 282-294 15615697-2 2005 Tyrosine (Tyr) 845 of ErbB1 is phosphorylated by Src and has been implicated in control of malignant behavior. Tyrosine 0-3 epidermal growth factor receptor Homo sapiens 22-27 15707681-9 2005 This synthetic peptide inhibited mitogenesis as well as epidermal growth factor receptor tyrosine phosphorylation, which is induced by epidermal growth factor. Tyrosine 89-97 epidermal growth factor receptor Homo sapiens 56-88 15618223-5 2005 PMA-induced phosphorylation of the EGFR at Tyr(1068) was blocked by bisindolylmaleimide (BIM), a PKC inhibitor, and rottlerin, a PKCdelta-specific inhibitor. Tyrosine 43-46 epidermal growth factor receptor Homo sapiens 35-39 15749028-5 2005 IL-8 transiently induced EGFR tyrosine phosphorylation after 5-90 min and this was completely inhibited by ADAM inhibitor. Tyrosine 30-38 epidermal growth factor receptor Homo sapiens 25-29 15791567-3 2005 The results were linked with expression of cyclin D1, one of the target genes of Wnt signaling, expression of epidermal growth factor receptor (EGFR) relevant to beta-catenin tyrosine phosphorylation, Ki-67 labeling index, clinicopathological features, and survival. Tyrosine 175-183 epidermal growth factor receptor Homo sapiens 110-142 15618223-2 2005 Treatment with EGF stimulated global phosphorylation of the EGFR at Tyr(845), Tyr(992), Tyr(1068), and Tyr(1045) in glioblastoma cell lines (U-1242 MG and U-87 MG). Tyrosine 68-71 epidermal growth factor receptor Homo sapiens 60-64 15618223-3 2005 Interestingly, phorbol 12-myristate 13-acetate (PMA) stimulated phosphorylation of the EGFR only at Tyr(1068) in the two glioblastoma cell lines. Tyrosine 100-103 epidermal growth factor receptor Homo sapiens 87-91 15618223-4 2005 Phosphorylation of the EGFR at Tyr(1068) was not detected in normal human astrocytes treated with the phorbol ester. Tyrosine 31-34 epidermal growth factor receptor Homo sapiens 23-27 15755991-6 2005 Tyrosine phosphorylation of HER2 and HER3, AR transactivation, and cell proliferation induced by heregulin were more potently inhibited by the EGFR/HER2 dual tyrosine kinase inhibitor GW572016 (lapatinib) than the EGFR-specific inhibitor ZD1839 (gefitinib). Tyrosine 0-8 epidermal growth factor receptor Homo sapiens 143-147 15755991-6 2005 Tyrosine phosphorylation of HER2 and HER3, AR transactivation, and cell proliferation induced by heregulin were more potently inhibited by the EGFR/HER2 dual tyrosine kinase inhibitor GW572016 (lapatinib) than the EGFR-specific inhibitor ZD1839 (gefitinib). Tyrosine 0-8 epidermal growth factor receptor Homo sapiens 214-218 15486348-8 2005 In addition, curcumin blocked EGF signaling by inhibiting EGF receptor (EGFR) tyrosine phosphorylation and suppressing the gene expression of EGFR mediated by activation of PPARgamma. Tyrosine 78-86 epidermal growth factor receptor Homo sapiens 58-70 15486348-8 2005 In addition, curcumin blocked EGF signaling by inhibiting EGF receptor (EGFR) tyrosine phosphorylation and suppressing the gene expression of EGFR mediated by activation of PPARgamma. Tyrosine 78-86 epidermal growth factor receptor Homo sapiens 72-76 15791567-3 2005 The results were linked with expression of cyclin D1, one of the target genes of Wnt signaling, expression of epidermal growth factor receptor (EGFR) relevant to beta-catenin tyrosine phosphorylation, Ki-67 labeling index, clinicopathological features, and survival. Tyrosine 175-183 epidermal growth factor receptor Homo sapiens 144-148 15708576-5 2005 The autophosphorylation of tyrosine residues Y1068 and Y1173 at the intracellular domain of EGFR, which is related to Ras activation under EGF treatment, was also not observed by MNNG exposure. Tyrosine 27-35 epidermal growth factor receptor Homo sapiens 92-96 15649431-3 2005 We also revealed that tyrosine phosphorylation of HER2 induced by both lysophospholipids was significantly attenuated by two inhibitors, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, AG1478, and a broad-spectrum matrix metalloproteinase inhibitor, GM6001. Tyrosine 22-30 epidermal growth factor receptor Homo sapiens 140-172 15649431-3 2005 We also revealed that tyrosine phosphorylation of HER2 induced by both lysophospholipids was significantly attenuated by two inhibitors, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, AG1478, and a broad-spectrum matrix metalloproteinase inhibitor, GM6001. Tyrosine 22-30 epidermal growth factor receptor Homo sapiens 174-178 15579470-3 2005 Data presented here demonstrate that epidermal growth factor (EGF) receptor ligands promote the tyrosine phosphorylation of endogenous and adenovirally transduced Srcasm in keratinocytes, and that increased levels of Srcasm activate endogenous SFKs, with a preference for Fyn and Src. Tyrosine 96-104 epidermal growth factor receptor Homo sapiens 37-75 15579470-5 2005 Tyrosine phosphorylation of Srcasm is dependent on growth factors and the activity of EGFR and SFKs. Tyrosine 0-8 epidermal growth factor receptor Homo sapiens 86-90 15660394-1 2005 Hyperosmolarity- and CD95 ligand (CD95L)-induced interactions between CD95 (Fas/APO-1) and the epidermal growth factor receptor (EGFR) involve EGFR-catalyzed CD95 tyrosine phosphorylation. Tyrosine 163-171 epidermal growth factor receptor Homo sapiens 95-127 15660394-1 2005 Hyperosmolarity- and CD95 ligand (CD95L)-induced interactions between CD95 (Fas/APO-1) and the epidermal growth factor receptor (EGFR) involve EGFR-catalyzed CD95 tyrosine phosphorylation. Tyrosine 163-171 epidermal growth factor receptor Homo sapiens 129-133 15660394-1 2005 Hyperosmolarity- and CD95 ligand (CD95L)-induced interactions between CD95 (Fas/APO-1) and the epidermal growth factor receptor (EGFR) involve EGFR-catalyzed CD95 tyrosine phosphorylation. Tyrosine 163-171 epidermal growth factor receptor Homo sapiens 143-147 15660394-4 2005 Inhibition of EGFR tyrosine kinase activity by AG1478 and cyclic adenosine monophosphate had no effect on hyperosmotic CD95-EGFR association in the cytosol but prevented CD95 tyrosine phosphorylation, targeting of the protein complex to the plasma membrane, and formation of the death-inducing signaling complex (DISC). Tyrosine 19-27 epidermal growth factor receptor Homo sapiens 14-18 15660394-5 2005 The requirement of EGFR-mediated CD95 tyrosine phosphorylation for hyperosmotic and CD95L-induced CD95 membrane targeting and DISC formation was also shown in CD95 mutagenesis experiments. Tyrosine 38-46 epidermal growth factor receptor Homo sapiens 19-23 15690085-1 2005 The EGF-like domain of smallpox growth factor (SPGF) targets human ErbB-1, inducing tyrosine phosphorylation of certain host cellular substrates via activation of the receptor"s kinase domain and thereby facilitating viral replication. Tyrosine 84-92 epidermal growth factor receptor Homo sapiens 67-73 15539407-7 2005 Overexpression of wild-type (wt)-Brk, kinase-inactive (KM)-Brk, or YF-Brk increased the Tyr phosphorylation of multiple signaling molecules including EGF receptor. Tyrosine 88-91 epidermal growth factor receptor Homo sapiens 150-162 15714117-8 2005 In normal melanocytes, HRGbeta1 activated the phosphorylation of tyrosine residues of proteins that immunoprecipitated with EGFR and ErbB4 antisera, and significantly enhanced cell migration but not proliferation. Tyrosine 65-73 epidermal growth factor receptor Homo sapiens 124-128 15650401-7 2005 Under oxidative stress, phosphorylation of the epidermal growth factor receptor (EGFR) is abrogated at tyrosine 1,045, the docking site for the ubiquitin ligase c-Cbl, rendering EGFR unable to recruit c-Cbl and be ubiquitylated and degraded. Tyrosine 103-111 epidermal growth factor receptor Homo sapiens 47-79 15650401-7 2005 Under oxidative stress, phosphorylation of the epidermal growth factor receptor (EGFR) is abrogated at tyrosine 1,045, the docking site for the ubiquitin ligase c-Cbl, rendering EGFR unable to recruit c-Cbl and be ubiquitylated and degraded. Tyrosine 103-111 epidermal growth factor receptor Homo sapiens 81-85 15650401-7 2005 Under oxidative stress, phosphorylation of the epidermal growth factor receptor (EGFR) is abrogated at tyrosine 1,045, the docking site for the ubiquitin ligase c-Cbl, rendering EGFR unable to recruit c-Cbl and be ubiquitylated and degraded. Tyrosine 103-111 epidermal growth factor receptor Homo sapiens 178-182 15650253-3 2004 Immunoprecipitation studies demonstrated a reduction of EGF-induced tyrosine phosphorylation of EGFR in PC3-AR cells. Tyrosine 68-76 epidermal growth factor receptor Homo sapiens 96-100 15543206-6 2005 Stimulation of the duct cells with epidermal growth factor (EGF) and betacellulin results in Tyr-phosphorylation of ErbB1 and ErbB2, followed by activation of Shc, MEK1/2 and ERK1/2. Tyrosine 93-96 epidermal growth factor receptor Homo sapiens 116-121 15596048-7 2004 ZD6474-mediated inhibition of tyrosine residue phosphorylation (Tyr992 and Tyr1045) on EGFR was greater in PC-9 cells than in PC-9/ZD cells. Tyrosine 30-38 epidermal growth factor receptor Homo sapiens 87-91 15226155-5 2004 TGHQ, H(2)O(2), and EGF induce different EGFR tyrosine phosphorylation profiles that likely influence the subsequent differential kinetics of MAPK activation. Tyrosine 46-54 epidermal growth factor receptor Homo sapiens 41-45 15548697-9 2004 However, LY294002 more specifically inhibited wild-type EGFR pTyr at residues Tyr(992) and Tyr(1068) in the COOH terminus. Tyrosine 62-65 epidermal growth factor receptor Homo sapiens 56-60 15548697-9 2004 However, LY294002 more specifically inhibited wild-type EGFR pTyr at residues Tyr(992) and Tyr(1068) in the COOH terminus. Tyrosine 78-81 epidermal growth factor receptor Homo sapiens 56-60 20704946-1 2004 Extract: The epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases [enzymes which phosphorylate (add phosphate groups to) tyrosine residues in proteins] is dysregulated in many human cancers and plays important roles in their development and progression. Tyrosine 72-80 epidermal growth factor receptor Homo sapiens 13-45 20704946-1 2004 Extract: The epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases [enzymes which phosphorylate (add phosphate groups to) tyrosine residues in proteins] is dysregulated in many human cancers and plays important roles in their development and progression. Tyrosine 72-80 epidermal growth factor receptor Homo sapiens 47-51 15556605-3 2004 We here demonstrated that S1P induces rapid and transient tyrosine phosphorylation of epidermal growth factor receptor (EGFR) and c-Met in gastric cancer cells, both of which have been proposed as prognostic markers of gastric cancers. Tyrosine 58-66 epidermal growth factor receptor Homo sapiens 86-118 15556605-3 2004 We here demonstrated that S1P induces rapid and transient tyrosine phosphorylation of epidermal growth factor receptor (EGFR) and c-Met in gastric cancer cells, both of which have been proposed as prognostic markers of gastric cancers. Tyrosine 58-66 epidermal growth factor receptor Homo sapiens 120-124 15367678-2 2004 Integrin-mediated activation of EGFR in epithelial cells is required for multiple signal transduction events previously shown to be induced by cell adhesion to matrix proteins, including tyrosine phosphorylation of Shc, Cbl, and phospholipase Cgamma, and activation of the Ras/Erk and phosphatidylinositol 3"-kinase/Akt signaling pathways. Tyrosine 187-195 epidermal growth factor receptor Homo sapiens 32-36 15476828-2 2004 In this study, we have investigated the molecular basis of specific association between the Dok1 PTB domain and the tyrosine-phosphorylated EGFR. Tyrosine 116-124 epidermal growth factor receptor Homo sapiens 140-144 15476828-3 2004 Using yeast two-hybrid and biochemical binding assays, we show that only the PTB domain from Dok1 but not Dok4 or Dok5 can selectively bind to two known tyrosine phosphorylation sites at Y1086 and Y1148 in EGFR. Tyrosine 153-161 epidermal growth factor receptor Homo sapiens 206-210 15492792-0 2004 Small cell lung cancer cells express EGFR and tyrosine phosphorylation of EGFR is inhibited by gefitinib ("Iressa", ZD1839). Tyrosine 46-54 epidermal growth factor receptor Homo sapiens 74-78 15247267-5 2004 Moreover, NT stimulated tyrosine phosphorylation of the EGFR, and pretreatment with a broad spectrum metalloproteinase inhibitor batimastat reduced NT-induced MAP kinase activation. Tyrosine 24-32 epidermal growth factor receptor Homo sapiens 56-60 15192046-3 2004 Analysis of site-specific EGFR phosphorylation demonstrated that the BTC and EGF tyrosine phosphorylation of Y1086 was not significantly different. Tyrosine 81-89 epidermal growth factor receptor Homo sapiens 26-30 15231819-5 2004 Thus, ligand changed the relative preference of the EGFR kinase for substrates as evidenced by EGF increases of approximately 5-fold in the specificity constants (k(cat)/K(m)) for EGFR peptides, whereas approximately 15-40-fold increases were observed for other peptides, such as Gab1 Tyr-627. Tyrosine 285-288 epidermal growth factor receptor Homo sapiens 52-56 15231819-5 2004 Thus, ligand changed the relative preference of the EGFR kinase for substrates as evidenced by EGF increases of approximately 5-fold in the specificity constants (k(cat)/K(m)) for EGFR peptides, whereas approximately 15-40-fold increases were observed for other peptides, such as Gab1 Tyr-627. Tyrosine 285-288 epidermal growth factor receptor Homo sapiens 180-184 15231819-6 2004 Furthermore, we demonstrate that EGF (i) increased the binding affinity of EGFR to Gab1 Tyr-627 and Shc Tyr-317 sites in purified GST fusion proteins approximately 4-6-fold, and (ii) EGF significantly enhanced the phosphorylation of these sites, relative to EGFR autophosphorylation, in cell lysates containing the full-length Gab1 and Shc proteins. Tyrosine 88-91 epidermal growth factor receptor Homo sapiens 75-79 15231819-6 2004 Furthermore, we demonstrate that EGF (i) increased the binding affinity of EGFR to Gab1 Tyr-627 and Shc Tyr-317 sites in purified GST fusion proteins approximately 4-6-fold, and (ii) EGF significantly enhanced the phosphorylation of these sites, relative to EGFR autophosphorylation, in cell lysates containing the full-length Gab1 and Shc proteins. Tyrosine 104-107 epidermal growth factor receptor Homo sapiens 75-79 15273741-0 2004 Interactions of EGFR and caveolin-1 in human glioblastoma cells: evidence that tyrosine phosphorylation regulates EGFR association with caveolae. Tyrosine 79-87 epidermal growth factor receptor Homo sapiens 114-118 15231819-1 2004 The epidermal growth factor receptor (EGFR) kinase catalyzes phosphorylation of tyrosines in its C terminus and in other cellular targets upon epidermal growth factor (EGF) stimulation. Tyrosine 80-89 epidermal growth factor receptor Homo sapiens 4-36 15231819-1 2004 The epidermal growth factor receptor (EGFR) kinase catalyzes phosphorylation of tyrosines in its C terminus and in other cellular targets upon epidermal growth factor (EGF) stimulation. Tyrosine 80-89 epidermal growth factor receptor Homo sapiens 38-42 15329413-7 2004 Immunoblotting of lysates from cells transiently transfected with various EGFR constructs demonstrated that, compared to wild-type protein, an exon 19 deletion mutant induced diminished levels of phosphotyrosine, whereas the phosphorylation at tyrosine 1092 of an exon 21 point mutant was inhibited at 10-fold lower concentrations of drug. Tyrosine 203-211 epidermal growth factor receptor Homo sapiens 74-78 15192046-9 2004 The increased BTC activation results from a greater extent of Y1068 EGFR tyrosine phosphorylation and subsequent increased recruitment of the Grb2-MEKK1 complex to the plasma membrane, compared with EGF stimulation. Tyrosine 73-81 epidermal growth factor receptor Homo sapiens 68-72 15453638-8 2004 Interestingly, EGF-induced tyrosine phosphorylation of the EGF receptor was strongly attenuated by 1O2 but unimpaired by C2-ceramide, implying that, although ceramide formation may mediate the above attenuation of ERK and Akt phosphorylation induced by 1O2, mechanisms beyond ceramide formation exist that mediate impairment of growth factor signaling by singlet oxygen. Tyrosine 27-35 epidermal growth factor receptor Homo sapiens 59-71 15205471-7 2004 Urotensin II promoted the tyrosine phosphorylation of epidermal growth factor receptors, which was inhibited by the selective epidermal growth factor receptor kinase inhibitor, AG1478. Tyrosine 26-34 epidermal growth factor receptor Homo sapiens 54-86 15291751-4 2004 Stimulation with IGF-I also promoted the tyrosine phosphorylation of epidermal growth factor receptor (EGFR). Tyrosine 41-49 epidermal growth factor receptor Homo sapiens 69-101 15291751-4 2004 Stimulation with IGF-I also promoted the tyrosine phosphorylation of epidermal growth factor receptor (EGFR). Tyrosine 41-49 epidermal growth factor receptor Homo sapiens 103-107 15282306-2 2004 This synergy is dependent upon c-Src-mediated phosphorylation of a unique tyrosine on the EGFR, namely, tyrosine 845 (Y845). Tyrosine 74-82 epidermal growth factor receptor Homo sapiens 90-94 15282306-2 2004 This synergy is dependent upon c-Src-mediated phosphorylation of a unique tyrosine on the EGFR, namely, tyrosine 845 (Y845). Tyrosine 104-112 epidermal growth factor receptor Homo sapiens 90-94 15254267-5 2004 Basal ErbB tyrosine phosphorylation and ERK phosphorylation were inhibited by two different ErbB receptor tyrosine kinase inhibitors, by the ErbB1-specific neutralizing monoclonal antibody 225 IgG, by two different metalloproteinase inhibitors, and by neutralizing antibodies against amphiregulin (AR). Tyrosine 11-19 epidermal growth factor receptor Homo sapiens 6-10 15254267-5 2004 Basal ErbB tyrosine phosphorylation and ERK phosphorylation were inhibited by two different ErbB receptor tyrosine kinase inhibitors, by the ErbB1-specific neutralizing monoclonal antibody 225 IgG, by two different metalloproteinase inhibitors, and by neutralizing antibodies against amphiregulin (AR). Tyrosine 11-19 epidermal growth factor receptor Homo sapiens 92-96 15254267-5 2004 Basal ErbB tyrosine phosphorylation and ERK phosphorylation were inhibited by two different ErbB receptor tyrosine kinase inhibitors, by the ErbB1-specific neutralizing monoclonal antibody 225 IgG, by two different metalloproteinase inhibitors, and by neutralizing antibodies against amphiregulin (AR). Tyrosine 11-19 epidermal growth factor receptor Homo sapiens 141-146 15288768-5 2004 Immunoprecipitation studies demonstrated a reduction of EGF-induced tyrosine phosphorylation of EGFR in PC3-AR cells. Tyrosine 68-76 epidermal growth factor receptor Homo sapiens 96-100 15166244-9 2004 Tau-Cl over the same concentration range and time scale stimulated epidermal growth factor (EGF) receptor tyrosine phosphorylation in A431 cells and HUVEC. Tyrosine 106-114 epidermal growth factor receptor Homo sapiens 67-105 15219825-4 2004 Eotaxin (1-100 nM) induced dose-dependent tyrosine phosphorylation of EGFR in NCI-H292 cells. Tyrosine 42-50 epidermal growth factor receptor Homo sapiens 70-74 15219850-3 2004 Time dependent increases in tyrosine phosphorylation of the EGFR after addition of extracellular calcium ([Ca2+]o, 3 mM) occurred in stably CaR-transfected HEK293 cells but not in non-transfected HEK293 cells. Tyrosine 28-36 epidermal growth factor receptor Homo sapiens 60-64 15117950-8 2004 Mutation of the homologous tyrosine residue in Cbl-b to glutamate also leads to E3 activation while retaining EGFR-binding ability. Tyrosine 27-35 epidermal growth factor receptor Homo sapiens 110-114 15213840-6 2004 Increased tyrosine phosphorylation of the EGFR was observed following TF/FVIIa complex formation on the cell surface. Tyrosine 10-18 epidermal growth factor receptor Homo sapiens 42-46 14699120-10 2004 To our knowledge, this is the first report that p56(lck) in presence of H/R regulates MEK-1-dependent ERK1/2 phosphorylation and uPA secretion through tyrosine phosphorylation of EGF receptor, and it further demonstrates that all of these signaling molecules ultimately control the motility of breast cancer cells. Tyrosine 151-159 epidermal growth factor receptor Homo sapiens 179-191 15158434-1 2004 The ErbB/HER protein-tyrosine kinases, which include the epidermal growth factor receptor, consist of a growth-factor-binding ectodomain, a single transmembrane segment, an intracellular protein-tyrosine kinase catalytic domain, and a tyrosine-containing cytoplasmic tail. Tyrosine 21-29 epidermal growth factor receptor Homo sapiens 57-89 15161351-0 2004 UV-radiation-induced internalization of the epidermal growth factor receptor requires distinct serine and tyrosine residues in the cytoplasmic carboxy-terminal domain. Tyrosine 106-114 epidermal growth factor receptor Homo sapiens 44-76 15161351-5 2004 Furthermore, the UV-radiation-induced internalization was abrogated for an EGFR mutated in tyrosine 1045 (Y1045F), the major c-Cbl binding site. Tyrosine 91-99 epidermal growth factor receptor Homo sapiens 75-79 15161351-7 2004 Our results suggest a mechanism for UV-radiation-induced internalization of EGFR involving a conformational change that is dependent on structural elements formed by specific serine and tyrosine residues in the carboxy-terminal domain. Tyrosine 186-194 epidermal growth factor receptor Homo sapiens 76-80 12972402-3 2004 Exposure to Zn(2+) induced phosphorylation of EGFR at tyrosine 1068, a major autophosphorylation site, in a dose- and time-dependent fashion. Tyrosine 54-62 epidermal growth factor receptor Homo sapiens 46-50 14699120-5 2004 We provide here evidence that H/R induces Lck kinase activity and Lck-dependent tyrosine phosphorylation of EGF receptor in highly invasive (MDA-MB-231) and low invasive (MCF-7) breast cancer cells. Tyrosine 80-88 epidermal growth factor receptor Homo sapiens 108-120 14704150-6 2004 Ligation of OPN with alpha(v)beta(3) integrin induces kinase activity and tyrosine phosphorylation of EGFR in MDA-MB-231 and wild type EGFR-transfected MCF-7 cells, and this was inhibited by the dominant negative form of c-Src (dn c-Src) indicating that c-Src kinase plays a crucial role in this process. Tyrosine 74-82 epidermal growth factor receptor Homo sapiens 102-106 14744244-2 2004 Receptor dimerization promotes activation of the intrinsic kinase, leading to phosphorylation of specific tyrosines located in the ErbB"s cytoplasmic region. Tyrosine 106-115 epidermal growth factor receptor Homo sapiens 131-135 15161014-8 2004 In KATO-III, a number of tyrosine phosphorylated proteins, including extracellular signal-regulated protein kinases (ERKs) and epidermal growth factor receptor (EGFR), were observed irrespective of EGF stimulation and induction of ERK activity and EGFR tyrosine phosphorylation by EGF were less than that in MKN7. Tyrosine 25-33 epidermal growth factor receptor Homo sapiens 127-159 15161014-8 2004 In KATO-III, a number of tyrosine phosphorylated proteins, including extracellular signal-regulated protein kinases (ERKs) and epidermal growth factor receptor (EGFR), were observed irrespective of EGF stimulation and induction of ERK activity and EGFR tyrosine phosphorylation by EGF were less than that in MKN7. Tyrosine 25-33 epidermal growth factor receptor Homo sapiens 248-252 14967460-2 2004 Ligand binding induces EGFR dimerization and autophosphorylation on several tyrosine residues in the intracellular domain, leading to mitogenic signal transduction. Tyrosine 76-84 epidermal growth factor receptor Homo sapiens 23-27 14967460-5 2004 ABX-EGF binds EGFR and blocks receptor binding of EGF and transforming growth factor-alpha, inhibiting EGFR tyrosine phosphorylation and tumor cell activation. Tyrosine 108-116 epidermal growth factor receptor Homo sapiens 103-107 15015657-6 2004 The erbB receptors expressed by SK-N-MC cells were constitutively tyrosine phosphorylated and inhibiting these kinases with the erbB specific inhibitor PD158780 reduced SK-N-MC DNA synthesis in a dose-dependent manner. Tyrosine 66-74 epidermal growth factor receptor Homo sapiens 4-8 14647423-3 2004 Our results show that GPCR ligands induce tyrosine phosphorylation of the epidermal growth factor receptor (EGFR) as well as downstream signalling events such as recruitment of the adapter protein Shc and activation of the mitogen-activated protein kinases (MAPK) ERK1/2, JNK and p38. Tyrosine 42-50 epidermal growth factor receptor Homo sapiens 74-106 14647423-3 2004 Our results show that GPCR ligands induce tyrosine phosphorylation of the epidermal growth factor receptor (EGFR) as well as downstream signalling events such as recruitment of the adapter protein Shc and activation of the mitogen-activated protein kinases (MAPK) ERK1/2, JNK and p38. Tyrosine 42-50 epidermal growth factor receptor Homo sapiens 108-112 14661053-10 2004 Moreover, these NRG2alpha and NRG2beta mutants reveal new insights into models for ligand-induced ErbB family receptor tyrosine phosphorylation and coupling to downstream signaling events. Tyrosine 119-127 epidermal growth factor receptor Homo sapiens 98-102 14593113-11 2004 Treatment of cells with IGF-I led to an increase in the amount of tyrosine-phosphorylated EGFR within these complexes. Tyrosine 66-74 epidermal growth factor receptor Homo sapiens 90-94 14593113-12 2004 ZD1839 had no effect on complex formation but completely abolished their associated EGFR tyrosine phosphorylation. Tyrosine 89-97 epidermal growth factor receptor Homo sapiens 84-88 14710234-4 2004 PS2-TAT treatment of the EGFR/c-erbB-2-positive cell line MDA-HER2 resulted in a reduction of the EGF-mediated PLC-gamma1 tyrosine phosphorylation of about 30%, concomitant with a complete abrogation of the EGF-driven calcium influx. Tyrosine 122-130 epidermal growth factor receptor Homo sapiens 25-29 14498832-1 2003 EGF (epidermal growth factor) binding to its receptor (EGFR) induces dimerization and autophosphorylation of the receptor at multiple tyrosine residues, which serve as docking sites for recruitment of proteins with SH2 (Src homology 2) domains that activate multiple downstream signalling pathways. Tyrosine 134-142 epidermal growth factor receptor Homo sapiens 55-59 14512423-7 2003 Stimulation of EGFR and mitogen-activated protein kinase signaling by GM3 depletion involves the phosphorylation of EGFR at tyrosine residues 845, 1068, and 1148 but not 1086 or 1173. Tyrosine 124-132 epidermal growth factor receptor Homo sapiens 15-19 14512423-7 2003 Stimulation of EGFR and mitogen-activated protein kinase signaling by GM3 depletion involves the phosphorylation of EGFR at tyrosine residues 845, 1068, and 1148 but not 1086 or 1173. Tyrosine 124-132 epidermal growth factor receptor Homo sapiens 116-120 14512423-0 2003 Ganglioside GM3 blocks the activation of epidermal growth factor receptor induced by integrin at specific tyrosine sites. Tyrosine 106-114 epidermal growth factor receptor Homo sapiens 41-73 14512423-5 2003 Consistently, endogenous depletion of GM3 markedly increases the association of EGFR with tyrosine-phosphorylated integrin beta1 and promotes cell proliferation. Tyrosine 90-98 epidermal growth factor receptor Homo sapiens 80-84 14498832-4 2003 Since Ras-MAPK and STAT pathways are simultaneously stimulated by EGF, and Tyr-1086 and Tyr-1068 of EGFR are reported to be the binding sites for both Grb2 and Stat3, we investigated the possible regulatory role of Grb2 in STAT activation. Tyrosine 75-78 epidermal growth factor receptor Homo sapiens 100-104 14498832-4 2003 Since Ras-MAPK and STAT pathways are simultaneously stimulated by EGF, and Tyr-1086 and Tyr-1068 of EGFR are reported to be the binding sites for both Grb2 and Stat3, we investigated the possible regulatory role of Grb2 in STAT activation. Tyrosine 88-91 epidermal growth factor receptor Homo sapiens 100-104 14674888-7 2003 Epidermal growth factor receptor (EGFR) tyrosine phosphorylation and recruitment of its adaptor proteins, Shc and Grb2, to EGFR were detected by immunoprecipitation and Western blot analysis. Tyrosine 40-48 epidermal growth factor receptor Homo sapiens 0-32 14674888-7 2003 Epidermal growth factor receptor (EGFR) tyrosine phosphorylation and recruitment of its adaptor proteins, Shc and Grb2, to EGFR were detected by immunoprecipitation and Western blot analysis. Tyrosine 40-48 epidermal growth factor receptor Homo sapiens 34-38 14674888-12 2003 To investigate a signalling pathway leading to activation of MEK1/2-ERK1/2, we examined the tyrosine phosphorylation of EGFR and Shc adapter protein. Tyrosine 92-100 epidermal growth factor receptor Homo sapiens 120-124 14674888-13 2003 Both arsenicals stimulated tyrosine phosphorylation of EGFR and Shc. Tyrosine 27-35 epidermal growth factor receptor Homo sapiens 55-59 12966092-6 2003 Consistent with this, PPAR agonists increased tyrosine autophosphorylation of the EGFR as well as phosphorylation at a putative Src-specific site, Tyr845. Tyrosine 46-54 epidermal growth factor receptor Homo sapiens 82-86 12900408-0 2003 Tyrosine phosphorylation of the beta2 subunit of clathrin adaptor complex AP-2 reveals the role of a di-leucine motif in the epidermal growth factor receptor trafficking. Tyrosine 0-8 epidermal growth factor receptor Homo sapiens 125-157 12970364-6 2003 D2 receptor stimulation by bromocriptine induced c-Src tyrosine 418 phosphorylation and EGFR phosphorylation specifically at tyrosine 845, a known substrate of Src kinase. Tyrosine 125-133 epidermal growth factor receptor Homo sapiens 88-92 14646241-4 2003 Using this technique, we have studied the process of early signal transduction of epidermal growth factor (EGF) in single molecules: binding of EGF to its receptor (EGFR) on the cell surface, dimerization of EGFR induced by binding of EGF, fluctuation of the structure of EGFR clusters, activation of EGFR through tyrosine phosphorylations on its cytoplasmic domain, and recognition of activated EGFR by a cytoplasmic adaptor protein, Grb2. Tyrosine 314-322 epidermal growth factor receptor Homo sapiens 208-212 14646241-4 2003 Using this technique, we have studied the process of early signal transduction of epidermal growth factor (EGF) in single molecules: binding of EGF to its receptor (EGFR) on the cell surface, dimerization of EGFR induced by binding of EGF, fluctuation of the structure of EGFR clusters, activation of EGFR through tyrosine phosphorylations on its cytoplasmic domain, and recognition of activated EGFR by a cytoplasmic adaptor protein, Grb2. Tyrosine 314-322 epidermal growth factor receptor Homo sapiens 208-212 14646241-4 2003 Using this technique, we have studied the process of early signal transduction of epidermal growth factor (EGF) in single molecules: binding of EGF to its receptor (EGFR) on the cell surface, dimerization of EGFR induced by binding of EGF, fluctuation of the structure of EGFR clusters, activation of EGFR through tyrosine phosphorylations on its cytoplasmic domain, and recognition of activated EGFR by a cytoplasmic adaptor protein, Grb2. Tyrosine 314-322 epidermal growth factor receptor Homo sapiens 208-212 14646241-4 2003 Using this technique, we have studied the process of early signal transduction of epidermal growth factor (EGF) in single molecules: binding of EGF to its receptor (EGFR) on the cell surface, dimerization of EGFR induced by binding of EGF, fluctuation of the structure of EGFR clusters, activation of EGFR through tyrosine phosphorylations on its cytoplasmic domain, and recognition of activated EGFR by a cytoplasmic adaptor protein, Grb2. Tyrosine 314-322 epidermal growth factor receptor Homo sapiens 208-212 12783862-5 2003 Association of Rin1 and specifically the SH2 domain of Rin1 with the EGFR was dependent on tyrosine phosphorylation of the intracellular domain of the EGFR. Tyrosine 91-99 epidermal growth factor receptor Homo sapiens 69-73 12954170-2 2003 Phosphorylation of specific tyrosine residues within the cytoplasmic domain of EGFR is part of the initial activation process that occurs upon ligand binding, and these phosphotyrosine residues subsequently serve as docking sites for intracellular signaling molecules. Tyrosine 28-36 epidermal growth factor receptor Homo sapiens 79-83 12954170-6 2003 Ligand concentrations were varied for epidermal growth factor (EGF) and transforming growth factor alpha (TGF alpha) as stimuli, and all of the EGFR tyrosine sites were consequently found to exhibit increased levels of phosphorylation, although at different rates and to different extents. Tyrosine 149-157 epidermal growth factor receptor Homo sapiens 144-148 12783862-5 2003 Association of Rin1 and specifically the SH2 domain of Rin1 with the EGFR was dependent on tyrosine phosphorylation of the intracellular domain of the EGFR. Tyrosine 91-99 epidermal growth factor receptor Homo sapiens 151-155 12915106-5 2003 Like EGF, Zn(2+) induced phosphorylation of EGFR at tyrosines 845, 1068, and 1173. Tyrosine 52-61 epidermal growth factor receptor Homo sapiens 44-48 12915106-10 2003 Exposure to Zn(2+), but not EGF, induced phosphorylation of the activating site of c-Src (tyrosine 416), and Zn(2+)-induced phosphorylation of EGFR at tyrosines 845 and 1068 was blocked by the c-Src kinase activity inhibitor PP2. Tyrosine 151-160 epidermal growth factor receptor Homo sapiens 143-147 12810757-6 2003 AG1478, an epidermal growth factor receptor (EGFR) inhibitor, suppressed the H2O2-induced phosphorylation of CREB and tyrosine phosphorylation of EGFR. Tyrosine 118-126 epidermal growth factor receptor Homo sapiens 11-43 12917021-8 2003 In contrast, tyrosine phosphorylation of EGFR was relatively unaffected at the concentrations of SUCI02 up to 40 microg/ml. Tyrosine 13-21 epidermal growth factor receptor Homo sapiens 41-45 12810757-6 2003 AG1478, an epidermal growth factor receptor (EGFR) inhibitor, suppressed the H2O2-induced phosphorylation of CREB and tyrosine phosphorylation of EGFR. Tyrosine 118-126 epidermal growth factor receptor Homo sapiens 45-49 12810757-6 2003 AG1478, an epidermal growth factor receptor (EGFR) inhibitor, suppressed the H2O2-induced phosphorylation of CREB and tyrosine phosphorylation of EGFR. Tyrosine 118-126 epidermal growth factor receptor Homo sapiens 146-150 12855621-11 2003 There was a significant decrease in phospho-EGFR (Tyr 1173) expression as determined semiquantitatively with OSI-774 treatment [2.75 +/- 0.51 (mean +/- SD) pretreatment versus 2.36 +/- 0.76 after treatment, pair comparison P = 0.01]. Tyrosine 50-53 epidermal growth factor receptor Homo sapiens 44-48 12811831-5 2003 The Ang II-induced proliferation of breast cancer cells was reduced by (a) Go6976, an inhibitor of conventional PKC-alpha and -beta1, (b) AG1478, an inhibitor of the tyrosine kinase of the EGF receptor (EGFR), and (c) downregulation of 1,2-diacylglycerol-sensitive PKCs achieved by phorbol 12-myristate 13-acetate (PMA). Tyrosine 166-174 epidermal growth factor receptor Homo sapiens 189-201 12867061-5 2003 Subsequently, erlotinib, another EGFR specific tyrosine inhibitor, has also demonstrated single agent activity in non-small cell lung cancer. Tyrosine 47-55 epidermal growth factor receptor Homo sapiens 33-37 12861030-5 2003 Epidermal growth factor receptor stimulation can affect cyt-PTP epsilon dimerization and tyrosine phosphorylation in either direction, suggesting that cell surface receptors can relay extracellular signals to cyt-PTP epsilon, which lacks extracellular domains of its own. Tyrosine 89-97 epidermal growth factor receptor Homo sapiens 0-32 12925758-6 2003 Phosphorylation of cortactin tyrosine 421 and 466 was elevated in response to Src, epidermal growth factor receptor and Rac1 activation, and tyrosine 421 phosphorylated cortactin localized with F-actin in lamellipodia and podosomes. Tyrosine 29-37 epidermal growth factor receptor Homo sapiens 83-115 12948142-4 2003 This tyrosine-targeted tandem mass spectrometry strategy is demonstrated for epidermal growth factor receptor showing that phosphotyrosine-containing tryptic peptides invisible in the survey spectrum can be safely identified. Tyrosine 5-13 epidermal growth factor receptor Homo sapiens 77-109 12828935-3 2003 We have now found that activation of the epidermal growth factor receptor (EGFR) induces NOS-2 in astrocytes of the human optic nerve head (ONH) in vitro and EGFR is significantly upregulated and tyrosine phosphorylated in reactive astrocytes in human glaucomatous ONHs in vivo. Tyrosine 196-204 epidermal growth factor receptor Homo sapiens 41-73 12828935-3 2003 We have now found that activation of the epidermal growth factor receptor (EGFR) induces NOS-2 in astrocytes of the human optic nerve head (ONH) in vitro and EGFR is significantly upregulated and tyrosine phosphorylated in reactive astrocytes in human glaucomatous ONHs in vivo. Tyrosine 196-204 epidermal growth factor receptor Homo sapiens 75-79 12588871-4 2003 Phosphorylation on Tyr(168) was mediated by the epidermal growth factor receptor (EGFR). Tyrosine 19-22 epidermal growth factor receptor Homo sapiens 48-80 12734385-6 2003 The intracellular C terminus and tyrosine autophosphorylation pattern of DeltaEGFR are similar to wild-type EGFR, but it signals at a lower intensity as determined by levels of EGFR phosphotyrosine. Tyrosine 33-41 epidermal growth factor receptor Homo sapiens 78-82 12743035-4 2003 Moreover, AR gene silencing by siRNA or inhibition of AR biological activity by neutralizing antibodies and heparin prevents GPCR-induced EGFR tyrosine phosphorylation, downstream mitogenic signalling events, cell proliferation, migration and activation of the survival mediator Akt/PKB. Tyrosine 143-151 epidermal growth factor receptor Homo sapiens 138-142 12588871-4 2003 Phosphorylation on Tyr(168) was mediated by the epidermal growth factor receptor (EGFR). Tyrosine 19-22 epidermal growth factor receptor Homo sapiens 82-86 12522132-0 2003 Phosphorylation of tyrosine 319 of the angiotensin II type 1 receptor mediates angiotensin II-induced trans-activation of the epidermal growth factor receptor. Tyrosine 19-27 epidermal growth factor receptor Homo sapiens 126-158 12748850-9 2003 RESULTS: Carbachol induced tyrosine phosphorylation of EGFR, which was abolished by an EGFR tyrosine kinase inhibitor AG1478. Tyrosine 27-35 epidermal growth factor receptor Homo sapiens 55-59 12748850-9 2003 RESULTS: Carbachol induced tyrosine phosphorylation of EGFR, which was abolished by an EGFR tyrosine kinase inhibitor AG1478. Tyrosine 27-35 epidermal growth factor receptor Homo sapiens 87-91 12748850-11 2003 The tyrosine-phosphorylated EGFR was immunoprecipitated together with GRB2 and tyrosine-phosphorylated Shc, indicating that transactivated EGFR is able to generate downstream signals. Tyrosine 4-12 epidermal growth factor receptor Homo sapiens 28-32 12748850-11 2003 The tyrosine-phosphorylated EGFR was immunoprecipitated together with GRB2 and tyrosine-phosphorylated Shc, indicating that transactivated EGFR is able to generate downstream signals. Tyrosine 4-12 epidermal growth factor receptor Homo sapiens 139-143 12748850-11 2003 The tyrosine-phosphorylated EGFR was immunoprecipitated together with GRB2 and tyrosine-phosphorylated Shc, indicating that transactivated EGFR is able to generate downstream signals. Tyrosine 79-87 epidermal growth factor receptor Homo sapiens 28-32 12748850-11 2003 The tyrosine-phosphorylated EGFR was immunoprecipitated together with GRB2 and tyrosine-phosphorylated Shc, indicating that transactivated EGFR is able to generate downstream signals. Tyrosine 79-87 epidermal growth factor receptor Homo sapiens 139-143 12633740-7 2003 Furthermore, the highest dose of UVA (9 J/cm(2)) prevented the EGF-induced Tyr-phosphorylation of the EGF-receptor (EGF-R). Tyrosine 75-78 epidermal growth factor receptor Homo sapiens 102-121 12694196-2 2003 It also inhibits tyrosine phosphorylation of a 170-kDa band corresponding to the epidermal growth factor receptor (EGFR) and induces the phosphorylation at tyrosine residue(s) of a 58-kDa protein which we have denoted NOIPP-58 (nitric oxide-induced 58-kDa phosphoprotein). Tyrosine 17-25 epidermal growth factor receptor Homo sapiens 81-113 12694196-2 2003 It also inhibits tyrosine phosphorylation of a 170-kDa band corresponding to the epidermal growth factor receptor (EGFR) and induces the phosphorylation at tyrosine residue(s) of a 58-kDa protein which we have denoted NOIPP-58 (nitric oxide-induced 58-kDa phosphoprotein). Tyrosine 17-25 epidermal growth factor receptor Homo sapiens 115-119 12586744-5 2003 Stimulation of EGF receptor overexpressing cells with 11,12-EET or transfection of these cells with CYP 2C9 enhanced the tyrosine phosphorylation of the EGF receptor. Tyrosine 121-129 epidermal growth factor receptor Homo sapiens 15-27 12586744-5 2003 Stimulation of EGF receptor overexpressing cells with 11,12-EET or transfection of these cells with CYP 2C9 enhanced the tyrosine phosphorylation of the EGF receptor. Tyrosine 121-129 epidermal growth factor receptor Homo sapiens 153-165 12522132-12 2003 In summary, Tyr-319 of the AT1 receptor is phosphorylated in response to Ang II and plays a key role in mediating Ang II-induced transactivation of EGFR and cell proliferation, possibly through its interaction with SHP-2 and EGFR. Tyrosine 12-15 epidermal growth factor receptor Homo sapiens 148-152 12522132-12 2003 In summary, Tyr-319 of the AT1 receptor is phosphorylated in response to Ang II and plays a key role in mediating Ang II-induced transactivation of EGFR and cell proliferation, possibly through its interaction with SHP-2 and EGFR. Tyrosine 12-15 epidermal growth factor receptor Homo sapiens 225-229 12522132-4 2003 The role of the conserved YIPP motif in this sequence in transactivation of EGFR was investigated by mutating tyrosine 319. Tyrosine 110-118 epidermal growth factor receptor Homo sapiens 76-80 12522132-5 2003 Ang II failed to activate EGFR in cells expressing AT1-Y319F, whereas EGFR was activated even without Ang II in cells expressing AT1-Y319E, which mimics the AT1 receptor phosphorylated at Tyr-319. Tyrosine 188-191 epidermal growth factor receptor Homo sapiens 70-74 12522132-8 2003 The requirement of Tyr-319 seems specific for EGFR because Ang II-induced activation of other tyrosine kinases, including Src and JAK2, was preserved in cells expressing AT1-Y319F. Tyrosine 19-22 epidermal growth factor receptor Homo sapiens 46-50 12708492-0 2003 Redifferentiation and ZO-1 reexpression in liver-metastasized colorectal cancer: possible association with epidermal growth factor receptor-induced tyrosine phosphorylation of ZO-1. Tyrosine 148-156 epidermal growth factor receptor Homo sapiens 107-139 12604628-5 2003 Furthermore, tyrosine-phosphorylated EGFR was specifically immunoprecipitated with antiphosphotyrosine antibodies from EGF-treated cumulus cells isolated from the large follicles. Tyrosine 13-21 epidermal growth factor receptor Homo sapiens 37-41 14681060-4 2003 This activation results in tyrosine phosphorylation of known EGFR substrates and reduction in focal adhesions. Tyrosine 27-35 epidermal growth factor receptor Homo sapiens 61-65 12496267-6 2003 However, compared with EGF, CCK caused only small increases in tyrosine phosphorylation of the EGFR and Shc, Shc-Grb2 complex formation, and Ras activation. Tyrosine 63-71 epidermal growth factor receptor Homo sapiens 95-99 12502502-6 2003 A time-dependent increase in tyrosine phosphorylation of the EGFR in response to GLP-1 was observed in INS(832/13) cells. Tyrosine 29-37 epidermal growth factor receptor Homo sapiens 61-65 12429742-2 2003 Previous studies have shown that EGFR and c-Src co-overexpression and association leads to the c-Src-mediated phosphorylation of tyrosine 845 of the EGFR and that mutation of Tyr(845) ablates epidermal growth factor (EGF)-induced DNA synthesis. Tyrosine 129-137 epidermal growth factor receptor Homo sapiens 33-37 12429742-2 2003 Previous studies have shown that EGFR and c-Src co-overexpression and association leads to the c-Src-mediated phosphorylation of tyrosine 845 of the EGFR and that mutation of Tyr(845) ablates epidermal growth factor (EGF)-induced DNA synthesis. Tyrosine 129-137 epidermal growth factor receptor Homo sapiens 149-153 12429742-2 2003 Previous studies have shown that EGFR and c-Src co-overexpression and association leads to the c-Src-mediated phosphorylation of tyrosine 845 of the EGFR and that mutation of Tyr(845) ablates epidermal growth factor (EGF)-induced DNA synthesis. Tyrosine 175-178 epidermal growth factor receptor Homo sapiens 33-37 12429742-4 2003 We demonstrate that 1) activation of STAT5b by EGF requires overexpression of the EGFR, 2) co-overexpression of c-Src alone does not result in EGF-induced activation of STAT5b but enhances that seen in EGFR-overexpressing cells, and 3) EGF-induced tyrosine phosphorylation of STAT5b requires Tyr(845) of the EGFR. Tyrosine 248-256 epidermal growth factor receptor Homo sapiens 82-86 12429742-4 2003 We demonstrate that 1) activation of STAT5b by EGF requires overexpression of the EGFR, 2) co-overexpression of c-Src alone does not result in EGF-induced activation of STAT5b but enhances that seen in EGFR-overexpressing cells, and 3) EGF-induced tyrosine phosphorylation of STAT5b requires Tyr(845) of the EGFR. Tyrosine 292-295 epidermal growth factor receptor Homo sapiens 82-86 12429742-5 2003 Furthermore, the stable overexpression of a kinase-defective c-Src in the context of EGFR overexpression results in a decrease in the tyrosine phosphorylation of STAT5b in response to EGF and a more dramatic decrease in EGF-induced transcriptional activation of STAT5b, suggesting an integral role for c-Src in the physiological actions of STAT5b. Tyrosine 134-142 epidermal growth factor receptor Homo sapiens 85-89 14521055-2 2003 Recently, we showed that EGF initiated a rapid tyrosine phosphorylation of both EGF-receptor and STAT factors with simultaneous increase in the intracellular ROS level. Tyrosine 47-55 epidermal growth factor receptor Homo sapiens 80-92 12447997-5 2002 Furthermore, treatment with LPA alone induces the rapid (maximal signal within 2 min) tyrosine phosphorylation of EGFR, and subsequent (maximal signal after 5 min) activation of ERK, suggesting that EGFR activation precedes ERK phosphorylation and may constitute a required component for signal relay from the LPA receptor to ERK. Tyrosine 86-94 epidermal growth factor receptor Homo sapiens 114-118 14521054-6 2003 Consistent with this observation, H2O2-stimulated EGFR tyrosine phosphorylation was abolished by specific Src kinase family inhibitor CGP77675, implicating Src in H2O2-induced EGFR activation. Tyrosine 55-63 epidermal growth factor receptor Homo sapiens 50-54 14521054-6 2003 Consistent with this observation, H2O2-stimulated EGFR tyrosine phosphorylation was abolished by specific Src kinase family inhibitor CGP77675, implicating Src in H2O2-induced EGFR activation. Tyrosine 55-63 epidermal growth factor receptor Homo sapiens 176-180 12447997-7 2002 In addition, we find that the LPA-regulated tyrosine phosphorylation of EGFR and activation of ERK are attenuated by batimastat, a generic inhibitor of matrix metalloproteinases (MMP). Tyrosine 44-52 epidermal growth factor receptor Homo sapiens 72-76 12354760-5 2002 GM3 overexpression inhibits EGFR tyrosine phosphorylation and receptor dimerization and concurrently increases both the content and tyrosine phosphorylation of EGFR-associated caveolin-1, providing evidence that tyrosine phosphorylation of caveolin-1 inhibits EGFR signaling. Tyrosine 132-140 epidermal growth factor receptor Homo sapiens 160-164 12354760-5 2002 GM3 overexpression inhibits EGFR tyrosine phosphorylation and receptor dimerization and concurrently increases both the content and tyrosine phosphorylation of EGFR-associated caveolin-1, providing evidence that tyrosine phosphorylation of caveolin-1 inhibits EGFR signaling. Tyrosine 33-41 epidermal growth factor receptor Homo sapiens 28-32 12354760-5 2002 GM3 overexpression inhibits EGFR tyrosine phosphorylation and receptor dimerization and concurrently increases both the content and tyrosine phosphorylation of EGFR-associated caveolin-1, providing evidence that tyrosine phosphorylation of caveolin-1 inhibits EGFR signaling. Tyrosine 132-140 epidermal growth factor receptor Homo sapiens 160-164 12354760-5 2002 GM3 overexpression inhibits EGFR tyrosine phosphorylation and receptor dimerization and concurrently increases both the content and tyrosine phosphorylation of EGFR-associated caveolin-1, providing evidence that tyrosine phosphorylation of caveolin-1 inhibits EGFR signaling. Tyrosine 132-140 epidermal growth factor receptor Homo sapiens 160-164 12354760-5 2002 GM3 overexpression inhibits EGFR tyrosine phosphorylation and receptor dimerization and concurrently increases both the content and tyrosine phosphorylation of EGFR-associated caveolin-1, providing evidence that tyrosine phosphorylation of caveolin-1 inhibits EGFR signaling. Tyrosine 132-140 epidermal growth factor receptor Homo sapiens 160-164 12244120-13 2002 Furthermore, aldosterone enhanced Tyr phosphorylation of c-Src and EGFR, and an inhibitor of cytosolic tyrosine kinases (4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyriociaine) prevented the action of aldosterone. Tyrosine 34-37 epidermal growth factor receptor Homo sapiens 67-71 12506397-2 2002 Among them, compounds 4d and 4h showed potencies against both EGFR tyrosine and the A431 cell line similar to that of PD153035 with greater aqueous solubilities of their HCl salts. Tyrosine 67-75 epidermal growth factor receptor Homo sapiens 62-66 12223352-4 2002 IFN-gamma increased tyrosine phosphorylation in T84 cells at 24 h, including the EGFr. Tyrosine 20-28 epidermal growth factor receptor Homo sapiens 81-85 12226085-7 2002 We show that these two E3 ligases are involved in EGFR signaling because both become phosphorylated on tyrosine following epidermal growth factor stimulation. Tyrosine 103-111 epidermal growth factor receptor Homo sapiens 50-54 12419447-3 2002 Immunoblots were screened for EGFR expression and the ability of IMC-C225 to block EGF-induced tyrosine phosphorylation of EGFR. Tyrosine 95-103 epidermal growth factor receptor Homo sapiens 123-127 12414665-4 2002 Using the metalloprotease inhibitor batimastat, the EGFR-specific tyrphostin AG1478, and a dominant-negative EGFR mutant, we show that in HNSCC cell lines, EGFR tyrosine phosphorylation, recruitment of the adaptor proteins SHC and Gab1, and activation of the ERK/mitogen-activated protein kinase pathway in response to LPA depend both on metalloprotease function and EGFR tyrosine kinase activity. Tyrosine 161-169 epidermal growth factor receptor Homo sapiens 109-113 12414665-4 2002 Using the metalloprotease inhibitor batimastat, the EGFR-specific tyrphostin AG1478, and a dominant-negative EGFR mutant, we show that in HNSCC cell lines, EGFR tyrosine phosphorylation, recruitment of the adaptor proteins SHC and Gab1, and activation of the ERK/mitogen-activated protein kinase pathway in response to LPA depend both on metalloprotease function and EGFR tyrosine kinase activity. Tyrosine 161-169 epidermal growth factor receptor Homo sapiens 109-113 12414665-4 2002 Using the metalloprotease inhibitor batimastat, the EGFR-specific tyrphostin AG1478, and a dominant-negative EGFR mutant, we show that in HNSCC cell lines, EGFR tyrosine phosphorylation, recruitment of the adaptor proteins SHC and Gab1, and activation of the ERK/mitogen-activated protein kinase pathway in response to LPA depend both on metalloprotease function and EGFR tyrosine kinase activity. Tyrosine 161-169 epidermal growth factor receptor Homo sapiens 109-113 12373311-7 2002 This observation could be explained by the fact that the PLCgamma1 association sites in the EGFR, tyrosine residues 992 and 1173, were phosphorylated to a lower degree when the receptor was stimulated with EGF-dextran as compared to with EGF. Tyrosine 98-106 epidermal growth factor receptor Homo sapiens 92-96 12354693-0 2002 Induction of cancer cell migration by epidermal growth factor is initiated by specific phosphorylation of tyrosine 1248 of c-erbB-2 receptor via EGFR. Tyrosine 106-114 epidermal growth factor receptor Homo sapiens 145-149 12354693-3 2002 EGF stimulation of EGF receptor (EGFR) overexpressing cells resulted in long-term PLC-gamma1 tyrosine phosphorylation and sustained levels of inositol-1,4,5-triphosphate (IP3) and diacylglycerol (DAG) producing sinusoidal calcium oscillations. Tyrosine 93-101 epidermal growth factor receptor Homo sapiens 19-31 12354693-3 2002 EGF stimulation of EGF receptor (EGFR) overexpressing cells resulted in long-term PLC-gamma1 tyrosine phosphorylation and sustained levels of inositol-1,4,5-triphosphate (IP3) and diacylglycerol (DAG) producing sinusoidal calcium oscillations. Tyrosine 93-101 epidermal growth factor receptor Homo sapiens 33-37 12354693-4 2002 In contrast, c-erbB-2/EGFR expressing cells displayed baseline transient calcium oscillations after EGF treatment due to short-term PLC-gamma1 tyrosine phosphorylation and short-term IP3 and DAG turnover. Tyrosine 143-151 epidermal growth factor receptor Homo sapiens 22-26 12372346-1 2002 Previous studies have shown that EGF can induce the tyrosine phosphorylation of caveolin-1 in murine fibroblasts following ErbB1 (EGF receptor) mutation or overexpression, but the cell signaling events linking EGF action with caveolin phosphorylation are not fully established. Tyrosine 52-60 epidermal growth factor receptor Homo sapiens 123-128 12359775-4 2002 In all four cell lines, AdtrEGFR markedly attenuated EGF and heparin-binding EGF-dependent cell growth, EGFR family tyrosine phosphorylation, and phosphorylation of MAPK, c-Jun NH2-terminal kinase, p38 MAPK, and activating transcription factor 2. Tyrosine 116-124 epidermal growth factor receptor Homo sapiens 28-32 12095417-5 2002 Further, we documented for the first time that C/EBPbeta was tyrosine-phosphorylated in vivo during differentiation and in vitro by activated epidermal growth factor receptor. Tyrosine 61-69 epidermal growth factor receptor Homo sapiens 142-174 12358735-3 2002 Immunoprecipitation and western blot analysis of the EGF receptor (EGFR) revealed a significant reduction of its EGF-induced tyrosine phosphorylation in cells treated with the NO donor 2-(N,N-diethylamino)-diazenolate-2-oxide (DEA-NO). Tyrosine 125-133 epidermal growth factor receptor Homo sapiens 53-65 12358735-3 2002 Immunoprecipitation and western blot analysis of the EGF receptor (EGFR) revealed a significant reduction of its EGF-induced tyrosine phosphorylation in cells treated with the NO donor 2-(N,N-diethylamino)-diazenolate-2-oxide (DEA-NO). Tyrosine 125-133 epidermal growth factor receptor Homo sapiens 67-71 12169572-4 2002 MUC5AC induction was preceded by epidermal growth factor receptor (EGFR) tyrosine phosphorylation and was prevented by selective EGFR tyrosine kinase inhibitors, implicating EGFR activation. Tyrosine 73-81 epidermal growth factor receptor Homo sapiens 67-71 12214266-3 2002 GW572016 markedly reduced tyrosine phosphorylation of EGFR and erbB2, and inhibited activation of Erk1/2 and AKT, downstream effectors of proliferation and cell survival, respectively. Tyrosine 26-34 epidermal growth factor receptor Homo sapiens 54-58 12115517-7 2002 In vitro, ipriflavone inhibited the proliferation and DNA synthesis of MDA-231 cells and blocked the ligand-induced phosphorylation of Tyr(845) of the EGFR. Tyrosine 135-138 epidermal growth factor receptor Homo sapiens 151-155 12127526-2 2002 These compounds selectively inhibit EGF-R kinase activity at low nanomolar concentration and tyrosine autophosphorylation in cells expressing EGF-R or Her2 (p185(erbB)). Tyrosine 93-101 epidermal growth factor receptor Homo sapiens 142-147 12070153-1 2002 The cytoplasmic region of human epidermal growth factor receptor (EGFR) contains an intrinsic tyrosine kinase (697-955) followed by a 231-residue-long COOH-terminal tail (C-tail), which contains multiple tyrosine residues. Tyrosine 94-102 epidermal growth factor receptor Homo sapiens 32-64 12070153-1 2002 The cytoplasmic region of human epidermal growth factor receptor (EGFR) contains an intrinsic tyrosine kinase (697-955) followed by a 231-residue-long COOH-terminal tail (C-tail), which contains multiple tyrosine residues. Tyrosine 94-102 epidermal growth factor receptor Homo sapiens 66-70 12070153-3 2002 Transient transfection of 293 cells with EGFR lacking the C-tail, i.e. Y974DeltaEGFR or Y992DeltaEGFR, led to EGF-independent or constitutive STAT activation, whereas EGF-dependent STAT activation was restored with truncations made COOH-terminal to the next tyrosine residue, i.e. EGFR-Y1045Delta. Tyrosine 258-266 epidermal growth factor receptor Homo sapiens 41-45 12070153-4 2002 Transfection with the-truncated form EGFR-Y954Delta resulted in the loss of STAT activation, suggesting that the sequence between Tyr(974) and Tyr(954) is essential for STAT activation. Tyrosine 130-133 epidermal growth factor receptor Homo sapiens 37-41 12070153-4 2002 Transfection with the-truncated form EGFR-Y954Delta resulted in the loss of STAT activation, suggesting that the sequence between Tyr(974) and Tyr(954) is essential for STAT activation. Tyrosine 143-146 epidermal growth factor receptor Homo sapiens 37-41 12101233-7 2002 Irradiation of keratinocytes increases the phosphorylation of EGFR on tyrosine residues Y845, Y992, Y1045, Y1068, Y1086, Y1148, and Y1173 above the basal levels and leads to the increased recruitment of the adaptor proteins Grb2 and ShcA and of a p55 form of the regulatory subunit of the phosphatidylinositide 3-kinase to the UVB-activated EGFR. Tyrosine 70-78 epidermal growth factor receptor Homo sapiens 62-66 12115721-3 2002 We found that both EGF and Cpd 5 induced tyrosine phosphorylation of EGF receptor (EGFR) and ERK. Tyrosine 41-49 epidermal growth factor receptor Homo sapiens 69-81 12115721-3 2002 We found that both EGF and Cpd 5 induced tyrosine phosphorylation of EGF receptor (EGFR) and ERK. Tyrosine 41-49 epidermal growth factor receptor Homo sapiens 83-87 11934884-2 2002 Herstatin binds to human epidermal growth factor receptor 2 and to the epidermal growth factor receptor (EGFR), blocking receptor oligomerization and tyrosine phosphorylation. Tyrosine 150-158 epidermal growth factor receptor Homo sapiens 25-57 12099696-2 2002 This study demonstrates that H. pylori exposure to MKN-1, ST42, and MKN-28 gastric epithelial tumour cells results in the activation of HB-EGF gene expression and EGFR tyrosine phosphorylation. Tyrosine 168-176 epidermal growth factor receptor Homo sapiens 163-167 12011079-0 2002 Src-dependent tyrosine phosphorylation regulates dynamin self-assembly and ligand-induced endocytosis of the epidermal growth factor receptor. Tyrosine 14-22 epidermal growth factor receptor Homo sapiens 109-141 12011079-4 2002 Tyrosine 597 was identified as being phosphorylated both in vitro and in cultured cells following epidermal growth factor receptor stimulation. Tyrosine 0-8 epidermal growth factor receptor Homo sapiens 98-130 11934884-2 2002 Herstatin binds to human epidermal growth factor receptor 2 and to the epidermal growth factor receptor (EGFR), blocking receptor oligomerization and tyrosine phosphorylation. Tyrosine 150-158 epidermal growth factor receptor Homo sapiens 105-109 11934884-4 2002 Herstatin expression decreased EGF-induced EGFR tyrosine phosphorylation and delayed receptor down-regulation despite receptor occupancy by ligand with normal binding affinity. Tyrosine 48-56 epidermal growth factor receptor Homo sapiens 43-47 11912208-4 2002 Cdc25A inhibitor Cpd 5, a vitamin K analog, inhibited Cdc25A activity in the Cdc25A-EGFR immunocomplex and consequently caused prolonged EGFR tyrosine phosphorylation. Tyrosine 142-150 epidermal growth factor receptor Homo sapiens 137-141 11992539-4 2002 This study demonstrates that [D-Trp(6)]LHRH decreased the basal and EGF-induced total cellular kinase activity, particularly the tyrosine phosphorylation of several cellular proteins including the EGFR. Tyrosine 129-137 epidermal growth factor receptor Homo sapiens 197-201 12058069-5 2002 In addition, we demonstrated that W-13 stimulated the tyrosine phosphorylation of EGFR and consequent recruitment of Shc adaptor protein with EGFR, presumably through inhibition of the calmodulin-dependent protein kinase II (CaM kinase II). Tyrosine 54-62 epidermal growth factor receptor Homo sapiens 82-86 11912208-5 2002 Both purified GST-Cdc25A protein and endogenous Hep3B cellular Cdc25A dephosphorylated tyrosine-phosphorylated EGFR, and Cpd 5 antagonized the phosphatase activity of Cdc25A. Tyrosine 87-95 epidermal growth factor receptor Homo sapiens 111-115 12006662-1 2002 Current models put forward that the epidermal growth factor receptor (EGFR) is efficiently internalized via clathrin-coated pits only in response to ligand-induced activation of its intrinsic tyrosine kinase and is subsequently directed into a lysosomal-proteasomal degradation pathway by mechanisms that include receptor tyrosine phosphorylation and ubiquitylation. Tyrosine 192-200 epidermal growth factor receptor Homo sapiens 36-68 12069816-2 2002 In the last several years, the epidermal growth factor (EGF) receptor has been recognized as a protein tyrosine kinase that plays a central role in mediating LPA-induced tyrosine phosphorylation and Erk MAP kinase activation. Tyrosine 103-111 epidermal growth factor receptor Homo sapiens 31-69 11979431-10 2002 This disaccharide increased tyrosine phosphorylation of erb-B1 and erb-B2 receptors, effects that were abolished by AG825. Tyrosine 28-36 epidermal growth factor receptor Homo sapiens 56-62 12006662-1 2002 Current models put forward that the epidermal growth factor receptor (EGFR) is efficiently internalized via clathrin-coated pits only in response to ligand-induced activation of its intrinsic tyrosine kinase and is subsequently directed into a lysosomal-proteasomal degradation pathway by mechanisms that include receptor tyrosine phosphorylation and ubiquitylation. Tyrosine 192-200 epidermal growth factor receptor Homo sapiens 70-74 11880263-4 2002 Furthermore, we demonstrate that pretreatment with KN-93 or a CaM kinase II inhibitor peptide inhibits Ca(2+)-dependent PYK2 activation and EGF receptor tyrosine phosphorylation in response to ionomycin, ATP, and platelet-derived growth factor but has no effect on phorbol 12,13-dibutyrate- or EGF-induced responses. Tyrosine 153-161 epidermal growth factor receptor Homo sapiens 140-152 12034491-8 2002 When a chimeric receptor (EGFR-Xksy), composed of the extracellular region of epidermal growth factor (EGF) receptor and the transmembrane/intracellular regions of Xksy, was expressed in a doxycycline repressive manner in HEK 293 cells, EGF-stimulus without doxycycline induced tyrosine phosphorylation of the chimeric receptor and evoke morphological changes. Tyrosine 278-286 epidermal growth factor receptor Homo sapiens 26-30 11953857-2 2002 Here we show that treatment of A431 cells with different epidermal growth factor receptor ligands can cause growth inhibition to an extent paralleling ErbB2 tyrosine phosphorylation. Tyrosine 157-165 epidermal growth factor receptor Homo sapiens 57-89 11920601-7 2002 This effect was accompanied by a dose-dependent inhibition of EGFR tyrosine autophosphorylation and of the production of TGF-alpha, basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF). Tyrosine 67-75 epidermal growth factor receptor Homo sapiens 62-66 11952645-8 2002 EGFR tyrosine phosphorylation, however, was incrementally stimulated by EGF concentrations from 1 to 100 ng/ml. Tyrosine 5-13 epidermal growth factor receptor Homo sapiens 0-4 11756413-0 2002 Integrin-induced epidermal growth factor (EGF) receptor activation requires c-Src and p130Cas and leads to phosphorylation of specific EGF receptor tyrosines. Tyrosine 148-157 epidermal growth factor receptor Homo sapiens 17-55 11799369-8 2002 In scrape-wounded epithelial monolayers, tyrosine phosphorylation of EGFR, c-erbB2, and c-erbB3 occurred immediately after damage; however, only EGFR showed a change in expression in response to damage. Tyrosine 41-49 epidermal growth factor receptor Homo sapiens 69-73 11756413-0 2002 Integrin-induced epidermal growth factor (EGF) receptor activation requires c-Src and p130Cas and leads to phosphorylation of specific EGF receptor tyrosines. Tyrosine 148-157 epidermal growth factor receptor Homo sapiens 135-147 11756413-6 2002 We show that integrins induce phosphorylation of EGF receptor on tyrosine residues 845, 1068, 1086, and 1173, but not on residue 1148, a major site of phosphorylation in response to EGF. Tyrosine 65-73 epidermal growth factor receptor Homo sapiens 49-61 11756413-8 2002 Therefore these data indicate that integrin-mediated adhesion induces assembly of a macromolecular complex containing c-Src and p130Cas and leads to phosphorylation of specific EGF receptor tyrosine residues. Tyrosine 190-198 epidermal growth factor receptor Homo sapiens 177-189 11857451-4 2002 Cpd 5 treatment resulted in enhanced phosphorylation of EGFR at carboxyl-terminal tyrosines. Tyrosine 82-91 epidermal growth factor receptor Homo sapiens 56-60 11809859-6 2002 EGF caused much greater tyrosine phosphorylation of the EGF-R than Ang II and PMA. Tyrosine 24-32 epidermal growth factor receptor Homo sapiens 56-61 11894013-4 2002 ABX-EGF blocks binding of both epidermal growth factor and transforming growth factor alpha to the EGFR, inhibits tyrosine phosphorylation of the EGFR, and inhibits cellular proliferation. Tyrosine 114-122 epidermal growth factor receptor Homo sapiens 146-150 11772030-1 2002 Stimulation of isolated hepatocytes with epidermal growth factor (EGF) causes rapid tyrosine phosphorylation of the EGF receptor (EGFR) and adapter/target proteins, which was monitored with 1 and 2 s resolution at 37, 20, and 4 degrees C. The temporal responses detected for multiple signaling proteins involve both transient and sustained phosphorylation patterns, which change dramatically at low temperatures. Tyrosine 84-92 epidermal growth factor receptor Homo sapiens 116-128 11772030-1 2002 Stimulation of isolated hepatocytes with epidermal growth factor (EGF) causes rapid tyrosine phosphorylation of the EGF receptor (EGFR) and adapter/target proteins, which was monitored with 1 and 2 s resolution at 37, 20, and 4 degrees C. The temporal responses detected for multiple signaling proteins involve both transient and sustained phosphorylation patterns, which change dramatically at low temperatures. Tyrosine 84-92 epidermal growth factor receptor Homo sapiens 130-134 11865035-2 2002 Tyrosine phosphorylation of EGFR was not detected in UV-exposed cells by immunoblotting of whole cell lysates or EGFR immunoprecipitates with antibodies specific for each of the five activated autophosphorylation sites of EGFR. Tyrosine 0-8 epidermal growth factor receptor Homo sapiens 28-32 11865035-8 2002 Whereas inhibition of the EGFR tyrosine kinase effectively inhibited tyrosine phosphorylation and internalisation of EGF-activated EGFR, internalisation of UV-exposed EGFR was unaffected. Tyrosine 31-39 epidermal growth factor receptor Homo sapiens 26-30 11865035-8 2002 Whereas inhibition of the EGFR tyrosine kinase effectively inhibited tyrosine phosphorylation and internalisation of EGF-activated EGFR, internalisation of UV-exposed EGFR was unaffected. Tyrosine 31-39 epidermal growth factor receptor Homo sapiens 131-135 11865035-8 2002 Whereas inhibition of the EGFR tyrosine kinase effectively inhibited tyrosine phosphorylation and internalisation of EGF-activated EGFR, internalisation of UV-exposed EGFR was unaffected. Tyrosine 31-39 epidermal growth factor receptor Homo sapiens 131-135 11863114-6 2002 Treatment of SK-Br-3 cells with ZD1839 produced a significant, dose-dependent reduction of the tyrosine phosphorylation of both EGFR and ErbB-2. Tyrosine 95-103 epidermal growth factor receptor Homo sapiens 128-132 11483589-5 2001 We also show that the activated EGF-R phosphorylates the MUC1 cytoplasmic tail on tyrosine at a YEKV motif that functions as a binding site for the c-Src SH2 domain. Tyrosine 82-90 epidermal growth factor receptor Homo sapiens 32-37 12455381-5 2002 Active (tyrosine phosphorylated) EGF receptor is a target of proteolysis by proteasomes. Tyrosine 8-16 epidermal growth factor receptor Homo sapiens 33-45 11585822-10 2001 The activated EGF-R is localized in focal adhesions together with tyrosine-phosphorylated caveolin. Tyrosine 66-74 epidermal growth factor receptor Homo sapiens 14-19 11598902-4 2001 Inhibition was also effected by phorbol myristoyl acetate (PMA), which reduced the rate of EGFR tyrosine phosphorylation. Tyrosine 96-104 epidermal growth factor receptor Homo sapiens 91-95 11602604-0 2001 RGS16 function is regulated by epidermal growth factor receptor-mediated tyrosine phosphorylation. Tyrosine 73-81 epidermal growth factor receptor Homo sapiens 31-63 11602604-7 2001 Purified EGFR phosphorylated only recombinant RGS16 wild-type or Y177F in vitro, implying that EGFR-mediated phosphorylation depended on residue Tyr(168). Tyrosine 145-148 epidermal growth factor receptor Homo sapiens 9-13 11602604-7 2001 Purified EGFR phosphorylated only recombinant RGS16 wild-type or Y177F in vitro, implying that EGFR-mediated phosphorylation depended on residue Tyr(168). Tyrosine 145-148 epidermal growth factor receptor Homo sapiens 95-99 11602604-11 2001 These data suggest that tyrosine phosphorylation regulates RGS16 function and that EGFR may potentially inhibit Galpha(i)-dependent MAPK activation in a feedback loop by enhancing RGS16 activity through tyrosine phosphorylation. Tyrosine 203-211 epidermal growth factor receptor Homo sapiens 83-87 11585822-5 2001 Here we show that cholesterol depletion by beta-cyclodextrin disrupts caveolae structure and concomitantly inhibits tyrosine phosphorylation of the EGF-R and subsequent activation of protein kinase B (PKB)/Akt induced by angiotensin II. Tyrosine 116-124 epidermal growth factor receptor Homo sapiens 148-153 11755203-6 2001 The inhibition of EGF-induced EGFR tyrosine phosphorylation by butein was also observed in human hepatocellular carcinoma HepG2 cells, while marein and phloretin were inactive at the doses tested. Tyrosine 35-43 epidermal growth factor receptor Homo sapiens 30-34 11726515-0 2001 Tyrosine phosphorylation of Grb2 by Bcr/Abl and epidermal growth factor receptor: a novel regulatory mechanism for tyrosine kinase signaling. Tyrosine 0-8 epidermal growth factor receptor Homo sapiens 48-80 11697324-8 2001 The overexpression of EGFR-CD533 after infection with Ad-EGFR-CD533 completely inhibited the radiation-induced stimulation of EGFR Tyr-P relative to the immediate 2.4- to 3.1-fold increases in EGFR Tyr-P in control infected cells (Ad-LacZ). Tyrosine 131-134 epidermal growth factor receptor Homo sapiens 22-26 11697324-8 2001 The overexpression of EGFR-CD533 after infection with Ad-EGFR-CD533 completely inhibited the radiation-induced stimulation of EGFR Tyr-P relative to the immediate 2.4- to 3.1-fold increases in EGFR Tyr-P in control infected cells (Ad-LacZ). Tyrosine 131-134 epidermal growth factor receptor Homo sapiens 57-61 11697324-8 2001 The overexpression of EGFR-CD533 after infection with Ad-EGFR-CD533 completely inhibited the radiation-induced stimulation of EGFR Tyr-P relative to the immediate 2.4- to 3.1-fold increases in EGFR Tyr-P in control infected cells (Ad-LacZ). Tyrosine 131-134 epidermal growth factor receptor Homo sapiens 57-61 11697324-8 2001 The overexpression of EGFR-CD533 after infection with Ad-EGFR-CD533 completely inhibited the radiation-induced stimulation of EGFR Tyr-P relative to the immediate 2.4- to 3.1-fold increases in EGFR Tyr-P in control infected cells (Ad-LacZ). Tyrosine 131-134 epidermal growth factor receptor Homo sapiens 57-61 11697324-8 2001 The overexpression of EGFR-CD533 after infection with Ad-EGFR-CD533 completely inhibited the radiation-induced stimulation of EGFR Tyr-P relative to the immediate 2.4- to 3.1-fold increases in EGFR Tyr-P in control infected cells (Ad-LacZ). Tyrosine 198-201 epidermal growth factor receptor Homo sapiens 22-26 11697324-8 2001 The overexpression of EGFR-CD533 after infection with Ad-EGFR-CD533 completely inhibited the radiation-induced stimulation of EGFR Tyr-P relative to the immediate 2.4- to 3.1-fold increases in EGFR Tyr-P in control infected cells (Ad-LacZ). Tyrosine 198-201 epidermal growth factor receptor Homo sapiens 57-61 11697324-8 2001 The overexpression of EGFR-CD533 after infection with Ad-EGFR-CD533 completely inhibited the radiation-induced stimulation of EGFR Tyr-P relative to the immediate 2.4- to 3.1-fold increases in EGFR Tyr-P in control infected cells (Ad-LacZ). Tyrosine 198-201 epidermal growth factor receptor Homo sapiens 57-61 11697324-8 2001 The overexpression of EGFR-CD533 after infection with Ad-EGFR-CD533 completely inhibited the radiation-induced stimulation of EGFR Tyr-P relative to the immediate 2.4- to 3.1-fold increases in EGFR Tyr-P in control infected cells (Ad-LacZ). Tyrosine 198-201 epidermal growth factor receptor Homo sapiens 57-61 11788791-7 2001 EGFR tyrosine phosphorylation was detected by immunoprecipitation and Western blot analysis. Tyrosine 5-13 epidermal growth factor receptor Homo sapiens 0-4 11573205-3 2001 Stimulation of cells with EGF induced tyrosine phosphorylation of EGFR and activation of PLCgamma, as assessed by the production of a second messenger diacylglycerol (DAG), without any significant increase in the amount of EGFR-bound PLCgamma. Tyrosine 38-46 epidermal growth factor receptor Homo sapiens 66-70 11457825-9 2001 Furthermore, wild-type MOR stimulated EGFR Tyr phosphorylation 3-fold more than K273A MOR, indicating that direct CaM-MOR interaction plays a key role in the transactivation process. Tyrosine 43-46 epidermal growth factor receptor Homo sapiens 38-42 11488908-3 2001 268, 25-34], epidermal growth factor (EGF) gave rise to transient tyrosine phosphorylation of insulin receptor substrates (IRS-1 and IRS-2), thereby activating the bound phosphatidylinositol 3-kinase in human epidermoid carcinoma A431 cells normally abundant in EGF receptors (EGFR) and Chinese hamster ovary (CHO) cells transfected with full-length EGFR. Tyrosine 66-74 epidermal growth factor receptor Homo sapiens 262-275 11507066-6 2001 Additionally, preincubation of serum-starved A431 cells with SAGP decreased the epidermal growth factor-induced tyrosine phosphorylation of EGFR, and the effect of SAGP was sodium orthovanadate sensitive. Tyrosine 112-120 epidermal growth factor receptor Homo sapiens 140-144 11488908-3 2001 268, 25-34], epidermal growth factor (EGF) gave rise to transient tyrosine phosphorylation of insulin receptor substrates (IRS-1 and IRS-2), thereby activating the bound phosphatidylinositol 3-kinase in human epidermoid carcinoma A431 cells normally abundant in EGF receptors (EGFR) and Chinese hamster ovary (CHO) cells transfected with full-length EGFR. Tyrosine 66-74 epidermal growth factor receptor Homo sapiens 277-281 11488908-3 2001 268, 25-34], epidermal growth factor (EGF) gave rise to transient tyrosine phosphorylation of insulin receptor substrates (IRS-1 and IRS-2), thereby activating the bound phosphatidylinositol 3-kinase in human epidermoid carcinoma A431 cells normally abundant in EGF receptors (EGFR) and Chinese hamster ovary (CHO) cells transfected with full-length EGFR. Tyrosine 66-74 epidermal growth factor receptor Homo sapiens 350-354 11488908-4 2001 These actions of EGF, although much smaller in magnitude than those of insulin or IGF-I in the same cells, were accompanied by tyrosine phosphorylation of EGFR rather than insulin or IGF-I receptors, never observed in wild-type CHO cells expressing no EGFR, and totally inhibited by an inhibitor of EGFR kinase, AG1478, that was without effect on insulin or IGF-I actions. Tyrosine 127-135 epidermal growth factor receptor Homo sapiens 155-159 11488908-5 2001 Recombinant IRS-1 was phosphorylated on tyrosines upon incubation with purified EGFR from A431 cells and 32P-labeled ATP. Tyrosine 40-49 epidermal growth factor receptor Homo sapiens 80-84 11488908-7 2001 We suggest that tyrosine phosphorylation of IRS-1 or IRS-2 could mediate EGFR-induced activation of phosphatidylinositol 3-kinase in mammalian cells. Tyrosine 16-24 epidermal growth factor receptor Homo sapiens 73-77 11335725-6 2001 Analysis of deletion and point mutants defined the primary EGFR-dependent targets as one or more of three C-terminal tyrosine residues. Tyrosine 117-125 epidermal growth factor receptor Homo sapiens 59-63 11352836-9 2001 AVP treatment appeared to transactivate EGF-R by inducing tyrosine phosphorylation of the Ca(2+)/protein kinase C (PKC)-dependent nonreceptor tyrosine kinase, Pyk2, leading to Pyk2/c-Src association and c-Src activation. Tyrosine 58-66 epidermal growth factor receptor Homo sapiens 40-45 11516625-4 2001 The expression of epidermal growth factor receptor (EGFR) and epidermal growth factor (EGF)-induced EGFR tyrosine phosphorylation were lower in drug-resistant SKNSH cells than their wild-type counterparts. Tyrosine 105-113 epidermal growth factor receptor Homo sapiens 18-50 11516625-4 2001 The expression of epidermal growth factor receptor (EGFR) and epidermal growth factor (EGF)-induced EGFR tyrosine phosphorylation were lower in drug-resistant SKNSH cells than their wild-type counterparts. Tyrosine 105-113 epidermal growth factor receptor Homo sapiens 100-104 11416113-5 2001 The transduced tumors were then exposed to radiation in the therapeutic dose range, and radiation-induced EGFR activation was assessed by examining the tyrosine phosphorylation of immunoprecipitated EGFR. Tyrosine 152-160 epidermal growth factor receptor Homo sapiens 106-110 11416113-5 2001 The transduced tumors were then exposed to radiation in the therapeutic dose range, and radiation-induced EGFR activation was assessed by examining the tyrosine phosphorylation of immunoprecipitated EGFR. Tyrosine 152-160 epidermal growth factor receptor Homo sapiens 199-203 11352836-11 2001 These data suggested that AVP-stimulated Pyk2 tyrosine phosphorylation to activate c-Src, thereby leading to EGF-R transactivation. Tyrosine 46-54 epidermal growth factor receptor Homo sapiens 109-114 11370743-3 2001 We show that a substantial fraction of tyrosine-phosphorylated epidermal growth factor receptor (EGFR) and Shc, Grb2 and Cbl after internalization relocates from early endosomes to compartments which are negative for the early endosomes, recycling vesicle markers EEA1 and transferrin in EGF-stimulated cells. Tyrosine 39-47 epidermal growth factor receptor Homo sapiens 97-101 11371122-3 2001 The present study aimed to confirm the hypothesis that EGF/epidermal growth factor receptor (EGFR) was related with the E-cadherin adhesion system in cervical cancer cells and that EGF might induce tyrosine phosphorylation of beta- and gamma-catenin. Tyrosine 198-206 epidermal growth factor receptor Homo sapiens 93-97 11262408-1 2001 Gab-1 is a multiple docking protein that is tyrosine phosphorylated by receptor tyrosine kinases such as c-Met, hepatocyte growth factor/scatter factor receptor, and epidermal growth factor receptor. Tyrosine 44-52 epidermal growth factor receptor Homo sapiens 112-198 11408594-4 2001 In addition, we developed antibodies specific to tyrosine-phosphorylated EGFR. Tyrosine 49-57 epidermal growth factor receptor Homo sapiens 73-77 11278982-6 2001 Consistent with this observation, H(2)O(2) stimulated EGFR tyrosine phosphorylation and complex formation with Shc-Grb2 that was abolished by PP2, implicating Src in H(2)O(2)-induced EGFR activation. Tyrosine 59-67 epidermal growth factor receptor Homo sapiens 54-58 11278982-7 2001 Tyrosine phosphorylation of the EGFR by H(2)O(2) did not involve receptor autophosphorylation at Tyr(1173) as assessed by an autophosphorylation-specific antibody. Tyrosine 0-8 epidermal growth factor receptor Homo sapiens 32-36 11278982-7 2001 Tyrosine phosphorylation of the EGFR by H(2)O(2) did not involve receptor autophosphorylation at Tyr(1173) as assessed by an autophosphorylation-specific antibody. Tyrosine 0-3 epidermal growth factor receptor Homo sapiens 32-36 11359909-2 2001 We show here that, in various human carcinoma cells that overexpress EGFR, EGF treatment induced rapid tyrosine dephosphorylation of focal adhesion kinase (FAK) associated with downregulation of its kinase activity. Tyrosine 103-111 epidermal growth factor receptor Homo sapiens 69-73 11255078-4 2001 ABX-EGF binds EGFr with high affinity (5x10(-11) M), blocks the binding of both EGF and transforming growth factor-alpha (TGF-alpha) to various EGFr-expressing human carcinoma cell lines, and inhibits EGF-dependent tumor cell activation, including EGFr tyrosine phosphorylation, increased extracellular acidification rate, and cell proliferation. Tyrosine 253-261 epidermal growth factor receptor Homo sapiens 14-18 11370743-7 2001 Treatment with the weak base chloroquine or inhibitors of lysosomal enzymes after EGF stimulation induced an accumulation of tyrosine-phosphorylated EGFR and Shc in EEA1-negative and CD63-positive vesicles after a 120-min chase period. Tyrosine 125-133 epidermal growth factor receptor Homo sapiens 149-153 11179516-7 2001 IL-1 beta-induced EGF receptor tyrosine phosphorylation started at 5 min and peaked at 10 min and remained elevated up to 40 min post IL-1 beta treatment. Tyrosine 31-39 epidermal growth factor receptor Homo sapiens 18-30 11267961-17 2001 The tyrosine phosphorylation of EGFR or c-met by VK3 activated the Ras signaling pathway. Tyrosine 4-12 epidermal growth factor receptor Homo sapiens 32-36 11297265-2 2001 We have demonstrated that radiation activates EGFR Tyr-phosphorylation (EGFR Tyr-P) and the proliferation of surviving human carcinoma cells, a likely mechanism of accelerated cellular repopulation, a major cytoprotective response after radiation. Tyrosine 51-54 epidermal growth factor receptor Homo sapiens 46-50 11297265-2 2001 We have demonstrated that radiation activates EGFR Tyr-phosphorylation (EGFR Tyr-P) and the proliferation of surviving human carcinoma cells, a likely mechanism of accelerated cellular repopulation, a major cytoprotective response after radiation. Tyrosine 51-54 epidermal growth factor receptor Homo sapiens 72-76 11297265-2 2001 We have demonstrated that radiation activates EGFR Tyr-phosphorylation (EGFR Tyr-P) and the proliferation of surviving human carcinoma cells, a likely mechanism of accelerated cellular repopulation, a major cytoprotective response after radiation. Tyrosine 77-80 epidermal growth factor receptor Homo sapiens 46-50 11297265-2 2001 We have demonstrated that radiation activates EGFR Tyr-phosphorylation (EGFR Tyr-P) and the proliferation of surviving human carcinoma cells, a likely mechanism of accelerated cellular repopulation, a major cytoprotective response after radiation. Tyrosine 77-80 epidermal growth factor receptor Homo sapiens 72-76 11297265-6 2001 After irradiation at 2 Gy, both of the cell lines exhibited a mean 3-fold increase in EGFR Tyr-P. Tyrosine 91-94 epidermal growth factor receptor Homo sapiens 86-90 11179516-8 2001 EGF receptor kinase inhibitor PD153035 and AG1478 inhibited IL-1 beta-induced EGF receptor tyrosine phosphorylation. Tyrosine 91-99 epidermal growth factor receptor Homo sapiens 0-12 11179516-8 2001 EGF receptor kinase inhibitor PD153035 and AG1478 inhibited IL-1 beta-induced EGF receptor tyrosine phosphorylation. Tyrosine 91-99 epidermal growth factor receptor Homo sapiens 78-90 11226410-6 2001 Cleavage of EGFR by caspase-3 significantly impaired the tyrosine phosphorylation of PLC-gamma1 in vitro. Tyrosine 57-65 epidermal growth factor receptor Homo sapiens 12-16 11257459-5 2001 This study showed that UV (30 mJ/cm(2))-induced EGFR tyrosine phosphorylation in a manner similar to EGF (100 ng/ml), or IL-1beta (10 ng/ml) in cultured human keratinocytes. Tyrosine 53-61 epidermal growth factor receptor Homo sapiens 48-52 11162642-3 2001 Here we found that an antioxidant, N-acetylcysteine, inhibited ERK activation and EGF receptor tyrosine phosphorylation induced by Ang II. Tyrosine 95-103 epidermal growth factor receptor Homo sapiens 82-94 11162642-4 2001 Moreover, H(2)O(2) stimulates EGF receptor tyrosine phosphorylation and EGF receptor inhibitors attenuated H(2)O(2)-induced ERK activation. Tyrosine 43-51 epidermal growth factor receptor Homo sapiens 30-42 11257459-6 2001 In all cases, EGFR tyrosine phosphorylation was completely inhibited by pretreatment of PD153035 (100 nM, 1 h). Tyrosine 19-27 epidermal growth factor receptor Homo sapiens 14-18 11329622-3 2001 Incubation of human keratinocytes with a relatively low concentration (50 microM) of acrolein caused a prompt and selective induction of tyrosine phosphorylation of the epidermal growth factor receptor (EGFR) as a 180-kDa molecule during the period from 5-30 min after the start of incubation. Tyrosine 137-145 epidermal growth factor receptor Homo sapiens 169-201 11299771-1 2001 We have previously reported that apigenin inhibits the growth of thyroid cancer cells by attenuating epidermal growth factor receptor (EGF-R) tyrosine phosphorylation and phosphorylation of ERK mitogen-activated protein (MAP) kinase. Tyrosine 142-150 epidermal growth factor receptor Homo sapiens 135-140 11329622-3 2001 Incubation of human keratinocytes with a relatively low concentration (50 microM) of acrolein caused a prompt and selective induction of tyrosine phosphorylation of the epidermal growth factor receptor (EGFR) as a 180-kDa molecule during the period from 5-30 min after the start of incubation. Tyrosine 137-145 epidermal growth factor receptor Homo sapiens 203-207 21340815-6 2001 Binding of EGF to the receptor domain results in receptor dimerisation and subsequent autophosphorylation of the cytoplasmic domain of EGFr at specific tyrosine residues. Tyrosine 152-160 epidermal growth factor receptor Homo sapiens 135-139 21340815-8 2001 The phosphorylated tyrosine residues of the EGFr are involved in binding enzymes containing SH2 or SH3 domains (5). Tyrosine 19-27 epidermal growth factor receptor Homo sapiens 44-48 10982794-0 2000 Stimulation of the mitogen-activated protein kinase cascade and tyrosine phosphorylation of the epidermal growth factor receptor by hepatopoietin. Tyrosine 64-72 epidermal growth factor receptor Homo sapiens 96-128 10993906-1 2000 In an effort to clone novel tyrosine-phosphorylated substrates of the epidermal growth factor receptor, we have initiated an approach coupling affinity purification using anti-phosphotyrosine antibodies to mass spectrometry-based identification. Tyrosine 28-36 epidermal growth factor receptor Homo sapiens 70-102 11102970-7 2000 The observation that these cells synthesize and secrete their own NRGs, and possibly express a tyrosine-phosphorylated erbB receptor, is consistent with autocrine and/or paracrine signaling. Tyrosine 95-103 epidermal growth factor receptor Homo sapiens 119-123 10982794-6 2000 HPO stimulates tyrosine phosphorylation of epidermal growth factor receptor (EGFR). Tyrosine 15-23 epidermal growth factor receptor Homo sapiens 43-75 10982794-6 2000 HPO stimulates tyrosine phosphorylation of epidermal growth factor receptor (EGFR). Tyrosine 15-23 epidermal growth factor receptor Homo sapiens 77-81 10982794-9 2000 In contrast, genistein, a general tyrosine kinase inhibitor, significantly attenuated the tyrosine phosphorylation of EGFR in response to HPO. Tyrosine 34-42 epidermal growth factor receptor Homo sapiens 118-122 10982794-10 2000 In conclusion, our results suggest that tyrosine phosphorylation of EGFR may play a critical role in MAPK activation and mitogenic stimulation by HPO. Tyrosine 40-48 epidermal growth factor receptor Homo sapiens 68-72 11185568-9 2000 EGFR-13 increased the tyrosine phosphorylation of G(alpha)s by two-fold whereas EGFR-14 decreased the phosphorylation of the G protein. Tyrosine 22-30 epidermal growth factor receptor Homo sapiens 0-4 11060327-6 2000 This reduction in proliferation correlated with reduced EGFr tyrosine phosphorylation and a reduction in phosphorylated signal transducer and activator of transcription-3 (STAT-3) protein (known to protect cells from apoptosis). Tyrosine 61-69 epidermal growth factor receptor Homo sapiens 56-60 11058872-4 2000 In accordance with the reduced levels of EGFR in EGFR anti-sense-expressing cells, tyrosine phosphorylation of EGFR was decreased compared to untransfected parental cells treated with EGF. Tyrosine 83-91 epidermal growth factor receptor Homo sapiens 41-45 11058872-4 2000 In accordance with the reduced levels of EGFR in EGFR anti-sense-expressing cells, tyrosine phosphorylation of EGFR was decreased compared to untransfected parental cells treated with EGF. Tyrosine 83-91 epidermal growth factor receptor Homo sapiens 49-53 11058872-4 2000 In accordance with the reduced levels of EGFR in EGFR anti-sense-expressing cells, tyrosine phosphorylation of EGFR was decreased compared to untransfected parental cells treated with EGF. Tyrosine 83-91 epidermal growth factor receptor Homo sapiens 49-53 11058872-6 2000 In addition, basal and heregulin-beta 1-stimulated tyrosine phosphorylation of erbB-3 was higher in EGFR anti-sense vector-transfected cells. Tyrosine 51-59 epidermal growth factor receptor Homo sapiens 100-104 11010818-6 2000 However, the EGFR substrates Shc and c-Cbl were as efficiently tyrosine phosphorylated in endocytosis-deficient HeLa cells exhibiting only low-affinity EGFRs as in HeLa cells with intact endocytosis and with both high- and low-affinity EGFRs. Tyrosine 63-71 epidermal growth factor receptor Homo sapiens 13-17 11062256-8 2000 EGF activation of Rab5a function was dependent on tyrosine residues in the COOH-terminal domain of the EGF receptor (EGFR). Tyrosine 50-58 epidermal growth factor receptor Homo sapiens 103-115 11062256-8 2000 EGF activation of Rab5a function was dependent on tyrosine residues in the COOH-terminal domain of the EGF receptor (EGFR). Tyrosine 50-58 epidermal growth factor receptor Homo sapiens 117-121 11010818-11 2000 The EGFR was weakly tyrosine phosphorylated by potassium depletion even in the absence of EGF, and this activation resulted in detectable activation of MAPK. Tyrosine 20-28 epidermal growth factor receptor Homo sapiens 4-8 10962556-9 2000 These data reveal a pathway that negatively regulates EGFR-induced PI3-K activation in glioblastoma cells and involves interactions between SHP2 and tyrosine phosphorylated SIRPalpha1. Tyrosine 149-157 epidermal growth factor receptor Homo sapiens 54-58 10987838-8 2000 These data show a cross-talk between LPA and EGF limited to a branch of EGFR-mediated signaling, which may be explained by a LPA-induced, G(alphai)-protein-mediated translocation of PLCgamma-1 to EGFR in the absence of detectable tyrosine phosphorylation of both proteins. Tyrosine 230-238 epidermal growth factor receptor Homo sapiens 72-76 10987838-8 2000 These data show a cross-talk between LPA and EGF limited to a branch of EGFR-mediated signaling, which may be explained by a LPA-induced, G(alphai)-protein-mediated translocation of PLCgamma-1 to EGFR in the absence of detectable tyrosine phosphorylation of both proteins. Tyrosine 230-238 epidermal growth factor receptor Homo sapiens 196-200 10846186-5 2000 In U-373 MG cells, which express functional NK-1, SP induced tyrosine phosphorylation of several proteins including EGFR. Tyrosine 61-69 epidermal growth factor receptor Homo sapiens 116-120 10953014-4 2000 Eps15, an endocytic protein that is tyrosine phosphorylated by EGFR, is a candidate for such a function. Tyrosine 36-44 epidermal growth factor receptor Homo sapiens 63-67 10953014-5 2000 Here, we show that tyrosine phosphorylation of Eps15 is necessary for internalization of the EGFR, but not of the TfR. Tyrosine 19-27 epidermal growth factor receptor Homo sapiens 93-97 10978177-12 2000 Recently, we identified a similar cohort of tyrosine phosphorylation sites for the epidermal growth factor receptor (EGFR) with a predominant phosphorylation of tyrosine residue Y657 and binding of Syp [Lehr, S. et al. Tyrosine 44-52 epidermal growth factor receptor Homo sapiens 83-115 10978177-12 2000 Recently, we identified a similar cohort of tyrosine phosphorylation sites for the epidermal growth factor receptor (EGFR) with a predominant phosphorylation of tyrosine residue Y657 and binding of Syp [Lehr, S. et al. Tyrosine 44-52 epidermal growth factor receptor Homo sapiens 117-121 10978177-12 2000 Recently, we identified a similar cohort of tyrosine phosphorylation sites for the epidermal growth factor receptor (EGFR) with a predominant phosphorylation of tyrosine residue Y657 and binding of Syp [Lehr, S. et al. Tyrosine 161-169 epidermal growth factor receptor Homo sapiens 83-115 10978177-12 2000 Recently, we identified a similar cohort of tyrosine phosphorylation sites for the epidermal growth factor receptor (EGFR) with a predominant phosphorylation of tyrosine residue Y657 and binding of Syp [Lehr, S. et al. Tyrosine 161-169 epidermal growth factor receptor Homo sapiens 117-121 10916078-5 2000 RESULTS: A time-dependent tyrosine phosphorylation of the EGFR in response to Ang II was observed that was mediated by the Ang II type 1 receptor. Tyrosine 26-34 epidermal growth factor receptor Homo sapiens 58-62 10916078-7 2000 The tyrphostin AG 1478, a selective EGFR antagonist, inhibited both Ang II- and EGF-induced tyrosine phosphorylation of the EGFR. Tyrosine 92-100 epidermal growth factor receptor Homo sapiens 36-40 10916078-7 2000 The tyrphostin AG 1478, a selective EGFR antagonist, inhibited both Ang II- and EGF-induced tyrosine phosphorylation of the EGFR. Tyrosine 92-100 epidermal growth factor receptor Homo sapiens 124-128 10877829-8 2000 Intrinsic activation of the EGFR was confirmed by analysis of tyrosine phosphorylated proteins, which revealed a rapid, damage-induced phosphorylation of the EGFR, irrespective of the presence of exogenous EGF. Tyrosine 62-70 epidermal growth factor receptor Homo sapiens 28-32 10880237-4 2000 EGF-mediated tyrosine phosphorylation of EGF receptor (EGFR) was suppressed by 55% in 72-h OM pretreated H3922 cells. Tyrosine 13-21 epidermal growth factor receptor Homo sapiens 41-53 10880237-4 2000 EGF-mediated tyrosine phosphorylation of EGF receptor (EGFR) was suppressed by 55% in 72-h OM pretreated H3922 cells. Tyrosine 13-21 epidermal growth factor receptor Homo sapiens 55-59 10897003-5 2000 RESULTS: IMC-C225 inhibited exogenous ligand-stimulated tyrosine phosphorylation of the EGF receptor on BxPC-3 tumor cells. Tyrosine 56-64 epidermal growth factor receptor Homo sapiens 88-100 10877829-8 2000 Intrinsic activation of the EGFR was confirmed by analysis of tyrosine phosphorylated proteins, which revealed a rapid, damage-induced phosphorylation of the EGFR, irrespective of the presence of exogenous EGF. Tyrosine 62-70 epidermal growth factor receptor Homo sapiens 158-162 10834929-8 2000 Epidermal growth factor receptor (EGFR) -induced tyrosine phosphorylation of PLC-gamma1 resulted in resistance to cleavage by caspase-3 in vitro. Tyrosine 49-57 epidermal growth factor receptor Homo sapiens 0-32 10816385-8 2000 Retinoic acid caused a decrease in tyrosine phosphorylation of EGF-R. Tyrosine 35-43 epidermal growth factor receptor Homo sapiens 63-68 10834929-8 2000 Epidermal growth factor receptor (EGFR) -induced tyrosine phosphorylation of PLC-gamma1 resulted in resistance to cleavage by caspase-3 in vitro. Tyrosine 49-57 epidermal growth factor receptor Homo sapiens 34-38 10773880-8 2000 In addition, the tethered TGFalpha was resistant to the ability of protein-tyrosine phosphatases (PTPs) to reduce EGFR tyrosine phosphorylation, also contributing to higher activation of EGFR. Tyrosine 75-83 epidermal growth factor receptor Homo sapiens 114-118 10777553-6 2000 CCh (100 microM) stimulated tyrosine phosphorylation and association of the Ca(2+)-dependent tyrosine kinase, PYK-2, with the EGFR, which was inhibited by the Ca(2+) chelator, BAPTA (20 microM). Tyrosine 28-36 epidermal growth factor receptor Homo sapiens 126-130 10781813-6 2000 In mammalian cells, DroVav is tyrosine-phosphorylated in response to epidermal growth factor receptor (EGFR) induction; in vitro, the DroVav SH2 region is associated with tyrosine-phosphorylated EGFR. Tyrosine 30-38 epidermal growth factor receptor Homo sapiens 69-101 10781813-6 2000 In mammalian cells, DroVav is tyrosine-phosphorylated in response to epidermal growth factor receptor (EGFR) induction; in vitro, the DroVav SH2 region is associated with tyrosine-phosphorylated EGFR. Tyrosine 30-38 epidermal growth factor receptor Homo sapiens 103-107 10781813-6 2000 In mammalian cells, DroVav is tyrosine-phosphorylated in response to epidermal growth factor receptor (EGFR) induction; in vitro, the DroVav SH2 region is associated with tyrosine-phosphorylated EGFR. Tyrosine 30-38 epidermal growth factor receptor Homo sapiens 195-199 10781813-6 2000 In mammalian cells, DroVav is tyrosine-phosphorylated in response to epidermal growth factor receptor (EGFR) induction; in vitro, the DroVav SH2 region is associated with tyrosine-phosphorylated EGFR. Tyrosine 171-179 epidermal growth factor receptor Homo sapiens 69-101 10781813-6 2000 In mammalian cells, DroVav is tyrosine-phosphorylated in response to epidermal growth factor receptor (EGFR) induction; in vitro, the DroVav SH2 region is associated with tyrosine-phosphorylated EGFR. Tyrosine 171-179 epidermal growth factor receptor Homo sapiens 103-107 10781813-6 2000 In mammalian cells, DroVav is tyrosine-phosphorylated in response to epidermal growth factor receptor (EGFR) induction; in vitro, the DroVav SH2 region is associated with tyrosine-phosphorylated EGFR. Tyrosine 171-179 epidermal growth factor receptor Homo sapiens 195-199 10640773-5 2000 Neutrophil supernatant-induced EGFR tyrosine phosphorylation, activation of p44/42mapk, and MUC5AC synthesis were inhibited by antioxidants (N-acetyl-cysteine, DMSO, dimethyl thiourea, or superoxide dismutase); neutralizing Abs to EGFR ligands (EGF and TGF-alpha) were without effect, and no TGF-alpha protein was found in the neutrophil supernatant. Tyrosine 36-44 epidermal growth factor receptor Homo sapiens 31-35 10734059-8 2000 Moreover, phosphotyrosine immunoblots of the EGF receptor demonstrated an increase in tyrosine residues phosphorylated by 0.5 and 6.5 h. At both these time points, TNF-alpha and IL-1beta also decreased the binding of EGF to its cell surface receptor. Tyrosine 17-25 epidermal growth factor receptor Homo sapiens 45-57 10640773-3 2000 Exogenous hydrogen peroxide and neutrophils activated by IL-8, FMLP, or TNF-alpha increased EGFR tyrosine phosphorylation and subsequent activation of p44/42mapk and up-regulated the expression of MUC5AC at both mRNA and protein levels in NCI-H292 cells. Tyrosine 97-105 epidermal growth factor receptor Homo sapiens 92-96 10640773-6 2000 In contrast, the EGFR ligand, TGF-alpha, increased EGFR tyrosine phosphorylation, activation of p44/42mapk, and subsequent MUC5AC synthesis, but these effects were not inhibited by antioxidants. Tyrosine 56-64 epidermal growth factor receptor Homo sapiens 17-21 10640773-6 2000 In contrast, the EGFR ligand, TGF-alpha, increased EGFR tyrosine phosphorylation, activation of p44/42mapk, and subsequent MUC5AC synthesis, but these effects were not inhibited by antioxidants. Tyrosine 56-64 epidermal growth factor receptor Homo sapiens 51-55 10610698-9 2000 Our assay provides a rapid and sensitive method of determining EGFR activation status and could be easily modified to evaluate any tyrosine-phosphorylated protein. Tyrosine 131-139 epidermal growth factor receptor Homo sapiens 63-67 11281284-2 2000 In this study, monoclonal antibodies against proteins from the growth factor-mediated signalling pathway were used to identify a set of 126-, 56-, 43-, and 40-kDa proteins phosphorylated on tyrosine at NO stimulation of murine fibroblasts overexpressing the human epidermal growth factor receptor. Tyrosine 190-198 epidermal growth factor receptor Homo sapiens 264-296 10618391-4 2000 To identify several components of the EGFR signaling pathway in a single step, we have immunoprecipitated molecules that are tyrosine phosphorylated in response to EGF and analyzed them by one-dimensional gel electrophoresis followed by mass spectrometry. Tyrosine 125-133 epidermal growth factor receptor Homo sapiens 38-42 10618391-8 2000 We demonstrate that Vav-2 is phosphorylated on tyrosine residues in response to EGF and associates with the EGFR in vivo. Tyrosine 47-55 epidermal growth factor receptor Homo sapiens 108-112 10653583-1 2000 After binding of epidermal growth factor (EGF), the EGF receptor (EGFR) becomes autophosphorylated via tyrosine. Tyrosine 103-111 epidermal growth factor receptor Homo sapiens 52-64 10653583-1 2000 After binding of epidermal growth factor (EGF), the EGF receptor (EGFR) becomes autophosphorylated via tyrosine. Tyrosine 103-111 epidermal growth factor receptor Homo sapiens 66-70 10653583-12 2000 Our results indicate that EGFR activation of Shc via tyrosine-phosphorylated Y992 and Y1173 occurred in early endocytic compartments, and support a role for membrane trafficking in intracellular signaling. Tyrosine 53-61 epidermal growth factor receptor Homo sapiens 26-30 10584873-6 1999 Conversely, we found an increase of EGF-R expression and EGF-R tyrosine phosphorylation when KB cells were growth inhibited by 8-Cl-cAMP. Tyrosine 63-71 epidermal growth factor receptor Homo sapiens 57-62 10525095-5 1999 CP-358,774 is an effective, orally active inhibitor of EGFr-specific tyrosine phosphorylation (ED(50) = 10 mg/kg, single dose). Tyrosine 69-77 epidermal growth factor receptor Homo sapiens 55-59 10567412-6 1999 By exploiting the differences in postendocytic signaling of two EGFR ligands, epidermal growth factor and transforming growth factor-alpha, we found that activated EGFR located at the cell surface and in internal compartments contribute equally to the membrane recruitment and tyrosine phosphorylation of Shc in NR6 fibroblasts expressing wild-type EGFR. Tyrosine 277-285 epidermal growth factor receptor Homo sapiens 164-168 10567412-6 1999 By exploiting the differences in postendocytic signaling of two EGFR ligands, epidermal growth factor and transforming growth factor-alpha, we found that activated EGFR located at the cell surface and in internal compartments contribute equally to the membrane recruitment and tyrosine phosphorylation of Shc in NR6 fibroblasts expressing wild-type EGFR. Tyrosine 277-285 epidermal growth factor receptor Homo sapiens 164-168 10525095-0 1999 Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. Tyrosine 58-66 epidermal growth factor receptor Homo sapiens 14-46 10559135-3 1999 In the ECV-304 endothelial cell line, unsaturated fatty acids triggered a time- and dose-dependent tyrosine phosphorylation of EGFR (polyunsaturated fatty acids [PUFAs] were the most active), whereas saturated FAs were inactive. Tyrosine 99-107 epidermal growth factor receptor Homo sapiens 127-131 10535875-9 1999 HRG-alpha activated tyrosine phosphorylation of epidermal growth factor receptor (EGFR), erbB2, and erbB3 and induced not only erbB3/erbB2 but also erbB3/EGFR and erbB2/EGFR heterodimer formation in MKN-28 cancer cells. Tyrosine 20-28 epidermal growth factor receptor Homo sapiens 48-80 10535875-9 1999 HRG-alpha activated tyrosine phosphorylation of epidermal growth factor receptor (EGFR), erbB2, and erbB3 and induced not only erbB3/erbB2 but also erbB3/EGFR and erbB2/EGFR heterodimer formation in MKN-28 cancer cells. Tyrosine 20-28 epidermal growth factor receptor Homo sapiens 82-86 10525095-1 1999 Phosphorylation of tyrosine residues on the epidermal growth factor (EGF) receptor (EGFr) is an important early event in signal transduction, leading to cell replication for major human carcinomas. Tyrosine 19-27 epidermal growth factor receptor Homo sapiens 44-82 10486467-4 1999 The effects of RC-160 on epidermal growth factor-stimulated cell proliferation and tyrosine phosphorylation of epidermal growth factor receptor were examined by colorimetric assay and Western blotting, respectively. Tyrosine 83-91 epidermal growth factor receptor Homo sapiens 111-143 10525095-1 1999 Phosphorylation of tyrosine residues on the epidermal growth factor (EGF) receptor (EGFr) is an important early event in signal transduction, leading to cell replication for major human carcinomas. Tyrosine 19-27 epidermal growth factor receptor Homo sapiens 84-88 10525095-3 1999 To assess the pharmacodynamic aspects of EGFr inhibition, we devised an ex vivo enzyme-linked immunosorbent assay for quantification of EGFr-specific tyrosine phosphorylation in human tumor tissue specimens obtained from xenografts growing s.c. in athymic mice. Tyrosine 150-158 epidermal growth factor receptor Homo sapiens 136-140 10533979-1 1999 Previous studies demonstrated that ionizing radiation activates the epidermal growth factor receptor (EGFR), as measured by Tyr autophosphorylation, and induces transient increases in cytosolic free [Ca2+], [Ca2+]f. The mechanistic linkage between these events has been investigated in A431 squamous carcinoma cells with the EGFR Tyr kinase inhibitor, AG1478. Tyrosine 124-127 epidermal growth factor receptor Homo sapiens 68-100 10533979-1 1999 Previous studies demonstrated that ionizing radiation activates the epidermal growth factor receptor (EGFR), as measured by Tyr autophosphorylation, and induces transient increases in cytosolic free [Ca2+], [Ca2+]f. The mechanistic linkage between these events has been investigated in A431 squamous carcinoma cells with the EGFR Tyr kinase inhibitor, AG1478. Tyrosine 124-127 epidermal growth factor receptor Homo sapiens 102-106 10521482-1 1999 A role in c-Cbl"s tyrosine phosphorylation and its association with epidermal growth factor receptor. Tyrosine 18-26 epidermal growth factor receptor Homo sapiens 68-100 10541432-2 1999 Kinase-deficient erbB proteins reduced epidermal growth factor (EGF)-induced tyrosine phosphorylation of endogenous Shc proteins and also reduced immediate and sustained EGF-induced ERK MAPK activities in human glioblastoma cells, although basal ERK MAPK activities were unaffected. Tyrosine 77-85 epidermal growth factor receptor Homo sapiens 17-21 10595738-3 1999 EGF stimulation of glioma cells induced the phosphorylation of tyrosine 221 of the CrkII protein, which correlates with its dissociation from the EGFR. Tyrosine 63-71 epidermal growth factor receptor Homo sapiens 146-150 10595738-5 1999 In A431 cells, epidermoid carcinoma cells which overexpress EGFR, CrkII was tyrosine-phosphorylated and associated with the EGFR in an EGF-dependent manner. Tyrosine 76-84 epidermal growth factor receptor Homo sapiens 60-64 10546558-10 1999 The UVB irradiation of human epidermoid carcinoma cells resulted in 3.3-fold induction of tyrosine phosphorylation of EGFR. Tyrosine 90-98 epidermal growth factor receptor Homo sapiens 118-122 10533979-5 1999 The increased erbB-3 Tyr phosphorylation is to a significant extent due to transactivation by EGFR as >70% of radiation- and EGF-induced erbB-3 Tyr phosphorylation is inhibited by AG 1478. Tyrosine 21-24 epidermal growth factor receptor Homo sapiens 94-98 10533979-5 1999 The increased erbB-3 Tyr phosphorylation is to a significant extent due to transactivation by EGFR as >70% of radiation- and EGF-induced erbB-3 Tyr phosphorylation is inhibited by AG 1478. Tyrosine 147-150 epidermal growth factor receptor Homo sapiens 94-98 10514507-4 1999 The experimental data show transient tyrosine phosphorylation of the EGF receptor (EGFR) and transient or sustained response patterns in multiple signaling proteins targeted by EGFR. Tyrosine 37-45 epidermal growth factor receptor Homo sapiens 69-81 10499523-7 1999 The ET-1-induced tyrosine phosphorylation of EGFR, as well as MAP kinase activation, was inhibited by an ETA receptor antagonist and intracellular Ca2+ antagonists but not by an ETB receptor antagonist, pertussis toxin, or protein kinase C inhibitors. Tyrosine 17-25 epidermal growth factor receptor Homo sapiens 45-49 10490623-5 1999 AP1510 treatment induced tyrosine phosphorylation of ErbB1 and ErbB2 homodimers and recruitment of Src homology 2 domain-containing proteins (Shc and Grb2). Tyrosine 25-33 epidermal growth factor receptor Homo sapiens 53-58 10628390-4 1999 Using Western blot method, it was shown that the inhibitory effect of apigenin on ARO cell proliferation is associated with an inhibition of both EGFR tyrosine autophosphorylation and phosphorylation of its downstream effector mitogen activated protein (MAP) kinase. Tyrosine 151-159 epidermal growth factor receptor Homo sapiens 146-150 10486467-8 1999 Western blotting revealed that epidermal growth factor-induced tyrosine phosphorylation of epidermal growth factor receptor was inhibited by RC-160, which suggests that the direct inhibitory effect of RC-160 on HEC-1 cell growth might be mediated in part by interference with epidermal growth factor receptor phosphorylation. Tyrosine 63-71 epidermal growth factor receptor Homo sapiens 91-123 10486467-8 1999 Western blotting revealed that epidermal growth factor-induced tyrosine phosphorylation of epidermal growth factor receptor was inhibited by RC-160, which suggests that the direct inhibitory effect of RC-160 on HEC-1 cell growth might be mediated in part by interference with epidermal growth factor receptor phosphorylation. Tyrosine 63-71 epidermal growth factor receptor Homo sapiens 276-308 9863009-8 1999 Furthermore, we provide evidence that stable Ki-Ras expression attenuates the ability of EGF receptor to activate the MAP kinase pathway by interfering with the receptor ability to autophosphorylate at tyrosine residues and not by down regulating receptor expression. Tyrosine 202-210 epidermal growth factor receptor Homo sapiens 89-101 10436007-1 1999 Exposure of A431 squamous and MDA-MB-231 mammary carcinoma cells to ionizing radiation has been associated with short transient increases in epidermal growth factor receptor (EGFR) tyrosine phosphorylation and activation of the mitogen-activated protein kinase (MAPK) and c-Jun NH(2)-terminal kinase (JNK) pathways. Tyrosine 181-189 epidermal growth factor receptor Homo sapiens 141-173 10436007-1 1999 Exposure of A431 squamous and MDA-MB-231 mammary carcinoma cells to ionizing radiation has been associated with short transient increases in epidermal growth factor receptor (EGFR) tyrosine phosphorylation and activation of the mitogen-activated protein kinase (MAPK) and c-Jun NH(2)-terminal kinase (JNK) pathways. Tyrosine 181-189 epidermal growth factor receptor Homo sapiens 175-179 10413509-1 1999 This study examines the effects of mutations at and in the vicinity of tyrosine 992 of the epidermal growth factor receptor (EGFr) on epidermal growth factor- (EGF-) stimulated internalization of the receptor. Tyrosine 71-79 epidermal growth factor receptor Homo sapiens 91-123 10413509-1 1999 This study examines the effects of mutations at and in the vicinity of tyrosine 992 of the epidermal growth factor receptor (EGFr) on epidermal growth factor- (EGF-) stimulated internalization of the receptor. Tyrosine 71-79 epidermal growth factor receptor Homo sapiens 125-129 10400318-7 1999 Results obtained with peptide competitors derived from the phage sequences demonstrated that nonphosphotyrosine-containing peptides identified with the phage display technology had an affinity for the receptor similar to tyrosine-phosphorylated peptides derived from the EGFR natural substrate. Tyrosine 103-111 epidermal growth factor receptor Homo sapiens 271-275 10187826-7 1999 Indeed, tyrosine phosphorylation of the EGFR was evident as early as 10 min following cell contact with collagen. Tyrosine 8-16 epidermal growth factor receptor Homo sapiens 40-44 10075741-4 1999 Here we provide evidence that association between c-Src and EGFR can occur directly, as shown by receptor overlay experiments, and that it results in the appearance of two novel tyrosine phosphorylations on the receptor that are seen both in vitro and in vivo following EGF stimulation. Tyrosine 178-186 epidermal growth factor receptor Homo sapiens 60-64 10068444-3 1999 EGFR-13 increased the stoichiometry of tyrosine phosphorylation of the full-length receptor from 4.2 to 10.1 mol Pi/mol EGFR and that of EGFRDelta1022-1186 from 1.0 to 2 mol Pi/mol receptor. Tyrosine 39-47 epidermal growth factor receptor Homo sapiens 0-4 10068444-3 1999 EGFR-13 increased the stoichiometry of tyrosine phosphorylation of the full-length receptor from 4.2 to 10.1 mol Pi/mol EGFR and that of EGFRDelta1022-1186 from 1.0 to 2 mol Pi/mol receptor. Tyrosine 39-47 epidermal growth factor receptor Homo sapiens 120-124 10068444-9 1999 This change increases the protein tyrosine kinase activity of the EGFR and provides access to additional tyrosine autophosphorylation sites in the receptor. Tyrosine 34-42 epidermal growth factor receptor Homo sapiens 66-70 9927298-6 1999 The initial events in EGFR (i.e. ErbB1) mitogenic signal transduction are dimer formation with another ErbB protein and tyrosine cross-phosphorylation. Tyrosine 120-128 epidermal growth factor receptor Homo sapiens 22-26 9927298-6 1999 The initial events in EGFR (i.e. ErbB1) mitogenic signal transduction are dimer formation with another ErbB protein and tyrosine cross-phosphorylation. Tyrosine 120-128 epidermal growth factor receptor Homo sapiens 33-38 9927298-6 1999 The initial events in EGFR (i.e. ErbB1) mitogenic signal transduction are dimer formation with another ErbB protein and tyrosine cross-phosphorylation. Tyrosine 120-128 epidermal growth factor receptor Homo sapiens 33-37 9892212-6 1999 Sialidase expression did not modify the binding of epidermal growth factor (EGF) to its receptor but enhanced EGF receptor (EGFR) tyrosine autophosphorylation as compared to that of parental cells or cells transfected with the vector (pcDNA3) alone. Tyrosine 130-138 epidermal growth factor receptor Homo sapiens 124-128 10467423-1 1999 Exposure of MDA-MB-231 human mammary carcinoma cells to an ionizing radiation dose of 2 Gy results in immediate activation and Tyr phosphorylation of the epidermal growth factor receptor (EGFR). Tyrosine 127-130 epidermal growth factor receptor Homo sapiens 154-186 10467423-1 1999 Exposure of MDA-MB-231 human mammary carcinoma cells to an ionizing radiation dose of 2 Gy results in immediate activation and Tyr phosphorylation of the epidermal growth factor receptor (EGFR). Tyrosine 127-130 epidermal growth factor receptor Homo sapiens 188-192 10428778-2 1999 c-Cbl, a tyrosine phosphorylation substrate shared by several signaling pathways, accelerates desensitization by recruiting EGFR and increasing receptor polyubiquitination. Tyrosine 9-17 epidermal growth factor receptor Homo sapiens 124-128 10085141-4 1999 We found that EGF continues to stimulate maximal tyrosine phosphorylation of EGFR following internalization, while, as expected, TGFalpha stimulates markedly less. Tyrosine 49-57 epidermal growth factor receptor Homo sapiens 77-81 10085141-7 1999 In contrast to PIP2 hydrolysis, PLC-gamma1 tyrosine phosphorylation correlated linearly with the total level of Tyr(P)-EGFR stimulated by either ligand, indicating that the functional deficiency of internal EGFR cannot be attributed to an inability to interact with and phosphorylate signaling proteins. Tyrosine 112-115 epidermal growth factor receptor Homo sapiens 119-123 10069801-0 1999 Phosphorylation of tyrosine 992, 1068, and 1086 is required for conformational change of the human epidermal growth factor receptor c-terminal tail. Tyrosine 19-27 epidermal growth factor receptor Homo sapiens 99-131 10069801-1 1999 We reported previously that a conformation-specific antibody, Ab P2, to a 16-amino acid peptide (Glu-Gly-Tyr-Lys-Lys-Lys-Tyr-Gln-Gln-Val-Asp-Glu-Glu-Phe-Leu-Arg) of the cytoplasmic domain of the beta-type platelet-derived growth factor receptor also recognizes the epidermal growth factor (EGF) receptor. Tyrosine 105-108 epidermal growth factor receptor Homo sapiens 265-303 10069801-1 1999 We reported previously that a conformation-specific antibody, Ab P2, to a 16-amino acid peptide (Glu-Gly-Tyr-Lys-Lys-Lys-Tyr-Gln-Gln-Val-Asp-Glu-Glu-Phe-Leu-Arg) of the cytoplasmic domain of the beta-type platelet-derived growth factor receptor also recognizes the epidermal growth factor (EGF) receptor. Tyrosine 121-124 epidermal growth factor receptor Homo sapiens 265-303 10069801-3 1999 In P2 peptide, there are two tripeptide sequences, Asp-Glu-Glu and Tyr-Gln-Gln, that are also present in the EGF receptor. Tyrosine 67-70 epidermal growth factor receptor Homo sapiens 109-121 10069801-5 1999 Of the five phosphate acceptor sites in the EGF receptor, clustered in the extreme C-terminal tail, phosphorylation of three tyrosine residues (992, 1068, and 1086) located between Asp-Glu-Glu and Gln-Gln is necessary for Ab P2 binding. Tyrosine 125-133 epidermal growth factor receptor Homo sapiens 44-56 10069801-9 1999 In conclusion, we have identified a domain within the cytoplasmic part of the EGF receptor whose conformation is altered by receptor phosphorylation; furthermore, we have identified the tyrosine residues that positively regulate this conformation. Tyrosine 186-194 epidermal growth factor receptor Homo sapiens 78-90 10023672-3 1999 Prior to the onset of apoptosis, TNF caused a significant reduction in the level of EGFr tyrosine phosphorylation in Sen cells but mediated only limited suppression of EGFr tyrosine phosphorylation in apoptotically resistant Res cells. Tyrosine 89-97 epidermal growth factor receptor Homo sapiens 84-88 10023672-4 1999 In vitro incubation of cellular membranes with TNF derived from Sen cells stimulated a resident protein tyrosine phosphatase (PTP) activity which was able to dephosphorylate EGFr or tyrosine phosphopeptides mimicking an EGFr autophosphorylation site. Tyrosine 104-112 epidermal growth factor receptor Homo sapiens 174-178 10023672-4 1999 In vitro incubation of cellular membranes with TNF derived from Sen cells stimulated a resident protein tyrosine phosphatase (PTP) activity which was able to dephosphorylate EGFr or tyrosine phosphopeptides mimicking an EGFr autophosphorylation site. Tyrosine 104-112 epidermal growth factor receptor Homo sapiens 220-224 10023672-5 1999 In membrane preparations, PTPIB complexed with tyrosine phosphorylated EGFr and this association was disrupted by TNF through an apparent stimulation of PTP activity and turnover of phosphotyrosine. Tyrosine 47-55 epidermal growth factor receptor Homo sapiens 71-75 9857032-3 1998 EGFR-GFP becomes phosphorylated at tyrosine residues in response to EGF and is capable of phosphorylating endogenous substrates and initiating signaling cascades. Tyrosine 35-43 epidermal growth factor receptor Homo sapiens 0-4 10365089-3 1999 There is increasing experimental evidence to suggest that epidermal growth factor receptor tyrosine phosphorylation may lead to the inactivation of the E-cadherin/catenin complex in cancer cells through its interaction with beta- or gamma-catenin in the cytoskeleton. Tyrosine 91-99 epidermal growth factor receptor Homo sapiens 58-90 9837959-5 1998 PLD2, but not PLD1, associates with the EGF receptor in a ligand-independent manner and becomes tyrosine-phosphorylated upon EGF receptor activation. Tyrosine 96-104 epidermal growth factor receptor Homo sapiens 125-137 9922143-3 1998 The fluoromalonyl tyrosine residue was incorporated within a cyclic hexapeptide modeled on an autophosphorylation site of the epidermal growth factor receptor. Tyrosine 18-26 epidermal growth factor receptor Homo sapiens 126-158 9786938-6 1998 Immunoprecipitation and immunoblotting demonstrated increased tyrosine phosphorylation of PI3-kinase and epidermal growth factor receptor (EGFR) within 1 min of EET administration. Tyrosine 62-70 epidermal growth factor receptor Homo sapiens 139-143 9843701-5 1998 Tyrosine phosphorylation of EGFR substrates known to mediate cell proliferation, Src-homologous and collagen protein (SHC), extracellularly regulated kinase 1 (ERK1), and ERK2 could be induced similarly by activation of apical or basolateral EGFR. Tyrosine 0-8 epidermal growth factor receptor Homo sapiens 28-32 9843701-5 1998 Tyrosine phosphorylation of EGFR substrates known to mediate cell proliferation, Src-homologous and collagen protein (SHC), extracellularly regulated kinase 1 (ERK1), and ERK2 could be induced similarly by activation of apical or basolateral EGFR. Tyrosine 0-8 epidermal growth factor receptor Homo sapiens 242-246 9822654-3 1998 Exposure of epidermoid carcinoma A431 cells to 0.1-1.0 mM ONOO- resulted in tyrosine nitration on EGFR and other proteins but did not significantly affect EGFR tyrosine autophosphorylation. Tyrosine 76-84 epidermal growth factor receptor Homo sapiens 98-102 9822654-4 1998 A high molecular mass tyrosine-phosphorylated protein (approximately 340 kDa) was detected in A431 cell lysates after exposure to ONOO-, most likely representing a covalently dimerized form of EGFR, based on immunoprecipitation and/or immunoblotting with alpha-EGFR antibodies and co-migration with ligand-induced EGFR dimers cross-linked with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide. Tyrosine 22-30 epidermal growth factor receptor Homo sapiens 193-197 9822654-4 1998 A high molecular mass tyrosine-phosphorylated protein (approximately 340 kDa) was detected in A431 cell lysates after exposure to ONOO-, most likely representing a covalently dimerized form of EGFR, based on immunoprecipitation and/or immunoblotting with alpha-EGFR antibodies and co-migration with ligand-induced EGFR dimers cross-linked with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide. Tyrosine 22-30 epidermal growth factor receptor Homo sapiens 261-265 9822654-4 1998 A high molecular mass tyrosine-phosphorylated protein (approximately 340 kDa) was detected in A431 cell lysates after exposure to ONOO-, most likely representing a covalently dimerized form of EGFR, based on immunoprecipitation and/or immunoblotting with alpha-EGFR antibodies and co-migration with ligand-induced EGFR dimers cross-linked with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide. Tyrosine 22-30 epidermal growth factor receptor Homo sapiens 261-265 9822654-6 1998 Furthermore, irreversibly cross-linked EGFR was more extensively tyrosine-phosphorylated compared with the monomeric form, indicating that ONOO- preferentially cross-links activated EGFR. Tyrosine 65-73 epidermal growth factor receptor Homo sapiens 39-43 9822654-6 1998 Furthermore, irreversibly cross-linked EGFR was more extensively tyrosine-phosphorylated compared with the monomeric form, indicating that ONOO- preferentially cross-links activated EGFR. Tyrosine 65-73 epidermal growth factor receptor Homo sapiens 182-186 9822606-1 1998 Adhesion of human primary skin fibroblasts and ECV304 endothelial cells to immobilized matrix proteins, beta1 or alphav integrin antibodies stimulates tyrosine phosphorylation of the epidermal growth factor (EGF) receptor. Tyrosine 151-159 epidermal growth factor receptor Homo sapiens 183-221 9822606-4 1998 Use of a kinase-negative EGF receptor mutant demonstrates that the integrin-stimulated tyrosine phosphorylation is due to activation of the receptor"s intrinsic kinase activity. Tyrosine 87-95 epidermal growth factor receptor Homo sapiens 25-37 9848510-3 1998 In membrane preparations from mammalian cells, genistein is a potent and specific inhibitor of tyrosine autophosphorylation of the epidermal growth factor (EGF) receptor. Tyrosine 95-103 epidermal growth factor receptor Homo sapiens 131-169 9865906-5 1998 C225 also inhibited exogenous ligand-stimulated tyrosine phosphorylation of EGF receptor on RCC cells. Tyrosine 48-56 epidermal growth factor receptor Homo sapiens 76-88 9822654-7 1998 Exposure of A431 cells to ONOO- markedly reduced the kinetics of tyrosine phosphorylation of a downstream EGFR substrate, phospholipase C-gamma1, which may be related to covalent alterations in EGFR. Tyrosine 65-73 epidermal growth factor receptor Homo sapiens 106-110 9822654-7 1998 Exposure of A431 cells to ONOO- markedly reduced the kinetics of tyrosine phosphorylation of a downstream EGFR substrate, phospholipase C-gamma1, which may be related to covalent alterations in EGFR. Tyrosine 65-73 epidermal growth factor receptor Homo sapiens 194-198 9716460-6 1998 When surface-bound TGFalpha was removed by acid stripping and endosomal pH was neutralized with bafilomycin A1, TGFalpha stimulated EGFR tyrosine phosphorylation, induced p21/CIP1, and inhibited DNA synthesis. Tyrosine 137-145 epidermal growth factor receptor Homo sapiens 132-136 9765228-9 1998 Immunoprecipitation/Western blot studies revealed that CCh stimulated tyrosine phosphorylation of the EGF receptor (EGFr) and increased co-immunoprecipitation of the adapter proteins, Shc and Grb2, with the EGFr. Tyrosine 70-78 epidermal growth factor receptor Homo sapiens 102-114 9765228-9 1998 Immunoprecipitation/Western blot studies revealed that CCh stimulated tyrosine phosphorylation of the EGF receptor (EGFr) and increased co-immunoprecipitation of the adapter proteins, Shc and Grb2, with the EGFr. Tyrosine 70-78 epidermal growth factor receptor Homo sapiens 116-120 9648731-3 1998 Ang II induced a rapid tyrosine phosphorylation of EGF-R in association with phosphorylation of Shc protein and ERK activation. Tyrosine 23-31 epidermal growth factor receptor Homo sapiens 51-56 9685397-1 1998 Upon ligand activation, the epidermal growth factor receptor (EGFR) becomes tyrosine-phosphorylated, thereby recruiting intracellular signaling proteins such as Shc. Tyrosine 76-84 epidermal growth factor receptor Homo sapiens 28-60 9685397-1 1998 Upon ligand activation, the epidermal growth factor receptor (EGFR) becomes tyrosine-phosphorylated, thereby recruiting intracellular signaling proteins such as Shc. Tyrosine 76-84 epidermal growth factor receptor Homo sapiens 62-66 9685397-2 1998 EGFR binding of Shc proteins results in their tyrosine phosphorylation and subsequent activation of the Ras and Erk pathways. Tyrosine 46-54 epidermal growth factor receptor Homo sapiens 0-4 9664130-5 1998 We found that both the anti-EGFR mAbs and the TK inhibitor produce similar biological changes namely, they inhibit the EGF and TGFa-induced tyrosine phosphorylation of the receptor and the growth in culture of HN5 cells. Tyrosine 140-148 epidermal growth factor receptor Homo sapiens 28-32 9642287-0 1998 Phosphorylation of CrkII adaptor protein at tyrosine 221 by epidermal growth factor receptor. Tyrosine 44-52 epidermal growth factor receptor Homo sapiens 60-92 9642287-2 1998 We examined whether tyrosine 221, which has been shown to be phosphorylated by c-Abl, was phosphorylated also by other tyrosine kinases, such as epidermal growth factor (EGF) receptor. Tyrosine 20-28 epidermal growth factor receptor Homo sapiens 145-183 9581834-7 1998 Silymarin treatment of cells also resulted in a significant decrease in tyrosine phosphorylation of an immediate downstream target of erbB1, the adapter protein SHC, together with a decrease in its binding to erbB1. Tyrosine 72-80 epidermal growth factor receptor Homo sapiens 134-139 9642119-2 1998 Epidermal growth factor receptor (EGFR)-mediated tyrosine phosphorylation may be a primary indicator of signal transduction regulating cell growth and proliferation. Tyrosine 49-57 epidermal growth factor receptor Homo sapiens 0-32 9642119-2 1998 Epidermal growth factor receptor (EGFR)-mediated tyrosine phosphorylation may be a primary indicator of signal transduction regulating cell growth and proliferation. Tyrosine 49-57 epidermal growth factor receptor Homo sapiens 34-38 9581810-6 1998 Heregulin (HRG)-beta2, a ligand for erbB3 and erbB4 receptors, stimulated tyrosine phosphorylation of the erbB receptors, which was accompanied by activation of Erk1 and Erk2, two mitogen-activated protein kinases with a functional role in mitogenesis. Tyrosine 74-82 epidermal growth factor receptor Homo sapiens 36-40 9619445-4 1998 We report that oxLDL elicit, in intact cells, tyrosine phosphorylation of the epithelial growth factor receptor (EGFR) and activation of its signaling pathway. Tyrosine 46-54 epidermal growth factor receptor Homo sapiens 78-111 9619445-4 1998 We report that oxLDL elicit, in intact cells, tyrosine phosphorylation of the epithelial growth factor receptor (EGFR) and activation of its signaling pathway. Tyrosine 46-54 epidermal growth factor receptor Homo sapiens 113-117 9581834-10 1998 In additional studies, treatment of cells grown in 10% serum with anti-epidermal growth factor receptor monoclonal antibody clone 225 or different doses of silymarin also resulted in significant inhibition of constitutive tyrosine phosphorylation of both erbB1 and SHC but no change in their protein levels. Tyrosine 222-230 epidermal growth factor receptor Homo sapiens 71-103 9581834-10 1998 In additional studies, treatment of cells grown in 10% serum with anti-epidermal growth factor receptor monoclonal antibody clone 225 or different doses of silymarin also resulted in significant inhibition of constitutive tyrosine phosphorylation of both erbB1 and SHC but no change in their protein levels. Tyrosine 222-230 epidermal growth factor receptor Homo sapiens 255-260 9615231-0 1998 GBAS, a novel gene encoding a protein with tyrosine phosphorylation sites and a transmembrane domain, is co-amplified with EGFR. Tyrosine 43-51 epidermal growth factor receptor Homo sapiens 123-127 9692677-3 1998 At 0 degrees C, binding of EGF induced tyrosine phosphorlyation of EGFR and, when the cells were subsequently broken by scraping and warmed in the presence of exogenous cytosol, activation of ERK2 occurred. Tyrosine 39-47 epidermal growth factor receptor Homo sapiens 67-71 9692677-8 1998 Our observation that EGFR tyrosine dephosphorylation is incomplete above pH 5.5 suggests that signalling is initiated in early endosomes. Tyrosine 26-34 epidermal growth factor receptor Homo sapiens 21-25 9790226-3 1998 We now show that GH stimulated tyrosine phosphorylation of epidermal growth factor receptor (EGFR) and its association with Grb2, and concomitantly stimulated MAP kinase activity in liver, a major target tissue. Tyrosine 31-39 epidermal growth factor receptor Homo sapiens 59-91 9790226-3 1998 We now show that GH stimulated tyrosine phosphorylation of epidermal growth factor receptor (EGFR) and its association with Grb2, and concomitantly stimulated MAP kinase activity in liver, a major target tissue. Tyrosine 31-39 epidermal growth factor receptor Homo sapiens 93-97 9790226-4 1998 Expression of EGFR and its mutants into CHO-GH receptor (GHR) cells revealed that GH-induced full activation of MAP kinase and c-fos expression required tyrosine phosphorylation sites of EGFR but not its intrinsic tyrosine kinase activity. Tyrosine 153-161 epidermal growth factor receptor Homo sapiens 14-18 9790226-4 1998 Expression of EGFR and its mutants into CHO-GH receptor (GHR) cells revealed that GH-induced full activation of MAP kinase and c-fos expression required tyrosine phosphorylation sites of EGFR but not its intrinsic tyrosine kinase activity. Tyrosine 153-161 epidermal growth factor receptor Homo sapiens 187-191 9790226-5 1998 Moreover, by also using dominant negative JAK2 and in vitro kinase assay, we demonstrated that tyrosine 1068 of EGFR was evidently one of the major phosphorylation and Grb2 binding sites stimulated by GH via JAK2. Tyrosine 95-103 epidermal growth factor receptor Homo sapiens 112-116 9528863-3 1998 BTC-TX50 induced tyrosine phosphorylation of both EGFR and HER4, whereas BTC-TX48 induced phosphorylation of HER4 but to a much lesser extent EGFR, indicating that the presence of two additional amino acid residues, Arg62 and Lys63, contribute to full kinase activity. Tyrosine 17-25 epidermal growth factor receptor Homo sapiens 50-54 9544989-2 1998 We have shown previously that tyrosine 1148 of the activated epidermal growth factor (EGF) receptor is a major binding site for Shc while tyrosine 1173 is a secondary binding site in intact cells. Tyrosine 30-38 epidermal growth factor receptor Homo sapiens 61-99 9544989-12 1998 The present results indicate that tyrosine 1148 of the activated EGF receptor mainly interacts with the Shc PTB domain in intact cells. Tyrosine 34-42 epidermal growth factor receptor Homo sapiens 65-77 15678850-1 1998 The human protooncogene c-erbB2, also known as HER-2/neu is sited on 17q21 chromosome and codifies a transmembranous glycoprotein of 185 KD, named c-erbB2 protein, with tyrosin-kinasic activity and homologue from molecular point of view with the epidermal growth factor receptor (EGFR). Tyrosine 169-176 epidermal growth factor receptor Homo sapiens 246-278 9513602-5 1998 These were evaluated for their ability to inhibit the tyrosine phosphorylating action of EGF-stimulated full-length EGFR enzyme and for inhibition of autophosphorylation of the EGFR in A431 human epidermoid carcinoma cells in culture. Tyrosine 54-62 epidermal growth factor receptor Homo sapiens 116-120 9462724-5 1998 Like EGF, we found that both the epiregulin-induced growth inhibition of HN5 and MDA-MB468 cells and tyrosine phosphorylation of the 170 kDa EGFR on HN5 cells are reversed in the presence of anti-EGFR MAbs ICR62 and ICR80. Tyrosine 101-109 epidermal growth factor receptor Homo sapiens 141-145 9462724-5 1998 Like EGF, we found that both the epiregulin-induced growth inhibition of HN5 and MDA-MB468 cells and tyrosine phosphorylation of the 170 kDa EGFR on HN5 cells are reversed in the presence of anti-EGFR MAbs ICR62 and ICR80. Tyrosine 101-109 epidermal growth factor receptor Homo sapiens 196-200 9585125-3 1998 ARIA stimulates tyrosine phosphorylation of the erbB proteins and activates the MAP kinase pathway which is required for the ARIA-mediated induction of AChR genes. Tyrosine 16-24 epidermal growth factor receptor Homo sapiens 48-52 15678850-1 1998 The human protooncogene c-erbB2, also known as HER-2/neu is sited on 17q21 chromosome and codifies a transmembranous glycoprotein of 185 KD, named c-erbB2 protein, with tyrosin-kinasic activity and homologue from molecular point of view with the epidermal growth factor receptor (EGFR). Tyrosine 169-176 epidermal growth factor receptor Homo sapiens 280-284 9407973-3 1997 The functional activity of the induced protein was proven by the finding of epidermal growth factor receptor (EGFR) tyrosine phosphorylation on induction of TGF-alpha. Tyrosine 116-124 epidermal growth factor receptor Homo sapiens 76-108 9407973-3 1997 The functional activity of the induced protein was proven by the finding of epidermal growth factor receptor (EGFR) tyrosine phosphorylation on induction of TGF-alpha. Tyrosine 116-124 epidermal growth factor receptor Homo sapiens 110-114 9406816-4 1997 Coupled to growth arrest is the suppression of HER-1 tyrosine autophosphorylation in inhibitor-treated human keratinocytes. Tyrosine 53-61 epidermal growth factor receptor Homo sapiens 47-52 9419966-4 1997 Stimulation of PDGFR"s and EGFR"s induced tyrosine phosphorylation of the Shc adaptor protein and its association with Grb2, suggesting a mechanism by which Ras may be activated in human malignant astrocytoma cells. Tyrosine 42-50 epidermal growth factor receptor Homo sapiens 27-31 9419975-0 1997 Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4. Tyrosine 76-84 epidermal growth factor receptor Homo sapiens 104-136 9419975-5 1997 Furthermore, although epiregulin stimulated tyrosine phosphorylation of all four ErbB receptors, the main intracellular signal was mediated by ErbB-4 and/or EGFR. Tyrosine 44-52 epidermal growth factor receptor Homo sapiens 81-85 9346957-9 1997 Together, these data indicate that the serine/threonine phosphorylation of 66-kDa Shc impairs its ability to associate with the tyrosine-phosphorylated EGF receptor and can function in a dominant-interfering manner by inhibiting EGF receptor downstream signaling pathways. Tyrosine 128-136 epidermal growth factor receptor Homo sapiens 152-164 9426392-8 1997 Tyrosine phosphorylation of beta-catenin and epidermal growth factor receptor seems to be involved in this process. Tyrosine 0-8 epidermal growth factor receptor Homo sapiens 45-77 9348331-4 1997 Previous work has shown that there is a large increase in the tyrosine phosphorylation of Kv1.3 when it is coexpressed with the EGFr. Tyrosine 62-70 epidermal growth factor receptor Homo sapiens 128-132 9393980-2 1997 Here we use both an ErbB2 phosphoantibody (aPY1222) and an activation-specific EGFR antibody to show that low concentrations of EGF induce more efficient tyrosine phosphorylation of ErbB2 in A431 cells than does equimolar TGFalpha, while EGFR is more potently activated by TGFalpha. Tyrosine 154-162 epidermal growth factor receptor Homo sapiens 79-83 9393980-2 1997 Here we use both an ErbB2 phosphoantibody (aPY1222) and an activation-specific EGFR antibody to show that low concentrations of EGF induce more efficient tyrosine phosphorylation of ErbB2 in A431 cells than does equimolar TGFalpha, while EGFR is more potently activated by TGFalpha. Tyrosine 154-162 epidermal growth factor receptor Homo sapiens 238-242 9366260-3 1997 Here we report that ionizing radiation enhances epidermal growth factor (EGF) receptor tyrosine phosphorylation in intact cells as well as in isolated membranes of A431 cells. Tyrosine 87-95 epidermal growth factor receptor Homo sapiens 48-86 9355745-0 1997 Protein tyrosine phosphatase 1B interacts with and is tyrosine phosphorylated by the epidermal growth factor receptor. Tyrosine 8-16 epidermal growth factor receptor Homo sapiens 85-117 9355745-4 1997 After binding to EGFR, PTP1B becomes tyrosine-phosphorylated at Tyr-66, a site that conforms to the consensus binding sequence for the Src homology 2 (SH2) domains of the adapter protein Grb2. Tyrosine 37-45 epidermal growth factor receptor Homo sapiens 17-21 9355745-4 1997 After binding to EGFR, PTP1B becomes tyrosine-phosphorylated at Tyr-66, a site that conforms to the consensus binding sequence for the Src homology 2 (SH2) domains of the adapter protein Grb2. Tyrosine 64-67 epidermal growth factor receptor Homo sapiens 17-21 9205094-4 1997 In transformed murine and human cells, levels of p215BRCA1 tyrosine phosphorylation were inversely correlated with the activity of the erbB family receptor-tyrosine-kinases and with the transformed growth features of these cells. Tyrosine 59-67 epidermal growth factor receptor Homo sapiens 135-139 9294612-0 1997 Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Tyrosine 96-104 epidermal growth factor receptor Homo sapiens 91-95 9233779-6 1997 Tyrosine phosphorylation of beta-catenin was concomitantly induced with association of beta-catenin with EGF receptor (EGFR) when quiescent cells at confluence were dissociated into single cells by tryptic digestion, being accompanied by dissociation of alpha-catenin from E-cadherin. Tyrosine 0-8 epidermal growth factor receptor Homo sapiens 119-123 9233779-7 1997 Both tyrosine phosphorylation and association of beta-catenin with EGFR were inhibited by tyrphostin, a specific inhibitor of the EGFR tyrosine kinase, whereas dissociation of alpha-catenin from E-cadherin was not. Tyrosine 5-13 epidermal growth factor receptor Homo sapiens 130-134 9233779-8 1997 The results suggest that tyrosine phosphorylation of beta-catenin is achieved by EGFR upon tryptic digestion of cells and concurrent with but independent of dissociation of alpha-catenin from E-cadherin. Tyrosine 25-33 epidermal growth factor receptor Homo sapiens 81-85 9194569-16 1997 The 180 kDa protein is likely to be the epidermal growth factor (EGF) receptor because exposure of the cells to EGF also leads to enhanced tyrosine phosphorylation of a protein of similar molecular size. Tyrosine 139-147 epidermal growth factor receptor Homo sapiens 40-78 9178760-6 1997 Competitive inhibition of substrate binding and mutagenesis experiments with EGFR/Ufo constructs revealed C-terminal tyrosine 821 (EILpYVNMDEG) as a docking site for multiple effectors, namely PLCgamma, p85 proteins, GRB2, c-src and lck. Tyrosine 117-125 epidermal growth factor receptor Homo sapiens 77-81 9194569-19 1997 These data suggest that ATA influences ATB(0) activity in JAR cells most likely by activating the EGF receptor through tyrosine phosphorylation. Tyrosine 119-127 epidermal growth factor receptor Homo sapiens 98-110 9079622-2 1997 We found that huntingtin is associated with Grb2, RasGAP, and tyrosine-phosphorylated EGF receptor. Tyrosine 62-70 epidermal growth factor receptor Homo sapiens 86-98 9194028-0 1997 Role of tyrosine specific phosphorylation of cellular proteins, especially EGF receptor and p125FAK in human lung cancer cells. Tyrosine 8-16 epidermal growth factor receptor Homo sapiens 75-87 9060993-7 1997 In contrast, tyrphostin AG1478 had no effect on SP-A levels despite a greater inhibitory effect than genistein on EGF receptor tyrosine autophosphorylation. Tyrosine 127-135 epidermal growth factor receptor Homo sapiens 114-126 21533382-6 1997 Despite these differences, we show that like EGF, AR could induce the tyrosine phosphorylation of the 170 kDa EGF receptor on HN5 cells and that this effect could be blocked in the presence of anti-EGFR mAbs ICR62 and ICR80. Tyrosine 70-78 epidermal growth factor receptor Homo sapiens 110-122 9041204-15 1997 Constitutively tyrosine-phosphorylated STAT-3 homodimers were also detected in another breast cancer cell line, MDA468, which has an EGFR amplification and also has constitutive EGFR activity. Tyrosine 15-23 epidermal growth factor receptor Homo sapiens 133-137 9041204-15 1997 Constitutively tyrosine-phosphorylated STAT-3 homodimers were also detected in another breast cancer cell line, MDA468, which has an EGFR amplification and also has constitutive EGFR activity. Tyrosine 15-23 epidermal growth factor receptor Homo sapiens 178-182 21533382-6 1997 Despite these differences, we show that like EGF, AR could induce the tyrosine phosphorylation of the 170 kDa EGF receptor on HN5 cells and that this effect could be blocked in the presence of anti-EGFR mAbs ICR62 and ICR80. Tyrosine 70-78 epidermal growth factor receptor Homo sapiens 198-202 9006938-0 1997 The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. Tyrosine 151-159 epidermal growth factor receptor Homo sapiens 46-78 8995250-1 1997 Role in EGF receptor-mediated tyrosine phosphorylation. Tyrosine 30-38 epidermal growth factor receptor Homo sapiens 8-20 8995250-6 1997 The elimination of H2O2 by catalase also inhibited the EGF-induced tyrosine phosphorylation of various cellular proteins including the EGF receptor and phospholipase C-gamma1. Tyrosine 67-75 epidermal growth factor receptor Homo sapiens 135-147 9049062-1 1997 Detergent-permeabilized EGFR-T17 fibroblasts, which overexpress the human epidermal growth factor (EGF) receptor, phosphorylate both poly-L-(glutamic acid, tyrosine) and exogenous calmodulin in an EGF-stimulated manner. Tyrosine 156-164 epidermal growth factor receptor Homo sapiens 24-28 9049062-1 1997 Detergent-permeabilized EGFR-T17 fibroblasts, which overexpress the human epidermal growth factor (EGF) receptor, phosphorylate both poly-L-(glutamic acid, tyrosine) and exogenous calmodulin in an EGF-stimulated manner. Tyrosine 156-164 epidermal growth factor receptor Homo sapiens 74-112 8959326-6 1996 By using a systematic mutagenesis approach, phosphorylation of additional tyrosines in each of the SH2 domains of SHP-2 was detected after coexpression of epidermal growth factor receptor, but not after coexpression of platelet-derived growth factor receptor, whereas tyrosine 263 located in the interspace between SH2 and catalytic domain appears to be exclusively recognized by platelet-derived growth factor receptor. Tyrosine 74-83 epidermal growth factor receptor Homo sapiens 155-187 8980184-6 1996 In these clones, there was a marked attenuation in EGF- and TGF-alpha-mediated EGF-R tyrosine phosphorylation and c-fos induction. Tyrosine 85-93 epidermal growth factor receptor Homo sapiens 79-84 8959326-6 1996 By using a systematic mutagenesis approach, phosphorylation of additional tyrosines in each of the SH2 domains of SHP-2 was detected after coexpression of epidermal growth factor receptor, but not after coexpression of platelet-derived growth factor receptor, whereas tyrosine 263 located in the interspace between SH2 and catalytic domain appears to be exclusively recognized by platelet-derived growth factor receptor. Tyrosine 74-82 epidermal growth factor receptor Homo sapiens 155-187 8790376-3 1996 Ligand activation of c-ErbB induced the tyrosine phosphorylation, DNA-binding, and reporter gene transcription of Stat 5b in erythroblasts. Tyrosine 40-48 epidermal growth factor receptor Homo sapiens 23-27 8910327-6 1996 These results indicate that the binding of Grb2 to the phosphorylated Tyr-1068 of EGFR is crucial to the EGF-induced Ras/mitogen-activated protein kinase signaling pathway. Tyrosine 70-73 epidermal growth factor receptor Homo sapiens 82-86 8917420-6 1996 TNF alpha could also enhance the tyrosine phosphorylation of the EGF receptor of HepG2 cells. Tyrosine 33-41 epidermal growth factor receptor Homo sapiens 65-77 8917420-8 1996 Therefore, the effect of TNF alpha on EGF receptor tyrosine phosphorylation in HepG2 cells was due to enhancing the receptor"s response to EGF. Tyrosine 51-59 epidermal growth factor receptor Homo sapiens 38-50 8710366-4 1996 In these cells, EGF induced tyrosine phosphorylation of the EGFR and several substrates was greatly reduced. Tyrosine 28-36 epidermal growth factor receptor Homo sapiens 60-64 8702638-0 1996 An epidermal growth factor receptor/Jak2 tyrosine kinase domain chimera induces tyrosine phosphorylation of Stat5 and transduces a growth signal in hematopoietic cells. Tyrosine 41-49 epidermal growth factor receptor Homo sapiens 3-35 8702638-4 1996 EGF stimulation of the transfectants induced dose-dependent tyrosine phosphorylation of the EGFR/Jak2 chimera and Stat5, which correlated with the EGF dose dependence of cell proliferation. Tyrosine 60-68 epidermal growth factor receptor Homo sapiens 92-96 8761292-4 1996 Our findings show that hydrogen peroxide stimulates tyrosine phosphorylation of several proteins including epidermal growth factor receptor (EGFR) in VSMC. Tyrosine 52-60 epidermal growth factor receptor Homo sapiens 107-139 8761292-4 1996 Our findings show that hydrogen peroxide stimulates tyrosine phosphorylation of several proteins including epidermal growth factor receptor (EGFR) in VSMC. Tyrosine 52-60 epidermal growth factor receptor Homo sapiens 141-145 8761292-5 1996 Hydrogen peroxide-induced tyrosine phosphorylation of EGFR was found to be time dependent; with a threefold increase at 5 min and a 20-fold increase at 30 min of treatment as compared to control levels. Tyrosine 26-34 epidermal growth factor receptor Homo sapiens 54-58 8761292-7 1996 In addition, hydrogen peroxide-induced tyrosine-phosphorylated EGFR formed a complex with SHC-Grb2-SOS. Tyrosine 39-47 epidermal growth factor receptor Homo sapiens 63-67 8702388-1 1996 In this work, using the ECL Western blotting assay system, it was found that genistein, a specific tyrosine kinase inhibitor, was able to inhibit EGF-induced EGF receptor degradation and tyrosine phosphorylation in human hepatoma HepG2 cells. Tyrosine 99-107 epidermal growth factor receptor Homo sapiens 158-170 8797110-9 1996 Herbimycin A suppressed the tyrosine autophosphorylation of EGFR and IL-6 mRNA expression and production, all of which were stimulated by EGF. Tyrosine 28-36 epidermal growth factor receptor Homo sapiens 60-64 8700557-3 1996 Transformation was correlated with tyrosine phosphorylation of only a subset of the proteins observed in cells overexpressing the normal EGF receptor. Tyrosine 35-43 epidermal growth factor receptor Homo sapiens 137-149 8698818-3 1996 Experiments of immunoblotting with anti-phosphotyrosine antibodies and immunoprecipitation followed by phosphoamino acid analysis and phosphopeptide mapping showed that activation of the EGFR causes phosphorylation of the beta4 subunit at multiple tyrosine residues, and this event requires ligation of the integrin by laminins or specific antibodies. Tyrosine 47-55 epidermal growth factor receptor Homo sapiens 187-191 8650580-4 1996 The effect of EGF to regulate ZPR1 binding is dependent on tyrosine phosphorylation of the EGFR. Tyrosine 59-67 epidermal growth factor receptor Homo sapiens 91-95 8647858-1 1996 Screening of a human breast epithelial cell cDNA library with the tyrosine-phosphorylated C terminus of the epidermal growth factor receptor identified a novel member of the GRB7 gene family, designated GRB14. Tyrosine 66-74 epidermal growth factor receptor Homo sapiens 108-140 8672543-1 1996 The Epidermal Growth Factor Receptor (EGF-R) becomes constitutively tyrosine phosphorylated on two novel sites in v-Src transformed cells, and these phosphorylations are associated with enhanced signaling activity [1]. Tyrosine 68-76 epidermal growth factor receptor Homo sapiens 4-36 8672543-1 1996 The Epidermal Growth Factor Receptor (EGF-R) becomes constitutively tyrosine phosphorylated on two novel sites in v-Src transformed cells, and these phosphorylations are associated with enhanced signaling activity [1]. Tyrosine 68-76 epidermal growth factor receptor Homo sapiens 38-43 8662849-3 1996 Mutation of tyrosine 974 alone or together with surrounding residues and the deletion of residues 973-975 essentially eliminated AP-2 co-immunoprecipitation with the EGF receptor. Tyrosine 12-20 epidermal growth factor receptor Homo sapiens 166-178 8647855-3 1996 In this study, platelet-derived growth factor receptor phosphorylation of Src on Tyr-213 specifically blocked binding of its SH2 domain to a phosphopeptide corresponding to the C-terminal regulatory sequence, while binding to other sequences, such as the platelet-derived growth factor receptor or a peptide from the epidermal growth factor receptor, was unaffected. Tyrosine 81-84 epidermal growth factor receptor Homo sapiens 317-349 8662907-2 1996 The SH2 domain of CRK binds to several tyrosine-phosphorylated proteins, including the epidermal growth factor receptor, p130(Cas), Shc, and paxillin. Tyrosine 39-47 epidermal growth factor receptor Homo sapiens 87-119 8621421-3 1996 The data revealed new potential Grb2 binding sites at Tyr-1114 (epidermal growth factor receptor (EGFR) C-tail); Tyr-743 (platelet-derived growth factor receptor (PDGFR) insert region), Tyr-1110 from the E-helix of the catalytic domain of insulin receptor (IR), and Tyr-47, Tyr-939, and Tyr-727 in IRS-1. Tyrosine 54-57 epidermal growth factor receptor Homo sapiens 64-96 8603380-1 1996 We have previously demonstrated that O-phospho-L-tyrosine (P-Tyr), a substrate for a wide range of PTPases, inhibits the growth of human renal cell carcinoma and human breast cancer cell lines and suppresses EGF-mediated EGFR tyrosine phosphorylation. Tyrosine 49-57 epidermal growth factor receptor Homo sapiens 221-225 8626530-6 1996 EGF markedly increased ErbB2 tyrosine phosphorylation in wild type EGFR cells. Tyrosine 29-37 epidermal growth factor receptor Homo sapiens 67-71 8626530-7 1996 In Delta973-EGFR cells, ErbB2 was tyrosine phosphorylated in the basal state and EGFR stimulated further phosphorylation of ErbB2. Tyrosine 34-42 epidermal growth factor receptor Homo sapiens 12-16 8626530-8 1996 In addition to ErbB2, additional proteins were tyrosine phosphorylated in Delta973-EGFR cells, mostly in the molecular mass range of 120 170 kDa. Tyrosine 47-55 epidermal growth factor receptor Homo sapiens 83-87 9162524-0 1996 Activation of epidermal growth factor receptor tyrosine phosphorylation by tumor necrosis factor correlates with loss of cytotoxic activity. Tyrosine 47-55 epidermal growth factor receptor Homo sapiens 14-46 9162524-4 1996 ME-180R cells expressed threefold higher EGFR than the ME-180S cell line and TNF treatment stimulated EGFR tyrosine phosphorylation only in resistant cells. Tyrosine 107-115 epidermal growth factor receptor Homo sapiens 102-106 8626392-5 1996 We show that all the EGF agonists, but not NDF, stimulated tyrosine phosphorylation of ErbB-1. Tyrosine 59-67 epidermal growth factor receptor Homo sapiens 87-93 8621421-6 1996 With regard to Shc binding, the data revealed new potential binding sites at Tyr-703 and Tyr-789 from the catalytic domain of EGFR and at Tyr-557 in the juxtamembrane region of PDGFR. Tyrosine 77-80 epidermal growth factor receptor Homo sapiens 126-130 8621421-6 1996 With regard to Shc binding, the data revealed new potential binding sites at Tyr-703 and Tyr-789 from the catalytic domain of EGFR and at Tyr-557 in the juxtamembrane region of PDGFR. Tyrosine 89-92 epidermal growth factor receptor Homo sapiens 126-130 8621421-6 1996 With regard to Shc binding, the data revealed new potential binding sites at Tyr-703 and Tyr-789 from the catalytic domain of EGFR and at Tyr-557 in the juxtamembrane region of PDGFR. Tyrosine 89-92 epidermal growth factor receptor Homo sapiens 126-130 8621421-8 1996 The study confirmed the previous identification of Tyr-992 and Tyr-1173 in the C-tail of EGFR and several phosphopeptides from the PDGFR as medium strength binding sites for the SH2 domain of Shc. Tyrosine 51-54 epidermal growth factor receptor Homo sapiens 89-93 8621421-3 1996 The data revealed new potential Grb2 binding sites at Tyr-1114 (epidermal growth factor receptor (EGFR) C-tail); Tyr-743 (platelet-derived growth factor receptor (PDGFR) insert region), Tyr-1110 from the E-helix of the catalytic domain of insulin receptor (IR), and Tyr-47, Tyr-939, and Tyr-727 in IRS-1. Tyrosine 54-57 epidermal growth factor receptor Homo sapiens 98-102 8621421-8 1996 The study confirmed the previous identification of Tyr-992 and Tyr-1173 in the C-tail of EGFR and several phosphopeptides from the PDGFR as medium strength binding sites for the SH2 domain of Shc. Tyrosine 63-66 epidermal growth factor receptor Homo sapiens 89-93 8621421-5 1996 Tyr-1068 and -1086 from the C-tail of EGFR, Tyr-684 from the kinase insert region of PDGFR, and Tyr-895 from IRS-1 were confirmed as major binding sites for the Grb2 SH2 domain. Tyrosine 0-3 epidermal growth factor receptor Homo sapiens 38-42 21544401-5 1996 Western blotting revealed RG13022 caused an inhibition of EGF stimulated tyrosine phosphorylation of EGFr in A431 cells and both EGFr and c-erbB-2 in MKN45 cells. Tyrosine 73-81 epidermal growth factor receptor Homo sapiens 101-105 8649804-3 1996 We report that c-Cbl undergoes rapid and sustained phosphorylation on tyrosine residues upon stimulation of fibroblast and epithelial cell lines with ligands of ErbB-1. Tyrosine 70-78 epidermal growth factor receptor Homo sapiens 161-167 8577724-3 1996 In response to calcium influx, Shc, Grb2, and Sos1 inducibly associate with a 180-kDa tyrosine-phosphorylated protein, which was determined to be the epidermal growth factor receptor (EGFR). Tyrosine 86-94 epidermal growth factor receptor Homo sapiens 150-182 8617744-3 1996 The PI domain forms 1:1 complexes of similar affinity with a 12-mer peptide (ISLDNPDpYQQDF) derived from Tyr-1148 of the epidermal growth factor receptor (EGFR) (KD = 28 nm) and an 18-mer (LQGHIIENPQpYFSDACVH) derived from Tyr-490 of Trk (KD = 42 nM). Tyrosine 105-108 epidermal growth factor receptor Homo sapiens 155-159 8617744-3 1996 The PI domain forms 1:1 complexes of similar affinity with a 12-mer peptide (ISLDNPDpYQQDF) derived from Tyr-1148 of the epidermal growth factor receptor (EGFR) (KD = 28 nm) and an 18-mer (LQGHIIENPQpYFSDACVH) derived from Tyr-490 of Trk (KD = 42 nM). Tyrosine 223-226 epidermal growth factor receptor Homo sapiens 155-159 8617744-6 1996 Alteration of the Asn or Pro to Ala in the NPXpY motif of the EGFR Tyr-1148 peptide increased the KD of PI domain interactions to 238 and 370 nM, respectively. Tyrosine 67-70 epidermal growth factor receptor Homo sapiens 62-66 8617744-7 1996 Alteration of a Leu at position -5 (with respect to Tyr(P)) in the EGFR peptide to Gly also reduced the binding affinity (KD = 580 nM). Tyrosine 52-55 epidermal growth factor receptor Homo sapiens 67-71 8774427-7 1996 Coexpression with a receptor tyrosine kinase, the human epidermal growth factor receptor, also causes an increase in tyrosine phosphorylation of Kv1.3. Tyrosine 29-37 epidermal growth factor receptor Homo sapiens 56-88 8577724-3 1996 In response to calcium influx, Shc, Grb2, and Sos1 inducibly associate with a 180-kDa tyrosine-phosphorylated protein, which was determined to be the epidermal growth factor receptor (EGFR). Tyrosine 86-94 epidermal growth factor receptor Homo sapiens 184-188 8577724-4 1996 Calcium influx induces tyrosine phosphorylation of the EGFR to levels that can activate the MAPK signaling pathway. Tyrosine 23-31 epidermal growth factor receptor Homo sapiens 55-59 8824347-1 1996 PD153035 is a potent (Ki = 6 pm) and specific inhibitor of the epidermal growth factor (EGF) receptor tyrosine kinase that suppresses tyrosine phosphorylation of the EGF receptor in A431 cells at nanomolar concentrations in cell culture. Tyrosine 102-110 epidermal growth factor receptor Homo sapiens 63-101 8567619-5 1996 We then screened the mutants for binding to the tyrosine-phosphorylated carboxyl-terminal tail of the epidermal growth factor (EGF) receptor. Tyrosine 48-56 epidermal growth factor receptor Homo sapiens 102-140 8855443-2 1996 It is generally accepted that reversible phosphorylation of protein tyrosine residues by polypeptide growth factor receptor protein tyrosine kinases (e.g., epidermal growth factor receptor, platelet derived growth factor receptor, insulin receptor) is a signalling mechanism implicated in cell proliferation, adhesion, differentiation, transformation, and apoptosis. Tyrosine 68-76 epidermal growth factor receptor Homo sapiens 156-188 8824347-1 1996 PD153035 is a potent (Ki = 6 pm) and specific inhibitor of the epidermal growth factor (EGF) receptor tyrosine kinase that suppresses tyrosine phosphorylation of the EGF receptor in A431 cells at nanomolar concentrations in cell culture. Tyrosine 102-110 epidermal growth factor receptor Homo sapiens 166-178 8824347-6 1996 The tyrosine phosphorylation of the EGF receptor was rapidly suppressed by 80-90% in the tumors. Tyrosine 4-12 epidermal growth factor receptor Homo sapiens 36-48 8845374-12 1995 A subset of peptides corresponding to the eight possible tyrosine phosphorylation sites within the EGFR autophosphorylation domain was demonstrated to bind to the SH2 domain of c-src. Tyrosine 57-65 epidermal growth factor receptor Homo sapiens 99-103 8532841-2 1996 Human malignant mammary, MCF-7, and squamous, A431, cells showed low baseline phospho-tyrosine levels of epidermal growth factor receptor, permitting reproducible dose-dependent stimulation of epidermal growth factor receptor autophosphorylation after exposure to epidermal growth factor. Tyrosine 86-94 epidermal growth factor receptor Homo sapiens 105-137 9045422-5 1996 Analysis of tyrosine phosphorylation of the receptor, being performed in Mn(2+)-pretreated A431 cells, has confirmed the significant increase of 32P-incorporation into unoccupied EGFR. Tyrosine 12-20 epidermal growth factor receptor Homo sapiens 179-183 8545122-2 1995 One event that occurs rapidly following EGF binding is the covalent modification of the EGF receptor (EGF-R) by phosphorylation on Ser, Thr, and Tyr residues. Tyrosine 145-148 epidermal growth factor receptor Homo sapiens 88-100 8545122-2 1995 One event that occurs rapidly following EGF binding is the covalent modification of the EGF receptor (EGF-R) by phosphorylation on Ser, Thr, and Tyr residues. Tyrosine 145-148 epidermal growth factor receptor Homo sapiens 102-107 7488034-0 1995 c-Src phosphorylates epidermal growth factor receptor on tyrosine 845. Tyrosine 57-65 epidermal growth factor receptor Homo sapiens 21-53 8616601-1 1995 We have previously reported that the activity of low molecular weight (LMW) acid phosphatase, which can remove tyrosine-linked phosphates of epidermal growth factor receptor, was significantly decreased in Alzheimer brains. Tyrosine 111-119 epidermal growth factor receptor Homo sapiens 141-173 8849331-4 1995 Neither compound directly inhibited EGF-induced tyrosine phosphorylation of the EGF-R in HN5 cells. Tyrosine 48-56 epidermal growth factor receptor Homo sapiens 80-85 7488034-8 1995 We have focused our attention to tyrosine residue 845 (Y845) of EGF receptor as a candidate for the phosphorylation site. Tyrosine 33-41 epidermal growth factor receptor Homo sapiens 64-76 21552904-4 1995 It (a) blocks the binding of EGF, TGF alpha and HB-EGF to the EGFR, (b) prevents the EGF, TGF alpha and HB-EGF induced tyrosine phosphorylation of the EGFR, and (c) inhibits the growth in vitro of the head and neck tumour (HN5) cell line overexpressing the EGF receptor. Tyrosine 119-127 epidermal growth factor receptor Homo sapiens 62-66 21552904-4 1995 It (a) blocks the binding of EGF, TGF alpha and HB-EGF to the EGFR, (b) prevents the EGF, TGF alpha and HB-EGF induced tyrosine phosphorylation of the EGFR, and (c) inhibits the growth in vitro of the head and neck tumour (HN5) cell line overexpressing the EGF receptor. Tyrosine 119-127 epidermal growth factor receptor Homo sapiens 151-155 21552904-4 1995 It (a) blocks the binding of EGF, TGF alpha and HB-EGF to the EGFR, (b) prevents the EGF, TGF alpha and HB-EGF induced tyrosine phosphorylation of the EGFR, and (c) inhibits the growth in vitro of the head and neck tumour (HN5) cell line overexpressing the EGF receptor. Tyrosine 119-127 epidermal growth factor receptor Homo sapiens 257-269 7561890-3 1995 SDGF binds to and causes the phosphorylation on tyrosine of the EGF receptor but not HER2/neu. Tyrosine 48-56 epidermal growth factor receptor Homo sapiens 64-76 7634398-0 1995 Inhibition of ligand-induced activation of epidermal growth factor receptor tyrosine phosphorylation by curcumin. Tyrosine 76-84 epidermal growth factor receptor Homo sapiens 43-75 7657591-3 1995 Here we show that upon stimulation of human epidermal growth factor (EGF) receptor, p12ocbl becomes strongly tyrosine-phosphorylated and associates with activated EGF receptor in vivo. Tyrosine 109-117 epidermal growth factor receptor Homo sapiens 44-82 7657591-3 1995 Here we show that upon stimulation of human epidermal growth factor (EGF) receptor, p12ocbl becomes strongly tyrosine-phosphorylated and associates with activated EGF receptor in vivo. Tyrosine 109-117 epidermal growth factor receptor Homo sapiens 163-175 7634398-3 1995 There was no effect of curcumin treatment on the amount of surface expression of labeled EGF-R and inhibition of EGF-mediated tyrosine phosphorylation of EGF-R by curcumin was mediated by a reversible mechanism. Tyrosine 126-134 epidermal growth factor receptor Homo sapiens 154-159 7608194-0 1995 Structural requirements of the epidermal growth factor receptor for tyrosine phosphorylation of eps8 and eps15, substrates lacking Src SH2 homology domains. Tyrosine 68-76 epidermal growth factor receptor Homo sapiens 31-63 7769701-7 1995 Stimulation of LMP1-expressing C33A cells with epidermal growth factor (EGF) caused rapid tyrosine phosphorylation of the EGFR (pp170) as well as several other proteins, including pp120, pp85, pp75, and pp55, indicating that the EGFR induced by LMP1 is functional. Tyrosine 90-98 epidermal growth factor receptor Homo sapiens 122-126 7539258-4 1995 Interestingly, we identified the epidermal growth factor receptor as a novel target for bradykinin-induced tyrosine phosphorylation. Tyrosine 107-115 epidermal growth factor receptor Homo sapiens 33-65 7782294-4 1995 c-Cbl was also tyrosine-phosphorylated in epidermal growth factor (EGF) receptor-overexpressing cells upon EGF stimulation, in macrophages in response to CSF-1 treatment, and in v-src transformed cells. Tyrosine 15-23 epidermal growth factor receptor Homo sapiens 42-80 7797556-1 1995 Following ligand binding, the epidermal growth factor receptor (EGF-R) autophosphorylates itself on tyrosine residues located in its carboxyl terminus; in vitro, three sites are highly phosphorylated, while two other sites are phosphorylated to lesser extents. Tyrosine 100-108 epidermal growth factor receptor Homo sapiens 30-62 7797556-1 1995 Following ligand binding, the epidermal growth factor receptor (EGF-R) autophosphorylates itself on tyrosine residues located in its carboxyl terminus; in vitro, three sites are highly phosphorylated, while two other sites are phosphorylated to lesser extents. Tyrosine 100-108 epidermal growth factor receptor Homo sapiens 64-69 7538132-3 1995 Following EGF stimulation of B82L cells expressing a kinase-defective EGF receptor mutant (K721M), we found that ERK2 and ERK1 MAP kinases, as well as MEK1 and MEK2 were all activated, and SHC became prominently tyrosine-phosphorylated. Tyrosine 212-220 epidermal growth factor receptor Homo sapiens 70-82 7755568-3 1995 In the corresponding region of the epidermal growth factor (EGF) receptor, a potential phosphorylation site, Tyr-845, does not appear to have a major regulatory role. Tyrosine 109-112 epidermal growth factor receptor Homo sapiens 35-73 7755568-4 1995 In order to find out whether this variable loop can modulate the peptide phosphorylation and self-phosphorylation activities of the EGF receptor kinase, we investigated the role of residues around Tyr-845, using site-directed mutagenesis. Tyrosine 197-200 epidermal growth factor receptor Homo sapiens 132-144 8519490-6 1995 The Authors suggest that the mechanism of EGFr-mediated cell differentiation and mitosis might short-circuit EGFr in some instances and lead to the phosphorilation of Tyrosine, probably following the stimulation by other factors. Tyrosine 167-175 epidermal growth factor receptor Homo sapiens 42-46 7729946-7 1995 EGF-induced tyrosine (tyr) phosphorylation both of total cellular protein extracts and of the immunoprecipitated EGF-R is increased in IFN alpha-treated cells. Tyrosine 12-20 epidermal growth factor receptor Homo sapiens 113-118 7729946-7 1995 EGF-induced tyrosine (tyr) phosphorylation both of total cellular protein extracts and of the immunoprecipitated EGF-R is increased in IFN alpha-treated cells. Tyrosine 12-15 epidermal growth factor receptor Homo sapiens 113-118 7534311-0 1995 Association of epidermal growth factor receptors with coated pit adaptins via a tyrosine phosphorylation-regulated mechanism. Tyrosine 80-88 epidermal growth factor receptor Homo sapiens 15-48 7655171-2 1995 In this report, the effects of EGCase on epidermal growth factor (EGF)-dependent tyrosine-specific EGF receptor (EGFR) phosphorylation of A431 cells are described. Tyrosine 81-89 epidermal growth factor receptor Homo sapiens 113-117 7737361-3 1995 In accordance, confocal laser scanning microscopy shows that newly assembled actin filaments localize selectively to the tyrosine-phosphorylated EGFR in the plasma membrane, since actin polymerization is not observed at the internalized tyrosine-phosphorylated EGFR. Tyrosine 121-129 epidermal growth factor receptor Homo sapiens 145-149 7534311-6 1995 Once formed, EGFR AP complexes were resistant to disassembly by dephosphorylation of EGFR or competition with phosphotyrosine, indicating that phosphorylated tyrosine residues do not directly participate in AP binding. Tyrosine 117-125 epidermal growth factor receptor Homo sapiens 13-17 7534311-9 1995 We conclude that tyrosine autophosphorylation of EGFR exposes structural motif(s) in the carboxyl terminus of EGFR that interact specifically with AP2. Tyrosine 17-25 epidermal growth factor receptor Homo sapiens 49-53 7534311-9 1995 We conclude that tyrosine autophosphorylation of EGFR exposes structural motif(s) in the carboxyl terminus of EGFR that interact specifically with AP2. Tyrosine 17-25 epidermal growth factor receptor Homo sapiens 110-114 7756169-4 1995 Before stimulating cell proliferation, vanadate induces accumulation of tyrosine phosphorylation in several proteins including estradiol receptor and epidermal growth factor receptor. Tyrosine 72-80 epidermal growth factor receptor Homo sapiens 150-182 7864629-0 1995 Analysis of substrate recognition determinants in a synthetic peptide containing the Tyr 1173 autophosphorylation site of the epidermal growth factor receptor. Tyrosine 85-88 epidermal growth factor receptor Homo sapiens 126-158 7864629-2 1995 Synthetic peptides based on the major autophosphorylation site at Tyr 1173 were tested as substrates of the intracellular domain of the epidermal growth factor receptor. Tyrosine 66-69 epidermal growth factor receptor Homo sapiens 136-168 8581000-1 1995 Epidermal growth factor (EGF) and transforming growth factor-alpha (TGF alpha) are two closely related peptides that interact with cell-surface epidermal growth factor receptors (EGFR) to induce receptor tyrosine phosphorylation and activation of intracellular signal-transduction pathways. Tyrosine 204-212 epidermal growth factor receptor Homo sapiens 179-183 7814452-2 1995 At the same time, Con A also inhibited both dimerization and tyrosine phosphorylation of the EGF receptor. Tyrosine 61-69 epidermal growth factor receptor Homo sapiens 93-105 7814452-3 1995 Tyrosine phosphorylation of the enzyme phospholipase C-gamma, a substrate of the phosphorylated EGF receptor kinase, was also inhibited. Tyrosine 0-8 epidermal growth factor receptor Homo sapiens 96-108 7815495-0 1995 A minor tyrosine phosphorylation site located within the CAIN domain plays a critical role in regulating tissue-specific transformation by erbB kinase. Tyrosine 8-16 epidermal growth factor receptor Homo sapiens 139-143 7815495-3 1995 Here we show that mutation of a single tyrosine residue, p5, in the carboxyl terminus of the erbB oncogene product allows it to become sarcomagenic in vivo and to transform fibroblasts in vitro. Tyrosine 39-47 epidermal growth factor receptor Homo sapiens 93-97 7805884-0 1995 Hydrogen peroxide preferentially enhances the tyrosine phosphorylation of epidermal growth factor receptor. Tyrosine 46-54 epidermal growth factor receptor Homo sapiens 74-106 7773170-1 1995 Activated epidermal growth factor receptor (EGFR) undergoes autophosphorylation on several cytoplasmic tyrosine residues, which may then associate with the src homology-2 (SH2) domains of effector proteins such as phospholipase C gamma-1 (PLC gamma-1). Tyrosine 103-111 epidermal growth factor receptor Homo sapiens 10-42 7773170-1 1995 Activated epidermal growth factor receptor (EGFR) undergoes autophosphorylation on several cytoplasmic tyrosine residues, which may then associate with the src homology-2 (SH2) domains of effector proteins such as phospholipase C gamma-1 (PLC gamma-1). Tyrosine 103-111 epidermal growth factor receptor Homo sapiens 44-48 7963660-1 1994 In the epidermis tyrosine kinases such as those found in the epidermal growth factor receptor (EGF-R) phosphorylate regulatory molecules on tyrosine and play an important role in controlling epidermal growth. Tyrosine 17-25 epidermal growth factor receptor Homo sapiens 61-93 7963660-1 1994 In the epidermis tyrosine kinases such as those found in the epidermal growth factor receptor (EGF-R) phosphorylate regulatory molecules on tyrosine and play an important role in controlling epidermal growth. Tyrosine 17-25 epidermal growth factor receptor Homo sapiens 95-100 7963660-2 1994 Phosphotyrosyl phosphatases (PTPase) that dephosphorylate EGF-R and other proteins phosphorylated on tyrosine must also play an important role in controlling epidermal growth. Tyrosine 101-109 epidermal growth factor receptor Homo sapiens 58-63 7523189-6 1994 Phosphoamino acid analysis demonstrated that the kinase domain of the epidermal growth factor receptor, p56lck and p60c-src phosphorylated myelin basic protein on tyrosines, that the protamine kinase phosphorylated myelin basic protein on serines, and that myelin basic protein kinase-1 phosphorylated myelin basic protein on threonines. Tyrosine 163-172 epidermal growth factor receptor Homo sapiens 70-102 7929459-7 1994 Chlorate, heparitinase, or heparinase treatment inhibited AR-induced autophosphorylation of tyrosine residues in the EGF receptor. Tyrosine 92-100 epidermal growth factor receptor Homo sapiens 117-129 8034616-3 1994 Binding of Shc to EGF receptor mutants lacking single tyrosine residues at 1148 or 1173 decreased by approximately 60 or approximately 15%, respectively, whereas other single point mutants bound the wild-type level of Shc. Tyrosine 54-62 epidermal growth factor receptor Homo sapiens 18-30 7523156-3 1994 Apparent phosphorylation of tyrosine residues was observed in addition to serine/threonine of the EGF receptor by EGF, but only a slightly if any tyrosine phosphorylation by TNF-alpha. Tyrosine 28-36 epidermal growth factor receptor Homo sapiens 98-110 7923365-5 1994 Indeed, UVC induces the suramin-inhibitable immediate tyrosine phosphorylation of the EGF receptor. Tyrosine 54-62 epidermal growth factor receptor Homo sapiens 86-98 7518560-9 1994 These analyses reveal a hierarchy of interactions between Grb2 and Shc with the EGFR and indicate that Grb2 can bind the tyrosine-phosphorylated EGFR directly, as well as indirectly via Shc. Tyrosine 121-129 epidermal growth factor receptor Homo sapiens 145-149 7907978-2 1994 We have been cloning SH2 domain proteins by bacterial expression cloning using the tyrosine phosphorylated C-terminus of the epidermal growth factor receptor as a probe. Tyrosine 83-91 epidermal growth factor receptor Homo sapiens 125-157 8070968-1 1994 The 13 amino acid EGFR-sequence AENAEYLRVAPQS-NH2 containing the in vivo autophosphorylated Tyr 1171, was synthesized by Fmoc continuous-flow SPPS with and without N-terminal Boc protection. Tyrosine 92-95 epidermal growth factor receptor Homo sapiens 18-22 7971947-14 1994 Using this information we propose a model for Tyr substrate binding to the catalytic domain of the epidermal growth factor receptor (EGFR). Tyrosine 46-49 epidermal growth factor receptor Homo sapiens 99-131 7971947-14 1994 Using this information we propose a model for Tyr substrate binding to the catalytic domain of the epidermal growth factor receptor (EGFR). Tyrosine 46-49 epidermal growth factor receptor Homo sapiens 133-137 7961591-2 1994 Many synthetic polypeptides containing glutamine as well as casein were phosphorylated, while polycationic compounds with tyrosine residues were not phosphorylatable and thus inhibited the EGF-R activity. Tyrosine 122-130 epidermal growth factor receptor Homo sapiens 189-194 8106395-8 1994 Furthermore, anti-phosphotyrosine immunoblot analysis revealed UVB-induced phosphorylation of tyrosine residues of EGF-R, an indicator of receptor activation. Tyrosine 25-33 epidermal growth factor receptor Homo sapiens 115-120 8106395-10 1994 The antioxidant N-acetylcysteine decreased UVB-induced EGF-R tyrosine phosphorylation and PGE2 synthesis to near-basal levels. Tyrosine 61-69 epidermal growth factor receptor Homo sapiens 55-60 7506422-6 1994 Endogenous pp60c-src was found to tightly associate with tyrosine-phosphorylated EGFR. Tyrosine 57-65 epidermal growth factor receptor Homo sapiens 81-85 8276804-5 1994 These results indicate that a significant conformational change occurs in the intracellular portion of the epidermal growth factor receptor upon tyrosine autophosphorylation. Tyrosine 145-153 epidermal growth factor receptor Homo sapiens 107-139 7507488-15 1994 Findings iii and iv suggest that deNAcGM3 strongly promotes serine phosphorylation (in addition to Tyr phosphorylation) of EGF-R and may function as a second messenger in the process of cell growth stimulation. Tyrosine 99-102 epidermal growth factor receptor Homo sapiens 123-128 8275472-3 1994 We show here for the first time that physiologically relevant doses of ultraviolet radiation induce phosphorylation of the epidermal growth factor receptor in A431 keratinocytes at tyrosine sites within 30 min. Tyrosine 181-189 epidermal growth factor receptor Homo sapiens 123-155 7508718-0 1994 Epidermal growth factor induced tyrosine phosphorylation of nuclear proteins associated with translocation of epidermal growth factor receptor into the nucleus. Tyrosine 32-40 epidermal growth factor receptor Homo sapiens 110-142 7508718-2 1994 The major tyrosine phosphorylated protein was indistinguishable from the plasma membrane form of the epidermal growth factor receptor and was shown by enzyme linked immunosorbent assay (ELISA) to be translocated into the nucleus from extra-nuclear sites upon ligand stimulation. Tyrosine 10-18 epidermal growth factor receptor Homo sapiens 101-133 7508718-5 1994 These observations suggest that EGF-R may exert some of its physiological functions by directly inducing tyrosine phosphorylation of specific nuclear proteins. Tyrosine 105-113 epidermal growth factor receptor Homo sapiens 32-37 7506413-9 1994 Thus, tyrosine phosphorylation of Shc may play a crucial role for activating Ras and generating mitotic signals by the activated EGFR mutant. Tyrosine 6-14 epidermal growth factor receptor Homo sapiens 129-133 7506422-7 1994 Association of the SRC SH2 with the EGFR was blocked by tyrosyl phosphopeptides containing the sequences surrounding tyrosine-530, the regulatory site in the SRC C terminus, or sequences surrounding the major sites of autophosphorylation in the EGFR. Tyrosine 117-125 epidermal growth factor receptor Homo sapiens 36-40 8018955-8 1993 These cells overexpressed p53 protein and had an amplified epidermal growth factor (EGF) receptor gene that resulted in high level expression of tyrosine phosphorylated EGF receptor protein. Tyrosine 145-153 epidermal growth factor receptor Homo sapiens 59-97 7503985-2 1993 Previous studies indicated that Tyr-457 of bovine GAP (Tyr-460 of human GAP) is the major site of phosphorylation by viral Src (v-Src) kinase and epidermal growth factor receptor. Tyrosine 32-35 epidermal growth factor receptor Homo sapiens 146-178 7503985-2 1993 Previous studies indicated that Tyr-457 of bovine GAP (Tyr-460 of human GAP) is the major site of phosphorylation by viral Src (v-Src) kinase and epidermal growth factor receptor. Tyrosine 55-58 epidermal growth factor receptor Homo sapiens 146-178 8264617-7 1994 In addition, though certain signal transmitters, including Shc and GRB2, were recruited by both kinases, EGFR and ErbB-3 elicited tyrosine phosphorylation of distinct sets of intracellular substrates. Tyrosine 130-138 epidermal growth factor receptor Homo sapiens 105-109 8253771-11 1993 Analysis of the tyrosine kinase-negative human EGF-R in these cells revealed significant tyrosine phosphorylation of the EGF-R. Tyrosine 16-24 epidermal growth factor receptor Homo sapiens 47-52 8253771-11 1993 Analysis of the tyrosine kinase-negative human EGF-R in these cells revealed significant tyrosine phosphorylation of the EGF-R. Tyrosine 16-24 epidermal growth factor receptor Homo sapiens 121-126 8018955-8 1993 These cells overexpressed p53 protein and had an amplified epidermal growth factor (EGF) receptor gene that resulted in high level expression of tyrosine phosphorylated EGF receptor protein. Tyrosine 145-153 epidermal growth factor receptor Homo sapiens 169-181 8018955-11 1993 These results suggest that the high level of tyrosine phosphorylated EGF receptor present in these cells is the direct result of receptor overexpression and not the result of the presence of a stimulatory ligand. Tyrosine 45-53 epidermal growth factor receptor Homo sapiens 69-81 8396132-0 1993 Ligand-induced internalization of the epidermal growth factor receptor is mediated by multiple endocytic codes analogous to the tyrosine motif found in constitutively internalized receptors. Tyrosine 128-136 epidermal growth factor receptor Homo sapiens 38-70 8162346-11 1993 Immunoblot analysis of extracts from irradiated cells showed that UVB induced tyrosine phosphorylation of EGFR and that the quantity of EGFR protein was unaffected by UVB treatment. Tyrosine 78-86 epidermal growth factor receptor Homo sapiens 106-110 7689859-5 1993 Previously, it had been shown that PLC-gamma 1 was phosphorylated on tyrosine residues by the agonist-occupied platelet-derived growth factor (PDGF) receptor and epidermal growth factor (EGF) receptor in cells other than platelets. Tyrosine 69-77 epidermal growth factor receptor Homo sapiens 162-200 7694547-0 1993 Dephosphorylation on tyrosine of epidermal growth factor receptor is inhibited by Ca2+ pretreatment in isolated liver membrane. Tyrosine 21-29 epidermal growth factor receptor Homo sapiens 33-65 7686167-8 1993 In the MDA-MB-468 cell line, pretreatment with retinol resulted in a decrease in tyrosine phosphorylation of the EGF receptor. Tyrosine 81-89 epidermal growth factor receptor Homo sapiens 113-125 7690546-2 1993 EGF and TGF-alpha induced a rapid increase in tyrosine phosphorylation of the EGF receptor, in both fibroblasts and keratinocytes, but failed to induce tyrosine phosphorylation of PLC-gamma 1 or detectable phosphoinositide hydrolysis, as measured by two sensitive assays. Tyrosine 46-54 epidermal growth factor receptor Homo sapiens 78-90 8225779-2 1993 The peptides were derived from tyrosine autophosphorylation sites in the epidermal growth factor receptor (EGFR): Tyr 992, 1068, 1148 and 1173. Tyrosine 31-39 epidermal growth factor receptor Homo sapiens 73-105 8225779-2 1993 The peptides were derived from tyrosine autophosphorylation sites in the epidermal growth factor receptor (EGFR): Tyr 992, 1068, 1148 and 1173. Tyrosine 31-39 epidermal growth factor receptor Homo sapiens 107-111 8225779-2 1993 The peptides were derived from tyrosine autophosphorylation sites in the epidermal growth factor receptor (EGFR): Tyr 992, 1068, 1148 and 1173. Tyrosine 114-117 epidermal growth factor receptor Homo sapiens 73-105 8225779-2 1993 The peptides were derived from tyrosine autophosphorylation sites in the epidermal growth factor receptor (EGFR): Tyr 992, 1068, 1148 and 1173. Tyrosine 114-117 epidermal growth factor receptor Homo sapiens 107-111 8225779-3 1993 Peptide 1, derived from the Tyr 992 site, inhibited binding of a 35S-labelled fusion protein containing both of the SH2 domains from PLC gamma 1 to the phosphorylated EGFR with an IC50 of 8 microM. Tyrosine 28-31 epidermal growth factor receptor Homo sapiens 167-171 8101647-3 1993 Shc products are phosphorylated on tyrosine by the activated epidermal growth factor receptor (EGFR) and become physically associated with EGFR via their SH2 domain. Tyrosine 35-43 epidermal growth factor receptor Homo sapiens 95-99 8317888-2 1993 We now demonstrate that interferon increases tyrosine phosphorylation of EGFR in the human breast carcinoma cell line MDA 468, in the presence of EGF. Tyrosine 45-53 epidermal growth factor receptor Homo sapiens 73-77 8317888-4 1993 Antiphosphotyrosine immunoblotting revealed that phosphorylation was increased two-fold on tyrosine residues in EGFR. Tyrosine 11-19 epidermal growth factor receptor Homo sapiens 112-116 1512257-8 1992 Because epidermal growth factor receptor phosphorylates the equivalent tyrosine residue in human GAP (Tyr-460), these findings are consistent with the hypothesis that specific phosphorylation of GAP at this site may have a physiologically important role in regulating mitogenic Ras signaling pathways. Tyrosine 71-79 epidermal growth factor receptor Homo sapiens 8-40 7679104-0 1993 Amphiregulin induces tyrosine phosphorylation of the epidermal growth factor receptor and p185erbB2. Tyrosine 21-29 epidermal growth factor receptor Homo sapiens 53-85 7678776-4 1993 P-Tyr incubation led to activation of cellular protein tyrosine phosphatases resulting in the inhibition of tyrosine phosphorylation of epidermal growth factor receptor as well as of p34cdc2. Tyrosine 55-63 epidermal growth factor receptor Homo sapiens 136-168 8382707-1 1993 Monoclonal antibodies prepared against tyrosine phosphorylated epidermal growth factor receptor (EGFR) were tested for their effects on transmembrane signal transduction in A431 tumor cells. Tyrosine 39-47 epidermal growth factor receptor Homo sapiens 97-101 8382707-6 1993 This mab induced EGFR tyrosine phosphorylation in cell lysates and tyrosine-specific autophosphorylation of insolubilized EGFR immune complexes. Tyrosine 22-30 epidermal growth factor receptor Homo sapiens 17-21 8382707-6 1993 This mab induced EGFR tyrosine phosphorylation in cell lysates and tyrosine-specific autophosphorylation of insolubilized EGFR immune complexes. Tyrosine 67-75 epidermal growth factor receptor Homo sapiens 122-126 8382707-10 1993 Blocking of the EGFR kinase site by mab 1-594 also abolished EGF-induced tyrosine phosphorylation of endogenous cellular substrates with molecular masses of 145, 97, 85, 37, and 32 kDa, as well as of exogenous substrates such as GAT copolymer. Tyrosine 73-81 epidermal growth factor receptor Homo sapiens 16-20 7678418-6 1993 Here, we report that the kinase-negative EGF-R is phosphorylated on tyrosine in EGF-treated cells. Tyrosine 68-76 epidermal growth factor receptor Homo sapiens 41-46 7678418-7 1993 The mechanism of tyrosine phosphorylation can be accounted for by the action of EGF to stimulate a protein kinase activity that is associated with the kinase-negative EGF-R. Tyrosine 17-25 epidermal growth factor receptor Homo sapiens 167-172 1331123-4 1992 Our results indicate that in MDA-468 cells, both the EGFR and PLC-gamma are phosphorylated on tyrosine residues and can be co-immunoprecipitated. Tyrosine 94-102 epidermal growth factor receptor Homo sapiens 53-57 7682060-5 1993 Increases in calcium induced by the ionophore resulted in activation of cellular PTPases as indicated by increased dephosphorylation of tyrosine phosphorylated EGFR by cellular lysates. Tyrosine 136-144 epidermal growth factor receptor Homo sapiens 160-164 7679612-0 1993 Exogenous phosphotyrosine modulates epidermal growth factor receptor tyrosine phosphorylation. Tyrosine 17-25 epidermal growth factor receptor Homo sapiens 36-68 7679612-7 1993 Epidermal growth factor (EGF)-mediated tyrosine phosphorylation of EGFR was decreased in situ in a time- and dose-dependent manner in P-Tyr-treated cells. Tyrosine 39-47 epidermal growth factor receptor Homo sapiens 67-71 7679612-7 1993 Epidermal growth factor (EGF)-mediated tyrosine phosphorylation of EGFR was decreased in situ in a time- and dose-dependent manner in P-Tyr-treated cells. Tyrosine 136-139 epidermal growth factor receptor Homo sapiens 67-71 7679612-8 1993 Orthovanadate (100 microM for 4 h) inhibited this decrease, implicating the role of cellular PTPase in P-Tyr-mediated control of EGFR tyrosine phosphorylation. Tyrosine 105-108 epidermal growth factor receptor Homo sapiens 129-133 7679612-8 1993 Orthovanadate (100 microM for 4 h) inhibited this decrease, implicating the role of cellular PTPase in P-Tyr-mediated control of EGFR tyrosine phosphorylation. Tyrosine 134-142 epidermal growth factor receptor Homo sapiens 129-133 7679612-9 1993 Further, EGFR kinase activity was found to be decreased in P-Tyr-treated cells. Tyrosine 61-64 epidermal growth factor receptor Homo sapiens 9-13 1356764-6 1992 Moreover, significant differences were detected in the pattern of intracellular proteins phosphorylated on tyrosine in vivo by EGFR and EGFRThr662 in response to EGF. Tyrosine 107-115 epidermal growth factor receptor Homo sapiens 127-131 1512257-8 1992 Because epidermal growth factor receptor phosphorylates the equivalent tyrosine residue in human GAP (Tyr-460), these findings are consistent with the hypothesis that specific phosphorylation of GAP at this site may have a physiologically important role in regulating mitogenic Ras signaling pathways. Tyrosine 102-105 epidermal growth factor receptor Homo sapiens 8-40 1349015-6 1992 Addition of EGF to transfected cells co-expressing HER2 with a kinase negative point mutant of EGFR (K721A) stimulated heterodimer formation, tyrosine phosphorylation of K721A and HER2, and tyrosine phosphorylation of one of their known substrates, phospholipase C gamma. Tyrosine 142-150 epidermal growth factor receptor Homo sapiens 95-99 1323290-2 1992 The tyrosine residue at 845 in EGF-R corresponds to Y416 of v/c-src kinase, which is highly conserved and functionally important in many tyrosine kinases. Tyrosine 4-12 epidermal growth factor receptor Homo sapiens 31-36 1323290-3 1992 To clarify the functional role of Y845, we constructed a mutant human EGF-R in which this tyrosine was replaced with phenylalanine and transfected it to NIH3T3 cells. Tyrosine 90-98 epidermal growth factor receptor Homo sapiens 70-75 1323290-4 1992 EGF-R F845 induced EGF-dependent cellular transformation and revealed tyrosine-autophosphorylation of a 170 kDa protein, and initiated DNA synthesis similar to the wild-type EGF-R. Tyrosine 70-78 epidermal growth factor receptor Homo sapiens 0-5 1352397-5 1992 An EGFR/erbB-2 mutant bearing multiple Tyr----Phe substitutions at erbB-2 autophosphorylation sites (EGFR/erbB-2 5P) displayed markedly reduced phosphotyrosine content following EGF stimulation in comparison with the non-mutated chimera. Tyrosine 39-42 epidermal growth factor receptor Homo sapiens 3-7 1352397-5 1992 An EGFR/erbB-2 mutant bearing multiple Tyr----Phe substitutions at erbB-2 autophosphorylation sites (EGFR/erbB-2 5P) displayed markedly reduced phosphotyrosine content following EGF stimulation in comparison with the non-mutated chimera. Tyrosine 39-42 epidermal growth factor receptor Homo sapiens 101-105 1378752-1 1992 Previous studies of tumor necrosis factor (TNF) action on tumor cells revealed a possible role for tyrosine phosphorylation of epidermal growth factor (EGF) receptor in the growth-regulatory activities of this cytokine (N. J. Donato, G. E. Gallick, P. A. Steck, and M. G. Rosenblum, J. Biol. Tyrosine 99-107 epidermal growth factor receptor Homo sapiens 127-165 1321807-1 1992 Epidermal growth factor (EGF) treatment of cells expressing the human EGF receptor (EGFr) results in rapid tyrosine phosphorylation of several cellular proteins including mitogen-activated protein (MAP) kinase. Tyrosine 107-115 epidermal growth factor receptor Homo sapiens 70-82 1321807-1 1992 Epidermal growth factor (EGF) treatment of cells expressing the human EGF receptor (EGFr) results in rapid tyrosine phosphorylation of several cellular proteins including mitogen-activated protein (MAP) kinase. Tyrosine 107-115 epidermal growth factor receptor Homo sapiens 84-88 1321807-2 1992 EGF treatment of cells expressing a tyrosine kinase-inactive EGFr failed to induce the tyrosine phosphorylation of endogenous substrates in response to EGF; however, the tyrosine phosphorylation and activation of MAP kinase did occur. Tyrosine 36-44 epidermal growth factor receptor Homo sapiens 61-65 1321046-18 1992 The random polymer of Glu, Lys, Ala, Tyr (2:5:6:1), which was not phosphorylated by the EGF-R kinase, dramatically activates autophosphorylation of the EGF-R. Tyrosine 37-40 epidermal growth factor receptor Homo sapiens 152-157 1349015-6 1992 Addition of EGF to transfected cells co-expressing HER2 with a kinase negative point mutant of EGFR (K721A) stimulated heterodimer formation, tyrosine phosphorylation of K721A and HER2, and tyrosine phosphorylation of one of their known substrates, phospholipase C gamma. Tyrosine 190-198 epidermal growth factor receptor Homo sapiens 95-99 1370492-6 1992 Quantitative estimates of specific radioactivity of the EGFR in these two compartments revealed that tyrosine phosphorylation of the EGFR was observed at the cell surface within 30 s of ligand administration. Tyrosine 101-109 epidermal growth factor receptor Homo sapiens 56-60 1347529-1 1992 To gain insight into the mechanisms which control the mitogenic response to epidermal growth factor (EGF), we have partially purified and characterized several intracellular proteins which are phosphorylated on tyrosine residues following activation of the epidermal growth factor receptor (EGFR). Tyrosine 211-219 epidermal growth factor receptor Homo sapiens 257-289 1347529-1 1992 To gain insight into the mechanisms which control the mitogenic response to epidermal growth factor (EGF), we have partially purified and characterized several intracellular proteins which are phosphorylated on tyrosine residues following activation of the epidermal growth factor receptor (EGFR). Tyrosine 211-219 epidermal growth factor receptor Homo sapiens 291-295 1537871-5 1992 Tyrosine phosphorylation induced by the TCR and the EGFR occurred on substrates unique to each receptor as well as on several shared substrates, including the zeta chain of the TCR. Tyrosine 0-8 epidermal growth factor receptor Homo sapiens 52-56 1504015-8 1992 In cells cultured with TGF-beta, the phosphorylation of EGF receptor tyrosines induced by 20-min exposure to EGF was further increased 2-3-fold, suggesting additive effects upon receptor phosphorylation. Tyrosine 69-78 epidermal growth factor receptor Homo sapiens 56-68 1730638-2 1992 A much broader spectrum of tyrosine phosphorylated proteins was found following EGF treatment of 973-EGFR expressing cells compared with cells expressing wild-type receptors. Tyrosine 27-35 epidermal growth factor receptor Homo sapiens 101-105 1730638-3 1992 Several additional ras GTPase activating protein-associated tyrosine phosphorylated proteins were found in EGF-treated 973-EGFR cells relative to WT-EGFR cells. Tyrosine 60-68 epidermal growth factor receptor Homo sapiens 123-127 1730638-3 1992 Several additional ras GTPase activating protein-associated tyrosine phosphorylated proteins were found in EGF-treated 973-EGFR cells relative to WT-EGFR cells. Tyrosine 60-68 epidermal growth factor receptor Homo sapiens 149-153 1730638-4 1992 Additional tyrosine-phosphorylated proteins were also found to co-immunoprecipitate with phospholipase C gamma 1 (PLC gamma 1) following EGF treatment of cells expressing 973-EGFR relative to cells expressing WT-EGFR. Tyrosine 11-19 epidermal growth factor receptor Homo sapiens 175-179 1730638-4 1992 Additional tyrosine-phosphorylated proteins were also found to co-immunoprecipitate with phospholipase C gamma 1 (PLC gamma 1) following EGF treatment of cells expressing 973-EGFR relative to cells expressing WT-EGFR. Tyrosine 11-19 epidermal growth factor receptor Homo sapiens 212-216 1730638-5 1992 EGF-stimulated tyrosine phosphorylation of PLC gamma 1 was found in cells expressing WT-EGFR, but not in cells expressing 973-EGFR. Tyrosine 15-23 epidermal growth factor receptor Homo sapiens 88-92 1370492-6 1992 Quantitative estimates of specific radioactivity of the EGFR in these two compartments revealed that tyrosine phosphorylation of the EGFR was observed at the cell surface within 30 s of ligand administration. Tyrosine 101-109 epidermal growth factor receptor Homo sapiens 133-137 1370492-7 1992 However, the EGFR was also highly phosphorylated in endosomes reaching levels of tyrosine phosphorylation significantly higher than those of the cell surface receptor at 5 and 15 min after EGF injection. Tyrosine 81-89 epidermal growth factor receptor Homo sapiens 13-17 1370492-8 1992 A 55-kD tyrosine phosphorylated polypeptide (pyp55) was observed in association with the EGFR at the cell surface within 30 s of EGF injection. Tyrosine 8-16 epidermal growth factor receptor Homo sapiens 89-93 1370492-10 1992 Limited proteolysis of isolated endosomes indicated that the tyrosine phosphorylated domains of the EGFR and associated pyp55 were cytosolically oriented while internalized EGF was intraluminal. Tyrosine 61-69 epidermal growth factor receptor Homo sapiens 100-104 1729595-0 1992 A site of tyrosine phosphorylation in the C terminus of the epidermal growth factor receptor is required to activate phospholipase C. Cells expressing mutant epidermal growth factor (EGF) receptors have been used to study mechanisms through which EGF increases phospholipase C (PLC) activity. Tyrosine 10-18 epidermal growth factor receptor Homo sapiens 60-92 2072905-8 1991 In addition, the EGF receptor was found to be phosphorylated on tyrosine in LIM 1215 cells proliferating at high density, suggesting that the autocrine production of transforming growth factor alpha (TGF alpha) and subsequent ligation to the EGF receptor was occurring. Tyrosine 64-72 epidermal growth factor receptor Homo sapiens 17-29 1683701-6 1991 All carcinomas in which tyrosine phosphorylated PLC-gamma 1 was present also expressed detectable levels of the epidermal growth factor receptor or erbB-2, two tyrosine kinases known to phosphorylate this enzyme. Tyrosine 24-32 epidermal growth factor receptor Homo sapiens 112-144 1663789-1 1991 Treatment of normal human fibroblasts with epidermal growth factor (EGF) results in the rapid (0.5 min) and simultaneous tyrosine phosphorylation of the EGF receptor (EGFr) and several other proteins. Tyrosine 121-129 epidermal growth factor receptor Homo sapiens 153-165 1663789-1 1991 Treatment of normal human fibroblasts with epidermal growth factor (EGF) results in the rapid (0.5 min) and simultaneous tyrosine phosphorylation of the EGF receptor (EGFr) and several other proteins. Tyrosine 121-129 epidermal growth factor receptor Homo sapiens 167-171 1903921-7 1991 Functional coupling of the EGF receptor to PLA2 occurred despite the absence of a demonstrable Ca(2+)-signalling response and the detection of diminished but persistent PLC-gamma phosphorylation on tyrosine residues in the CD126 deletion mutants. Tyrosine 198-206 epidermal growth factor receptor Homo sapiens 27-39 1647028-3 1991 Here, we show that protein 4.1 is phosphorylated on tyrosine by the epidermal growth factor receptor (EGFR) tyrosine kinase. Tyrosine 52-60 epidermal growth factor receptor Homo sapiens 68-100 1647028-3 1991 Here, we show that protein 4.1 is phosphorylated on tyrosine by the epidermal growth factor receptor (EGFR) tyrosine kinase. Tyrosine 52-60 epidermal growth factor receptor Homo sapiens 102-106 1647028-6 1991 Immunoblotting with anti-phosphotyrosine antibodies showed that purified protein 4.1 contained phosphorylated tyrosine, and this increased upon phosphorylation by EGFR. Tyrosine 32-40 epidermal growth factor receptor Homo sapiens 163-167 2022652-0 1991 Internalization and down-regulation of the human epidermal growth factor receptor are regulated by the carboxyl-terminal tyrosines. Tyrosine 121-130 epidermal growth factor receptor Homo sapiens 49-81 2022652-1 1991 The C terminus of the epidermal growth factor receptor (EGF-R) contains three tyrosines (Y1068, Y1148, and Y1173) which correspond to the major autophosphorylation sites. Tyrosine 78-87 epidermal growth factor receptor Homo sapiens 22-54 2022652-1 1991 The C terminus of the epidermal growth factor receptor (EGF-R) contains three tyrosines (Y1068, Y1148, and Y1173) which correspond to the major autophosphorylation sites. Tyrosine 78-87 epidermal growth factor receptor Homo sapiens 56-61 2022652-2 1991 To investigate the role of the tyrosines in internalization and down-regulation of the EGF-R, mutational analysis was performed with receptors in which 1, 2, or all 3 tyrosines were changed to phenylalanines. Tyrosine 31-40 epidermal growth factor receptor Homo sapiens 87-92 2022652-9 1991 Our results show that in the full-length EGF-R all three C-terminal tyrosines are necessary for rapid internalization, suggesting that autophosphorylation is required for efficient EGF-dependent receptor endocytosis. Tyrosine 68-77 epidermal growth factor receptor Homo sapiens 41-46 2058454-5 1991 In this light, we could show that tyrosine phosphorylation of the RR-SRC peptide substrate and the autophosphorylation of the epidermal growth factor (EGF) receptor were, dose dependently, inhibited by leflunomide. Tyrosine 34-42 epidermal growth factor receptor Homo sapiens 126-164 1646987-0 1991 The biological activity of the human epidermal growth factor receptor is positively regulated by its C-terminal tyrosines. Tyrosine 112-121 epidermal growth factor receptor Homo sapiens 37-69 1646987-1 1991 The epidermal growth factor receptor (EGF-R) C-terminus contains three conserved tyrosines (Y-1068, Y-1148, Y-1173) which are phosphorylated upon EGF activation. Tyrosine 81-90 epidermal growth factor receptor Homo sapiens 4-36 1646987-1 1991 The epidermal growth factor receptor (EGF-R) C-terminus contains three conserved tyrosines (Y-1068, Y-1148, Y-1173) which are phosphorylated upon EGF activation. Tyrosine 81-90 epidermal growth factor receptor Homo sapiens 38-43 1646987-8 1991 The EGF-R kinase activity is affected by tyrosine substitution since in vitro phosphorylation of exogenous substrates is reduced in the double and triple mutants. Tyrosine 41-49 epidermal growth factor receptor Homo sapiens 4-9 1646987-11 1991 We conclude, therefore, that the tyrosines at the extreme C-terminus positively regulate the biological and transforming activity of the EGF-R, probably via autophosphorylation. Tyrosine 33-42 epidermal growth factor receptor Homo sapiens 137-142 1850098-0 1991 The epidermal growth factor receptor phosphorylates GTPase-activating protein (GAP) at Tyr-460, adjacent to the GAP SH2 domains. Tyrosine 87-90 epidermal growth factor receptor Homo sapiens 4-36 1850098-8 1991 We conclude that Tyr-460 is a site of GAP tyrosine phosphorylation by the EGF receptor in vitro and likely in vivo. Tyrosine 17-20 epidermal growth factor receptor Homo sapiens 74-86 1850098-8 1991 We conclude that Tyr-460 is a site of GAP tyrosine phosphorylation by the EGF receptor in vitro and likely in vivo. Tyrosine 42-50 epidermal growth factor receptor Homo sapiens 74-86 1993654-3 1991 The EGF receptor is phosphorylated at tyrosine residues although we have not yet established if this represents direct phosphorylation by the PDGF receptor kinase or is mediated by activation of other cell membrane-associated tyrosine kinases. Tyrosine 38-46 epidermal growth factor receptor Homo sapiens 4-16 1988447-2 1991 In A431 membrane preparations and permeabilized cells, all antibodies were able to activate the EGF-R tyrosine kinase, as measured by EGF-R autophosphorylation and phosphorylation of other substrates on tyrosine residues. Tyrosine 102-110 epidermal growth factor receptor Homo sapiens 96-101 1988447-2 1991 In A431 membrane preparations and permeabilized cells, all antibodies were able to activate the EGF-R tyrosine kinase, as measured by EGF-R autophosphorylation and phosphorylation of other substrates on tyrosine residues. Tyrosine 102-110 epidermal growth factor receptor Homo sapiens 134-139 2218496-3 1990 An antibody to EGFR abolished the tyrosine phosphorylation induced by EGF and transforming growth factor-alpha (TGF-alpha) but only partially blocked that produced by gp30 in SK-BR-3 breast cancer cells. Tyrosine 34-42 epidermal growth factor receptor Homo sapiens 15-19 1722417-5 1991 The reactivity of mAb74 towards EGFr was closely correlated with the EGF-dependent tyrosine phosphorylation of endogenous substrates. Tyrosine 83-91 epidermal growth factor receptor Homo sapiens 32-36 2166944-7 1990 Treatment of cells with PMA caused greater than 90% inhibition of the EGF-stimulated tyrosine phosphorylation of the EGF receptor and abolished the EGF-stimulated formation of soluble inositol phosphates. Tyrosine 85-93 epidermal growth factor receptor Homo sapiens 117-129 1974718-0 1990 The epidermal growth factor receptor and the product of the neu protooncogene are members of a receptor tyrosine phosphorylation cascade. Tyrosine 104-112 epidermal growth factor receptor Homo sapiens 4-36 2392327-7 1990 At high cell density, where paracrine as well as autocrine effects of these growth factors would be evident, TGF alpha transfectants displayed at least as high or higher levels of EGF receptor (EGFR) tyrosine phosphorylation than preproEGF transfectants. Tyrosine 200-208 epidermal growth factor receptor Homo sapiens 194-198 2156836-2 1990 During the course of these studies we discovered that a low molecular mass, high affinity GTP-binding protein from bovine brain (designated as the 22-kDa protein) served as an excellent phosphosubstrate for the tyrosine-agarose-purified human placental EGF receptor. Tyrosine 211-219 epidermal growth factor receptor Homo sapiens 253-265 1696547-2 1990 We detected epidermal growth factor (EGF) induced tyrosine phosphorylation of EGF-R not occupied with ligand. Tyrosine 50-58 epidermal growth factor receptor Homo sapiens 78-83 2142159-9 1990 However, decreased levels of ganglioside expression were associated with 1) increased EGF receptor autophosphorylation on tyrosine residues, and 2) increased EGF-stimulated cellular proliferation. Tyrosine 122-130 epidermal growth factor receptor Homo sapiens 86-98 2153302-5 1990 High-performance liquid chromatographic comparison of tryptic phosphopeptides from PLC-gamma phosphorylated by both forms of the EGF receptor kinase indicated similar patterns of multiple tyrosine phosphorylations. Tyrosine 188-196 epidermal growth factor receptor Homo sapiens 129-141 2105948-8 1990 In contrast, the inhibition of EGF receptor tyrosine phosphorylation caused by phorbol ester was not observed for any of the mutated EGF receptors that lacked Thr654. Tyrosine 44-52 epidermal growth factor receptor Homo sapiens 31-43 2155244-1 1990 A preliminary characterization of the protein phosphotyrosine phosphatase (PTPase) activity in human peripheral blood lymphocytes (PBL) has been made using two tyrosine-containing peptides and the epidermal growth factor receptor from A-431 cells as substrates. Tyrosine 53-61 epidermal growth factor receptor Homo sapiens 197-229 2302227-9 1990 Tyrosine phosphorylation of EGF receptor from cells treated with TGF-alpha decreased more rapidly following removal of TGF-alpha compared to cells treated similarly with EGF. Tyrosine 0-8 epidermal growth factor receptor Homo sapiens 28-40 1706616-9 1990 However, each of these peptides contains tyrosines that correspond to major autophosphorylation sites of the epidermal growth factor receptor, suggesting that, in addition to Y1023 and Y1248, Y1139 and Y1222 also serve as autophosphorylation sites of HER2. Tyrosine 41-50 epidermal growth factor receptor Homo sapiens 109-141 2105948-7 1990 Analysis of the regulation of the EGF receptor tyrosine protein kinase activity demonstrated that phorbol ester caused an inhibition of the tyrosine phosphorylation of wild-type receptors and receptors lacking Thr669, Ser1046, or Ser1047. Tyrosine 47-55 epidermal growth factor receptor Homo sapiens 34-46 1688559-0 1990 Analysis of deletions of the carboxyl terminus of the epidermal growth factor receptor reveals self-phosphorylation at tyrosine 992 and enhanced in vivo tyrosine phosphorylation of cell substrates. Tyrosine 119-127 epidermal growth factor receptor Homo sapiens 54-86 1688559-0 1990 Analysis of deletions of the carboxyl terminus of the epidermal growth factor receptor reveals self-phosphorylation at tyrosine 992 and enhanced in vivo tyrosine phosphorylation of cell substrates. Tyrosine 153-161 epidermal growth factor receptor Homo sapiens 54-86 33786875-2 2021 Immunohistochemistry and immunoblotting were conducted to determine expression of ADAM 9 and the levels of EGFR phosphorylated at the tyrosine 1173 residue (p-EGFRtyr1173 ) and AKT phosphorylated at the serine 473 residue (p-AKTser473 ) in oral cancer tissues and in the oral cancer cell lines HN5, HN6, HN15, and HN008. Tyrosine 134-142 epidermal growth factor receptor Homo sapiens 107-111 34111559-2 2022 We unraveled a mechanism for radiation resistance; radiation induces EGFR, which phosphorylates TRIP13 on tyrosine 56. Tyrosine 106-114 epidermal growth factor receptor Homo sapiens 69-73 34742684-1 2022 Epithelial growth factor receptor (EGFR) is a cell surface transmembrane receptor that mediates the tyrosine signaling pathway to carry the extracellular messages inside the cell and thereby alter the function of nucleus. Tyrosine 100-108 epidermal growth factor receptor Homo sapiens 0-33 34742684-1 2022 Epithelial growth factor receptor (EGFR) is a cell surface transmembrane receptor that mediates the tyrosine signaling pathway to carry the extracellular messages inside the cell and thereby alter the function of nucleus. Tyrosine 100-108 epidermal growth factor receptor Homo sapiens 35-39 34917992-7 2021 Conclusions: EGFR tyrosine inhibitors plus irinotecan plus cisplatin chemotherapy might be a potential treatment option for advanced pulmonary neuroendocrine neoplasms harboring EGFR mutations. Tyrosine 18-26 epidermal growth factor receptor Homo sapiens 13-17 34415295-6 2021 We show that by incorporating halogenated tyrosines, the affinity of 9G8 nanobody can be improved toward epidermal growth factor receptor (EGFR), a crucial cancer target. Tyrosine 42-51 epidermal growth factor receptor Homo sapiens 105-137 34415295-6 2021 We show that by incorporating halogenated tyrosines, the affinity of 9G8 nanobody can be improved toward epidermal growth factor receptor (EGFR), a crucial cancer target. Tyrosine 42-51 epidermal growth factor receptor Homo sapiens 139-143 34066157-4 2021 We further explored the molecular mechanisms that enables these cells to be primarily resistant to T-DM1 and found that EGFR was activated in the spheroids, leading to an increased HER2 tyrosine phosphorylation. Tyrosine 186-194 epidermal growth factor receptor Homo sapiens 120-124 34725466-0 2021 EGFR Regulates the Hippo pathway by promoting the tyrosine phosphorylation of MOB1. Tyrosine 50-58 epidermal growth factor receptor Homo sapiens 0-4 34066157-7 2021 Blocking EGFR activity by erlotinib reduces HER2 tyrosine phosphorylation and enhances HER2 cell surface expression. Tyrosine 49-57 epidermal growth factor receptor Homo sapiens 9-13 35197444-10 2022 Conversely, Numb-PRRL silencing inhibited EGF-induced EMT in AsPC-1 and BxPC-3 cells following the activation of EGFR-ERK/MAPK signaling via phosphorylating EGFR at tyrosine 1045. Tyrosine 165-173 epidermal growth factor receptor Homo sapiens 113-117 35197444-10 2022 Conversely, Numb-PRRL silencing inhibited EGF-induced EMT in AsPC-1 and BxPC-3 cells following the activation of EGFR-ERK/MAPK signaling via phosphorylating EGFR at tyrosine 1045. Tyrosine 165-173 epidermal growth factor receptor Homo sapiens 157-161 2548197-1 1989 In this paper we show that epidermal growth factor (EGF) stimulates the phosphorylation of lipocortin 1, at threonine as well as at tyrosine residues, by a highly purified preparation of the EGF receptor. Tyrosine 132-140 epidermal growth factor receptor Homo sapiens 191-203 2824482-1 1987 We have examined the effect of tyrosine phosphorylation of microtubule-associated protein 2 (MAP2) by the epidermal growth factor (EGF) receptor kinase on its functions. Tyrosine 31-39 epidermal growth factor receptor Homo sapiens 106-144 2464783-1 1989 Treatment of intact cells with media containing high concentrations of ionic and non-ionic solutes induced increased tyrosine phosphorylation of the epidermal growth factor (EGF) receptor and the protein product of the erbB-2/neu proto-oncogene. Tyrosine 117-125 epidermal growth factor receptor Homo sapiens 149-187 3377786-1 1988 Different tyrosines are autophosphorylated on the native and on the protease-generated 150 kDa forms of the epidermal growth factor receptor. Tyrosine 10-19 epidermal growth factor receptor Homo sapiens 108-140 3367910-0 1988 Kinetics and regulation of the tyrosine phosphorylation of epidermal growth factor receptor in intact A431 cells. Tyrosine 31-39 epidermal growth factor receptor Homo sapiens 59-91 2755700-8 1989 Moreover, high levels of EGF-independent tyrosine phosphorylation of the EGFR were detected both in NIH-EGFR expressing TGF alpha and in high EGFR and TGF alpha coexpressing human tumor cell lines. Tyrosine 41-49 epidermal growth factor receptor Homo sapiens 73-77 2755700-8 1989 Moreover, high levels of EGF-independent tyrosine phosphorylation of the EGFR were detected both in NIH-EGFR expressing TGF alpha and in high EGFR and TGF alpha coexpressing human tumor cell lines. Tyrosine 41-49 epidermal growth factor receptor Homo sapiens 100-108 2755700-8 1989 Moreover, high levels of EGF-independent tyrosine phosphorylation of the EGFR were detected both in NIH-EGFR expressing TGF alpha and in high EGFR and TGF alpha coexpressing human tumor cell lines. Tyrosine 41-49 epidermal growth factor receptor Homo sapiens 104-108 2854198-15 1988 Hydrolysis of phosphate from tyrosine residues in the immunoprecipitated EGF receptor catalyzed by purified prostatic phosphotyrosyl-protein phosphatase caused a 40 to 50% decrease in the receptor tyrosine kinase activity with angiotensin as the substrate. Tyrosine 29-37 epidermal growth factor receptor Homo sapiens 73-85 2824482-6 1987 These data indicate that tyrosine phosphorylation of MAP2 by the EGF receptor kinase inactivates both the tubulin polymerizing activity and actin filament cross-linking activity of MAP2. Tyrosine 25-33 epidermal growth factor receptor Homo sapiens 65-77 2418017-11 1986 Antibody 2913 activates the EGF receptor kinase in solubilized A431 membranes causing autophosphorylation on tyrosine residues only. Tyrosine 109-117 epidermal growth factor receptor Homo sapiens 28-31 3015611-6 1986 The antibodies inhibited EGF-stimulated receptor protein-tyrosine kinase autophosphorylation and phosphorylation of an exogenous peptide substrate containing tyrosine. Tyrosine 57-65 epidermal growth factor receptor Homo sapiens 25-28 2418024-11 1986 (i) EGF-dependent tyrosine phosphorylation of the EGF receptor and its inhibition by GM3 were also demonstrated on isolated EGF receptor after adsorption on the anti-receptor antibody-Sepharose complex, and the receptor phosphorylation was enhanced on addition of phosphatidylethanolamine. Tyrosine 18-26 epidermal growth factor receptor Homo sapiens 50-62 2418024-11 1986 (i) EGF-dependent tyrosine phosphorylation of the EGF receptor and its inhibition by GM3 were also demonstrated on isolated EGF receptor after adsorption on the anti-receptor antibody-Sepharose complex, and the receptor phosphorylation was enhanced on addition of phosphatidylethanolamine. Tyrosine 18-26 epidermal growth factor receptor Homo sapiens 124-136 3426916-6 1987 The EGF receptor isolated from this tumour showed a normal pattern of tyrosine phosphorylation at all three major autophosphorylation sites. Tyrosine 70-78 epidermal growth factor receptor Homo sapiens 4-16 6321473-8 1984 This phosphorylation of EGF receptors results in decreased self-phosphorylation of the EGF receptor at tyrosine residues both in vivo and in vitro and in decreased EGF-stimulated tyrosine kinase activity in vivo. Tyrosine 103-111 epidermal growth factor receptor Homo sapiens 24-36 3332005-7 1986 On the other hand, the erbB-1/EGF (epidermal growth factor) receptor gene and the erbB-2/neu gene have completely different splicing junctions from those of the above gene group even in the kinase domain, although these genes also have protein kinase activity specific for tyrosine residues and the erbB-1 and -2 genes share splicing sites. Tyrosine 273-281 epidermal growth factor receptor Homo sapiens 23-29 2413042-8 1985 The EGF-R and several high molecular weight cytoskeletal proteins were phosphorylated on tyrosine residues; two of the latter proteins were phosphorylated transiently as a consequence of EGF action, suggesting that EGF caused the active redistribution of the protein substrates relative to protein kinases. Tyrosine 89-97 epidermal growth factor receptor Homo sapiens 4-9 3000427-10 1985 Hence, autophosphorylation of the tyrosine sites in the 150-kDa form of the EGF receptor is markedly enhanced by removing the major sites autophosphorylated on the native form of the receptor. Tyrosine 34-42 epidermal growth factor receptor Homo sapiens 76-88 2994662-1 1985 The EGF receptor has been purified from human epidermoid carcinoma A431 cells by affinity chromatography on wheat germ agglutinin-agarose and tyrosine-Sepharose. Tyrosine 142-150 epidermal growth factor receptor Homo sapiens 4-16 2982824-2 1985 The tyrosine phosphorylation of histone H2B catalyzed by an affinity-purified preparation of EGF receptor was also inhibited by amiloride. Tyrosine 4-12 epidermal growth factor receptor Homo sapiens 93-105 2982824-4 1985 The tyrosine phosphorylation of histone H2B catalyzed by the purified EGF receptor was inhibited by amiloride at concentrations identical to those previously reported to block EGF action on cell proliferation (Ki = 350 microM). Tyrosine 4-12 epidermal growth factor receptor Homo sapiens 70-82 2982824-6 1985 Immunoprecipitation of the EGF receptor from A431 cells labeled for 24 h with [32P]phosphate demonstrated that amiloride decreased the phosphorylation of the EGF receptor on serine and threonine residues and blocked the effect of EGF to cause phosphorylation of the receptor on tyrosine residues. Tyrosine 278-286 epidermal growth factor receptor Homo sapiens 158-170 6092336-5 1984 OADG, like TPA, caused loss of binding to an apparent high affinity class of receptors, blocked EGF-induced tyrosine phosphorylation of the EGF receptor, and stimulated phosphorylation of the EGF receptor at both serine and threonine residues. Tyrosine 108-116 epidermal growth factor receptor Homo sapiens 140-152 6328489-0 1984 Tumor promoters block tyrosine-specific phosphorylation of the epidermal growth factor receptor. Tyrosine 22-30 epidermal growth factor receptor Homo sapiens 63-95 6328489-1 1984 Tyrosine-specific phosphorylation of the epidermal growth factor (EGF) receptor in hormonally stimulated A431 cells is blocked by three chemically distinct classes of tumor promoters. Tyrosine 0-8 epidermal growth factor receptor Homo sapiens 41-79 6328489-7 1984 The dose-responses for tumor-promoter inhibition of EGF receptor tyrosine phosphorylation and high-affinity EGF binding were similar, suggesting that the same initial event is responsible for both effects. Tyrosine 65-73 epidermal growth factor receptor Homo sapiens 52-64 6328489-8 1984 This demonstrates a correlation between modulation of EGF receptor binding and phosphorylation of tyrosine by tumor promoters. Tyrosine 98-106 epidermal growth factor receptor Homo sapiens 54-66 6265789-4 1981 We show here that TGFs produced by human tumour cells induce phosphorylation of specific tyrosine acceptor sites in the 160,000-molecular weight (160 K) EGF receptor. Tyrosine 89-97 epidermal growth factor receptor Homo sapiens 153-165 6101263-1 1983 The protein kinase associated with the purified epidermal growth factor (EGF) receptor from membrane (Mr = 150,000) or vesicle (Mr = 170,000) preparations of A-431 cells was shown to catalyze the phosphorylation of the peptide Leu-Glu-Asp-Ala-Glu-Tyr-Ala-Ala-Arg-Arg-Arg-Gly at the tyrosine residue. Tyrosine 247-250 epidermal growth factor receptor Homo sapiens 48-86 6101263-1 1983 The protein kinase associated with the purified epidermal growth factor (EGF) receptor from membrane (Mr = 150,000) or vesicle (Mr = 170,000) preparations of A-431 cells was shown to catalyze the phosphorylation of the peptide Leu-Glu-Asp-Ala-Glu-Tyr-Ala-Ala-Arg-Arg-Arg-Gly at the tyrosine residue. Tyrosine 282-290 epidermal growth factor receptor Homo sapiens 48-86 33976119-6 2021 Specifically, we discover that EGFR activity promotes the tyrosine phosphorylation of HDAC1, which is necessary for its protein stability. Tyrosine 58-66 epidermal growth factor receptor Homo sapiens 31-35 33976119-8 2021 Given that HDAC1 overexpression and EGFR activity are strongly related with tumor progression and cancer cell survival, HDAC1 tyrosine phosphorylation may present a possible target to manipulate HDAC1 protein levels in future potential cancer treatment strategies. Tyrosine 126-134 epidermal growth factor receptor Homo sapiens 36-40 33883672-0 2021 EGFR-dependent tyrosine phosphorylation of integrin beta4 is not required for downstream signaling events in cancer cell lines. Tyrosine 15-23 epidermal growth factor receptor Homo sapiens 0-4 33883672-3 2021 In EGFR-overexpressing carcinoma cells, we found that the Src family kinase (SFK) inhibitor PP2 reduces beta4 tyrosine phosphorylation following the activation of EGFR. Tyrosine 110-118 epidermal growth factor receptor Homo sapiens 3-7 31957251-2 2021 Despite the traditional methods including radiotherapy and chemotherapy, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) might benefit patients on survival and quality of life. Tyrosine 106-114 epidermal growth factor receptor Homo sapiens 134-138 33655823-8 2022 The deregulation in the checkpoints is caused due to the changes brought in the tyrosine residues of TPKs via PDGFR, EGFR, FGFR, and VEGFR-mediated signalling pathways. Tyrosine 80-88 epidermal growth factor receptor Homo sapiens 117-121 33319463-7 2021 These piptides also caused apoptotic cell death, and antagonized EGF-induced phosphorylation of intracellular tyrosine residues in EGFR. Tyrosine 110-118 epidermal growth factor receptor Homo sapiens 131-135 33328764-6 2020 Increased tyrosine phosphorylation in multiple receptor/protein tyrosine kinases (EPHA2, EGFR, IGF1R, ABL1 and LYN) was identified in CNE2-IR vs CNE2 cells. Tyrosine 10-18 epidermal growth factor receptor Homo sapiens 89-93 31657688-1 2021 BACKGROUND: Epidermal growth factor receptor (EGFR, ErBb) belongs to family of receptor tyrosine kinase (RTKs) played important role in multiple cell signaling pathways, which includes cell growth, multiplication and apoptosis etc. Tyrosine 88-96 epidermal growth factor receptor Homo sapiens 12-44 31657688-1 2021 BACKGROUND: Epidermal growth factor receptor (EGFR, ErBb) belongs to family of receptor tyrosine kinase (RTKs) played important role in multiple cell signaling pathways, which includes cell growth, multiplication and apoptosis etc. Tyrosine 88-96 epidermal growth factor receptor Homo sapiens 46-50 31657688-1 2021 BACKGROUND: Epidermal growth factor receptor (EGFR, ErBb) belongs to family of receptor tyrosine kinase (RTKs) played important role in multiple cell signaling pathways, which includes cell growth, multiplication and apoptosis etc. Tyrosine 88-96 epidermal growth factor receptor Homo sapiens 52-56 33529490-1 2021 BACKGROUND: In this study, we investigated the risk factors of acquired T790M mutation among patients with lung adenocarcinoma with epidermal growth factor receptor (EGFR) tyrosine mutation who were treated with EGFR-tyrosine kinase inhibitors (TKIs). Tyrosine 172-180 epidermal growth factor receptor Homo sapiens 132-164 33529490-1 2021 BACKGROUND: In this study, we investigated the risk factors of acquired T790M mutation among patients with lung adenocarcinoma with epidermal growth factor receptor (EGFR) tyrosine mutation who were treated with EGFR-tyrosine kinase inhibitors (TKIs). Tyrosine 172-180 epidermal growth factor receptor Homo sapiens 166-170 33338921-7 2021 While Hex decreased EGFR phosphorylation at Tyr 1068, it increased EGFR Tyr 1045 phosphorylation. Tyrosine 44-47 epidermal growth factor receptor Homo sapiens 20-24 33338921-7 2021 While Hex decreased EGFR phosphorylation at Tyr 1068, it increased EGFR Tyr 1045 phosphorylation. Tyrosine 72-75 epidermal growth factor receptor Homo sapiens 67-71 33000220-0 2020 Gangliosides and CD82 inhibit the motility of colon cancer by downregulating the phosphorylation of EGFR at different tyrosine sites and signaling pathways. Tyrosine 118-126 epidermal growth factor receptor Homo sapiens 100-104 32860853-5 2020 Reciprocally, TRIP13 was phosphorylated at tyrosine(Y) 56 by EGFRvIII and EGF-activated EGFR. Tyrosine 43-51 epidermal growth factor receptor Homo sapiens 61-65 33179922-2 2020 The carboxyl-terminus domain is a disordered region of EGFR that contains the tyrosine residues, which undergo autophosphorylation followed by docking of signaling proteins. Tyrosine 78-86 epidermal growth factor receptor Homo sapiens 55-59 31988476-2 2020 However, EGFR-tyrosine kinase inhibitors (TKIs), including gefitinib, have not yet shown clear clinical benefit and the underlying mechanisms remain largely unexplored. Tyrosine 14-22 epidermal growth factor receptor Homo sapiens 9-13 31659695-8 2020 Drug association analysis demonstrated that both hesperetin and the erbB receptor inhibitors, i.e., monoclonal antibody and tyrosine kinase inhibitor, target the same mRNA expression. Tyrosine 124-132 epidermal growth factor receptor Homo sapiens 68-72 32692593-3 2020 To enable signal initiation and termination while simultaneously accounting for suppression of aberrant signaling, a coordinated coupling of EGFR kinase and protein tyrosine phosphatase activity is established through space by vesicular dynamics. Tyrosine 165-173 epidermal growth factor receptor Homo sapiens 141-145 31869496-6 2020 In contrast, PKCalpha depletion in A431-A6 tumors is associated with strongly reduced pT654 EGFR levels, yet increased EGFR tyrosine phosphorylation and MAPK activity. Tyrosine 124-132 epidermal growth factor receptor Homo sapiens 119-123 32964398-4 2021 The increase in EGFR tyrosine phosphorylation caused by PACAP was blocked by the EGFR tyrosine kinase inhibitor (TKI) gefitinib, or PACAP(6-38), a PAC1 antagonist. Tyrosine 21-29 epidermal growth factor receptor Homo sapiens 16-20 31945786-7 2020 RESULTS: EDY was likely to occur in multiple nondiseased tissues (P<0.001) and statistically significantly associated with the EGFR tyrosine kinase inhibitor resistance pathway (FDR=0.028). Tyrosine 135-143 epidermal growth factor receptor Homo sapiens 130-134 32439698-10 2020 CONCLUSIONS: Collectively, the studies presented herein suggest that tyrosine 821 of AXL mediates resistance to cetuximab by activation of c-ABL kinase in HNSCC and that targeting of both EGFR and c-ABL leads to a robust anti-tumor response. Tyrosine 69-77 epidermal growth factor receptor Homo sapiens 188-192 32018052-3 2020 Here, we investigated the mechanism underlying AXL-mediated acquired resistance to first and third generation small molecule EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC). Tyrosine 130-138 epidermal growth factor receptor Homo sapiens 125-129 32011193-2 2020 Consistent data have demonstrated that these patients have a better outcome when treated with specific tyrosine-kinase inhibitors (EGFR-TKIs). Tyrosine 103-111 epidermal growth factor receptor Homo sapiens 131-135 32069373-1 2020 WHAT IS KNOWN AND OBJECTIVE: Targeted small molecule EGFR Tyrosine Kinase Inhibitors (TKI"s) and the Anaplastic Lymphoma Kinase (ALK) inhibitors have been promising tools for advanced non-small-cell lung cancers (NSCLCs). Tyrosine 58-66 epidermal growth factor receptor Homo sapiens 53-57 31869496-0 2020 Annexin A6 improves anti-migratory and anti-invasive properties of tyrosine kinase inhibitors in EGFR overexpressing human squamous epithelial cells. Tyrosine 67-75 epidermal growth factor receptor Homo sapiens 97-101 32014348-0 2020 Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: A Clash of the Generations. Tyrosine 0-8 epidermal growth factor receptor Homo sapiens 48-52 32439863-3 2020 Here we found that EGFR induced PPARdelta phosphorylation at tyrosine-108 leading to increased binding of LC3 to PPARdelta by its LIR (LC3 interacting region) motif, consequently, inhibited autophagic flux. Tyrosine 61-69 epidermal growth factor receptor Homo sapiens 19-23 32439863-5 2020 Furthermore, EGFR-mediated PPARdelta phosphorylation at tyrosine-108 led to autophagy inhibition and tumor growth. Tyrosine 56-64 epidermal growth factor receptor Homo sapiens 13-17 31735523-1 2020 BACKGROUND: Insights into the mechanism of resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) could provide important information for further patient management, including the choice of second-line treatment. Tyrosine 97-105 epidermal growth factor receptor Homo sapiens 57-89 31735523-1 2020 BACKGROUND: Insights into the mechanism of resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) could provide important information for further patient management, including the choice of second-line treatment. Tyrosine 97-105 epidermal growth factor receptor Homo sapiens 91-95 32014348-1 2020 The availability of 3 generations of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) with different pharmacologic characteristics and clinical profiles has provided oncologists with a potentially confusing choice for the treatment of EGFR mutation-positive non-small-cell lung cancer. Tyrosine 77-85 epidermal growth factor receptor Homo sapiens 37-69 32014348-1 2020 The availability of 3 generations of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) with different pharmacologic characteristics and clinical profiles has provided oncologists with a potentially confusing choice for the treatment of EGFR mutation-positive non-small-cell lung cancer. Tyrosine 77-85 epidermal growth factor receptor Homo sapiens 71-75 32014348-1 2020 The availability of 3 generations of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) with different pharmacologic characteristics and clinical profiles has provided oncologists with a potentially confusing choice for the treatment of EGFR mutation-positive non-small-cell lung cancer. Tyrosine 77-85 epidermal growth factor receptor Homo sapiens 260-264 32017710-4 2020 RESULTS: Whole-exome sequencing within a precision oncology program identified an activating mutation (p.Asp769Tyr) in the catalytic domain of the ERBB2 receptor tyrosine kinase in a patient with schwannomatosis-associated N/S HNST, and targeted treatment with the small-molecule ERBB inhibitor lapatinib led to prolonged clinical benefit and a lasting radiographic and metabolic response. Tyrosine 162-170 epidermal growth factor receptor Homo sapiens 147-151 32029440-4 2020 In this study, we examined whether another important downstream effector of RTK/EGFR, the non-receptor tyrosine kinase c-Src, affects CIC repressor function in GBM. Tyrosine 103-111 epidermal growth factor receptor Homo sapiens 80-84 31747091-5 2020 EGFR inhibitors including both monoclonal antibodies (cetuximab and panitumumab) and tyrosine kinase inhibitors (erlotinib, gefitinib and dasatinib) have been used in clinical trials for the treatment of advanced cSCC, achieving only partial clinical benefit. Tyrosine 85-93 epidermal growth factor receptor Homo sapiens 0-4 31901678-1 2020 The oncogenic receptor tyrosine kinase family ErbB consists of four members (ErbB1, ErbB2, ErbB3 and ErbB4); they are involved in the tumorgenesis of diverse cancers. Tyrosine 23-31 epidermal growth factor receptor Homo sapiens 46-50 31901678-1 2020 The oncogenic receptor tyrosine kinase family ErbB consists of four members (ErbB1, ErbB2, ErbB3 and ErbB4); they are involved in the tumorgenesis of diverse cancers. Tyrosine 23-31 epidermal growth factor receptor Homo sapiens 77-82 31931137-1 2020 INTRODUCTION: Limited clinical data are available regarding the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in patients with non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations. Tyrosine 109-117 epidermal growth factor receptor Homo sapiens 137-141 31778239-1 2020 WHAT IS KNOWN AND OBJECTIVE: Erlotinib is a small molecule tyrosine kinase inhibitor which blocks the activation of epidermal growth factor receptor (EGFR), a transmembrane receptor that is upregulated in many cancer types. Tyrosine 59-67 epidermal growth factor receptor Homo sapiens 116-148 31907582-8 2020 By using the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478, it was found that EGFR is critical for ERK phosphorylation induced by CsA. Tyrosine 53-61 epidermal growth factor receptor Homo sapiens 13-45 31907582-8 2020 By using the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478, it was found that EGFR is critical for ERK phosphorylation induced by CsA. Tyrosine 53-61 epidermal growth factor receptor Homo sapiens 47-51 31907582-8 2020 By using the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478, it was found that EGFR is critical for ERK phosphorylation induced by CsA. Tyrosine 53-61 epidermal growth factor receptor Homo sapiens 105-109 31931029-4 2020 Here we found that EGFR-stimulated phosphorylation of SQSTM1 at tyrosine 433 induces dimerization of its UBA domain, which disturbs the sequestration function of SQSTM1 and causes autophagic flux blocking. Tyrosine 64-72 epidermal growth factor receptor Homo sapiens 19-23 31778239-1 2020 WHAT IS KNOWN AND OBJECTIVE: Erlotinib is a small molecule tyrosine kinase inhibitor which blocks the activation of epidermal growth factor receptor (EGFR), a transmembrane receptor that is upregulated in many cancer types. Tyrosine 59-67 epidermal growth factor receptor Homo sapiens 150-154 31957595-1 2020 Several reports have investigated relationships between epidermal growth factor receptor (EGFR) mutations and the efficacy of EGFR-tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer; however, there have been insufficient analyses of relationships between EGFR mutations and adverse reactions. Tyrosine 131-139 epidermal growth factor receptor Homo sapiens 56-88 31957595-1 2020 Several reports have investigated relationships between epidermal growth factor receptor (EGFR) mutations and the efficacy of EGFR-tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer; however, there have been insufficient analyses of relationships between EGFR mutations and adverse reactions. Tyrosine 131-139 epidermal growth factor receptor Homo sapiens 90-94 31957595-1 2020 Several reports have investigated relationships between epidermal growth factor receptor (EGFR) mutations and the efficacy of EGFR-tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer; however, there have been insufficient analyses of relationships between EGFR mutations and adverse reactions. Tyrosine 131-139 epidermal growth factor receptor Homo sapiens 126-130 31957595-1 2020 Several reports have investigated relationships between epidermal growth factor receptor (EGFR) mutations and the efficacy of EGFR-tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer; however, there have been insufficient analyses of relationships between EGFR mutations and adverse reactions. Tyrosine 131-139 epidermal growth factor receptor Homo sapiens 126-130 31957595-1 2020 Several reports have investigated relationships between epidermal growth factor receptor (EGFR) mutations and the efficacy of EGFR-tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer; however, there have been insufficient analyses of relationships between EGFR mutations and adverse reactions. Tyrosine 131-139 epidermal growth factor receptor Homo sapiens 126-130 31743131-5 2020 EGFR tyrosine kinase domain Sanger sequencing was performed on all lrHPV RNA positive and 15 randomly selected lrHPV RNA negative IPs. Tyrosine 5-13 epidermal growth factor receptor Homo sapiens 0-4 31761448-10 2020 Of the 12 cases of NTRK1+ lung cancer, 6 had had concurrent activating EGFR mutations and/or had received previous treatment with EGFR tyrosine kinase inhibitors (TKIs), with 2 having concurrent EGFR T790M and 1 additional EGFR C797S. Tyrosine 135-143 epidermal growth factor receptor Homo sapiens 130-134 31761448-10 2020 Of the 12 cases of NTRK1+ lung cancer, 6 had had concurrent activating EGFR mutations and/or had received previous treatment with EGFR tyrosine kinase inhibitors (TKIs), with 2 having concurrent EGFR T790M and 1 additional EGFR C797S. Tyrosine 135-143 epidermal growth factor receptor Homo sapiens 130-134 31761448-10 2020 Of the 12 cases of NTRK1+ lung cancer, 6 had had concurrent activating EGFR mutations and/or had received previous treatment with EGFR tyrosine kinase inhibitors (TKIs), with 2 having concurrent EGFR T790M and 1 additional EGFR C797S. Tyrosine 135-143 epidermal growth factor receptor Homo sapiens 130-134 31859066-7 2020 Patients with EGFR exon 20 insertions had a median PFS to EGFR tyrosine kinase inhibitors (TKIs) of 5 months and an OS of 16 months-significantly worse than exon 19 del and L858R (Bonferroni correction; P < .001), but not G719X or L861Q. Tyrosine 63-71 epidermal growth factor receptor Homo sapiens 14-18 31964750-2 2020 Chlamydia binds several receptor tyrosine kinases (RTKs) on host cells, including the epidermal growth factor receptor (EGFR) and activates cellular signaling cascades for host invasion, cytoskeletal remodeling, optimal inclusion development, and induction of pathogenic epithelial-mesenchyme transition (EMT). Tyrosine 33-41 epidermal growth factor receptor Homo sapiens 86-118 31964750-2 2020 Chlamydia binds several receptor tyrosine kinases (RTKs) on host cells, including the epidermal growth factor receptor (EGFR) and activates cellular signaling cascades for host invasion, cytoskeletal remodeling, optimal inclusion development, and induction of pathogenic epithelial-mesenchyme transition (EMT). Tyrosine 33-41 epidermal growth factor receptor Homo sapiens 120-124 31932478-1 2020 EGFR is a prototype receptor tyrosine kinase and an oncogene in many solid tumors. Tyrosine 29-37 epidermal growth factor receptor Homo sapiens 0-4 32024694-7 2020 A phosphorylated form of this peptide inhibits SHP2 activity in vitro and EGFR and HER2 signaling in cells, suggesting inhibition of SHP2 protein tyrosine phosphatase activity by this peptide. Tyrosine 146-154 epidermal growth factor receptor Homo sapiens 74-78 31841994-1 2020 Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib, have been established as first-line treatments for non-small cell lung cancer (NSCLC) patients and have exhibited notable clinical efficacy. Tyrosine 40-48 epidermal growth factor receptor Homo sapiens 0-32 31841994-1 2020 Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib, have been established as first-line treatments for non-small cell lung cancer (NSCLC) patients and have exhibited notable clinical efficacy. Tyrosine 40-48 epidermal growth factor receptor Homo sapiens 34-38 31991049-3 2020 However, many patients with suspected advanced nonsmall cell lung cancer are unable to undergo biopsy thus forgoing potential treatment with highly effective tyrosine kinase inhibitors (TKIs) in patients with sensitizing EGFR mutations. Tyrosine 158-166 epidermal growth factor receptor Homo sapiens 221-225 31922964-0 2020 Successful immune checkpoint inhibition in an EGFR-mutant lung cancer patient refractory to epidermal growth factor receptor tyrosine kinase inhibitor treatment. Tyrosine 125-133 epidermal growth factor receptor Homo sapiens 46-50 31926441-1 2020 OBJECTIVES: Epidermal growth factor receptor (EGFR) exon 20 insertions comprise 4-10 % of EGFR mutations in non-small cell lung cancer (NSCLC) and are associated with primary resistance to first and second generation EGFR tyrosine kinase inhibitors (TKIs). Tyrosine 222-230 epidermal growth factor receptor Homo sapiens 12-44 31830556-4 2020 The ERBB family of receptor tyrosine kinases (EGFR/ERBB1, HER2/ERBB2, ERBB3, and ERBB4) are activated by extracellular ligands, inducing multiple pro-growth signaling cascades; among these, activation of signaling through the RAS GTPase, and the RAF, MEK1/2, and ERK1/2 kinases enhance cell proliferation and restrict apoptosis during renal tubuloepithelial cyst formation. Tyrosine 28-36 epidermal growth factor receptor Homo sapiens 4-8 31830556-4 2020 The ERBB family of receptor tyrosine kinases (EGFR/ERBB1, HER2/ERBB2, ERBB3, and ERBB4) are activated by extracellular ligands, inducing multiple pro-growth signaling cascades; among these, activation of signaling through the RAS GTPase, and the RAF, MEK1/2, and ERK1/2 kinases enhance cell proliferation and restrict apoptosis during renal tubuloepithelial cyst formation. Tyrosine 28-36 epidermal growth factor receptor Homo sapiens 46-50 31830556-4 2020 The ERBB family of receptor tyrosine kinases (EGFR/ERBB1, HER2/ERBB2, ERBB3, and ERBB4) are activated by extracellular ligands, inducing multiple pro-growth signaling cascades; among these, activation of signaling through the RAS GTPase, and the RAF, MEK1/2, and ERK1/2 kinases enhance cell proliferation and restrict apoptosis during renal tubuloepithelial cyst formation. Tyrosine 28-36 epidermal growth factor receptor Homo sapiens 51-56 31595681-1 2020 ATP-analogue inhibitors, Gefitinib (Iressa) and Erlotinib (Tarceva), had been approved for advanced and metastatic NSCLC against tyrosine kinase domain of EGFR. Tyrosine 129-137 epidermal growth factor receptor Homo sapiens 155-159 31839416-1 2020 OBJECTIVES: The 3rd generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR TKI) osimertinib has shown promising efficacy both in EGFR-mutant, T790M positive non-small cell lung cancer (NSCLC) patients who have become resistant to 1st or 2nd generation EGFR TKIs and patients with sensitizing EGFR mutations as the first line therapy. Tyrosine 64-72 epidermal growth factor receptor Homo sapiens 91-95 31982639-1 2020 OBJECTIVES: We aimed to investigate the clinical efficacy of EGFR tyrosine kinase inhibitor (TKI, T) plus bevacizumab (an antiangiogenic therapy, A) in a real-world population and to provide insights into their mechanism of resistance. Tyrosine 66-74 epidermal growth factor receptor Homo sapiens 61-65 31926441-1 2020 OBJECTIVES: Epidermal growth factor receptor (EGFR) exon 20 insertions comprise 4-10 % of EGFR mutations in non-small cell lung cancer (NSCLC) and are associated with primary resistance to first and second generation EGFR tyrosine kinase inhibitors (TKIs). Tyrosine 222-230 epidermal growth factor receptor Homo sapiens 46-50 31926441-1 2020 OBJECTIVES: Epidermal growth factor receptor (EGFR) exon 20 insertions comprise 4-10 % of EGFR mutations in non-small cell lung cancer (NSCLC) and are associated with primary resistance to first and second generation EGFR tyrosine kinase inhibitors (TKIs). Tyrosine 222-230 epidermal growth factor receptor Homo sapiens 90-94 31926441-1 2020 OBJECTIVES: Epidermal growth factor receptor (EGFR) exon 20 insertions comprise 4-10 % of EGFR mutations in non-small cell lung cancer (NSCLC) and are associated with primary resistance to first and second generation EGFR tyrosine kinase inhibitors (TKIs). Tyrosine 222-230 epidermal growth factor receptor Homo sapiens 90-94 31945708-0 2020 Clearing of circulating tumour DNA predicts clinical response to first line tyrosine kinase inhibitors in advanced epidermal growth factor receptor mutated non-small cell lung cancer. Tyrosine 76-84 epidermal growth factor receptor Homo sapiens 115-147 31945708-1 2020 OBJECTIVES: Epidermal growth factor receptor (EGFR) mutations confer sensitivity to tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC). Tyrosine 84-92 epidermal growth factor receptor Homo sapiens 12-44 31945708-1 2020 OBJECTIVES: Epidermal growth factor receptor (EGFR) mutations confer sensitivity to tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC). Tyrosine 84-92 epidermal growth factor receptor Homo sapiens 46-50 32069320-1 2020 Epidermal growth factor receptor (EGFR) is a pro-tumorigenic receptor tyrosine kinase that facilitates growth for cancer cells that overexpress the receptor. Tyrosine 70-78 epidermal growth factor receptor Homo sapiens 0-32 32201537-5 2020 Mechanistically, CD148 negatively regulated EGFR phosphorylation of multiple tyrosine residues, including Y1173, Y1068, and Y1092, and remarkably inhibited downstream PI3K/AKT and MEK/ERK pathways. Tyrosine 77-85 epidermal growth factor receptor Homo sapiens 44-48 31943845-1 2020 BACKGROUND: Abivertinib is a novel oral, third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that overcomes T790M-induced resistance in non-small cell lung cancer (NSCLC) patients. Tyrosine 98-106 epidermal growth factor receptor Homo sapiens 58-90 31943845-1 2020 BACKGROUND: Abivertinib is a novel oral, third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that overcomes T790M-induced resistance in non-small cell lung cancer (NSCLC) patients. Tyrosine 98-106 epidermal growth factor receptor Homo sapiens 92-96 31809241-1 2020 PURPOSE: In this phase I study (BLOOM), osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), was evaluated in patients with leptomeningeal metastases (LMs) from EGFR-mutated (EGFRm) advanced non-small-cell lung cancer (NSCLC) whose disease had progressed on previous EGFR-TKI therapy. Tyrosine 112-120 epidermal growth factor receptor Homo sapiens 106-110 32069320-1 2020 Epidermal growth factor receptor (EGFR) is a pro-tumorigenic receptor tyrosine kinase that facilitates growth for cancer cells that overexpress the receptor. Tyrosine 70-78 epidermal growth factor receptor Homo sapiens 34-38 32053675-2 2020 Some causative genomic alterations in epidermal growth factor receptor (EGFR), including deletions in exon 19 (E19 dels) and a point mutation in E21, are known to have favourable prognoses due to sensitivity to tyrosine kinase inhibitors; however, the prognoses of other uncommon mutations are unclear. Tyrosine 211-219 epidermal growth factor receptor Homo sapiens 38-70 32070026-3 2020 The amplification of MET (hepatocyte growth factor receptor) compensates for the inhibition of epidermal growth factor receptor (EGFR) activity due to tyrosine kinase inhibitor (TKI), leading to TKI resistance. Tyrosine 151-159 epidermal growth factor receptor Homo sapiens 95-127 32070026-3 2020 The amplification of MET (hepatocyte growth factor receptor) compensates for the inhibition of epidermal growth factor receptor (EGFR) activity due to tyrosine kinase inhibitor (TKI), leading to TKI resistance. Tyrosine 151-159 epidermal growth factor receptor Homo sapiens 129-133 32053675-2 2020 Some causative genomic alterations in epidermal growth factor receptor (EGFR), including deletions in exon 19 (E19 dels) and a point mutation in E21, are known to have favourable prognoses due to sensitivity to tyrosine kinase inhibitors; however, the prognoses of other uncommon mutations are unclear. Tyrosine 211-219 epidermal growth factor receptor Homo sapiens 72-76 31674165-7 2020 Results showed unusual EGFR mutations, which are associated with drug resistance to EGFR tyrosine kinase inhibitors, revealing the importance of identifying morule-like features in pulmonary adenocarcinoma and the need for additional study, since there are few reported cases. Tyrosine 89-97 epidermal growth factor receptor Homo sapiens 23-27 31782583-1 2020 Patients with EGFR-mutated non-small cell lung cancer (NSCLC) harboring BIM deletion-polymorphism (BIM deletion) have poor responses to EGFR-tyrosine kinase inhibitor (TKIs). Tyrosine 141-149 epidermal growth factor receptor Homo sapiens 14-18 31782583-1 2020 Patients with EGFR-mutated non-small cell lung cancer (NSCLC) harboring BIM deletion-polymorphism (BIM deletion) have poor responses to EGFR-tyrosine kinase inhibitor (TKIs). Tyrosine 141-149 epidermal growth factor receptor Homo sapiens 136-140 31846863-1 2020 PURPOSE: The first-line treatment of metastatic lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutation is tyrosine kinase inhibitor (TKI). Tyrosine 125-133 epidermal growth factor receptor Homo sapiens 73-105 31846863-1 2020 PURPOSE: The first-line treatment of metastatic lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutation is tyrosine kinase inhibitor (TKI). Tyrosine 125-133 epidermal growth factor receptor Homo sapiens 107-111 31884128-1 2020 OBJECTIVES: Tyrosine kinase inhibitor (TKI) has been the standard of care for advanced non-small cell lung cancers (NSCLC) harboring epidermal growth factor receptor (EGFR) mutation, but these tumors invariably develop drug resistance. Tyrosine 12-20 epidermal growth factor receptor Homo sapiens 133-165 31884128-1 2020 OBJECTIVES: Tyrosine kinase inhibitor (TKI) has been the standard of care for advanced non-small cell lung cancers (NSCLC) harboring epidermal growth factor receptor (EGFR) mutation, but these tumors invariably develop drug resistance. Tyrosine 12-20 epidermal growth factor receptor Homo sapiens 167-171 31672763-9 2020 Differential activation of tyrosine kinase receptors in 2D and 3D models of GBM explains the well documented discrepancy between pre-clinical and clinical effects of EGFR inhibitors. Tyrosine 27-35 epidermal growth factor receptor Homo sapiens 166-170 31910497-0 2020 Impact of clinicopathologic features on leptomeningeal metastasis from lung adenocarcinoma and treatment efficacy with epidermal growth factor receptor tyrosine kinase inhibitor. Tyrosine 152-160 epidermal growth factor receptor Homo sapiens 119-151 31910497-8 2020 EGFR-tyrosine kinase inhibitor (TKI) conferred survival benefits compared to cytotoxic chemotherapy or best supportive care (HR 2.222, P = 0.018; HR 5.638, P < 0.001, respectively). Tyrosine 5-13 epidermal growth factor receptor Homo sapiens 0-4 32025485-1 2020 Because epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are effective in the treatment of non-small cell lung cancer (NSCLC) patients with EGFR mutations, it is critical to obtain accurate EGFR mutation test results. Tyrosine 41-49 epidermal growth factor receptor Homo sapiens 8-40 32025485-1 2020 Because epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are effective in the treatment of non-small cell lung cancer (NSCLC) patients with EGFR mutations, it is critical to obtain accurate EGFR mutation test results. Tyrosine 41-49 epidermal growth factor receptor Homo sapiens 69-73 32025485-1 2020 Because epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are effective in the treatment of non-small cell lung cancer (NSCLC) patients with EGFR mutations, it is critical to obtain accurate EGFR mutation test results. Tyrosine 41-49 epidermal growth factor receptor Homo sapiens 163-167 32025485-1 2020 Because epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are effective in the treatment of non-small cell lung cancer (NSCLC) patients with EGFR mutations, it is critical to obtain accurate EGFR mutation test results. Tyrosine 41-49 epidermal growth factor receptor Homo sapiens 163-167 31956415-0 2020 Squamous cell transformation as a mechanism of acquired resistance to tyrosine kinase inhibitor in EGFR-mutated lung adenocarcinoma: a report of two cases. Tyrosine 70-78 epidermal growth factor receptor Homo sapiens 99-103 31956415-1 2020 Pathological transformation to squamous cell carcinoma after epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor treatment has been reported, but details of the transformation remain unclear. Tyrosine 101-109 epidermal growth factor receptor Homo sapiens 61-93 31956415-1 2020 Pathological transformation to squamous cell carcinoma after epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor treatment has been reported, but details of the transformation remain unclear. Tyrosine 101-109 epidermal growth factor receptor Homo sapiens 95-99 31935369-1 2020 Eradicating tumor dormancy that develops following epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment of EGFR-mutant non-small cell lung cancer, is an attractive therapeutic strategy but the mechanisms governing this process are poorly understood. Tyrosine 91-99 epidermal growth factor receptor Homo sapiens 51-83 31935369-1 2020 Eradicating tumor dormancy that develops following epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment of EGFR-mutant non-small cell lung cancer, is an attractive therapeutic strategy but the mechanisms governing this process are poorly understood. Tyrosine 91-99 epidermal growth factor receptor Homo sapiens 85-89 31935369-1 2020 Eradicating tumor dormancy that develops following epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment of EGFR-mutant non-small cell lung cancer, is an attractive therapeutic strategy but the mechanisms governing this process are poorly understood. Tyrosine 91-99 epidermal growth factor receptor Homo sapiens 136-140 31904278-2 2020 :: Advanced-stage non-small cell lung carcinoma patients on EGFR-targeted tyrosine kinase inhibitors frequently present with an acquired EGFR T790M resistance mutation. Tyrosine 74-82 epidermal growth factor receptor Homo sapiens 60-64 31904278-2 2020 :: Advanced-stage non-small cell lung carcinoma patients on EGFR-targeted tyrosine kinase inhibitors frequently present with an acquired EGFR T790M resistance mutation. Tyrosine 74-82 epidermal growth factor receptor Homo sapiens 137-141 31601525-1 2020 BACKGROUND: Clinical-pathologic predictors of acquired T790M epidermal growth factor receptor (EGFR) mutation in Caucasian patients with non-small-cell lung cancer (NSCLC) progressing after first-/second-generation tyrosine kinase inhibitors (TKIs) is an open field for research. Tyrosine 215-223 epidermal growth factor receptor Homo sapiens 61-93 31601525-1 2020 BACKGROUND: Clinical-pathologic predictors of acquired T790M epidermal growth factor receptor (EGFR) mutation in Caucasian patients with non-small-cell lung cancer (NSCLC) progressing after first-/second-generation tyrosine kinase inhibitors (TKIs) is an open field for research. Tyrosine 215-223 epidermal growth factor receptor Homo sapiens 95-99 31805304-2 2020 Results of kinase inhibitory assay showed that 20(S)-PPD was an EGFR tyrosine kinase inhibitor. Tyrosine 69-77 epidermal growth factor receptor Homo sapiens 64-68 31789388-2 2020 However, epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) resistance is a major challenge in the treatment of advanced and recurrent EGFR-mutant lung adenocarcinoma. Tyrosine 49-57 epidermal growth factor receptor Homo sapiens 9-41 31789388-2 2020 However, epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) resistance is a major challenge in the treatment of advanced and recurrent EGFR-mutant lung adenocarcinoma. Tyrosine 49-57 epidermal growth factor receptor Homo sapiens 43-47 31789388-2 2020 However, epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) resistance is a major challenge in the treatment of advanced and recurrent EGFR-mutant lung adenocarcinoma. Tyrosine 49-57 epidermal growth factor receptor Homo sapiens 156-160 31892990-1 2020 Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been widely used to treat non-small cell lung cancer (NSCLC) because they inhibit tumour growth and metastasis. Tyrosine 40-48 epidermal growth factor receptor Homo sapiens 0-32 31892990-1 2020 Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been widely used to treat non-small cell lung cancer (NSCLC) because they inhibit tumour growth and metastasis. Tyrosine 40-48 epidermal growth factor receptor Homo sapiens 34-38 32005236-0 2020 Correction to: Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. Tyrosine 145-153 epidermal growth factor receptor Homo sapiens 29-61 31736196-7 2020 Also, the level of tyrosine-phosphorylated epidermal growth factor receptor (EGFR)/ERBB2 family proteins was found to be lower in cells cultured in 3D collagen gel compared to those in cells cultured on TC plastic. Tyrosine 19-27 epidermal growth factor receptor Homo sapiens 77-81 31985315-2 2020 Patients with high serum CRP levels had lower therapeutic responses to EGFR-tyrosine kinase inhibitors (43.8%), and shorter time to treatment failure (TTF; 5.8 months) and overall survival (OS; 14.2 months) than those with low CRP levels. Tyrosine 76-84 epidermal growth factor receptor Homo sapiens 71-75 31785991-1 2020 Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) improved clinical outcome compared to chemotherapy in EGFR mutated advanced non-small cell lung cancer (NSCLC) patients. Tyrosine 33-41 epidermal growth factor receptor Homo sapiens 61-65 31777985-1 2020 The discovery of epidermal growth factor receptor (EGFR) mutations has made EGFR tyrosine kinase inhibitors (EGFR-TKIs) a milestone in the treatment for advanced non-small cell lung cancer (NSCLC). Tyrosine 81-89 epidermal growth factor receptor Homo sapiens 17-49 31777985-1 2020 The discovery of epidermal growth factor receptor (EGFR) mutations has made EGFR tyrosine kinase inhibitors (EGFR-TKIs) a milestone in the treatment for advanced non-small cell lung cancer (NSCLC). Tyrosine 81-89 epidermal growth factor receptor Homo sapiens 51-55 31777985-1 2020 The discovery of epidermal growth factor receptor (EGFR) mutations has made EGFR tyrosine kinase inhibitors (EGFR-TKIs) a milestone in the treatment for advanced non-small cell lung cancer (NSCLC). Tyrosine 81-89 epidermal growth factor receptor Homo sapiens 76-80 31777985-1 2020 The discovery of epidermal growth factor receptor (EGFR) mutations has made EGFR tyrosine kinase inhibitors (EGFR-TKIs) a milestone in the treatment for advanced non-small cell lung cancer (NSCLC). Tyrosine 81-89 epidermal growth factor receptor Homo sapiens 76-80 31698509-1 2020 Patients with non-small-cell lung cancer (NSCLC) containing epidermal growth factor receptor (EGFR) amplification or sensitive mutations initially respond to tyrosine kinase inhibitor gefitinib; however, the treatment is less effective over time. Tyrosine 158-166 epidermal growth factor receptor Homo sapiens 94-98 32023774-0 2020 [The influence of TP53 mutation on the therapeutic effect of EGFR tyrosine kinase inhibitor and prognosis of EGFR mutant non-small cell lung cancer patients]. Tyrosine 66-74 epidermal growth factor receptor Homo sapiens 61-65 32023774-4 2020 Whether EGFR mutation combined with TP53 mutation affects the sensitivity of lung cancer cells to tyrosine kinase inhibitor (TKI) and long-term prognosis of non-small cell lung cancer (NSCLC) patients is still unknown and has attracted more attentions. Tyrosine 98-106 epidermal growth factor receptor Homo sapiens 8-12 31969600-1 2020 Hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) have been shown to overcome tyrosine kinase inhibitor (TKI) resistance in epithelial growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) cells in vivo and in vitro. Tyrosine 102-110 epidermal growth factor receptor Homo sapiens 148-181 31969600-1 2020 Hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) have been shown to overcome tyrosine kinase inhibitor (TKI) resistance in epithelial growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) cells in vivo and in vitro. Tyrosine 102-110 epidermal growth factor receptor Homo sapiens 183-187 31755215-4 2020 o-Nitrobenzyl-protected tyrosine variants were incorporated into four nanobodies, including examples directed against EGFR and HER2, and photodeprotection restores the native sequence. Tyrosine 24-32 epidermal growth factor receptor Homo sapiens 118-122 31959859-1 2020 Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) were developed to target the EGFR T790M resistance mutation in non-small cell lung cancer (NSCLC) patients resistant to first- or second-generation EGFR-TKIs. Tyrosine 57-65 epidermal growth factor receptor Homo sapiens 17-49 31959859-1 2020 Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) were developed to target the EGFR T790M resistance mutation in non-small cell lung cancer (NSCLC) patients resistant to first- or second-generation EGFR-TKIs. Tyrosine 57-65 epidermal growth factor receptor Homo sapiens 51-55 31959859-1 2020 Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) were developed to target the EGFR T790M resistance mutation in non-small cell lung cancer (NSCLC) patients resistant to first- or second-generation EGFR-TKIs. Tyrosine 57-65 epidermal growth factor receptor Homo sapiens 120-124 31959859-1 2020 Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) were developed to target the EGFR T790M resistance mutation in non-small cell lung cancer (NSCLC) patients resistant to first- or second-generation EGFR-TKIs. Tyrosine 57-65 epidermal growth factor receptor Homo sapiens 120-124 31952541-6 2020 Meanwhile, MSI2 silencing inhibited EGF-enhanced EGFR phosphorylation at tyrosine 1068 and reversed EGF-induced change of the key proteins in EMT and ZEB1-ERK/MAPK signaling (ZEB1, E-cad, ZO-1, beta-catenin, pERK and c-Myc). Tyrosine 73-81 epidermal growth factor receptor Homo sapiens 49-53 31998131-1 2019 In the past decades, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) had been proved as an effective treatment strategy for the patients with EGFR-mutated non-small-cell lung cancer (NSCLC). Tyrosine 54-62 epidermal growth factor receptor Homo sapiens 82-86 31998131-1 2019 In the past decades, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) had been proved as an effective treatment strategy for the patients with EGFR-mutated non-small-cell lung cancer (NSCLC). Tyrosine 54-62 epidermal growth factor receptor Homo sapiens 166-170 32000647-5 2020 These compounds were tested for their inhibitory action against EGFR (Epidermal Growth Factor Receptor) tyrosine kinase taking into account their excellent action against colon and breast cancer cell lines. Tyrosine 104-112 epidermal growth factor receptor Homo sapiens 64-68 32000647-5 2020 These compounds were tested for their inhibitory action against EGFR (Epidermal Growth Factor Receptor) tyrosine kinase taking into account their excellent action against colon and breast cancer cell lines. Tyrosine 104-112 epidermal growth factor receptor Homo sapiens 70-102 32000647-8 2020 Again the above three compounds showed excellent inhibitory activity with the percentage inhibition of 64.5, 57.3 and 55.8 respectively against EGFR (Epidermal Growth Factor Receptor) tyrosine kinase. Tyrosine 184-192 epidermal growth factor receptor Homo sapiens 144-148 32000647-8 2020 Again the above three compounds showed excellent inhibitory activity with the percentage inhibition of 64.5, 57.3 and 55.8 respectively against EGFR (Epidermal Growth Factor Receptor) tyrosine kinase. Tyrosine 184-192 epidermal growth factor receptor Homo sapiens 150-182 31897229-1 2020 Background: The clinical application of EGFR tyrosine kinase inhibitors is always accompanied by inevitable drug resistance. Tyrosine 45-53 epidermal growth factor receptor Homo sapiens 40-44 31562907-1 2020 BACKGROUND & AIMS: Upon ligand-binding, tyrosine kinase receptors, such as Epidermal Growth Factor Receptor (EGFR), are recruited into clathrin-coated pits leading to endocytosis internalization, relevant for their signalling pathways and/or receptor degradation. Tyrosine 44-52 epidermal growth factor receptor Homo sapiens 79-111 31562907-1 2020 BACKGROUND & AIMS: Upon ligand-binding, tyrosine kinase receptors, such as Epidermal Growth Factor Receptor (EGFR), are recruited into clathrin-coated pits leading to endocytosis internalization, relevant for their signalling pathways and/or receptor degradation. Tyrosine 44-52 epidermal growth factor receptor Homo sapiens 113-117 31674165-7 2020 Results showed unusual EGFR mutations, which are associated with drug resistance to EGFR tyrosine kinase inhibitors, revealing the importance of identifying morule-like features in pulmonary adenocarcinoma and the need for additional study, since there are few reported cases. Tyrosine 89-97 epidermal growth factor receptor Homo sapiens 84-88 31710890-1 2020 OBJECTIVES: The T790M secondary mutation of epidermal growth factor receptor gene (EGFR) is the most common mechanism of acquired resistance to first- or second-generation EGFR tyrosine kinase inhibitors (TKIs). Tyrosine 177-185 epidermal growth factor receptor Homo sapiens 44-76 31710890-1 2020 OBJECTIVES: The T790M secondary mutation of epidermal growth factor receptor gene (EGFR) is the most common mechanism of acquired resistance to first- or second-generation EGFR tyrosine kinase inhibitors (TKIs). Tyrosine 177-185 epidermal growth factor receptor Homo sapiens 83-87 31710890-1 2020 OBJECTIVES: The T790M secondary mutation of epidermal growth factor receptor gene (EGFR) is the most common mechanism of acquired resistance to first- or second-generation EGFR tyrosine kinase inhibitors (TKIs). Tyrosine 177-185 epidermal growth factor receptor Homo sapiens 172-176 31715539-1 2020 OBJECTIVES: Mutations in the gene that encodes epidermal growth factor receptor (EGFR) are biomarkers that predict how non-small cell lung cancer (NSCLC) patients respond to EGFR-targeted therapies collectively known as tyrosine kinase inhibitors (TKIs). Tyrosine 220-228 epidermal growth factor receptor Homo sapiens 47-79 31715539-1 2020 OBJECTIVES: Mutations in the gene that encodes epidermal growth factor receptor (EGFR) are biomarkers that predict how non-small cell lung cancer (NSCLC) patients respond to EGFR-targeted therapies collectively known as tyrosine kinase inhibitors (TKIs). Tyrosine 220-228 epidermal growth factor receptor Homo sapiens 81-85 31715539-1 2020 OBJECTIVES: Mutations in the gene that encodes epidermal growth factor receptor (EGFR) are biomarkers that predict how non-small cell lung cancer (NSCLC) patients respond to EGFR-targeted therapies collectively known as tyrosine kinase inhibitors (TKIs). Tyrosine 220-228 epidermal growth factor receptor Homo sapiens 174-178 31715539-5 2020 The aim of this study was to determine the prevalence of rare mutations in the tyrosine kinase domain (exons 18-21) of the EGFR gene not targeted by the most frequently used real-time PCR approaches, i.e., the cobas EGFR Mutation Test, and the Idylla EGFR Mutation Assay. Tyrosine 79-87 epidermal growth factor receptor Homo sapiens 123-127 31715539-5 2020 The aim of this study was to determine the prevalence of rare mutations in the tyrosine kinase domain (exons 18-21) of the EGFR gene not targeted by the most frequently used real-time PCR approaches, i.e., the cobas EGFR Mutation Test, and the Idylla EGFR Mutation Assay. Tyrosine 79-87 epidermal growth factor receptor Homo sapiens 217-221 31715539-5 2020 The aim of this study was to determine the prevalence of rare mutations in the tyrosine kinase domain (exons 18-21) of the EGFR gene not targeted by the most frequently used real-time PCR approaches, i.e., the cobas EGFR Mutation Test, and the Idylla EGFR Mutation Assay. Tyrosine 79-87 epidermal growth factor receptor Homo sapiens 217-221 31751804-0 2020 Predictive impact of low-frequency pretreatment T790M mutation in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors. Tyrosine 138-146 epidermal growth factor receptor Homo sapiens 80-84 31751804-0 2020 Predictive impact of low-frequency pretreatment T790M mutation in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors. Tyrosine 138-146 epidermal growth factor receptor Homo sapiens 133-137 31751804-1 2020 OBJECTIVES: Low-frequency epidermal growth factor receptor (EGFR) T790M mutation could be detected by ultrasensitive methods in EGFR tyrosine kinase inhibitor (TKI)-naive non-small cell lung cancer (NSCLC). Tyrosine 133-141 epidermal growth factor receptor Homo sapiens 26-58 31751804-1 2020 OBJECTIVES: Low-frequency epidermal growth factor receptor (EGFR) T790M mutation could be detected by ultrasensitive methods in EGFR tyrosine kinase inhibitor (TKI)-naive non-small cell lung cancer (NSCLC). Tyrosine 133-141 epidermal growth factor receptor Homo sapiens 60-64 31751804-1 2020 OBJECTIVES: Low-frequency epidermal growth factor receptor (EGFR) T790M mutation could be detected by ultrasensitive methods in EGFR tyrosine kinase inhibitor (TKI)-naive non-small cell lung cancer (NSCLC). Tyrosine 133-141 epidermal growth factor receptor Homo sapiens 128-132 31786475-3 2020 PATIENTS AND METHODS: Patients with EGFR mutation and performed re-biopsy after progression on prior EGFR-tyrosine kinase inhibitors (TKIs) were reviewed and analyzed. Tyrosine 106-114 epidermal growth factor receptor Homo sapiens 101-105 31865062-4 2020 Naquotinib is an irreversible tyrosine kinase inhibitor (TKI) originally designed to target the epidermal growth factor receptor (EGFR). Tyrosine 30-38 epidermal growth factor receptor Homo sapiens 130-134 31898615-0 2020 T790M mutations identified by circulating tumor DNA test in lung adenocarcinoma patients who progressed on first-line epidermal growth factor receptor-tyrosine kinase inhibitors. Tyrosine 151-159 epidermal growth factor receptor Homo sapiens 118-150 31977865-1 2020 BACKGROUND: In recent studies, afatinib, a second-generation inhibitor, showed superior outcomes, when compared to the first-generation of EGFR-tyrosine kinase inhibitors (TKIs), such as erlotinib and gefitinib, in patients with advanced non-small cell lung cancer (NSCLC) harboring mutations of epidermal growth factor receptor (EGFR). Tyrosine 144-152 epidermal growth factor receptor Homo sapiens 139-143 31691525-0 2020 Circulating plasma lncRNAs as novel markers of EGFR mutation status and monitors of epidermal growth factor receptor-tyrosine kinase inhibitor therapy. Tyrosine 117-125 epidermal growth factor receptor Homo sapiens 84-116 31691525-1 2020 BACKGROUND: Epidermal growth factor receptor (EGFR) gene mutations predict tumor response to EGFR tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer (NSCLC). Tyrosine 98-106 epidermal growth factor receptor Homo sapiens 12-44 31691525-1 2020 BACKGROUND: Epidermal growth factor receptor (EGFR) gene mutations predict tumor response to EGFR tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer (NSCLC). Tyrosine 98-106 epidermal growth factor receptor Homo sapiens 46-50 31691525-1 2020 BACKGROUND: Epidermal growth factor receptor (EGFR) gene mutations predict tumor response to EGFR tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer (NSCLC). Tyrosine 98-106 epidermal growth factor receptor Homo sapiens 93-97 31691525-1 2020 BACKGROUND: Epidermal growth factor receptor (EGFR) gene mutations predict tumor response to EGFR tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer (NSCLC). Tyrosine 98-106 epidermal growth factor receptor Homo sapiens 93-97 31758670-1 2020 BACKGROUND: Osimertinib (AZD9291) is a third-generation EGFR-tyrosine kinase inhibitor (TKI) that selectively inhibits the activating EGFR mutation and T790M mutation, and is currently used globally to treat EGFR-mutant non-small cell lung cancer (NSCLC). Tyrosine 61-69 epidermal growth factor receptor Homo sapiens 56-60 31906113-1 2019 Neuregulins (NRGs) are a family of epidermal growth factor-related proteins, acting on tyrosine kinase receptors of the ErbB family. Tyrosine 87-95 epidermal growth factor receptor Homo sapiens 120-124 31921382-1 2019 Receptor tyrosine kinases (RTKs), such as HER2 and/or EGFR are important therapeutic targets in multiple cancer cells. Tyrosine 9-17 epidermal growth factor receptor Homo sapiens 54-58 31908655-8 2019 In regards to efficacy, pemetrexed/carboplatin (PC) plus gefitinib was superior in ORR and OS to chemotherapy and first-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs). Tyrosine 136-144 epidermal growth factor receptor Homo sapiens 131-135 31874554-0 2019 [Clinical research and drug review of epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer]. Tyrosine 71-79 epidermal growth factor receptor Homo sapiens 38-70 31874554-4 2019 During the last decade, the application of EGFR specific tyrosine kinase inhibitors (TKI) significantly improved prognosis of NSCLC patients with sensitive EGFR mutations. Tyrosine 57-65 epidermal growth factor receptor Homo sapiens 43-47 31874554-4 2019 During the last decade, the application of EGFR specific tyrosine kinase inhibitors (TKI) significantly improved prognosis of NSCLC patients with sensitive EGFR mutations. Tyrosine 57-65 epidermal growth factor receptor Homo sapiens 156-160 31908495-1 2019 Objective: We reported a case of pathologic type transformed from adenocarcinoma to small-cell lung cancer (SCLC) after being treated with third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). Tyrosine 189-197 epidermal growth factor receptor Homo sapiens 216-220 31614143-3 2019 Neurotensin increases tyrosine phosphorylation of the epidermal growth factor receptor (EGFR) and the neurotensin receptor 1 antagonist SR48692 blocks the transactivation of the EGFR. Tyrosine 22-30 epidermal growth factor receptor Homo sapiens 54-86 31614143-3 2019 Neurotensin increases tyrosine phosphorylation of the epidermal growth factor receptor (EGFR) and the neurotensin receptor 1 antagonist SR48692 blocks the transactivation of the EGFR. Tyrosine 22-30 epidermal growth factor receptor Homo sapiens 88-92 31614143-3 2019 Neurotensin increases tyrosine phosphorylation of the epidermal growth factor receptor (EGFR) and the neurotensin receptor 1 antagonist SR48692 blocks the transactivation of the EGFR. Tyrosine 22-30 epidermal growth factor receptor Homo sapiens 178-182 31843782-1 2019 Erlotinib used in the treatment of advanced non-small cell lung cancer (NSCLC) is a first-generation small-molecule tyrosine kinase inhibitor which reversibly inhibits the kinase domain of epithelial growth factor receptor (EGFR). Tyrosine 116-124 epidermal growth factor receptor Homo sapiens 189-222 31843782-1 2019 Erlotinib used in the treatment of advanced non-small cell lung cancer (NSCLC) is a first-generation small-molecule tyrosine kinase inhibitor which reversibly inhibits the kinase domain of epithelial growth factor receptor (EGFR). Tyrosine 116-124 epidermal growth factor receptor Homo sapiens 224-228 31609054-4 2019 Presence of photocaged tyrosine reduces 7D12-EGFR binding affinity by over 20-fold in two out of three 7D12 mutants studied, and binding is restored upon exposure to 365 nm light. Tyrosine 23-31 epidermal growth factor receptor Homo sapiens 45-49 31801598-1 2019 BACKGROUND: Although EGFR tyrosine kinase inhibitors (EGFR-TKIs) are beneficial to lung adenocarcinoma patients with sensitive EGFR mutations, resistance to these inhibitors induces a cancer stem cell (CSC) phenotype. Tyrosine 26-34 epidermal growth factor receptor Homo sapiens 21-25 31801598-1 2019 BACKGROUND: Although EGFR tyrosine kinase inhibitors (EGFR-TKIs) are beneficial to lung adenocarcinoma patients with sensitive EGFR mutations, resistance to these inhibitors induces a cancer stem cell (CSC) phenotype. Tyrosine 26-34 epidermal growth factor receptor Homo sapiens 54-58 31801598-1 2019 BACKGROUND: Although EGFR tyrosine kinase inhibitors (EGFR-TKIs) are beneficial to lung adenocarcinoma patients with sensitive EGFR mutations, resistance to these inhibitors induces a cancer stem cell (CSC) phenotype. Tyrosine 26-34 epidermal growth factor receptor Homo sapiens 54-58 31794427-6 2019 In human glioma tissues and cells, Ninj2 co-immunoprecipitated with multiple receptor tyrosine kinases (EGFR, PDGFRbeta and FGFR), required for downstream Akt and Erk activation. Tyrosine 86-94 epidermal growth factor receptor Homo sapiens 104-108 31709807-0 2019 Survival outcome of tyrosine kinase inhibitors beyond progression in association to radiotherapy in oligoprogressive EGFR-mutant non-small-cell lung cancer. Tyrosine 20-28 epidermal growth factor receptor Homo sapiens 117-121 31911857-0 2019 The potential role of YAP in Axl-mediated resistance to EGFR tyrosine kinase inhibitors. Tyrosine 61-69 epidermal growth factor receptor Homo sapiens 56-60 31911857-7 2019 In EGFR tyrosine kinase inhibitor (TKI)-sensitive lung cancer cells, YAP protein was downregulated in response to TKI treatment, while overexpression of YAP attenuated TKI sensitivity, suggesting that YAP is a key determinant of TKI response. Tyrosine 8-16 epidermal growth factor receptor Homo sapiens 3-7 31777268-0 2019 Radiographic appearance of leptomeningeal disease in patients with EGFR-mutated non-small-cell lung carcinoma treated with tyrosine kinase inhibitors: a case series. Tyrosine 123-131 epidermal growth factor receptor Homo sapiens 67-71 31777268-2 2019 Clinically available tyrosine kinase inhibitors (TKIs) are effective in treating EGFR-mutant NSCLC. Tyrosine 21-29 epidermal growth factor receptor Homo sapiens 81-85 31621403-0 2019 Patient preferences for attributes of tyrosine kinase inhibitor treatments for EGFR mutation-positive non-small-cell lung cancer. Tyrosine 38-46 epidermal growth factor receptor Homo sapiens 79-83 31621403-1 2019 Aim: EGFR-tyrosine kinase inhibitors (TKIs) vary in efficacy, side effects (SEs) and dosing regimen. Tyrosine 10-18 epidermal growth factor receptor Homo sapiens 5-9 31808254-1 2019 First-line tyrosine kinase inhibitors are standard of care for non-small-cell lung cancers (NSCLC) harbouring an epidermal growth factor receptor mutation, anaplastic lymphoma kinase fusion or c-ros oncogene 1 rearrangement. Tyrosine 11-19 epidermal growth factor receptor Homo sapiens 113-145 31950021-1 2019 Background: Resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, is a limited factor in the treatment of non-small-cell lung cancer (NSCLC) patients. Tyrosine 59-67 epidermal growth factor receptor Homo sapiens 87-91 31779765-1 2019 Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the standard therapy for patients with advanced non-small-cell lung cancer (NSCLC) harbouring common EGFR mutations. Tyrosine 33-41 epidermal growth factor receptor Homo sapiens 177-181 31587882-1 2019 BACKGROUND: Patients with EGFR-mutated non-small-cell lung cancer (NSCLC) given EGFR tyrosine kinase inhibitors (TKIs) inevitably become resistant to first-generation or second-generation drugs. Tyrosine 85-93 epidermal growth factor receptor Homo sapiens 26-30 31587882-1 2019 BACKGROUND: Patients with EGFR-mutated non-small-cell lung cancer (NSCLC) given EGFR tyrosine kinase inhibitors (TKIs) inevitably become resistant to first-generation or second-generation drugs. Tyrosine 85-93 epidermal growth factor receptor Homo sapiens 80-84 31689114-0 2019 Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors. Tyrosine 82-90 epidermal growth factor receptor Homo sapiens 77-81 31832192-0 2019 Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer. Tyrosine 56-64 epidermal growth factor receptor Homo sapiens 51-55 31832192-0 2019 Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer. Tyrosine 56-64 epidermal growth factor receptor Homo sapiens 87-91 31832192-1 2019 EGFR-tyrosine kinase inhibitors (EGFR-TKIs) have achieved remarkable outcomes in the treatment of patients with EGFR-mutant non-small-cell lung cancer, but acquired resistance is still the main factor restricting their long-term use. Tyrosine 5-13 epidermal growth factor receptor Homo sapiens 0-4 31832192-1 2019 EGFR-tyrosine kinase inhibitors (EGFR-TKIs) have achieved remarkable outcomes in the treatment of patients with EGFR-mutant non-small-cell lung cancer, but acquired resistance is still the main factor restricting their long-term use. Tyrosine 5-13 epidermal growth factor receptor Homo sapiens 33-37 31832192-1 2019 EGFR-tyrosine kinase inhibitors (EGFR-TKIs) have achieved remarkable outcomes in the treatment of patients with EGFR-mutant non-small-cell lung cancer, but acquired resistance is still the main factor restricting their long-term use. Tyrosine 5-13 epidermal growth factor receptor Homo sapiens 33-37 31756933-1 2019 :The epidermal growth factor receptor (EGFR) family contains four transmembrane tyrosine kinases (EGFR1/ErbB1, Her2/ErbB2, Her3/ErbB3 and Her4/ErbB4) and 13 secreted polypeptide ligands. Tyrosine 80-88 epidermal growth factor receptor Homo sapiens 5-37 31756933-1 2019 :The epidermal growth factor receptor (EGFR) family contains four transmembrane tyrosine kinases (EGFR1/ErbB1, Her2/ErbB2, Her3/ErbB3 and Her4/ErbB4) and 13 secreted polypeptide ligands. Tyrosine 80-88 epidermal growth factor receptor Homo sapiens 39-43 31756933-1 2019 :The epidermal growth factor receptor (EGFR) family contains four transmembrane tyrosine kinases (EGFR1/ErbB1, Her2/ErbB2, Her3/ErbB3 and Her4/ErbB4) and 13 secreted polypeptide ligands. Tyrosine 80-88 epidermal growth factor receptor Homo sapiens 104-109 31746315-10 2019 CONCLUSIONS Mutational profiles of the EGFR in NSCLC patients provide useful information for the use of tyrosine kinase inhibitors for adjuvant or neoadjuvant therapy and immunotherapy. Tyrosine 104-112 epidermal growth factor receptor Homo sapiens 39-43 31653451-1 2019 Dimerization or the formation of higher-order oligomers is required for the activation of ErbB receptor tyrosine kinases. Tyrosine 104-112 epidermal growth factor receptor Homo sapiens 90-94 31819480-1 2019 Objective: As an epidermal growth factor, receptor-tyrosine kinase inhibitor (EGFR-TKI), gefitinib demonstrates a good therapeutic effect in patients with EGFR-mutant non-small-cell lung cancer (NSCLC). Tyrosine 51-59 epidermal growth factor receptor Homo sapiens 78-82 31819477-0 2019 Association Of Initial Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment And EGFR Exon 19 Deletion With Frequency Of The T790M Mutation In Non-Small Cell Lung Cancer Patients After Resistance To First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Tyrosine 259-267 epidermal growth factor receptor Homo sapiens 97-101 31819477-1 2019 Background: The present study analyzed the relationship between clinical features and the T790M mutation in non-small cell lung cancer (NSCLC) patients resistant to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment. Tyrosine 198-206 epidermal growth factor receptor Homo sapiens 226-230 31694343-6 2019 The promotion of invadopodia following HCV infection was mediated by the sustained stimulation of epidermal growth factor receptor (EGFR) via the viral NS3/4A protease that inactivates the T-cell protein tyrosine phosphatase (TC-PTP), which inhibits EGFR signaling. Tyrosine 204-212 epidermal growth factor receptor Homo sapiens 132-136 31867165-1 2019 EGFR tyrosine kinase inhibitor (EGFR-TKI) has been used successfully in clinic for the treatment of solid tumors. Tyrosine 5-13 epidermal growth factor receptor Homo sapiens 0-4 31867165-1 2019 EGFR tyrosine kinase inhibitor (EGFR-TKI) has been used successfully in clinic for the treatment of solid tumors. Tyrosine 5-13 epidermal growth factor receptor Homo sapiens 32-36 31644442-1 2019 OBJECTIVES: The discovery of tyrosine kinase inhibitors (TKI) has remarkably improved the clinical course of patients with non-small cell lung cancer driven by Epidermal Growth Factor Receptor (EGFR) mutations. Tyrosine 29-37 epidermal growth factor receptor Homo sapiens 160-192 31644442-1 2019 OBJECTIVES: The discovery of tyrosine kinase inhibitors (TKI) has remarkably improved the clinical course of patients with non-small cell lung cancer driven by Epidermal Growth Factor Receptor (EGFR) mutations. Tyrosine 29-37 epidermal growth factor receptor Homo sapiens 194-198 31584455-1 2019 As a first-generation epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib was approved by the US Food and Drug Administration for treatment of advanced non-small cell carcinoma with sensitizing EGFR mutations. Tyrosine 55-63 epidermal growth factor receptor Homo sapiens 22-54 31584455-2 2019 Gefitinib is known to have adverse effects, which may necessitate dose reduction or even change to alternative preparation of epidermal growth factor receptor-tyrosine kinase inhibitor. Tyrosine 159-167 epidermal growth factor receptor Homo sapiens 126-158 31942192-1 2020 In the present study, we evaluated the efficacy and safety of epidermal growth factor receptor tyrosine kinases (EGFR-TKIs) combined with or without angiogenesis inhibitors in advanced non-small-cell lung cancer (NSCLC). Tyrosine 95-103 epidermal growth factor receptor Homo sapiens 113-117 31779765-1 2019 Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the standard therapy for patients with advanced non-small-cell lung cancer (NSCLC) harbouring common EGFR mutations. Tyrosine 33-41 epidermal growth factor receptor Homo sapiens 61-65 32030265-12 2019 Patients with adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment had significantly better OS compared with those with adjuvant chemotherapy treatment (P=0.015). Tyrosine 63-71 epidermal growth factor receptor Homo sapiens 23-55 32030265-12 2019 Patients with adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment had significantly better OS compared with those with adjuvant chemotherapy treatment (P=0.015). Tyrosine 63-71 epidermal growth factor receptor Homo sapiens 57-61 31554698-3 2019 We hypothesize that a flexible receptor tyrosine kinase co-activation signaling network supports HNSCC survival in the setting of EGFR blockade and that drugs disrupting this network will provide superior tumor control when combined with EGFR inhibitors. Tyrosine 40-48 epidermal growth factor receptor Homo sapiens 130-134 31554698-3 2019 We hypothesize that a flexible receptor tyrosine kinase co-activation signaling network supports HNSCC survival in the setting of EGFR blockade and that drugs disrupting this network will provide superior tumor control when combined with EGFR inhibitors. Tyrosine 40-48 epidermal growth factor receptor Homo sapiens 238-242 31788083-0 2019 EGFR tyrosine kinase inhibitor therapy for lung cancer treatments and their clinical outcomes: A cohort study in Taiwan. Tyrosine 5-13 epidermal growth factor receptor Homo sapiens 0-4 31788083-3 2019 Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are being increasingly used to treat lung cancer. Tyrosine 33-41 epidermal growth factor receptor Homo sapiens 61-65 31595714-0 2019 Post-progression survival is highly linked to overall survival in patients with non-small-cell lung cancer harboring sensitive EGFR mutations treated with first-line epidermal growth factor receptor-tyrosine kinase inhibitors. Tyrosine 199-207 epidermal growth factor receptor Homo sapiens 127-131 31595714-0 2019 Post-progression survival is highly linked to overall survival in patients with non-small-cell lung cancer harboring sensitive EGFR mutations treated with first-line epidermal growth factor receptor-tyrosine kinase inhibitors. Tyrosine 199-207 epidermal growth factor receptor Homo sapiens 166-198 31595714-1 2019 BACKGROUND: In patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC), epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment has shown a good response. Tyrosine 155-163 epidermal growth factor receptor Homo sapiens 29-61 31595714-1 2019 BACKGROUND: In patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC), epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment has shown a good response. Tyrosine 155-163 epidermal growth factor receptor Homo sapiens 63-67 31595714-1 2019 BACKGROUND: In patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC), epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment has shown a good response. Tyrosine 155-163 epidermal growth factor receptor Homo sapiens 122-154 31595714-1 2019 BACKGROUND: In patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC), epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment has shown a good response. Tyrosine 155-163 epidermal growth factor receptor Homo sapiens 182-186 32038921-0 2019 Adjuvant EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: still an investigational approach. Tyrosine 14-22 epidermal growth factor receptor Homo sapiens 9-13 32038921-0 2019 Adjuvant EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: still an investigational approach. Tyrosine 14-22 epidermal growth factor receptor Homo sapiens 44-48 31772161-2 2019 While epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are widely used for the treatment of diverse types of cancer, whether EGFR-TKIs are effective against chemoresistant CSCs in cervical cancer is largely unknown. Tyrosine 46-54 epidermal growth factor receptor Homo sapiens 40-44 31803256-1 2019 Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the currently recommended treatment for advanced EGFR mutation-positive non-small cell lung cancer (NSCLC). Tyrosine 33-41 epidermal growth factor receptor Homo sapiens 61-65 31803256-1 2019 Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the currently recommended treatment for advanced EGFR mutation-positive non-small cell lung cancer (NSCLC). Tyrosine 33-41 epidermal growth factor receptor Homo sapiens 125-129 32009817-1 2019 Purpose: Previous studies have shown that the presence of EGFR T790M mutation may reduce the treatment efficacy of tyrosine kinase inhibitors (TKIs) in EGFR-mutant lung cancer. Tyrosine 115-123 epidermal growth factor receptor Homo sapiens 58-62 32009817-1 2019 Purpose: Previous studies have shown that the presence of EGFR T790M mutation may reduce the treatment efficacy of tyrosine kinase inhibitors (TKIs) in EGFR-mutant lung cancer. Tyrosine 115-123 epidermal growth factor receptor Homo sapiens 152-156 31807071-0 2019 Glycodelin As A Biomarker Of Advanced Lung Adenocarcinoma Brain Metastases In Patients Treated With EGFR Tyrosine Kinase Inhibitors. Tyrosine 105-113 epidermal growth factor receptor Homo sapiens 100-104 31807071-2 2019 In this study, the expression of the glycodelin protein was analyzed in EGFR-mutant tyrosine kinase inhibitor-sensitive advanced lung adenocarcinoma. Tyrosine 84-92 epidermal growth factor receptor Homo sapiens 72-76 31750252-3 2019 The present study elucidated the IL-22-induced mechanism underlying EGFR-tyrosine kinase inhibitor (TKI) resistance in NSCLC. Tyrosine 73-81 epidermal growth factor receptor Homo sapiens 68-72 31709807-1 2019 Aim: The association of tyrosine kinase inhibitors (TKIs) and local radiotherapy in EGFR-mutated non-small-cell lung cancer patients experiencing disease progression under TKIs could be a valid an option. Tyrosine 24-32 epidermal growth factor receptor Homo sapiens 84-88 31793440-2 2019 The first- and second-generation EGFR tyrosine kinase inhibitors (TKIs) have shown considerable efficacy in EGFR-mutated NSCLC. Tyrosine 38-46 epidermal growth factor receptor Homo sapiens 33-37 31793440-2 2019 The first- and second-generation EGFR tyrosine kinase inhibitors (TKIs) have shown considerable efficacy in EGFR-mutated NSCLC. Tyrosine 38-46 epidermal growth factor receptor Homo sapiens 108-112 31933796-1 2019 The acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is the major reason for the failure of target therapy in advanced non small cell lung cancer (NSCLC) patients, the mechanism of which has not been fully elucidated yet. Tyrosine 60-68 epidermal growth factor receptor Homo sapiens 87-91 31568888-0 2019 Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Tyrosine 29-37 epidermal growth factor receptor Homo sapiens 66-98 31673738-12 2019 Gefitinib can inhibit EGFR signaling and block the autophosphorylation of critical tyrosine residues on EGFR. Tyrosine 83-91 epidermal growth factor receptor Homo sapiens 104-108 31561203-9 2019 High MET expression and MET copy number gain (two samples with high polysomy and three with true amplification) were observed in five cases with EGFR mutation treated with tyrosine kinase inhibitors (TKI). Tyrosine 172-180 epidermal growth factor receptor Homo sapiens 145-149 31568888-0 2019 Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Tyrosine 29-37 epidermal growth factor receptor Homo sapiens 100-104 31568888-3 2019 First-generation (gefitinib, erlotinib) and second-generation (afatinib, dacomitinib) EGFR-tyrosine kinase inhibitors (TKIs) have been standard-of-care (SoC) first-line treatment for patients with sensitizing EGFR mutation positive advanced NSCLC following Phase III trials versus platinum-based doublet chemotherapy. Tyrosine 91-99 epidermal growth factor receptor Homo sapiens 86-90 31857948-0 2019 Epidermal growth factor receptor first generation tyrosine-kinase inhibitors. Tyrosine 50-58 epidermal growth factor receptor Homo sapiens 0-32 31857948-3 2019 The discovery of EGFR kinase domain-activating mutations that significantly correlated with a high likelihood of response to EGFR tyrosine-kinase inhibitors (TKIs) allowed to design studies to test these drugs as potential first-line therapies. Tyrosine 130-138 epidermal growth factor receptor Homo sapiens 17-21 31857948-3 2019 The discovery of EGFR kinase domain-activating mutations that significantly correlated with a high likelihood of response to EGFR tyrosine-kinase inhibitors (TKIs) allowed to design studies to test these drugs as potential first-line therapies. Tyrosine 130-138 epidermal growth factor receptor Homo sapiens 125-129 31857949-0 2019 Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer. Tyrosine 50-58 epidermal growth factor receptor Homo sapiens 17-49 31857949-2 2019 The most common EGFR-activating mutations, the exon 19 deletion and the L858R point mutation occurring in the receptor tyrosine kinase domain, are susceptible to inhibition. Tyrosine 119-127 epidermal growth factor receptor Homo sapiens 16-20 31857949-3 2019 The first EGFR tyrosine kinase inhibitors (TKIs) to be evaluated were the reversible first-generation EGFR TKIs, gefitinib and erlotinib, followed by the irreversible second-generation EGFR TKIs, afatinib and dacomitinib. Tyrosine 15-23 epidermal growth factor receptor Homo sapiens 10-14 31857953-4 2019 First-generation EGFR/ALK tyrosine kinase inhibitors (TKI) demonstrates only limited efficacy for intracranial lesions probably because of low penetration through the blood-brain barrier (BBB). Tyrosine 26-34 epidermal growth factor receptor Homo sapiens 17-21 31671561-0 2019 FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management. Tyrosine 22-30 epidermal growth factor receptor Homo sapiens 61-65 31671561-2 2019 The discovery of several oncogenic driver mutations in patients with NSCLC has allowed the development of personalized treatments based on these specific molecular alterations, in particular in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene. Tyrosine 198-206 epidermal growth factor receptor Homo sapiens 233-265 31671561-2 2019 The discovery of several oncogenic driver mutations in patients with NSCLC has allowed the development of personalized treatments based on these specific molecular alterations, in particular in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene. Tyrosine 198-206 epidermal growth factor receptor Homo sapiens 267-271 31695493-11 2019 The administration of tyrosine kinase inhibitors to patients with LSCC after screening for EGFR mutations based on their clinical and imageological features would likely result in a population with a greater sensitivity to afatinib. Tyrosine 22-30 epidermal growth factor receptor Homo sapiens 91-95 31648503-1 2019 Objective: To investigate the clinical effects of first generation epithelial growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) compared with platinum-based chemotherapy as first-line therapy in advanced lung adenocarcinoma patients with uncommon EGFR mutations. Tyrosine 101-109 epidermal growth factor receptor Homo sapiens 129-133 31777595-1 2019 Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR)-sensitive mutations benefit from epidermal growth factor receptor tyrosine kinase inhibitors (EGFR- TKIs). Tyrosine 155-163 epidermal growth factor receptor Homo sapiens 49-81 31777595-1 2019 Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR)-sensitive mutations benefit from epidermal growth factor receptor tyrosine kinase inhibitors (EGFR- TKIs). Tyrosine 155-163 epidermal growth factor receptor Homo sapiens 83-87 31777595-1 2019 Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR)-sensitive mutations benefit from epidermal growth factor receptor tyrosine kinase inhibitors (EGFR- TKIs). Tyrosine 155-163 epidermal growth factor receptor Homo sapiens 122-154 31777595-1 2019 Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR)-sensitive mutations benefit from epidermal growth factor receptor tyrosine kinase inhibitors (EGFR- TKIs). Tyrosine 155-163 epidermal growth factor receptor Homo sapiens 183-187 32010368-3 2019 Epidermal growth factor receptor (EGFR) is a 170-kDa transmembrane tyrosine kinase receptor expressed in a variety of normal and malignant cells regulating critical cellular processes. Tyrosine 67-75 epidermal growth factor receptor Homo sapiens 34-38 31584260-7 2019 We previously developed a dual EGFR and cMET inhibitor (N19) that was able to inhibit tumor growth in nonsmall cell lung cancer models resistant to EGFR tyrosine kinase inhibitors (TKI). Tyrosine 153-161 epidermal growth factor receptor Homo sapiens 31-35 31619200-0 2019 STAT3 induces G9a to exacerbate HER3 expression for the survival of epidermal growth factor receptor-tyrosine kinase inhibitors in lung cancers. Tyrosine 101-109 epidermal growth factor receptor Homo sapiens 68-100 31619200-1 2019 BACKGROUND: HER3 mediates drug resistance against epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), resulting in tumor relapse in lung cancers. Tyrosine 90-98 epidermal growth factor receptor Homo sapiens 50-82 31619200-1 2019 BACKGROUND: HER3 mediates drug resistance against epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), resulting in tumor relapse in lung cancers. Tyrosine 90-98 epidermal growth factor receptor Homo sapiens 84-88 31636509-2 2019 The inhibition of epidermal growth factor receptor (EGFR) signaling by tyrosine kinase inhibitors or monoclonal antibodies plays a key role in NSCLC treatment. Tyrosine 71-79 epidermal growth factor receptor Homo sapiens 18-50 31636509-2 2019 The inhibition of epidermal growth factor receptor (EGFR) signaling by tyrosine kinase inhibitors or monoclonal antibodies plays a key role in NSCLC treatment. Tyrosine 71-79 epidermal growth factor receptor Homo sapiens 52-56 31681582-1 2019 Acquired resistance inevitably limits the curative effects of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), which represent the classical paradigm of molecular-targeted therapies in non-small-cell lung cancer (NSCLC). Tyrosine 95-103 epidermal growth factor receptor Homo sapiens 123-127 32010368-3 2019 Epidermal growth factor receptor (EGFR) is a 170-kDa transmembrane tyrosine kinase receptor expressed in a variety of normal and malignant cells regulating critical cellular processes. Tyrosine 67-75 epidermal growth factor receptor Homo sapiens 0-32 31762748-1 2019 Patients with epidermal growth factor receptor (EGFR) mutation positive non-small cell lung cancer (NSCLC) have several EGFR targeting tyrosine kinase inhibitors (TKIs) available in frontline management. Tyrosine 135-143 epidermal growth factor receptor Homo sapiens 14-46 31762748-1 2019 Patients with epidermal growth factor receptor (EGFR) mutation positive non-small cell lung cancer (NSCLC) have several EGFR targeting tyrosine kinase inhibitors (TKIs) available in frontline management. Tyrosine 135-143 epidermal growth factor receptor Homo sapiens 48-52 31395339-1 2019 Our previous study demonstrated that type II cGMP-dependent protein kinase (PKG II) inhibited epidermal growth factor (EGF) induced tyrosine phosphorylation/activation of the EGF receptor (EGFR). Tyrosine 132-140 epidermal growth factor receptor Homo sapiens 175-187 31762748-1 2019 Patients with epidermal growth factor receptor (EGFR) mutation positive non-small cell lung cancer (NSCLC) have several EGFR targeting tyrosine kinase inhibitors (TKIs) available in frontline management. Tyrosine 135-143 epidermal growth factor receptor Homo sapiens 120-124 31395339-1 2019 Our previous study demonstrated that type II cGMP-dependent protein kinase (PKG II) inhibited epidermal growth factor (EGF) induced tyrosine phosphorylation/activation of the EGF receptor (EGFR). Tyrosine 132-140 epidermal growth factor receptor Homo sapiens 189-193 31632080-2 2019 It is still controversial whether cranial radiotherapy could be delayed when the EGFR-tyrosine kinase inhibitors (TKIs) used as first-line therapy for EGFR-positive patients with BM. Tyrosine 86-94 epidermal growth factor receptor Homo sapiens 81-85 31728434-1 2019 First-line tyrosine-kinase inhibitor (TKI) treatment is the current standard for patients with metastasized non-small cell lung cancer (NSCLC) and sensitizing epidermal growth factor receptor (EGFR) mutations. Tyrosine 11-19 epidermal growth factor receptor Homo sapiens 159-191 31728434-1 2019 First-line tyrosine-kinase inhibitor (TKI) treatment is the current standard for patients with metastasized non-small cell lung cancer (NSCLC) and sensitizing epidermal growth factor receptor (EGFR) mutations. Tyrosine 11-19 epidermal growth factor receptor Homo sapiens 193-197 31584970-5 2019 Furthermore, in a subgroup analysis of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)-induced interstitial lung disease (ILD), we observed seven candidate SNVs that were possibly associated with ILD (P < 0.00001). Tyrosine 79-87 epidermal growth factor receptor Homo sapiens 39-71 31584970-5 2019 Furthermore, in a subgroup analysis of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)-induced interstitial lung disease (ILD), we observed seven candidate SNVs that were possibly associated with ILD (P < 0.00001). Tyrosine 79-87 epidermal growth factor receptor Homo sapiens 73-77 31585087-5 2019 We demonstrated how mutations near tyrosine residues introduce molecular switches that rewire cancer signaling networks, and we revealed oncogenic properties of such a lung cancer EGFR mutant. Tyrosine 35-43 epidermal growth factor receptor Homo sapiens 180-184 31642175-2 2019 In preclinical and clinical studies, the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor osimertinib has demonstrated activity in the central nervous system (CNS), and studies are ongoing. Tyrosine 98-106 epidermal growth factor receptor Homo sapiens 58-90 31642175-2 2019 In preclinical and clinical studies, the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor osimertinib has demonstrated activity in the central nervous system (CNS), and studies are ongoing. Tyrosine 98-106 epidermal growth factor receptor Homo sapiens 92-96 31564718-1 2019 Osimertinib is an irreversible, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that is highly selective for EGFR-activating mutations as well as the EGFR T790M mutation in patients with advanced non-small cell lung cancer (NSCLC) with EGFR oncogene addiction. Tyrosine 89-97 epidermal growth factor receptor Homo sapiens 49-81 31564718-1 2019 Osimertinib is an irreversible, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that is highly selective for EGFR-activating mutations as well as the EGFR T790M mutation in patients with advanced non-small cell lung cancer (NSCLC) with EGFR oncogene addiction. Tyrosine 89-97 epidermal growth factor receptor Homo sapiens 83-87 31620244-2 2019 Its clinical utility has been well demonstrated for EGFR T790M testing in lung cancer patients suffering progress after tyrosine kinase inhibitor treatment. Tyrosine 120-128 epidermal growth factor receptor Homo sapiens 52-56 31686847-4 2019 Recent studies have revealed that these rare genotypes could be targetable if appropriate EGFR tyrosine kinase inhibitors are selected. Tyrosine 95-103 epidermal growth factor receptor Homo sapiens 90-94 31754333-1 2019 Monotherapy with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) still leads to incomplete responses in most EGFR-mutation positive non-small cell lung cancer (NSCLC) patients, often due to acquired resistance through activation of parallel compensatory pathways. Tyrosine 57-65 epidermal growth factor receptor Homo sapiens 17-49 31754333-1 2019 Monotherapy with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) still leads to incomplete responses in most EGFR-mutation positive non-small cell lung cancer (NSCLC) patients, often due to acquired resistance through activation of parallel compensatory pathways. Tyrosine 57-65 epidermal growth factor receptor Homo sapiens 51-55 31754333-1 2019 Monotherapy with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) still leads to incomplete responses in most EGFR-mutation positive non-small cell lung cancer (NSCLC) patients, often due to acquired resistance through activation of parallel compensatory pathways. Tyrosine 57-65 epidermal growth factor receptor Homo sapiens 135-139 31075398-7 2019 We found AAMP interacted with EGFR and enhanced its dimerization and phosphorylation at tyrosine 1173 which activated ERK1/2 in NSCLC cells. Tyrosine 88-96 epidermal growth factor receptor Homo sapiens 30-34 31656643-0 2019 Intracavitary chemotherapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is not superior to TKI monotherapy in controlling malignant pleural effusion recurrence in EGFR-mutated lung cancer patients. Tyrosine 65-73 epidermal growth factor receptor Homo sapiens 32-64 31656643-1 2019 Background: Epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) patients benefit from EGFR-tyrosine kinase inhibitors (TKIs) therapy. Tyrosine 122-130 epidermal growth factor receptor Homo sapiens 12-44 31656643-1 2019 Background: Epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) patients benefit from EGFR-tyrosine kinase inhibitors (TKIs) therapy. Tyrosine 122-130 epidermal growth factor receptor Homo sapiens 46-50 31656643-1 2019 Background: Epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) patients benefit from EGFR-tyrosine kinase inhibitors (TKIs) therapy. Tyrosine 122-130 epidermal growth factor receptor Homo sapiens 117-121 31543779-2 2019 Acquired resistance to first-line EGFR-tyrosine kinase inhibitor (TKI) and subsequent disease progression is a common problem and mostly due to a secondary mutation (T790M) in EGFR. Tyrosine 39-47 epidermal growth factor receptor Homo sapiens 34-38 31543779-2 2019 Acquired resistance to first-line EGFR-tyrosine kinase inhibitor (TKI) and subsequent disease progression is a common problem and mostly due to a secondary mutation (T790M) in EGFR. Tyrosine 39-47 epidermal growth factor receptor Homo sapiens 176-180 31374910-4 2019 We describe furfuryl derivatives of 4-allyl-5-[2-(4-alkoxyphenyl)-quinolin-4-yl]-4H-1,2,4-triazole-3-thiol that bind to and weakly inhibit EGFR tyrosine phosphorylation and induce strong endocytic degradation of the receptor in cancer cells. Tyrosine 144-152 epidermal growth factor receptor Homo sapiens 139-143 30273693-4 2019 Addition of PACAP-38 to NCI-H838 or A549 cells increased the tyrosine phosphorylation of the EGFR, HER2 and ERK significantly by 4-, 3-, and 2-fold, respectively. Tyrosine 61-69 epidermal growth factor receptor Homo sapiens 93-97 31737502-1 2019 Background: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) induce significant responses in EGFR-mutation positive non-small cell lung cancer (NSCLC). Tyrosine 52-60 epidermal growth factor receptor Homo sapiens 12-44 31737502-1 2019 Background: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) induce significant responses in EGFR-mutation positive non-small cell lung cancer (NSCLC). Tyrosine 52-60 epidermal growth factor receptor Homo sapiens 46-50 31737502-1 2019 Background: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) induce significant responses in EGFR-mutation positive non-small cell lung cancer (NSCLC). Tyrosine 52-60 epidermal growth factor receptor Homo sapiens 118-122 31787809-3 2019 The study further subjects the filtered phytochemicals for their molecular docking analysis and molecular dynamics simulation studies against the prominent receptor tyrosine kinases EGFR, VEGFR-1 and VEGFR-2 involved in angiogenesis phenomenon. Tyrosine 165-173 epidermal growth factor receptor Homo sapiens 182-186 31570733-2 2019 Here, we investigate the clinical efficacy and safety of AM in the treatment of advanced progressed epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) resistant LA patients. Tyrosine 133-141 epidermal growth factor receptor Homo sapiens 161-165 31608233-5 2019 And the clinical response of patients who were detected as EGFR mutation in exosomes and treated with EGFR tyrosine kinase inhibitor (EGFR-TKI) was explored. Tyrosine 107-115 epidermal growth factor receptor Homo sapiens 102-106 31608233-5 2019 And the clinical response of patients who were detected as EGFR mutation in exosomes and treated with EGFR tyrosine kinase inhibitor (EGFR-TKI) was explored. Tyrosine 107-115 epidermal growth factor receptor Homo sapiens 102-106 31695757-1 2019 Background: Acquired resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) such as erlotinib is a major challenge to achieve an overall clinical benefit of the targeted therapy. Tyrosine 75-83 epidermal growth factor receptor Homo sapiens 35-67 31695757-1 2019 Background: Acquired resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) such as erlotinib is a major challenge to achieve an overall clinical benefit of the targeted therapy. Tyrosine 75-83 epidermal growth factor receptor Homo sapiens 69-73 31571924-1 2019 Background: Epidermal growth factor receptor (EGFR) is a member of the ErbB family of tyrosine kinase receptor proteins that plays important roles in tumour cell survival and proliferation. Tyrosine 86-94 epidermal growth factor receptor Homo sapiens 12-44 31571924-1 2019 Background: Epidermal growth factor receptor (EGFR) is a member of the ErbB family of tyrosine kinase receptor proteins that plays important roles in tumour cell survival and proliferation. Tyrosine 86-94 epidermal growth factor receptor Homo sapiens 46-50 31571924-1 2019 Background: Epidermal growth factor receptor (EGFR) is a member of the ErbB family of tyrosine kinase receptor proteins that plays important roles in tumour cell survival and proliferation. Tyrosine 86-94 epidermal growth factor receptor Homo sapiens 71-75 31554377-1 2019 BACKGROUND: Despite effective activity of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as erlotinib, all non-small cell lung cancer (NSCLC) patients eventually acquire resistance to these agents. Tyrosine 82-90 epidermal growth factor receptor Homo sapiens 76-80 31598253-1 2019 Nazartinib (EGF816, NZB) is a promising third-generation human epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Tyrosine 103-111 epidermal growth factor receptor Homo sapiens 63-95 31598253-1 2019 Nazartinib (EGF816, NZB) is a promising third-generation human epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Tyrosine 103-111 epidermal growth factor receptor Homo sapiens 97-101 31243371-5 2019 Here we show that, after activation of EGFR, UGDH is phosphorylated at tyrosine 473 in human lung cancer cells. Tyrosine 71-79 epidermal growth factor receptor Homo sapiens 39-43 31485130-1 2019 Epidermal growth factor receptor (EGFR) binds to EGF activating tyrosine phosphorylation through receptor dimerization prompting uncontrolled multiplication. Tyrosine 64-72 epidermal growth factor receptor Homo sapiens 0-32 31485130-1 2019 Epidermal growth factor receptor (EGFR) binds to EGF activating tyrosine phosphorylation through receptor dimerization prompting uncontrolled multiplication. Tyrosine 64-72 epidermal growth factor receptor Homo sapiens 34-38 31485130-3 2019 We report the predicted phosphorylation sites on Ser, Thr and Tyr residues in addition to 74 auto-phosphorylation sites on Tyr in human EGFR. Tyrosine 123-126 epidermal growth factor receptor Homo sapiens 136-140 31637005-1 2019 Tyrosine kinase inhibitors for epidermal growth factor receptor (EGFR TKIs) greatly improved clinical outcomes of patients with non-small cell lung cancer (NSCLC). Tyrosine 0-8 epidermal growth factor receptor Homo sapiens 31-63 31637005-1 2019 Tyrosine kinase inhibitors for epidermal growth factor receptor (EGFR TKIs) greatly improved clinical outcomes of patients with non-small cell lung cancer (NSCLC). Tyrosine 0-8 epidermal growth factor receptor Homo sapiens 65-69 31571631-1 2019 Background & objectives: Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR) have been evaluated in patients with advanced non-small cell lung cancer (NSCLC). Tyrosine 29-37 epidermal growth factor receptor Homo sapiens 77-109 31571631-1 2019 Background & objectives: Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR) have been evaluated in patients with advanced non-small cell lung cancer (NSCLC). Tyrosine 29-37 epidermal growth factor receptor Homo sapiens 111-115 30474276-4 2019 Epithelia established on the NMWs showed persistence of the activated state of the epidermal growth factor receptor (EGF-R), phosphorylated at the src-specific tyrosine 845 (EGF-RT845 ) throughout the observation period of 10 days. Tyrosine 160-168 epidermal growth factor receptor Homo sapiens 83-115 30604896-9 2019 Phospho-proteome profiling found HER-1 tyrosine phosphorylation was reduced with GRB7 knock down in JIMT1 cells. Tyrosine 39-47 epidermal growth factor receptor Homo sapiens 33-38 30910997-4 2019 DYRK1A (dual-specificity tyrosine-phosphorylated and tyrosine-regulated kinase 1A), an EGFR-stabilizing kinase, is downregulated by p53 and, when ectopically expressed, can attenuate p53 activation-induced EGFR reduction and cellular senescence. Tyrosine 25-33 epidermal growth factor receptor Homo sapiens 87-91 30910997-4 2019 DYRK1A (dual-specificity tyrosine-phosphorylated and tyrosine-regulated kinase 1A), an EGFR-stabilizing kinase, is downregulated by p53 and, when ectopically expressed, can attenuate p53 activation-induced EGFR reduction and cellular senescence. Tyrosine 25-33 epidermal growth factor receptor Homo sapiens 206-210 31110287-5 2019 EGFR-mediated phosphorylation of one tyrosine residue on the Fzd9b intracellular tail in response to Wnt9a promotes internalization of the Wnt9a-Fzd9b-LRP signalosome and subsequent signal transduction. Tyrosine 37-45 epidermal growth factor receptor Homo sapiens 0-4 31083325-1 2019 The partner of activated epidermal growth factor receptor (EGFR), growth factor receptor bound protein-7 (Grb7), a functionally multidomain adaptor protein, has been demonstrated to be a pivotal regulator for varied physiological and pathological processes by interacting with phospho-tyrosine-related signaling molecules to affect the transmission through a number of signaling pathways. Tyrosine 285-293 epidermal growth factor receptor Homo sapiens 25-57 31083325-1 2019 The partner of activated epidermal growth factor receptor (EGFR), growth factor receptor bound protein-7 (Grb7), a functionally multidomain adaptor protein, has been demonstrated to be a pivotal regulator for varied physiological and pathological processes by interacting with phospho-tyrosine-related signaling molecules to affect the transmission through a number of signaling pathways. Tyrosine 285-293 epidermal growth factor receptor Homo sapiens 59-63 30474276-4 2019 Epithelia established on the NMWs showed persistence of the activated state of the epidermal growth factor receptor (EGF-R), phosphorylated at the src-specific tyrosine 845 (EGF-RT845 ) throughout the observation period of 10 days. Tyrosine 160-168 epidermal growth factor receptor Homo sapiens 117-122 30521970-13 2019 Adjuvant tyrosine kinas inhibitors may be considered as a treatment option in resected stage N1-N2 EGFR-mutant NSCLC but longer duration should be explored. Tyrosine 9-17 epidermal growth factor receptor Homo sapiens 99-103 31616716-2 2019 Lung adenocarcinomas with epidermal growth factor receptor mutations have a good response to tyrosine kinase inhibitors (TKIs). Tyrosine 93-101 epidermal growth factor receptor Homo sapiens 26-58 31933871-3 2019 The patient was positive for the EGFR18 exon and had an excellent tumor response to the EGFR tyrosine kinase inhibitor (EGFR-TKI) with a duration of efficacy of up to 22 months. Tyrosine 93-101 epidermal growth factor receptor Homo sapiens 33-37 31933871-3 2019 The patient was positive for the EGFR18 exon and had an excellent tumor response to the EGFR tyrosine kinase inhibitor (EGFR-TKI) with a duration of efficacy of up to 22 months. Tyrosine 93-101 epidermal growth factor receptor Homo sapiens 88-92 30401746-4 2019 Cx32 contains two intracellular tyrosine residues, and tyrosine phosphorylation of Cx32 has been detected after activation of the epidermal growth factor receptor; however, the specific tyrosine residue and the functional implication of this phosphorylation remain unknown. Tyrosine 55-63 epidermal growth factor receptor Homo sapiens 130-162 30401746-4 2019 Cx32 contains two intracellular tyrosine residues, and tyrosine phosphorylation of Cx32 has been detected after activation of the epidermal growth factor receptor; however, the specific tyrosine residue and the functional implication of this phosphorylation remain unknown. Tyrosine 55-63 epidermal growth factor receptor Homo sapiens 130-162 31939440-1 2019 Context: Tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) play an indispensable role in the treatment of non-small cell lung cancer (NSCLC), leading to a survival major breakthrough, but there remains no uniform standard for predicting the efficacy of TKI therapy. Tyrosine 9-17 epidermal growth factor receptor Homo sapiens 53-85 30462558-5 2019 Western blot analysis confirmed the upregulation of EGFR ligands and the phosphorylation of EGFR at tyrosine-845 in colorectal cancer cells exposed to FVIIa. Tyrosine 100-108 epidermal growth factor receptor Homo sapiens 92-96 30198788-7 2019 P-ERK1/2 and P-AKT (Thr-308) signaling was mediated by Src-kinase and associated with phosphorylation of tyrosine residue of epidermal growth factor receptor (P-EGFR Y1173). Tyrosine 105-113 epidermal growth factor receptor Homo sapiens 125-157 30198788-7 2019 P-ERK1/2 and P-AKT (Thr-308) signaling was mediated by Src-kinase and associated with phosphorylation of tyrosine residue of epidermal growth factor receptor (P-EGFR Y1173). Tyrosine 105-113 epidermal growth factor receptor Homo sapiens 161-165 31755384-1 2019 BACKGROUND: The introduction of Monoclonal Antibodies (mAbs) and small molecule Tyrosine Kinase Inhibitors (TKIs) that target the Epidermal Growth Factor Receptor (EGFR), mark a huge step forward in the Pancreatic Cancer (PC) therapy. Tyrosine 80-88 epidermal growth factor receptor Homo sapiens 130-162 31755384-1 2019 BACKGROUND: The introduction of Monoclonal Antibodies (mAbs) and small molecule Tyrosine Kinase Inhibitors (TKIs) that target the Epidermal Growth Factor Receptor (EGFR), mark a huge step forward in the Pancreatic Cancer (PC) therapy. Tyrosine 80-88 epidermal growth factor receptor Homo sapiens 164-168 31939440-1 2019 Context: Tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) play an indispensable role in the treatment of non-small cell lung cancer (NSCLC), leading to a survival major breakthrough, but there remains no uniform standard for predicting the efficacy of TKI therapy. Tyrosine 9-17 epidermal growth factor receptor Homo sapiens 87-91 29885323-4 2018 Loss-of-function approaches were used to identify the cellular components involved in the tyrosine phosphorylation of G protein-coupled receptor kinase 2 (GRK2), which is responsible for EGFR-induced regulation of the functions of D3R. Tyrosine 90-98 epidermal growth factor receptor Homo sapiens 187-191 30242154-1 2018 Epidermal growth factor receptor (EGFR) activation by growth factors (GFs) relies on dimerization and allosteric activation of its intrinsic kinase activity, resulting in trans-phosphorylation of tyrosines on its C-terminal tail. Tyrosine 196-205 epidermal growth factor receptor Homo sapiens 0-32 30242154-1 2018 Epidermal growth factor receptor (EGFR) activation by growth factors (GFs) relies on dimerization and allosteric activation of its intrinsic kinase activity, resulting in trans-phosphorylation of tyrosines on its C-terminal tail. Tyrosine 196-205 epidermal growth factor receptor Homo sapiens 34-38 29885323-7 2018 Internalized EGFR in the cytosol mediated Src/Gbetagamma-dependent tyrosine phosphorylation of GRK2. Tyrosine 67-75 epidermal growth factor receptor Homo sapiens 13-17 30637689-3 2018 EGFR activation was probed via immunofluorescence-detected phosphorylation of tyrosines (pY-mAb) located in the kinase domain of EGFR (Y845) and at the EGFR cytoplasmic tail (Y1173). Tyrosine 78-87 epidermal growth factor receptor Homo sapiens 0-4 31949865-2 2018 The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are particularly effective in NSCLC patients harboring active EGFR mutations. Tyrosine 44-52 epidermal growth factor receptor Homo sapiens 4-36 31949865-2 2018 The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are particularly effective in NSCLC patients harboring active EGFR mutations. Tyrosine 44-52 epidermal growth factor receptor Homo sapiens 38-42 31949865-2 2018 The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are particularly effective in NSCLC patients harboring active EGFR mutations. Tyrosine 44-52 epidermal growth factor receptor Homo sapiens 140-144 30127519-0 2018 The tyrosine phosphorylated pro-survival form of Fas intensifies the EGF-induced signal in colorectal cancer cells through the nuclear EGFR/STAT3-mediated pathway. Tyrosine 4-12 epidermal growth factor receptor Homo sapiens 135-139 30012625-1 2018 Upon activation, the epidermal growth factor receptor (EGFR) phosphorylates tyrosine residues in its cytoplasmic tail, which triggers the binding of Src homology 2 (SH2) and phosphotyrosine-binding (PTB) domains and initiates downstream signaling. Tyrosine 76-84 epidermal growth factor receptor Homo sapiens 21-53 30012625-1 2018 Upon activation, the epidermal growth factor receptor (EGFR) phosphorylates tyrosine residues in its cytoplasmic tail, which triggers the binding of Src homology 2 (SH2) and phosphotyrosine-binding (PTB) domains and initiates downstream signaling. Tyrosine 76-84 epidermal growth factor receptor Homo sapiens 55-59 30012625-2 2018 The sequences flanking the tyrosine residues (referred to as "phosphosites") must be compatible with phosphorylation by the EGFR kinase domain and the recruitment of adapter proteins, while minimizing phosphorylation that would reduce the fidelity of signal transmission. Tyrosine 27-35 epidermal growth factor receptor Homo sapiens 124-128 30012625-6 2018 Although efficient phosphorylation by EGFR can occur with either acidic or large hydrophobic residues at the -1 position with respect to the tyrosine, hydrophobic residues are generally excluded from this position in tail sequences. Tyrosine 141-149 epidermal growth factor receptor Homo sapiens 38-42 29799091-5 2018 These agents include anaplastic lymphoma kinase (ALK) inhibitors such as alectinib, crizotinib, ceritinib, lorlatinib, and others; epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, including the recently developed third-generation inhibitor osimertinib, and even immune checkpoint inhibitors such as nivolumab, pembrolizumab, and atezolizumab. Tyrosine 171-179 epidermal growth factor receptor Homo sapiens 165-169 29795369-0 2018 NOTCH3 inactivation increases triple negative breast cancer sensitivity to gefitinib by promoting EGFR tyrosine dephosphorylation and its intracellular arrest. Tyrosine 103-111 epidermal growth factor receptor Homo sapiens 98-102 29795369-7 2018 Interestingly, these events are associated with the EGFR tyrosine dephosphorylation at Y1173 residue (but not at Y1068) by the protein tyrosine phosphatase H1 (PTPH1), thus suggesting its possible involvement in the observed Notch3-dependent TNBC sensitivity response to gefitinib. Tyrosine 57-65 epidermal growth factor receptor Homo sapiens 52-56 29531172-0 2018 Constitutively Bound EGFR-Mediated Tyrosine Phosphorylation of TLR9 Is Required for Its Ability To Signal. Tyrosine 35-43 epidermal growth factor receptor Homo sapiens 21-25 29531172-12 2018 EGFR is constitutively bound to TLR9; upon ligand stimulation, it mediates TLR9 Tyr phosphorylation, which leads to the recruitment of MyD88, activation of the signaling kinases and transcription factors, and gene induction. Tyrosine 80-83 epidermal growth factor receptor Homo sapiens 0-4 29255092-5 2018 This non-canonical, p38-mediated phosphorylation of the C-tail of EGFR, near Ser-1015, induces the clathrin-mediated endocytosis of the unliganded EGFR monomers, which occurs slightly later than the canonical endocytosis of ligand-bound EGFR dimers via tyrosine autophosphorylation. Tyrosine 253-261 epidermal growth factor receptor Homo sapiens 66-70 29255092-5 2018 This non-canonical, p38-mediated phosphorylation of the C-tail of EGFR, near Ser-1015, induces the clathrin-mediated endocytosis of the unliganded EGFR monomers, which occurs slightly later than the canonical endocytosis of ligand-bound EGFR dimers via tyrosine autophosphorylation. Tyrosine 253-261 epidermal growth factor receptor Homo sapiens 147-151 29255092-5 2018 This non-canonical, p38-mediated phosphorylation of the C-tail of EGFR, near Ser-1015, induces the clathrin-mediated endocytosis of the unliganded EGFR monomers, which occurs slightly later than the canonical endocytosis of ligand-bound EGFR dimers via tyrosine autophosphorylation. Tyrosine 253-261 epidermal growth factor receptor Homo sapiens 147-151 29164418-3 2018 Western blot analysis revealed both ferulic acid and 4-vinylguaiacol exhibit sustained inhibition of EGFR activation through down-regulation of Tyr 1068 autophosphorylation. Tyrosine 144-147 epidermal growth factor receptor Homo sapiens 101-105 29360846-10 2018 Western blot experiments in porcine coronary artery smooth muscle cells (PCASMC) showed that G-1 increased tyrosine phosphorylation of EGFR, which was inhibited by AG-1478. Tyrosine 107-115 epidermal growth factor receptor Homo sapiens 135-139 29162725-6 2018 We found that SH2 overexpression results in a significant, dose-dependent increase in EGFR tyrosine phosphorylation, particularly of sites corresponding to the binding specificity of the overexpressed SH2 domain. Tyrosine 91-99 epidermal growth factor receptor Homo sapiens 86-90 29492217-5 2018 Here, we show that inhibition of phosphatases leads to a marked increase in phosphorylation of wild-type EGFR and EGFRvIII, indicating that both undergo cyclic rounds of phosphorylation and dephosphorylation on all investigated tyrosine residues, including Tyr1045. Tyrosine 228-236 epidermal growth factor receptor Homo sapiens 105-109 29472535-2 2018 Here, we report that epidermal growth factor receptor (EGFR) kinase suppresses ciliogenesis by directly phosphorylating the deubiquitinase USP8 on Tyr-717 and Tyr-810 in RPE1 cells. Tyrosine 147-150 epidermal growth factor receptor Homo sapiens 21-53 29472535-2 2018 Here, we report that epidermal growth factor receptor (EGFR) kinase suppresses ciliogenesis by directly phosphorylating the deubiquitinase USP8 on Tyr-717 and Tyr-810 in RPE1 cells. Tyrosine 147-150 epidermal growth factor receptor Homo sapiens 55-59 29472535-2 2018 Here, we report that epidermal growth factor receptor (EGFR) kinase suppresses ciliogenesis by directly phosphorylating the deubiquitinase USP8 on Tyr-717 and Tyr-810 in RPE1 cells. Tyrosine 159-162 epidermal growth factor receptor Homo sapiens 21-53 29472535-2 2018 Here, we report that epidermal growth factor receptor (EGFR) kinase suppresses ciliogenesis by directly phosphorylating the deubiquitinase USP8 on Tyr-717 and Tyr-810 in RPE1 cells. Tyrosine 159-162 epidermal growth factor receptor Homo sapiens 55-59 30637689-3 2018 EGFR activation was probed via immunofluorescence-detected phosphorylation of tyrosines (pY-mAb) located in the kinase domain of EGFR (Y845) and at the EGFR cytoplasmic tail (Y1173). Tyrosine 78-87 epidermal growth factor receptor Homo sapiens 129-133 30637689-3 2018 EGFR activation was probed via immunofluorescence-detected phosphorylation of tyrosines (pY-mAb) located in the kinase domain of EGFR (Y845) and at the EGFR cytoplasmic tail (Y1173). Tyrosine 78-87 epidermal growth factor receptor Homo sapiens 129-133 30488756-4 2018 These studies demonstrated tyrosine-phosphorylated EGFR, AXL, and EPHA2 in four of six KIT-negative GIST lines (GIST62, GIST522, GIST54, GIST226, GIST48B, and GIST430B), and tyrosine-phosphorylated focal adhesion kinase (FAK) in each of the six KIT-negative lines. Tyrosine 27-35 epidermal growth factor receptor Homo sapiens 51-55 28830985-5 2017 We identified unique and tumor-specific tyrosine phosphorylation rewiring in tumors resistant to treatment with the irreversible third-generation EGFR-inhibitor, osimertinib, or the novel dual-targeting EGFR/Met antibody, JNJ-61186372. Tyrosine 40-48 epidermal growth factor receptor Homo sapiens 146-150 28830985-5 2017 We identified unique and tumor-specific tyrosine phosphorylation rewiring in tumors resistant to treatment with the irreversible third-generation EGFR-inhibitor, osimertinib, or the novel dual-targeting EGFR/Met antibody, JNJ-61186372. Tyrosine 40-48 epidermal growth factor receptor Homo sapiens 203-207 28978917-8 2017 With regard to underlying mechanism, EGFR-PPARGC1A protein causes constitutive tyrosine phosphorylation, and induces the phosphorylation of wild-type full-length epidermal growth factor receptor (EGFR) by dimerization. Tyrosine 79-87 epidermal growth factor receptor Homo sapiens 37-41 28830985-6 2017 Tumor-specific increases in tyrosine-phosphorylated peptides from EGFR family members, Shc1 and Gab1 or Src family kinase (SFK) substrates were observed, underscoring a differential ability of tumors to uniquely escape EGFR inhibition. Tyrosine 28-36 epidermal growth factor receptor Homo sapiens 66-70 28830985-6 2017 Tumor-specific increases in tyrosine-phosphorylated peptides from EGFR family members, Shc1 and Gab1 or Src family kinase (SFK) substrates were observed, underscoring a differential ability of tumors to uniquely escape EGFR inhibition. Tyrosine 28-36 epidermal growth factor receptor Homo sapiens 219-223 27458090-7 2017 EGFR tyrosine residue phosphorylation was decreased by PCBs in all models tested. Tyrosine 5-13 epidermal growth factor receptor Homo sapiens 0-4 28501600-11 2017 The same observations were also made for migration of cancer cells, especially induction of MDA-MB468 migration by mEGF was significantly lower than that of hEGF, suggesting a connection between tyrosine phosphorylation of EGFR and cell migration. Tyrosine 195-203 epidermal growth factor receptor Homo sapiens 223-227 28579429-0 2017 The EGF receptor inhibits the signaling of dopamine D3 receptor through the phosphorylation of GRK2 on tyrosine residues. Tyrosine 103-111 epidermal growth factor receptor Homo sapiens 4-16 28336235-4 2017 The tyrosine phosphorylation of Rab7 is physiologically induced by EGF, and impairs the interaction of Rab7 with RILP, consequently inhibiting EGFR degradation and sustaining Akt signaling. Tyrosine 4-12 epidermal growth factor receptor Homo sapiens 143-147 28486761-8 2017 Panitumumab and the tyrosine kinase inhibitor erlotinib reduced the basal level of EGFR tyrosine phosphorylation and reversed FTD-induced ERK/AKT/STAT3 and EGFR serine/threonine phosphorylation. Tyrosine 20-28 epidermal growth factor receptor Homo sapiens 83-87 28486761-8 2017 Panitumumab and the tyrosine kinase inhibitor erlotinib reduced the basal level of EGFR tyrosine phosphorylation and reversed FTD-induced ERK/AKT/STAT3 and EGFR serine/threonine phosphorylation. Tyrosine 20-28 epidermal growth factor receptor Homo sapiens 156-160 28785244-7 2017 BA1 increased tyrosine phosphorylation of the EGFR and ERK in lung cancer cells, which was blocked by AM-37 and ST-36. Tyrosine 14-22 epidermal growth factor receptor Homo sapiens 46-50 28320945-4 2017 Although both CC and SC expressed EGF receptor (EGFR), the EGFR-neutralizing monoclonal antibody, cetuximab, strongly inhibited growth of CC, whereas SC was resistant to growth inhibition, and this was coupled to increased tyrosine phosphorylation of MET and RON. Tyrosine 223-231 epidermal growth factor receptor Homo sapiens 59-63 28120452-7 2017 Molecular analysis showed that silibinin treatment decreased the level of phosphorylated EGFR (Tyrosine 1173) and total EGFR in ASZ001-Sant-1 cells, key signaling molecules responsible for BCC resistance toward hedgehog inhibitors. Tyrosine 95-103 epidermal growth factor receptor Homo sapiens 89-93 28331001-0 2017 Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response. Tyrosine 13-21 epidermal growth factor receptor Homo sapiens 43-75 28331001-0 2017 Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response. Tyrosine 13-21 epidermal growth factor receptor Homo sapiens 77-81 28331001-6 2017 Here, we sought to characterize the dynamics of tyrosine phosphorylation upon EGFR TKI treatment of mutant EGFR-driven human lung adenocarcinoma cell lines with varying sensitivity to EGFR TKIs, erlotinib and afatinib. Tyrosine 48-56 epidermal growth factor receptor Homo sapiens 78-82 28331001-6 2017 Here, we sought to characterize the dynamics of tyrosine phosphorylation upon EGFR TKI treatment of mutant EGFR-driven human lung adenocarcinoma cell lines with varying sensitivity to EGFR TKIs, erlotinib and afatinib. Tyrosine 48-56 epidermal growth factor receptor Homo sapiens 107-111 28331001-6 2017 Here, we sought to characterize the dynamics of tyrosine phosphorylation upon EGFR TKI treatment of mutant EGFR-driven human lung adenocarcinoma cell lines with varying sensitivity to EGFR TKIs, erlotinib and afatinib. Tyrosine 48-56 epidermal growth factor receptor Homo sapiens 107-111 28331001-9 2017 Afatinib, an irreversible EGFR TKI, more effectively inhibited tyrosine phosphorylation of a majority of the substrates. Tyrosine 63-71 epidermal growth factor receptor Homo sapiens 26-30 28019699-2 2017 These processes occur after EGFR binds to a ligand [epidermal growth factor (EGF)], thus inducing its dimerization and tyrosine autophosphorylation. Tyrosine 119-127 epidermal growth factor receptor Homo sapiens 28-32 27628902-5 2017 EGFR/Src-mediated tyrosine phosphorylation of synaptopodin in podocytes promotes binding to the serine/threonine phosphatase calcineurin. Tyrosine 18-26 epidermal growth factor receptor Homo sapiens 0-4 28791644-2 2017 Overexpression of EGFR leads to a constitutive tyrosine phosphorylation of multiple tyrosine residues in the EGFR. Tyrosine 47-55 epidermal growth factor receptor Homo sapiens 18-22 28791644-2 2017 Overexpression of EGFR leads to a constitutive tyrosine phosphorylation of multiple tyrosine residues in the EGFR. Tyrosine 47-55 epidermal growth factor receptor Homo sapiens 109-113 28791644-2 2017 Overexpression of EGFR leads to a constitutive tyrosine phosphorylation of multiple tyrosine residues in the EGFR. Tyrosine 84-92 epidermal growth factor receptor Homo sapiens 18-22 28791644-2 2017 Overexpression of EGFR leads to a constitutive tyrosine phosphorylation of multiple tyrosine residues in the EGFR. Tyrosine 84-92 epidermal growth factor receptor Homo sapiens 109-113 27816751-7 2016 Our findings demonstrate that in MDA-MB-468 cells the stimulatory activity of GHRH on tyrosine phosphorylation of EGFR is exerted by two different molecular mechanisms: i) through GHRH receptors, GHRH stimulates a ligand-independent activation of EGFR involving at least cAMP/PKA and Src family signaling pathways; ii) GHRH also stimulates a ligand-dependent activation of EGFR implicating an extracellular pathway with an important role for metalloproteinases. Tyrosine 86-94 epidermal growth factor receptor Homo sapiens 114-118 27905891-0 2016 Erratum to: Insulin-like growth factor 1 receptor mediated tyrosine 845 phosphorylation of epidermal growth factor receptor in the presence of monoclonal antibody cetuximab. Tyrosine 59-67 epidermal growth factor receptor Homo sapiens 91-123 27816751-7 2016 Our findings demonstrate that in MDA-MB-468 cells the stimulatory activity of GHRH on tyrosine phosphorylation of EGFR is exerted by two different molecular mechanisms: i) through GHRH receptors, GHRH stimulates a ligand-independent activation of EGFR involving at least cAMP/PKA and Src family signaling pathways; ii) GHRH also stimulates a ligand-dependent activation of EGFR implicating an extracellular pathway with an important role for metalloproteinases. Tyrosine 86-94 epidermal growth factor receptor Homo sapiens 247-251 27816751-7 2016 Our findings demonstrate that in MDA-MB-468 cells the stimulatory activity of GHRH on tyrosine phosphorylation of EGFR is exerted by two different molecular mechanisms: i) through GHRH receptors, GHRH stimulates a ligand-independent activation of EGFR involving at least cAMP/PKA and Src family signaling pathways; ii) GHRH also stimulates a ligand-dependent activation of EGFR implicating an extracellular pathway with an important role for metalloproteinases. Tyrosine 86-94 epidermal growth factor receptor Homo sapiens 247-251 27578003-7 2016 Wnt signaling upregulated WBP2 by disrupting ITCH-WBP2 interactions via EGFR-mediated tyrosine phosphorylation of WBP2 and TAZ/YAP competitive binding. Tyrosine 86-94 epidermal growth factor receptor Homo sapiens 72-76 27462018-8 2016 The data indicate that EGFR is translocated to the nucleus after stimulation with EGF, HB-EGF, TGF-alpha and beta-Cellulin, and that these ligands are related to increased phosphorylation of EGFR tyrosine residues, inducing migration of SkHep-1 cells. Tyrosine 196-204 epidermal growth factor receptor Homo sapiens 191-195 27716204-0 2016 Insulin-like growth factor 1 receptor mediated tyrosine 845 phosphorylation of epidermal growth factor receptor in the presence of monoclonal antibody cetuximab. Tyrosine 47-55 epidermal growth factor receptor Homo sapiens 79-111 27447558-4 2016 Mechanistically, SREBP inhibition decreases the cell membrane fluidity, results in a decreased tyrosine phosphorylation of EGFR. Tyrosine 95-103 epidermal growth factor receptor Homo sapiens 123-127 27259358-6 2016 Specifically, the third subtype exhibited enhanced tyrosine phosphorylation of multiple RTKs including the EGFR, ERBB3 and MET. Tyrosine 51-59 epidermal growth factor receptor Homo sapiens 107-111 27149518-8 2016 Furthermore, the trimeric TSP1 fragments containing the 1st type repeat increased the catalytic activity of CD148 and reduced phospho-tyrosine contents of EGFR and ERK1/2, defined CD148 substrates. Tyrosine 134-142 epidermal growth factor receptor Homo sapiens 155-159 27412859-5 2016 Additionally, we demonstrate that local administration of synthetic NATs accelerates wound closure in mice and stimulates repair-associated responses in primary cultures of human keratinocytes and fibroblasts, through a mechanism that involves tyrosine phosphorylation of the epidermal growth factor receptor and an increase in intracellular calcium levels, under the permissive control of transient receptor potential vanilloid-1 receptors. Tyrosine 244-252 epidermal growth factor receptor Homo sapiens 276-308 27463710-7 2016 The LZ-EGFR-GFP dimer autophosphorylated each of its five well-defined C-terminal tyrosine residues as the ligand-induced EGFR dimer does. Tyrosine 82-90 epidermal growth factor receptor Homo sapiens 7-11 27462018-8 2016 The data indicate that EGFR is translocated to the nucleus after stimulation with EGF, HB-EGF, TGF-alpha and beta-Cellulin, and that these ligands are related to increased phosphorylation of EGFR tyrosine residues, inducing migration of SkHep-1 cells. Tyrosine 196-204 epidermal growth factor receptor Homo sapiens 23-27 27166522-7 2016 Furthermore, we found that the tyrosine phosphorylation of EGFR (epidermal growth factor receptor) decreased after 16 h in hypoxia. Tyrosine 31-39 epidermal growth factor receptor Homo sapiens 59-63 27166522-7 2016 Furthermore, we found that the tyrosine phosphorylation of EGFR (epidermal growth factor receptor) decreased after 16 h in hypoxia. Tyrosine 31-39 epidermal growth factor receptor Homo sapiens 65-97 26928584-10 2016 This study provides a novel molecular mechanism of oxidative stress stimulated covalent EGFR dimerization via tyrosine dimerization that contributes into development of PH. Tyrosine 110-118 epidermal growth factor receptor Homo sapiens 88-92 26921391-6 2016 Depletion of beta-AR2 in LNCaP cells increased proliferation/colony formation and significantly increased activation of Src, phosphorylation of EGFR at Tyr-1110, and phosphorylation/activation of ERK1/2 compared with that with control shRNA. Tyrosine 152-155 epidermal growth factor receptor Homo sapiens 144-148 26781210-8 2016 Acquisition of resistance to these agents was accompanied by upregulation of p-c-MET, p-STAT3, CD44, increased autocrine production of EGFR ligand amphiregulin and differential activation status of EGFR tyrosine residues as well as downregulation of total and p-SRC. Tyrosine 203-211 epidermal growth factor receptor Homo sapiens 198-202 26840086-9 2016 B6H12 treatment also acutely inhibited EGF-induced EGFR tyrosine phosphorylation. Tyrosine 56-64 epidermal growth factor receptor Homo sapiens 51-55 26699146-3 2016 In this work, we show that, similar to epidermal growth factor (EGF), 20-HETE (10 nM) activates EGFR by stimulating tyrosine phosphorylation; however, unlike 20-HETE, EGF does not induce ACE expression, and pretreatment with a neutralizing antibody against EGF does not prevent the 20-HETE-mediated ACE induction. Tyrosine 116-124 epidermal growth factor receptor Homo sapiens 96-100 26883293-2 2016 It has been shown that lipophilic nitro-benzoxadiazole (NBD) compounds rapidly move across the plasma membrane and enhance Epidermal Growth Factor Receptor (EGFR) tyrosine phosphorylation in cancer cells. Tyrosine 163-171 epidermal growth factor receptor Homo sapiens 123-155 26883293-2 2016 It has been shown that lipophilic nitro-benzoxadiazole (NBD) compounds rapidly move across the plasma membrane and enhance Epidermal Growth Factor Receptor (EGFR) tyrosine phosphorylation in cancer cells. Tyrosine 163-171 epidermal growth factor receptor Homo sapiens 157-161 26290602-6 2015 Mechanistically, expression of Srx enhances the activation of MAPK signaling through increasing the C-terminal tyrosine phosphorylation levels of EGFR. Tyrosine 111-119 epidermal growth factor receptor Homo sapiens 146-150 26751287-2 2016 Here, we identify a cytoplasmic lncRNA, LINK-A (long intergenic non-coding RNA for kinase activation), which mediates HB-EGF-triggered, EGFR:GPNMB heterodimer-dependent HIF1alpha phosphorylation at Tyr 565 and Ser 797 by BRK and LRRK2, respectively. Tyrosine 198-201 epidermal growth factor receptor Homo sapiens 136-140 26429914-3 2015 In tumor cells, which frequently are characterized by constitutively high GSTP1 expression, GSTP1 undergoes phosphorylation by epidermal growth factor receptor (EGFR) at tyrosine residues 3, 7, and 198. Tyrosine 170-178 epidermal growth factor receptor Homo sapiens 127-159 26429914-3 2015 In tumor cells, which frequently are characterized by constitutively high GSTP1 expression, GSTP1 undergoes phosphorylation by epidermal growth factor receptor (EGFR) at tyrosine residues 3, 7, and 198. Tyrosine 170-178 epidermal growth factor receptor Homo sapiens 161-165 26429914-4 2015 Here we report on the effect of this EGFR-dependent GSTP1 tyrosine phosphorylation on the interaction of GSTP1 with JNK, on the regulation of JNK downstream signaling by GSTP1, and on tumor cell survival. Tyrosine 58-66 epidermal growth factor receptor Homo sapiens 37-41 26429914-6 2015 Targeted mutagenesis and functional analysis demonstrated that the increased GSTP1 binding to JNK results from phosphorylation of the GSTP1 C-terminal Tyr-198 by EGFR and is associated with a >2.5-fold decrease in JNK downstream signaling and a significant suppression of both spontaneous and drug-induced apoptosis in the tumor cells. Tyrosine 151-154 epidermal growth factor receptor Homo sapiens 162-166 26609808-4 2015 Autocatalytic phosphorylation of tyrosine 845 on unliganded EGFR monomers is suppressed by vesicular recycling through perinuclear areas with high PTP1B activity. Tyrosine 33-41 epidermal growth factor receptor Homo sapiens 60-64 26462152-9 2015 Neutralizing antibodies against IL-1beta or CXCL1 markedly inhibited the constitutive or IL-1beta-induced tyrosine phosphorylation of EGFR in OSCC cells. Tyrosine 106-114 epidermal growth factor receptor Homo sapiens 134-138 26572622-3 2015 We now demonstrate that oxidative stress serves as an activator of the ubiquitin ligase activity of ZNRF1 by inducing epidermal growth factor receptor (EGFR)-mediated phosphorylation at the 103rd tyrosine residue and that the up-regulation of ZNRF1 activity by oxidative stress leads to neuronal apoptosis and Wallerian degeneration. Tyrosine 196-204 epidermal growth factor receptor Homo sapiens 118-150 26572622-3 2015 We now demonstrate that oxidative stress serves as an activator of the ubiquitin ligase activity of ZNRF1 by inducing epidermal growth factor receptor (EGFR)-mediated phosphorylation at the 103rd tyrosine residue and that the up-regulation of ZNRF1 activity by oxidative stress leads to neuronal apoptosis and Wallerian degeneration. Tyrosine 196-204 epidermal growth factor receptor Homo sapiens 152-156 26462152-5 2015 In this study, we demonstrated that tyrosine phosphorylation of EGFR is crucial for the IL-1beta-mediated proliferation and subsequent bromodeoxyuridine (BrdU) incorporation of DOK cells because the EGFR inhibitors AG1478 and erlotinib inhibit these abilities in a dose-dependent manner. Tyrosine 36-44 epidermal growth factor receptor Homo sapiens 64-68 26462152-5 2015 In this study, we demonstrated that tyrosine phosphorylation of EGFR is crucial for the IL-1beta-mediated proliferation and subsequent bromodeoxyuridine (BrdU) incorporation of DOK cells because the EGFR inhibitors AG1478 and erlotinib inhibit these abilities in a dose-dependent manner. Tyrosine 36-44 epidermal growth factor receptor Homo sapiens 199-203 26462152-7 2015 Furthermore, tyrosine phosphorylation of EGFR was significantly enhanced in DOK (1 h) and OSCC (20 min) cell lines after IL-1beta treatment, and both cell lines were inhibited on the addition of an IL-1 receptor antagonist (IL-1Ra). Tyrosine 13-21 epidermal growth factor receptor Homo sapiens 41-45 26575183-1 2015 Signaling from the epidermal growth factor receptor (EGFR) via phosphorylation on its C-terminal tyrosine residues requires self-association, which depends on the diffusional properties of the receptor and its density in the plasma membrane. Tyrosine 97-105 epidermal growth factor receptor Homo sapiens 19-51 26575183-1 2015 Signaling from the epidermal growth factor receptor (EGFR) via phosphorylation on its C-terminal tyrosine residues requires self-association, which depends on the diffusional properties of the receptor and its density in the plasma membrane. Tyrosine 97-105 epidermal growth factor receptor Homo sapiens 53-57 26497368-7 2015 Therefore, our results demonstrate that besides the canonical role of EGFR as a receptor tyrosine, the mitochondrial translocation of EGFR may enhance cancer invasion and metastasis through regulating mitochondria dynamics. Tyrosine 89-97 epidermal growth factor receptor Homo sapiens 70-74 26497368-7 2015 Therefore, our results demonstrate that besides the canonical role of EGFR as a receptor tyrosine, the mitochondrial translocation of EGFR may enhance cancer invasion and metastasis through regulating mitochondria dynamics. Tyrosine 89-97 epidermal growth factor receptor Homo sapiens 134-138 26549523-4 2015 Moreover, EGFR/Src-signaling triggers the tyrosine phosphorylation of beta4 integrin, which, in turn, recruits FAK to beta4 integrin and leads to FAK activation and signaling. Tyrosine 42-50 epidermal growth factor receptor Homo sapiens 10-14 26079101-5 2015 In addition to significant activation of EGF receptor (EGFR) at tyrosine Tyr845, a remarkable redistribution was detectable for the focal adhesion constituents, integrin ss1 and ss3, and zyxin. Tyrosine 64-72 epidermal growth factor receptor Homo sapiens 41-53 26079101-5 2015 In addition to significant activation of EGF receptor (EGFR) at tyrosine Tyr845, a remarkable redistribution was detectable for the focal adhesion constituents, integrin ss1 and ss3, and zyxin. Tyrosine 64-72 epidermal growth factor receptor Homo sapiens 55-59 26141950-5 2015 Using in vitro studies, we tested the hypothesis that cisplatin and EGFR inhibitors rely on the activation of the tumor suppressor STAT1, characterized by its phosphorylation at serine (S727) or tyrosine (Y701) residues. Tyrosine 195-203 epidermal growth factor receptor Homo sapiens 68-72 25998839-7 2015 Moreover, PTPRS forms a complex with epithermal growth factor receptor (EGFR) and regulates its tyrosine residues" phosphorylation. Tyrosine 96-104 epidermal growth factor receptor Homo sapiens 37-70 25998839-7 2015 Moreover, PTPRS forms a complex with epithermal growth factor receptor (EGFR) and regulates its tyrosine residues" phosphorylation. Tyrosine 96-104 epidermal growth factor receptor Homo sapiens 72-76 25890253-9 2015 The P-Tyr-1000 was applied to EGFR mutated U87 cells. Tyrosine 6-9 epidermal growth factor receptor Homo sapiens 30-34 26304753-10 2015 Simvastatin evoked epidermal growth factor receptor-c-Src-increased Tyr phosphorylation of sEH and formation of an sEH-Akt-AMPK-eNOS complex, which was abolished by the c-Src kinase inhibitor PP1 or c-Src dominant-negative mutant K298M. Tyrosine 68-71 epidermal growth factor receptor Homo sapiens 19-51 26240294-0 2015 Correction: Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non-Small Cell Lung Cancer. Tyrosine 12-20 epidermal growth factor receptor Homo sapiens 110-114 25263444-5 2015 Interestingly, PTPN3-mediated tyrosine dephosphorylation of Eps15 promotes EGFR for lipid raft-mediated endocytosis and lysosomal degradation. Tyrosine 30-38 epidermal growth factor receptor Homo sapiens 75-79 25761747-5 2015 Addition of CCK-8 or gastrin-17 (100 nM) to NCI-H727 human lung cancer cells increased EGFR Tyr(1068) phosphorylation after 2 min. Tyrosine 92-95 epidermal growth factor receptor Homo sapiens 87-91 25761747-6 2015 The ability of CCK-8 to cause EGFR tyrosine phosphorylation was blocked by CI-988, gefitinib (EGFR tyrosine kinase inhibitor), PP2 (Src inhibitor), GM6001 (matrix metalloprotease inhibitor), and tiron (superoxide scavenger). Tyrosine 35-43 epidermal growth factor receptor Homo sapiens 30-34 25761747-6 2015 The ability of CCK-8 to cause EGFR tyrosine phosphorylation was blocked by CI-988, gefitinib (EGFR tyrosine kinase inhibitor), PP2 (Src inhibitor), GM6001 (matrix metalloprotease inhibitor), and tiron (superoxide scavenger). Tyrosine 35-43 epidermal growth factor receptor Homo sapiens 94-98 25907674-3 2015 Using a model non-genotoxic carcinogen, arsenic, we show here that exposure to arsenic inhibits mismatch repair (MMR) in human cells, possibly through its ability to stimulate epidermal growth factor receptor (EGFR)-dependent tyrosine phosphorylation of proliferating cellular nuclear antigen (PCNA). Tyrosine 226-234 epidermal growth factor receptor Homo sapiens 176-208 26171055-10 2015 In addition, EGF-induced tyrosine phosphorylation of the EGF receptor (EGFR) and tyrosine/serine phosphorylation of extracellular signal-regulated kinase (ERK) were also inhibited by infection with Ad-PKG II and treatment with the NO donor or precursor. Tyrosine 25-33 epidermal growth factor receptor Homo sapiens 57-69 26171055-10 2015 In addition, EGF-induced tyrosine phosphorylation of the EGF receptor (EGFR) and tyrosine/serine phosphorylation of extracellular signal-regulated kinase (ERK) were also inhibited by infection with Ad-PKG II and treatment with the NO donor or precursor. Tyrosine 25-33 epidermal growth factor receptor Homo sapiens 71-75 25907674-3 2015 Using a model non-genotoxic carcinogen, arsenic, we show here that exposure to arsenic inhibits mismatch repair (MMR) in human cells, possibly through its ability to stimulate epidermal growth factor receptor (EGFR)-dependent tyrosine phosphorylation of proliferating cellular nuclear antigen (PCNA). Tyrosine 226-234 epidermal growth factor receptor Homo sapiens 210-214 25971727-8 2015 In addition, although sialylation in the TKI-resistant mutants suppresses EGFR tyrosine phosphorylation, with the most significant effect on the Y1173 site, the sialylation effect is not strong enough to stop cancer progression by inhibiting the phosphorylation of these three sites. Tyrosine 79-87 epidermal growth factor receptor Homo sapiens 74-78 25971727-9 2015 These findings were supported further by the observation that the L858R/T790M EGFR mutant, when treated with sialidase or sialyltransferase inhibitor, showed an increase in tyrosine phosphorylation, and the sensitivity of the corresponding resistant lung cancer cells to gefitinib was reduced by desialylation and was enhanced by sialylation. Tyrosine 173-181 epidermal growth factor receptor Homo sapiens 78-82 26137146-5 2015 The results demonstrated that treatment with 100 ng/ml EGF for 5 min increased the tyrosine (Tyr)1068 phosphorylation of EGFR and the threonine 202/Tyr204 phosphorylation of MAPK/ERK. Tyrosine 83-91 epidermal growth factor receptor Homo sapiens 121-125 26137146-5 2015 The results demonstrated that treatment with 100 ng/ml EGF for 5 min increased the tyrosine (Tyr)1068 phosphorylation of EGFR and the threonine 202/Tyr204 phosphorylation of MAPK/ERK. Tyrosine 93-96 epidermal growth factor receptor Homo sapiens 121-125 26079946-0 2015 Tyrosine dephosphorylation enhances the therapeutic target activity of epidermal growth factor receptor (EGFR) by disrupting its interaction with estrogen receptor (ER). Tyrosine 0-8 epidermal growth factor receptor Homo sapiens 71-103 26079946-0 2015 Tyrosine dephosphorylation enhances the therapeutic target activity of epidermal growth factor receptor (EGFR) by disrupting its interaction with estrogen receptor (ER). Tyrosine 0-8 epidermal growth factor receptor Homo sapiens 105-109 26079946-2 2015 Here, we report that tyrosine-dephosphorylation of epidermal growth factor receptor (EGFR) increases its therapeutic target activity by disrupting its interaction with estrogen receptor (ER). Tyrosine 21-29 epidermal growth factor receptor Homo sapiens 51-83 26079946-2 2015 Here, we report that tyrosine-dephosphorylation of epidermal growth factor receptor (EGFR) increases its therapeutic target activity by disrupting its interaction with estrogen receptor (ER). Tyrosine 21-29 epidermal growth factor receptor Homo sapiens 85-89 26016774-6 2015 The obtained data suggest that sHB-EGF acts similarly to other EGFR ligands and is capable to induce EGFR nuclear translocation as a part of ligand-receptor complex in a tyrosine phosphorylation-dependent manner. Tyrosine 170-178 epidermal growth factor receptor Homo sapiens 101-105 25824408-4 2015 Among several important phosphorylation sites in cytoplasmic EGFR, Rg3 increased the phosphorylation of tyrosine 1045 (pY1045) and serine 1046/1047 (pS1046/1047) for EGFR degradation and coincidently, attenuated pY1173 and pY1068 for mitogen-activated protein kinase activity. Tyrosine 104-112 epidermal growth factor receptor Homo sapiens 61-65 25825764-2 2015 Earlier studies show that PCNA is regulated by posttranslational modifications, including phosphorylation of tyrosine 211 (Y211) by the epidermal growth factor receptor (EGFR). Tyrosine 109-117 epidermal growth factor receptor Homo sapiens 136-168 25825764-2 2015 Earlier studies show that PCNA is regulated by posttranslational modifications, including phosphorylation of tyrosine 211 (Y211) by the epidermal growth factor receptor (EGFR). Tyrosine 109-117 epidermal growth factor receptor Homo sapiens 170-174 25305142-4 2015 In addition, beta-adducin knockdown resulted in a substantial reduction of epidermal growth factor receptor (EGFR), cadherin and beta-catenin and enhanced phosphorylation of EGFR on tyrosine 1173 and Ca2+ prevented these changes. Tyrosine 182-190 epidermal growth factor receptor Homo sapiens 174-178 25744307-9 2015 We show that 10(-8)M levels of CdCl2 activate ERK1/2 (Tyr 204) and the p53 specific ubiquitin ligase Mdm2 (Ser 166) via Raf and MEK by acting through the epidermal growth factor receptor (EGFR). Tyrosine 54-57 epidermal growth factor receptor Homo sapiens 154-186 25744307-9 2015 We show that 10(-8)M levels of CdCl2 activate ERK1/2 (Tyr 204) and the p53 specific ubiquitin ligase Mdm2 (Ser 166) via Raf and MEK by acting through the epidermal growth factor receptor (EGFR). Tyrosine 54-57 epidermal growth factor receptor Homo sapiens 188-192 25006755-4 2015 Autophosphorylation of tyrosine residues on the cytoplasmic tail of EGFR induces recruitment of Grb2-fused Ggamma subunits to the inner leaflet of the plasma membrane in yeast cells, which leads to G-protein signal transduction and activation of downstream signaling events, including mating and diploid cell growth. Tyrosine 23-31 epidermal growth factor receptor Homo sapiens 68-72 25573954-5 2015 Distinct patterns for gefitinib and erlotinib inhibition of EGFR autophosphorylation at individual tyrosines were revealed for wild-type (WT) and L858R EGFR. Tyrosine 99-108 epidermal growth factor receptor Homo sapiens 60-64 25672442-5 2015 Furthermore, baicalein interfered with E2-induced novel G protein-coupled estrogen receptor (GPR30)-related signaling, including a decrease in tyrosine phosphorylation of epidermal growth factor receptor (EGFR) as well as phosphorylation of extracellular signal-regulated kinase (ERK) and serine/threonine kinase Akt, without affecting GPR30 expression. Tyrosine 143-151 epidermal growth factor receptor Homo sapiens 205-209 25701783-2 2015 In contrast to the canonical EGFR activation in which tyrosine residues are engaged, we have demonstrated that the non-canonical pathway is triggered by phosphorylation of serine and threonine residues through p38 and ERK MAPKs, respectively. Tyrosine 54-62 epidermal growth factor receptor Homo sapiens 29-33 25479591-6 2015 We showed that EGFR was strongly activated by EGF during mitosis as all the five major tyrosine residues including Y992, Y1045, Y1068, Y1086, and Y1173 were phosphorylated to a level similar to that in the interphase. Tyrosine 87-95 epidermal growth factor receptor Homo sapiens 15-19 25766325-5 2015 Here, we demonstrate that 5a potently inhibited both EGFR and HER2 activity by reducing EGFR and HER2 tyrosine phosphorylation and preventing downstream activation of PI3K/Akt and MEK/Erk pathways in vitro and in vivo. Tyrosine 102-110 epidermal growth factor receptor Homo sapiens 53-57 25303742-9 2015 Pharmacological inhibition of Src kinase activity abrogated O3-induced EGFR phosphorylation at tyrosines 1068 and 845. Tyrosine 95-104 epidermal growth factor receptor Homo sapiens 71-75 25562511-5 2015 Reactive oxygen species generated by dual oxidase 2 stabilize tyrosine phosphorylation of epidermal growth factor receptor and induce MUC3 and MUC5AC through persistent activation of extracellular signal-regulated kinases 1/2-protein kinase C. Knocking down dual oxidase 2 by selective RNA targeting (siRNA) reduced epidermal growth factor receptor phosphorylation, and MUC3 and MUC5AC gene expression. Tyrosine 62-70 epidermal growth factor receptor Homo sapiens 90-122 25562511-5 2015 Reactive oxygen species generated by dual oxidase 2 stabilize tyrosine phosphorylation of epidermal growth factor receptor and induce MUC3 and MUC5AC through persistent activation of extracellular signal-regulated kinases 1/2-protein kinase C. Knocking down dual oxidase 2 by selective RNA targeting (siRNA) reduced epidermal growth factor receptor phosphorylation, and MUC3 and MUC5AC gene expression. Tyrosine 62-70 epidermal growth factor receptor Homo sapiens 316-348 25519995-7 2015 We apply the theory to model, using only 11 ODEs, the dynamics of ligand-induced phosphorylation of nine tyrosines on epidermal growth factor receptor (EGFR) and primary recruitment of six signalling proteins (Grb2, PI3K, PLCgamma1, SHP2, RasA1 and Shc1). Tyrosine 105-114 epidermal growth factor receptor Homo sapiens 118-150 25519995-7 2015 We apply the theory to model, using only 11 ODEs, the dynamics of ligand-induced phosphorylation of nine tyrosines on epidermal growth factor receptor (EGFR) and primary recruitment of six signalling proteins (Grb2, PI3K, PLCgamma1, SHP2, RasA1 and Shc1). Tyrosine 105-114 epidermal growth factor receptor Homo sapiens 152-156 25554218-8 2015 ML-18 (16muM), but not EMY-98, inhibited the ability of 100nM BA1 to cause tyrosine phosphorylation of the EGFR and ERK in lung cancer cells. Tyrosine 75-83 epidermal growth factor receptor Homo sapiens 107-111 25607934-14 2015 Moreover, tyrosine-phosphorylated EGFR (the active EGFR) was greatly suppressed in HCC329 by LZ8 treatment. Tyrosine 10-18 epidermal growth factor receptor Homo sapiens 34-38 25607934-14 2015 Moreover, tyrosine-phosphorylated EGFR (the active EGFR) was greatly suppressed in HCC329 by LZ8 treatment. Tyrosine 10-18 epidermal growth factor receptor Homo sapiens 51-55 25164010-5 2014 Mutant EGFR preferentially bound to and tyrosine phosphorylated beta-catenin, leading to an increase in beta-catenin-mediated transactivation, particularly in cells harboring the gefitinib/erlotinib-resistant gatekeeper EGFR-T790M mutation. Tyrosine 40-48 epidermal growth factor receptor Homo sapiens 7-11 25348954-5 2014 Conversely, dasatinib enhanced tyrosine phosphorylation in a panel of RTK and their signaling adaptor complexes, including EGFR, MET/GAB1, and IGF1R/IRS2, implicating a RTK-driven adaptive response associated with dasatinib. Tyrosine 31-39 epidermal growth factor receptor Homo sapiens 123-127 25321192-7 2014 Blocking AnxA2 function at the cell surface by anti-AnxA2 antibody suppressed the EGF-induced EGFR tyrosine phosphorylation and internalisation by blocking its homodimerisation. Tyrosine 99-107 epidermal growth factor receptor Homo sapiens 94-98 25386651-5 2014 We here show that UVB illumination of the extracellular domain of EGFR (sEGFR) induces protein conformational changes, disulphide bridge breakage and formation of tryptophan and tyrosine photoproducts such as dityrosine, N-formylkynurenine and kynurenine. Tyrosine 178-186 epidermal growth factor receptor Homo sapiens 66-70 25317724-1 2014 We modeled cellular epidermal growth factor receptor (EGFR) tyrosine phosphorylation dynamics in the presence of receptor-targeting kinase inhibitors (e.g., gefitinib) or antibodies (e.g., cetuximab) to identify systematically the factors that contribute most to the ability of the therapeutics to antagonize EGFR phosphorylation, an effect we define here as biochemical efficacy. Tyrosine 60-68 epidermal growth factor receptor Homo sapiens 20-52 25348954-8 2014 Importantly, we observed high levels of tyrosine-phosphorylated EGFR and MET in a panel of human lung SCC tissues harboring DDR2 mutations. Tyrosine 40-48 epidermal growth factor receptor Homo sapiens 64-68 25164010-5 2014 Mutant EGFR preferentially bound to and tyrosine phosphorylated beta-catenin, leading to an increase in beta-catenin-mediated transactivation, particularly in cells harboring the gefitinib/erlotinib-resistant gatekeeper EGFR-T790M mutation. Tyrosine 40-48 epidermal growth factor receptor Homo sapiens 220-224 25317724-1 2014 We modeled cellular epidermal growth factor receptor (EGFR) tyrosine phosphorylation dynamics in the presence of receptor-targeting kinase inhibitors (e.g., gefitinib) or antibodies (e.g., cetuximab) to identify systematically the factors that contribute most to the ability of the therapeutics to antagonize EGFR phosphorylation, an effect we define here as biochemical efficacy. Tyrosine 60-68 epidermal growth factor receptor Homo sapiens 54-58 25125655-6 2014 We also find a kinase-dependent physical association between the Notch3 and EGFR receptors and tyrosine phosphorylation of Notch3. Tyrosine 95-103 epidermal growth factor receptor Homo sapiens 76-80 24960080-2 2014 Stimulation of different endothelial cell lines with bradykinin (BK) activates the endothelial NO synthase (eNOS) and promotes EGF-R tyrosine phosphorylation. Tyrosine 133-141 epidermal growth factor receptor Homo sapiens 127-132 24921970-2 2014 Numerous drugs have been developed in order to target the tyrosine domain of EGFR as an approach in cancer treatment. Tyrosine 58-66 epidermal growth factor receptor Homo sapiens 77-81 24096486-7 2014 EGF-induced EGF receptor (EGFR) tyrosine phosphorylation and extracellular signal-regulated kinase phosphorylation were enhanced by miR-10b, and these effects were mimicked by TIP30 silencing. Tyrosine 32-40 epidermal growth factor receptor Homo sapiens 12-24 24096486-7 2014 EGF-induced EGF receptor (EGFR) tyrosine phosphorylation and extracellular signal-regulated kinase phosphorylation were enhanced by miR-10b, and these effects were mimicked by TIP30 silencing. Tyrosine 32-40 epidermal growth factor receptor Homo sapiens 26-30 24960080-4 2014 NO-mediated stimulatory effects on tyrosine phosphorylation of the EGF-R, where cGMP independent. Tyrosine 35-43 epidermal growth factor receptor Homo sapiens 67-72 24890449-10 2014 Pharmacological inhibition of JAK2 and Src blunted tyrosine phosphorylation of EGFR and STAT3, while treatment with an EGFR tyrosine kinase inhibitor gefitinib inhibited phosphorylation of STAT3 without affecting that of JAK2 and Src in HCT116 cells. Tyrosine 51-59 epidermal growth factor receptor Homo sapiens 79-83 24838315-8 2014 Smoke-induced MUC1-C glycosylation modulated MUC1-C tyrosine phosphorylation (TyrP) that was essential for MUC1-C/p120ctn interaction through dose-dependent bridging of Src/MUC1-C/galectin-3/EGFR signalosomes. Tyrosine 52-60 epidermal growth factor receptor Homo sapiens 191-195 24919575-2 2014 We hypothesized that additional resistance mechanisms that cooperate with T790M could be identified by profiling tyrosine phosphorylation in NSCLC cells with acquired resistance to reversible EGFR-TKI and harboring T790M. Tyrosine 113-121 epidermal growth factor receptor Homo sapiens 192-196 25061874-3 2014 In multiple cancer cell lines, EGFR activated phosphorylation of tyrosine 750 (Y750) of DCBLD2, which is located within a recently identified binding motif for TNF receptor-associated factor 6 (TRAF6). Tyrosine 65-73 epidermal growth factor receptor Homo sapiens 31-35 24919575-0 2014 Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer. Tyrosine 0-8 epidermal growth factor receptor Homo sapiens 98-102 25073158-0 2014 EGFR modulates DNA synthesis and repair through Tyr phosphorylation of histone H4. Tyrosine 48-51 epidermal growth factor receptor Homo sapiens 0-4 24779031-1 2014 The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase (RTK), which catalyzes protein phosphorylation reactions by transferring the gamma-phosphoryl group from an ATP molecule to the hydroxyl group of tyrosine residues in protein substrates. Tyrosine 58-66 epidermal growth factor receptor Homo sapiens 4-36 24779031-1 2014 The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase (RTK), which catalyzes protein phosphorylation reactions by transferring the gamma-phosphoryl group from an ATP molecule to the hydroxyl group of tyrosine residues in protein substrates. Tyrosine 58-66 epidermal growth factor receptor Homo sapiens 38-42 24496451-5 2014 Inhibition of SNARE function impaired the delivery of Src and EGFR to developing invadopodia, as well as the beta1-integrin-dependent activation of Src and phosphorylation of EGFR on Tyr residue 845. Tyrosine 183-186 epidermal growth factor receptor Homo sapiens 175-179 23542172-4 2014 We previously reported that epidermal growth factor receptor (EGFR) triggered tyrosine 211 (Y211) phosphorylation of PCNA, which in turn stabilized PCNA on chromatin to promote cell proliferation. Tyrosine 78-86 epidermal growth factor receptor Homo sapiens 28-60 24496038-7 2014 SR48692 or gefitinib (EGFR tyrosine kinase inhibitor) inhibited the ability of NTS to cause EGFR and ERK tyrosine phosphorylation. Tyrosine 27-35 epidermal growth factor receptor Homo sapiens 22-26 24496038-7 2014 SR48692 or gefitinib (EGFR tyrosine kinase inhibitor) inhibited the ability of NTS to cause EGFR and ERK tyrosine phosphorylation. Tyrosine 27-35 epidermal growth factor receptor Homo sapiens 92-96 23542172-4 2014 We previously reported that epidermal growth factor receptor (EGFR) triggered tyrosine 211 (Y211) phosphorylation of PCNA, which in turn stabilized PCNA on chromatin to promote cell proliferation. Tyrosine 78-86 epidermal growth factor receptor Homo sapiens 62-66 24002698-1 2013 Treatment with epidermal growth factor receptor (EGFR) tyrosine inhibitors (EGFR-TKIs) provides encouraging outcomes for advanced non-small cell lung cancer (NSCLC) patients with EGFR mutations. Tyrosine 55-63 epidermal growth factor receptor Homo sapiens 15-47 24593867-7 2014 P-mTOR and p-TSC2 staining was found in a minority of cases.There was a significant correlation between p-EGFR Tyr-1068, p-EGFR Tyr-992 and hamartin, and also between p-mTOR and p-EGFR Tyr-1173 in AC. Tyrosine 111-114 epidermal growth factor receptor Homo sapiens 106-110 24593867-8 2014 In SCC an inverse correlation between hamartin and p-EGFR Tyr-992 was detected. Tyrosine 58-61 epidermal growth factor receptor Homo sapiens 53-57 24004111-0 2013 Tyrosine phosphorylation of mig6 reduces its inhibition of the epidermal growth factor receptor. Tyrosine 0-8 epidermal growth factor receptor Homo sapiens 63-95 23464360-0 2014 Phosphorylated EGFR at tyrosine 1173 correlates with poor prognosis in oral squamous cell carcinomas. Tyrosine 23-31 epidermal growth factor receptor Homo sapiens 15-19 24496106-3 2014 We describe the discovery of nitro-benzoxadiazole (NBD) compounds that enhance tyrosine phosphorylation of EGFR and thereby trigger downstream signaling pathways and other receptor tyrosine kinases in cancer cells. Tyrosine 79-87 epidermal growth factor receptor Homo sapiens 107-111 24264576-6 2014 Using the Ishikawa cell line as a model of endometrial cancer, we demonstrate that GnRH-(1-5) stimulates epidermal growth factor release, increases the phosphorylation of EGFR (P < .05) at three tyrosine sites (992, 1045, 1068), and promotes cellular migration. Tyrosine 198-206 epidermal growth factor receptor Homo sapiens 171-175 24046455-5 2013 Individual knockdown of TRIO, BMX or CHKA attenuated tyrosine phosphorylation of the EGFR by angiotensin II stimulation, but this did not occur following direct stimulation of the EGFR with EGF, indicating that these proteins function between the activated AT1R and the EGFR. Tyrosine 53-61 epidermal growth factor receptor Homo sapiens 85-89 24142702-6 2013 We show that EGFR Mut R1-6 with or without L393H exhibits enhanced basal tyrosine phosphorylation when ectopically expressed, and the ligand-independent transforming activity of EGFR Mut R1-6 is sensitive to inhibition of EGFR kinase activity and is particularly dependent on PI3K and mTOR activity. Tyrosine 73-81 epidermal growth factor receptor Homo sapiens 13-17 24180698-6 2013 Stimulation with EGF resulted in EGFR tyrosine autophosphorylation, activation of p42/p44 MAP kinases and stabilisation of HIF-1alpha and HIF-2alpha proteins. Tyrosine 38-46 epidermal growth factor receptor Homo sapiens 33-37 24002698-1 2013 Treatment with epidermal growth factor receptor (EGFR) tyrosine inhibitors (EGFR-TKIs) provides encouraging outcomes for advanced non-small cell lung cancer (NSCLC) patients with EGFR mutations. Tyrosine 55-63 epidermal growth factor receptor Homo sapiens 49-53 24002698-1 2013 Treatment with epidermal growth factor receptor (EGFR) tyrosine inhibitors (EGFR-TKIs) provides encouraging outcomes for advanced non-small cell lung cancer (NSCLC) patients with EGFR mutations. Tyrosine 55-63 epidermal growth factor receptor Homo sapiens 76-80 24002698-1 2013 Treatment with epidermal growth factor receptor (EGFR) tyrosine inhibitors (EGFR-TKIs) provides encouraging outcomes for advanced non-small cell lung cancer (NSCLC) patients with EGFR mutations. Tyrosine 55-63 epidermal growth factor receptor Homo sapiens 76-80 23822636-0 2013 Inverse correlation between Thr-669 and constitutive tyrosine phosphorylation in the asymmetric epidermal growth factor receptor dimer conformation. Tyrosine 53-61 epidermal growth factor receptor Homo sapiens 96-128 23822636-6 2013 Downregulation of constitutive tyrosine phosphorylation of EGFR in HEK293 cells stably expressing the wild type was abolished by substitution of Thr-669 for Ala. Tyrosine 31-39 epidermal growth factor receptor Homo sapiens 59-63 23822636-8 2013 Similarly, Thr-669 in an EGFR-ErbB3 heterodimer also participated in tyrosine dephosphorylation. Tyrosine 69-77 epidermal growth factor receptor Homo sapiens 25-29 23822636-9 2013 These results indicate that ERK-mediated Thr-669 phosphorylation suppresses constitutive tyrosine phosphosphorylation in the homo- and heterodimer asymmetric conformations of the EGFR. Tyrosine 89-97 epidermal growth factor receptor Homo sapiens 179-183 23880083-5 2013 Western blot analysis indicates the analogues containing hydroxyl group inhibited expression and tyrosine phosphorylation of EGFR. Tyrosine 97-105 epidermal growth factor receptor Homo sapiens 125-129 24034250-3 2013 Active EGFR binds the autophagy protein Beclin 1, leading to its multisite tyrosine phosphorylation, enhanced binding to inhibitors, and decreased Beclin 1-associated VPS34 kinase activity. Tyrosine 75-83 epidermal growth factor receptor Homo sapiens 7-11 24034250-4 2013 EGFR tyrosine kinase inhibitor (TKI) therapy disrupts Beclin 1 tyrosine phosphorylation and binding to its inhibitors and restores autophagy in non-small-cell lung carcinoma (NSCLC) cells with a TKI-sensitive EGFR mutation. Tyrosine 5-13 epidermal growth factor receptor Homo sapiens 0-4 24034250-4 2013 EGFR tyrosine kinase inhibitor (TKI) therapy disrupts Beclin 1 tyrosine phosphorylation and binding to its inhibitors and restores autophagy in non-small-cell lung carcinoma (NSCLC) cells with a TKI-sensitive EGFR mutation. Tyrosine 5-13 epidermal growth factor receptor Homo sapiens 209-213 23791551-10 2013 Activation of phospholipase C by Ca(2+)-ionophore or by activating the epidermal-growth-factor-receptor inhibits tyrosine phosphorylation of gelsolin. Tyrosine 113-121 epidermal growth factor receptor Homo sapiens 71-103 23765757-4 2013 METHODS: In this study, we determined the micro-domain of EGFR that is required for its interaction with SGLT1 and the effects of activation/inactivation of EGFR on EGFR-SGLT1 interaction, measured the expression of EGFR and SGLT1 in prostate cancer tissues, and tested the effect of inhibition of SGLT1 on the sensitivity of prostate cancer cells to EGFR tyrosine inhibitors. Tyrosine 356-364 epidermal growth factor receptor Homo sapiens 58-62 23836884-4 2013 Here we report that HIP1 is tyrosine phosphorylated in the presence of EGFR and platelet-derived growth factor beta receptor (PDGFbetaR) as well as the oncogenic derivatives EGFRvIII, HIP1/PDGFbetaR (H/P), and TEL/PDGFbetaR (T/P). Tyrosine 28-36 epidermal growth factor receptor Homo sapiens 71-75 23836884-5 2013 We identified a four-tyrosine "HIP1 phosphorylation motif" (HPM) in the N-terminal region of HIP1 that is required for phosphorylation mediated by both EGFR and PDGFbetaR but not by the oncoproteins H/P and T/P. Tyrosine 21-29 epidermal growth factor receptor Homo sapiens 152-156 23027125-5 2013 Specifically, HER2 overexpression blocks epidermal growth factor receptor (EGFR) tyrosine phosphorylation on Y1045 and Y1068, the known docking sites of c-Cbl and Grb2, respectively, whereas promoting phosphorylation on Y1173, the known docking site of the Gab adaptor proteins and phospholipase C gamma. Tyrosine 81-89 epidermal growth factor receptor Homo sapiens 41-73 23027125-5 2013 Specifically, HER2 overexpression blocks epidermal growth factor receptor (EGFR) tyrosine phosphorylation on Y1045 and Y1068, the known docking sites of c-Cbl and Grb2, respectively, whereas promoting phosphorylation on Y1173, the known docking site of the Gab adaptor proteins and phospholipase C gamma. Tyrosine 81-89 epidermal growth factor receptor Homo sapiens 75-79 23991179-5 2013 Receptor tyrosine kinase arrays further revealed that PP242 treatment increased the phosphorylated epidermal growth factor receptor (EGFR) at Tyr 1068 (EGFR(T1068)). Tyrosine 142-145 epidermal growth factor receptor Homo sapiens 99-131 23991179-5 2013 Receptor tyrosine kinase arrays further revealed that PP242 treatment increased the phosphorylated epidermal growth factor receptor (EGFR) at Tyr 1068 (EGFR(T1068)). Tyrosine 142-145 epidermal growth factor receptor Homo sapiens 133-137 23991179-5 2013 Receptor tyrosine kinase arrays further revealed that PP242 treatment increased the phosphorylated epidermal growth factor receptor (EGFR) at Tyr 1068 (EGFR(T1068)). Tyrosine 142-145 epidermal growth factor receptor Homo sapiens 152-156 23496660-9 2013 These results demonstrate the novel information that hSKCa1 channels are inhibited by genistein, T25 and AG556 via EGFR tyrosine kinase inhibition, which is related to the phosphorylation of Tyr(109) in the N-terminus. Tyrosine 191-194 epidermal growth factor receptor Homo sapiens 115-119 23507559-6 2013 Gefitinib, an inhibitor for EGFR tyrosine kinase, inhibited EGFR tyrosine phosphorylation/activation and proliferation of the cells. Tyrosine 33-41 epidermal growth factor receptor Homo sapiens 28-32 23507559-6 2013 Gefitinib, an inhibitor for EGFR tyrosine kinase, inhibited EGFR tyrosine phosphorylation/activation and proliferation of the cells. Tyrosine 33-41 epidermal growth factor receptor Homo sapiens 60-64 23825523-1 2013 The ANKS1A gene product, also known as Odin, was first identified as a tyrosine-phosphorylated component of the epidermal growth factor receptor network. Tyrosine 71-79 epidermal growth factor receptor Homo sapiens 112-144 23825523-3 2013 In EGF-stimulated HEK293 cells tyrosine phosphorylation of Odin was induced prior to EGFR internalization and independent of EGFR-to-ERK signaling. Tyrosine 31-39 epidermal growth factor receptor Homo sapiens 85-89 23764002-0 2013 Epidermal growth factor receptor potentiates MCM7-mediated DNA replication through tyrosine phosphorylation of Lyn kinase in human cancers. Tyrosine 83-91 epidermal growth factor receptor Homo sapiens 0-32 23702846-3 2013 In 1995, we reported that the human epidermoid carcinoma cells, A431, contain a small fraction of Src and EGFR in which these two kinase were in physical association with each other, and that Src phosphorylates EGFR on tyrosine 845 (Y845) in the Src-EGFR complex. Tyrosine 219-227 epidermal growth factor receptor Homo sapiens 106-110 23702846-3 2013 In 1995, we reported that the human epidermoid carcinoma cells, A431, contain a small fraction of Src and EGFR in which these two kinase were in physical association with each other, and that Src phosphorylates EGFR on tyrosine 845 (Y845) in the Src-EGFR complex. Tyrosine 219-227 epidermal growth factor receptor Homo sapiens 211-215 23702846-3 2013 In 1995, we reported that the human epidermoid carcinoma cells, A431, contain a small fraction of Src and EGFR in which these two kinase were in physical association with each other, and that Src phosphorylates EGFR on tyrosine 845 (Y845) in the Src-EGFR complex. Tyrosine 219-227 epidermal growth factor receptor Homo sapiens 211-215 22797061-1 2013 Protein kinase Calpha (PKCalpha) can phosphorylate the epidermal growth factor receptor (EGFR) at threonine 654 (T654) to inhibit EGFR tyrosine phosphorylation (pY-EGFR) and the associated activation of downstream effectors. Tyrosine 135-143 epidermal growth factor receptor Homo sapiens 55-87 22797061-1 2013 Protein kinase Calpha (PKCalpha) can phosphorylate the epidermal growth factor receptor (EGFR) at threonine 654 (T654) to inhibit EGFR tyrosine phosphorylation (pY-EGFR) and the associated activation of downstream effectors. Tyrosine 135-143 epidermal growth factor receptor Homo sapiens 89-93 22797061-1 2013 Protein kinase Calpha (PKCalpha) can phosphorylate the epidermal growth factor receptor (EGFR) at threonine 654 (T654) to inhibit EGFR tyrosine phosphorylation (pY-EGFR) and the associated activation of downstream effectors. Tyrosine 135-143 epidermal growth factor receptor Homo sapiens 130-134 22797061-1 2013 Protein kinase Calpha (PKCalpha) can phosphorylate the epidermal growth factor receptor (EGFR) at threonine 654 (T654) to inhibit EGFR tyrosine phosphorylation (pY-EGFR) and the associated activation of downstream effectors. Tyrosine 135-143 epidermal growth factor receptor Homo sapiens 130-134 23635774-4 2013 We uncovered a fundamental role for the dual-specificity tyrosine phosphorylation-regulated kinase, DYRK1A, in regulating EGFR in GBMs. Tyrosine 57-65 epidermal growth factor receptor Homo sapiens 122-126 23652202-4 2013 One EGF-activated pathway affected by the PhB-EGFR interaction is the loss of tyrosine phosphorylation of the scaffold protein RACK1. Tyrosine 78-86 epidermal growth factor receptor Homo sapiens 46-50 23636329-5 2013 Here we show that epidermal growth factor receptor (EGFR), which is the product of a well-characterized oncogene in human cancers, suppresses the maturation of specific tumour-suppressor-like miRNAs in response to hypoxic stress through phosphorylation of argonaute 2 (AGO2) at Tyr 393. Tyrosine 278-281 epidermal growth factor receptor Homo sapiens 18-50 23636329-5 2013 Here we show that epidermal growth factor receptor (EGFR), which is the product of a well-characterized oncogene in human cancers, suppresses the maturation of specific tumour-suppressor-like miRNAs in response to hypoxic stress through phosphorylation of argonaute 2 (AGO2) at Tyr 393. Tyrosine 278-281 epidermal growth factor receptor Homo sapiens 52-56 23652203-4 2013 This abrogation of EGFR signaling induced the dephosphorylation of receptor for activated C kinase 1 (RACK1) at Tyr(52), which then promoted the dephosphorylation of CAR at Thr(38) by the catalytic core subunit of protein phosphatase 2A. Tyrosine 112-115 epidermal growth factor receptor Homo sapiens 19-23 23593472-6 2013 The Y211F CPPP specifically targets EGFR and competes directly for PCNA tyrosine Y211 phosphorylation and prevents nEGFR from binding PCNA in vivo; it also suppresses tumor growth by sensitizing EGFR TKI resistant cells, which have enhanced nEGFR function and abrogated classical EGFR membrane signaling. Tyrosine 72-80 epidermal growth factor receptor Homo sapiens 116-120 23593472-6 2013 The Y211F CPPP specifically targets EGFR and competes directly for PCNA tyrosine Y211 phosphorylation and prevents nEGFR from binding PCNA in vivo; it also suppresses tumor growth by sensitizing EGFR TKI resistant cells, which have enhanced nEGFR function and abrogated classical EGFR membrane signaling. Tyrosine 72-80 epidermal growth factor receptor Homo sapiens 116-120 23333852-4 2013 We previously demonstrated that Usp8 is tyrosine phosphorylated in an EGFR- and SRC-kinase dependent manner. Tyrosine 40-48 epidermal growth factor receptor Homo sapiens 70-74 23333852-6 2013 We also show that enhanced endosomal recycling of the EGFR induced by TGFalpha stimulation is associated with decreased Usp8 tyrosine phosphorylation. Tyrosine 125-133 epidermal growth factor receptor Homo sapiens 54-58 23220008-7 2013 In all the three neuroendocrine cell lines studied, we found EGF, TGFalpha and the other growth-stimulating GI hormones increased Tyr(1068) EGFR phosphorylation. Tyrosine 130-133 epidermal growth factor receptor Homo sapiens 140-144 22430206-14 2013 SFKs have been shown to phosphorylate EGFR on tyrosines 845 and 1101 (Y845 and Y1101), and mutation of Y1101, but not Y845, impaired nuclear entry of the EGFR. Tyrosine 46-55 epidermal growth factor receptor Homo sapiens 38-42 23991943-3 2013 c-Cbl is an ubiquitin ligase which requires a phosphorylated tyrosine residue at position 1045 in the cytoplasmic domain of EGFR to interact and add ubiquitin molecules. Tyrosine 61-69 epidermal growth factor receptor Homo sapiens 124-128 23166300-1 2013 Tyrosine phosphorylation-dependent signaling, as mediated by members of the epidermal growth factor receptor (EGFR) family (ErbB1 to -4) of protein tyrosine kinases (PTKs), Src family PTKs (SFKs), and cytokines such as interleukin-6 (IL-6) that signal via signal transducer and activator of transcription 3 (STAT3), is critical to the development and progression of many human breast cancers. Tyrosine 0-8 epidermal growth factor receptor Homo sapiens 124-135 23085023-6 2013 When A549 cells were treated with each Tat-conjugated peptide, the peptides penetrated the cells and EGF-stimulated tyrosine phosphorylation of EGF receptor was significantly suppressed. Tyrosine 116-124 epidermal growth factor receptor Homo sapiens 144-156 23991943-4 2013 While activating mutations in exons 19 and 21 have been associated with the development of several cancers, the status of mutations at tyrosine 1045 coding exon 27 of EGFR remain to be investigated. Tyrosine 135-143 epidermal growth factor receptor Homo sapiens 167-171 23991943-6 2013 Hence in the present study we investigated the genetic status of the tyrosine 1045 coding site within exon 27 of EGFR gene to explore for possible occurrence of mutations in this region, especially since no studies have addressed this issue so far. Tyrosine 69-77 epidermal growth factor receptor Homo sapiens 113-117 22833523-8 2013 The MUC1-CT/p120ctn interaction was highly dependent on EGFR/Src/Jnk-mediated tyrosine phosphorylation (TyrP) of MUC1-CT. Tyrosine 78-86 epidermal growth factor receptor Homo sapiens 56-60 24044505-5 2013 RESULTS: The signaling analysis revealed that whereas HER2 was appropriately inhibited in lapatinib-resistant cells, EGFR tyrosine phosphorylation was incompletely inhibited. Tyrosine 122-130 epidermal growth factor receptor Homo sapiens 117-121 23174948-5 2013 Interestingly, an additional cellular effect with inhibition of tyrosine phosphorylation of the EGFR and subsequent downregulation of EGFR-induced signalling was also observed, suggesting an additional mechanism of action for microtubule destabilising agents. Tyrosine 64-72 epidermal growth factor receptor Homo sapiens 96-100 23174948-5 2013 Interestingly, an additional cellular effect with inhibition of tyrosine phosphorylation of the EGFR and subsequent downregulation of EGFR-induced signalling was also observed, suggesting an additional mechanism of action for microtubule destabilising agents. Tyrosine 64-72 epidermal growth factor receptor Homo sapiens 134-138 23037767-8 2012 RESULTS: We showed that tyrosine phosphorylation of NEDD9 was reduced by the inhibition of EGFR in NSCLC cell lines. Tyrosine 24-32 epidermal growth factor receptor Homo sapiens 91-95 23991943-0 2013 Tyrosine 1045 codon mutations in exon 27 of EGFR are infrequent in oral squamous cell carcinomas. Tyrosine 0-8 epidermal growth factor receptor Homo sapiens 44-48 22986230-4 2012 We found that BPD-mediated PDT stimulated EGFR tyrosine phosphorylation and nuclear translocation, and that EGFR inhibition by erlotinib resulted in reduction of PDT-mediated EGFR activation and nuclear translocation. Tyrosine 47-55 epidermal growth factor receptor Homo sapiens 42-46 22833206-1 2012 OPINION STATEMENT: Patients whose tumors harbor somatic-activating mutations within the epidermal growth factor receptor (EGFR) gene define a clinically distinct molecular cohort of lung cancers with increased sensitivity to the EGFR tyrosine kinase inhibitors (TKIs), including the "first-generation" reversible inhibitors, erlotinib and gefitinib, and the "second-generation" irreversible inhibitors, afatinib and dacomitinib. Tyrosine 234-242 epidermal growth factor receptor Homo sapiens 88-120 22833206-1 2012 OPINION STATEMENT: Patients whose tumors harbor somatic-activating mutations within the epidermal growth factor receptor (EGFR) gene define a clinically distinct molecular cohort of lung cancers with increased sensitivity to the EGFR tyrosine kinase inhibitors (TKIs), including the "first-generation" reversible inhibitors, erlotinib and gefitinib, and the "second-generation" irreversible inhibitors, afatinib and dacomitinib. Tyrosine 234-242 epidermal growth factor receptor Homo sapiens 122-126 22833206-1 2012 OPINION STATEMENT: Patients whose tumors harbor somatic-activating mutations within the epidermal growth factor receptor (EGFR) gene define a clinically distinct molecular cohort of lung cancers with increased sensitivity to the EGFR tyrosine kinase inhibitors (TKIs), including the "first-generation" reversible inhibitors, erlotinib and gefitinib, and the "second-generation" irreversible inhibitors, afatinib and dacomitinib. Tyrosine 234-242 epidermal growth factor receptor Homo sapiens 229-233 23037767-9 2012 Overexpression of constitutively active EGFR caused tyrosine phosphorylation of NEDD9 in the absence of integrin stimulation. Tyrosine 52-60 epidermal growth factor receptor Homo sapiens 40-44 22800866-9 2012 Using various EGFR-ErbB2 chimeras, we demonstrate that enhanced recycling, decreased Hrs tyrosine phosphorylation and decreased AMSH mediated deubiquitination of EGFR-ErbB2 chimeras is primarily due to the presence of ErbB2 sequences or the absence of EGFR sequences C-terminal to the Cbl binding site. Tyrosine 89-97 epidermal growth factor receptor Homo sapiens 14-18 22800866-10 2012 We conclude that endosomal recycling of the EGFR and ErbB2 receptors is associated with significantly impaired tyrosine phosphorylation of the ESCRT-0 subunit Hrs as well as decreased deubiquitination by AMSH, which is consistent with the finding that recycling receptors are not efficiently incorporated in the MVB pathway. Tyrosine 111-119 epidermal growth factor receptor Homo sapiens 44-48 22800866-0 2012 Recycling of EGFR and ErbB2 is associated with impaired Hrs tyrosine phosphorylation and decreased deubiquitination by AMSH. Tyrosine 60-68 epidermal growth factor receptor Homo sapiens 13-17 22786825-8 2012 The specific inhibition of EGFR, PKA, or MEK reduced capacitation and protein tyrosine phosphorylation induced by EGF. Tyrosine 78-86 epidermal growth factor receptor Homo sapiens 27-31 22800866-5 2012 EGF stimulation of the EGFR resulted in efficient Hrs tyrosine phosphorylation and deubiquitination by the K63-polyubiquitin chain-specific deubiquitinating enzyme AMSH. Tyrosine 54-62 epidermal growth factor receptor Homo sapiens 23-27 22800866-6 2012 In contrast, EGF activation of EGFR-ErbB2 showed significantly decreased Hrs tyrosine phosphorylation and deubiquitination by AMSH. Tyrosine 77-85 epidermal growth factor receptor Homo sapiens 31-35 22732145-7 2012 Furthermore, DGKtheta physically interacted with the EGFR and became tyrosine-phosphorylated upon EGFR stimulation. Tyrosine 69-77 epidermal growth factor receptor Homo sapiens 98-102 23213380-1 2012 Our previous study demonstrated that tyrosine phosphorylation of p145(met)/beta-subunit of hepatocyte growth factor receptor by epidermal growth factor receptor and Src contributes to the anti-apoptotic growth of human bladder carcinoma cell 5637 under serum-starved conditions. Tyrosine 37-45 epidermal growth factor receptor Homo sapiens 128-160 22824864-3 2012 The present study revealed that PQQ induces the activation (tyrosine autophosphorylation) of epidermal growth factor receptor (EGFR) and its downstream signaling in a ligand-independent manner, leading to increased cellular proliferation in an epithelial cell line A431. Tyrosine 60-68 epidermal growth factor receptor Homo sapiens 93-125 22480520-7 2012 KEY FINDINGS: In EOC cell lines, ET-1 induced Src-dependent EGFR transactivation, causing tyrosine (Y) phosphorylation of beta-catenin at the residue Y654, its dissociation from E-cadherin complexes and the accumulation as an active form. Tyrosine 90-98 epidermal growth factor receptor Homo sapiens 60-64 22959248-2 2012 Representative compounds showed potent and selective EGFR inhibitory activities in an in vitro EGFR kinase assay and an EGFR-mediated intracellular tyrosine phosphorylation assay. Tyrosine 148-156 epidermal growth factor receptor Homo sapiens 53-57 23066441-0 2012 EGFR Tyrosine 845 Phosphorylation-Dependent Proliferation and Transformation of Breast Cancer Cells Require Activation of p38 MAPK. Tyrosine 5-13 epidermal growth factor receptor Homo sapiens 0-4 23066441-1 2012 Phosphorylation of epidermal growth factor receptor (EGFR) on tyrosine 845 by c-Src has been shown to be important for cell proliferation and migration in several model systems. Tyrosine 62-70 epidermal growth factor receptor Homo sapiens 19-51 23066441-1 2012 Phosphorylation of epidermal growth factor receptor (EGFR) on tyrosine 845 by c-Src has been shown to be important for cell proliferation and migration in several model systems. Tyrosine 62-70 epidermal growth factor receptor Homo sapiens 53-57 23066441-3 2012 Here, we show that phosphorylation of tyrosine 845 on EGFR is required for proliferation and transformation using several cell models of breast cancer. Tyrosine 38-46 epidermal growth factor receptor Homo sapiens 54-58 23066441-4 2012 Overexpression of EGFR-Y845F or treating cells with the SFK inhibitor dasatinib abrogated tyrosine 845 phosphorylation, yet had little to no effect on other EGFR phosphorylation sites or EGFR kinase activity. Tyrosine 90-98 epidermal growth factor receptor Homo sapiens 18-22 23066441-7 2012 Taken together, these data demonstrate a novel role for p38 MAPK signaling downstream of EGFR tyrosine 845 phosphorylation in the regulation of breast cancer cell proliferation and transformation and implicate SFK inhibitors as a potential therapeutic mechanism for overcoming EGFR tyrosine kinase inhibitor resistance in breast cancer. Tyrosine 94-102 epidermal growth factor receptor Homo sapiens 89-93 22824864-3 2012 The present study revealed that PQQ induces the activation (tyrosine autophosphorylation) of epidermal growth factor receptor (EGFR) and its downstream signaling in a ligand-independent manner, leading to increased cellular proliferation in an epithelial cell line A431. Tyrosine 60-68 epidermal growth factor receptor Homo sapiens 127-131 22824864-4 2012 PQQ inhibited protein tyrosine phosphatase 1B (PTP1B), which negatively regulates the EGFR signaling by tyrosine dephosphorylation, to oxidatively modify the catalytic cysteine through its redox cycling activity to generate H(2)O(2). Tyrosine 22-30 epidermal growth factor receptor Homo sapiens 86-90 23264846-2 2012 Constitutively activated KRAS mutations are strongly associated with a resistance to anti-epidermal growth factor receptor (EGFR) therapies, such as panitumumab and cetuximab used for treating metastatic colorectal carcinoma and EGFR tyrosine inhibitors used for advanced non-small cell lung cancers. Tyrosine 234-242 epidermal growth factor receptor Homo sapiens 90-122 22878588-2 2012 We recently communicated the preliminary observation that nitric oxide (NO) signaling results in epidermal growth factor receptor (EGFR) tyrosine phosphorylation. Tyrosine 137-145 epidermal growth factor receptor Homo sapiens 97-129 22878588-2 2012 We recently communicated the preliminary observation that nitric oxide (NO) signaling results in epidermal growth factor receptor (EGFR) tyrosine phosphorylation. Tyrosine 137-145 epidermal growth factor receptor Homo sapiens 131-135 22901364-5 2012 The phosphorylation of EGFR at tyrosine 1068 (pTyr1068) and 1173 (pTyr1173) were assessed by immunohistochemistry, and EGFR mutations were detected by denaturing high performance liquid chromatograph (DHPLC). Tyrosine 31-39 epidermal growth factor receptor Homo sapiens 23-27 23342251-4 2012 Ligand binding is thought to be a prerequisite for dimerization of HER3 with other ERBB proteins, which results in phosphorylation of its c-terminal tyrosine residues and activation of downstream AKT and MAPK signaling pathways. Tyrosine 149-157 epidermal growth factor receptor Homo sapiens 83-87 22584669-7 2012 The involvement of EGFR-dependent MAPK/ERK1/2 signaling pathway in cytokine-induced damage was demonstrated by a significant increase in threonine/tyrosine phosphorylation of ERK1/2, already detectable after 5 min incubation. Tyrosine 147-155 epidermal growth factor receptor Homo sapiens 19-23 22683472-1 2012 Tyrosine autophosphorylation within the cytoplasmic tail of EGF-receptor is a key event, which in turn recruits several factors including Shc, Grb2 and Rin1 that are essential activities for receptor-mediated endocytosis and signaling. Tyrosine 0-8 epidermal growth factor receptor Homo sapiens 60-72 22833562-3 2012 In this study we show that EGFR activation leads to a pronounced src-mediated tyrosine phosphorylation of CIN85 that subsequently influences EGFR ubiquitination. Tyrosine 78-86 epidermal growth factor receptor Homo sapiens 27-31 22833562-3 2012 In this study we show that EGFR activation leads to a pronounced src-mediated tyrosine phosphorylation of CIN85 that subsequently influences EGFR ubiquitination. Tyrosine 78-86 epidermal growth factor receptor Homo sapiens 141-145 22692198-2 2012 It has been shown that phosphorylation of PCNA at Tyr-211 by the EGF receptor (EGFR) protects PCNA from polyubiquitylation and degradation, whereas blocking phosphorylation induces ubiquitylation-mediated degradation of the chromatin-bound, but not the -unbound, PCNA, and suppresses cell proliferation. Tyrosine 50-53 epidermal growth factor receptor Homo sapiens 65-77 22692198-2 2012 It has been shown that phosphorylation of PCNA at Tyr-211 by the EGF receptor (EGFR) protects PCNA from polyubiquitylation and degradation, whereas blocking phosphorylation induces ubiquitylation-mediated degradation of the chromatin-bound, but not the -unbound, PCNA, and suppresses cell proliferation. Tyrosine 50-53 epidermal growth factor receptor Homo sapiens 79-83 22810896-5 2012 We showed that two protein tyrosine kinases, the epidermal growth factor receptor (EGFR) ErbB1 and Src, bound sequentially to dsRNA-activated TLR3 and phosphorylated the two tyrosine residues. Tyrosine 27-35 epidermal growth factor receptor Homo sapiens 49-81 22810896-5 2012 We showed that two protein tyrosine kinases, the epidermal growth factor receptor (EGFR) ErbB1 and Src, bound sequentially to dsRNA-activated TLR3 and phosphorylated the two tyrosine residues. Tyrosine 27-35 epidermal growth factor receptor Homo sapiens 83-87 22810896-5 2012 We showed that two protein tyrosine kinases, the epidermal growth factor receptor (EGFR) ErbB1 and Src, bound sequentially to dsRNA-activated TLR3 and phosphorylated the two tyrosine residues. Tyrosine 27-35 epidermal growth factor receptor Homo sapiens 89-94 23264846-2 2012 Constitutively activated KRAS mutations are strongly associated with a resistance to anti-epidermal growth factor receptor (EGFR) therapies, such as panitumumab and cetuximab used for treating metastatic colorectal carcinoma and EGFR tyrosine inhibitors used for advanced non-small cell lung cancers. Tyrosine 234-242 epidermal growth factor receptor Homo sapiens 124-128 22657099-6 2012 These studies establish that there is a temporal order of autophosphorylation of key tyrosines involved in downstream signaling for WT EGFR and a loss of order for the oncogenic L834R mutant. Tyrosine 85-94 epidermal growth factor receptor Homo sapiens 135-139 22657099-7 2012 These studies also reveal unique signature patterns of drug sensitivity for inhibition of tyrosine autophosphorylation by gefitinib: distinct for WT and oncogenic L834R mutant forms of EGFR. Tyrosine 90-98 epidermal growth factor receptor Homo sapiens 185-189 22458527-5 2012 Two pharmacologic approaches have been successfully used to inhibit epidermal growth factor receptor function in cancer treatment: neutralizing monoclonal antibodies and small molecule tyrosine inhibitors. Tyrosine 185-193 epidermal growth factor receptor Homo sapiens 68-100 21963850-4 2012 In fact, ligation/activation of EGFR induces Src-dependent phosphorylation of two critical tyrosine residues of p130CAS, leading to the assembly of a Crk-associated substrate (CAS)/Nck1 complex that promotes Ras-associated protein-1 (Rap1) signaling. Tyrosine 91-99 epidermal growth factor receptor Homo sapiens 32-36 22389426-0 2012 Pituitary adenylate cyclase-activating polypeptide causes tyrosine phosphorylation of the epidermal growth factor receptor in lung cancer cells. Tyrosine 58-66 epidermal growth factor receptor Homo sapiens 90-122 22525372-9 2012 In contrast, tyrosine phosphorylation of EGFR was unaffected when the concentration of houttuyninum was increased to 40 mug/ml in both A431 cells and MDA-MB-468 cells. Tyrosine 13-21 epidermal growth factor receptor Homo sapiens 41-45 22305891-8 2012 Moreover, mutation of tyrosines 303/343/353 together enhances Spred2 binding to EGFR. Tyrosine 22-31 epidermal growth factor receptor Homo sapiens 80-84 22591401-0 2012 Impaired degradation followed by enhanced recycling of epidermal growth factor receptor caused by hypo-phosphorylation of tyrosine 1045 in RBE cells. Tyrosine 122-130 epidermal growth factor receptor Homo sapiens 55-87 22591401-8 2012 A disrupted association between EGFR and the E3 ubiquitin ligase c-Cbl, as well as hypo-phosphorylation of EGFR at tyrosine 1045 (Tyr1045), were also observed in RBE cells. Tyrosine 115-123 epidermal growth factor receptor Homo sapiens 107-111 22521882-8 2012 RESULTS: Tyrosine kinome profiling demonstrated upregulation of nine tyrosine kinases in tumors relative to matched normal thyroid tissue: EGFR, PTK6, BTK, HCK, ABL1, TNK1, GRB2, ERK, and SRC. Tyrosine 9-17 epidermal growth factor receptor Homo sapiens 139-143 22824264-1 2012 The tyrosine phosphorylated epidermal growth factor receptor (EGFR) initiates numerous cell signaling pathways. Tyrosine 4-12 epidermal growth factor receptor Homo sapiens 28-60 22824264-1 2012 The tyrosine phosphorylated epidermal growth factor receptor (EGFR) initiates numerous cell signaling pathways. Tyrosine 4-12 epidermal growth factor receptor Homo sapiens 62-66 22112293-3 2012 Icotinib blocked EGFR-mediated intracellular tyrosine phosphorylation (IC(50)=45 nM) in the human epidermoid carcinoma A431 cell line and inhibits tumor cell proliferation. Tyrosine 45-53 epidermal growth factor receptor Homo sapiens 17-21 22281474-6 2012 Aging is also associated with increased tyrosine-phosphorylated epidermal growth factor receptor (EGFR). Tyrosine 40-48 epidermal growth factor receptor Homo sapiens 64-96 22281474-6 2012 Aging is also associated with increased tyrosine-phosphorylated epidermal growth factor receptor (EGFR). Tyrosine 40-48 epidermal growth factor receptor Homo sapiens 98-102 22216880-12 2012 Thus we postulate that NRG2beta/Q43L and other antagonistic ligands stimulate ErbB tyrosine phosphorylation on a set of residues distinct from that stimulated by agonists, thus suggesting a novel mechanism of ErbB receptor regulation. Tyrosine 83-91 epidermal growth factor receptor Homo sapiens 78-82 22232557-2 2012 Here we show that knockdown of flotillin-1/reggie-2 results in reduced EGF-induced phosphorylation of specific tyrosines in the EGF receptor (EGFR) and in inefficient activation of the downstream mitogen-activated protein (MAP) kinase and Akt signaling. Tyrosine 111-120 epidermal growth factor receptor Homo sapiens 128-140 22247545-7 2012 NEU1 overexpression diminished EGF-stimulated EGFR Tyr-1068 autophosphorylation by up to 44% but enhanced MUC1-dependent Pseudomonas aeruginosa adhesion by 1.6-1.7-fold and flagellin-stimulated ERK1/2 activation by 1.7-1.9-fold. Tyrosine 51-54 epidermal growth factor receptor Homo sapiens 46-50 22337768-3 2012 In this study, we demonstrate that EGFR regulates the kinase activity of LRRK1 via tyrosine phosphorylation and that this is required for proper endosomal trafficking of EGFR. Tyrosine 83-91 epidermal growth factor receptor Homo sapiens 35-39 22232557-2 2012 Here we show that knockdown of flotillin-1/reggie-2 results in reduced EGF-induced phosphorylation of specific tyrosines in the EGF receptor (EGFR) and in inefficient activation of the downstream mitogen-activated protein (MAP) kinase and Akt signaling. Tyrosine 111-120 epidermal growth factor receptor Homo sapiens 142-146 22529914-4 2012 1) Prestimulation of CXCR4/HER1-positive 5637 or HeLa cells with CXCL12 modified the HB-EGF-dependent activation of HER1 by delaying the peak phosphorylation of tyrosine 1068 or 1173. Tyrosine 161-169 epidermal growth factor receptor Homo sapiens 27-31 22147103-3 2012 Kinetic models of the epidermal growth factor (EGF)/ErbB receptor signalling pathway describing activation, desensitization, and tyrosine phosphorylation of EGFR/ErbB followed by binding and activation of Src family kinases that is subsequently followed by phosphorylation of target proteins are available. Tyrosine 129-137 epidermal growth factor receptor Homo sapiens 52-56 22147103-3 2012 Kinetic models of the epidermal growth factor (EGF)/ErbB receptor signalling pathway describing activation, desensitization, and tyrosine phosphorylation of EGFR/ErbB followed by binding and activation of Src family kinases that is subsequently followed by phosphorylation of target proteins are available. Tyrosine 129-137 epidermal growth factor receptor Homo sapiens 157-161 22147103-3 2012 Kinetic models of the epidermal growth factor (EGF)/ErbB receptor signalling pathway describing activation, desensitization, and tyrosine phosphorylation of EGFR/ErbB followed by binding and activation of Src family kinases that is subsequently followed by phosphorylation of target proteins are available. Tyrosine 129-137 epidermal growth factor receptor Homo sapiens 162-166 22198508-11 2012 CONCLUSION: Our results demonstrate that human atrial I(to) and cloned hKv4.3 channels are modulated by EGFR kinase via phosphorylation of the Y136 residue and by Src-family kinases via phosphorylation of the Y108 residue; tyrosine phosphorylation of the channel may be involved in regulating cardiac electrophysiology. Tyrosine 223-231 epidermal growth factor receptor Homo sapiens 104-108 24970130-7 2012 In parallel a strong interaction of PTPIP51 with the epidermal growth factor receptor phosphorylating PTPIP51 at the tyrosine 176 residue was seen. Tyrosine 117-125 epidermal growth factor receptor Homo sapiens 53-85 22250084-10 2012 In conclusion, epidermal growth factor receptor tyrosine phosphorylates MUC1, leading to an increase in its association with TLR5, thereby competitively and reversibly inhibiting recruitment of MyD88 to TLR5 and downstream signaling events. Tyrosine 48-56 epidermal growth factor receptor Homo sapiens 15-47 22061963-8 2012 These results demonstrate for the first time that hEAG1 channel activity is regulated by EGFR kinase at the tyrosine residues Tyr90, Try344, and Try485. Tyrosine 108-116 epidermal growth factor receptor Homo sapiens 89-93 22012247-7 2012 Of note, PKG II inhibited the tyrosine phosphorylation of EGFR induced by EGF. Tyrosine 30-38 epidermal growth factor receptor Homo sapiens 70-74 22064379-9 2012 In addition the ER414 inhibited an EGF-induced tyrosine phosphorylation of EGFR with much lower efficacy compared to the A13 mAb and Cetuximab (Merck KgaA, Germany). Tyrosine 47-55 epidermal growth factor receptor Homo sapiens 75-79 22032630-5 2012 RESULTS: The results showed that, compared with sham exposure, exposure to RFR at specific absorption rate (SAR) of 0.5, 1.0, 2.0, or 4.0 W/kg for 15 min significantly induced EGF receptor clustering and enhanced phosphorylation on the tyrosine-1173 residue in FL cells, whereas exposure to a SAR 0.1 W/kg radiation for 15 min did not cause a significant effect. Tyrosine 236-244 epidermal growth factor receptor Homo sapiens 176-188 21725367-2 2012 ErbB3 binds heregulin beta-1 (HRGbeta1) and forms a heterodimer with other ErbB family members, such as ErbB2 (HER2) or EGF receptor (EGFR; HER1), enhancing phosphorylation of specific C-terminal tyrosine residues and activation of downstream signaling pathways. Tyrosine 196-204 epidermal growth factor receptor Homo sapiens 0-4 22382333-6 2012 The EGFR- and Lck-mediated phosphorylation was markedly inhibited by tyrosine halogenation. Tyrosine 69-77 epidermal growth factor receptor Homo sapiens 4-8 22645710-7 2012 Complex formation requires a dileucine motif (679-LL) in the intracellular juxtamembrane region of the EGF receptor that also controls whether or not the receptor undergoes Src kinase-dependent phosphorylation at Tyr-845. Tyrosine 213-216 epidermal growth factor receptor Homo sapiens 103-115 22239438-3 2012 EGFR binds to its cognate ligand EGF, which further induces tyrosine phosphorylation and receptor dimerization with other family members leading to enhanced uncontrolled proliferation. Tyrosine 60-68 epidermal growth factor receptor Homo sapiens 0-4 21866565-3 2012 In vitro kinase assays revealed that both the epidermal growth factor and platelet derived growth factor receptors (EGFR and PDGFR, respectively) tyrosine phosphorylate PKA-C. Mass spectrometry identified tyrosine 330 (Y330) as a receptor-mediated phosphorylation site and mutation of Y330 to phenylalanine (Y330F) all but abolished the RTK-mediated phosphorylation of PKA-C in vitro. Tyrosine 146-154 epidermal growth factor receptor Homo sapiens 116-120 21866565-3 2012 In vitro kinase assays revealed that both the epidermal growth factor and platelet derived growth factor receptors (EGFR and PDGFR, respectively) tyrosine phosphorylate PKA-C. Mass spectrometry identified tyrosine 330 (Y330) as a receptor-mediated phosphorylation site and mutation of Y330 to phenylalanine (Y330F) all but abolished the RTK-mediated phosphorylation of PKA-C in vitro. Tyrosine 205-213 epidermal growth factor receptor Homo sapiens 116-120 22988345-3 2012 We show that the EGFR is tyrosine-phosphorylated following treatment of IECs (HT-29 and IEC-6) with TNF-alpha. Tyrosine 25-33 epidermal growth factor receptor Homo sapiens 17-21 22952966-9 2012 Analysis with phosphorylation-specific antibodies determined that EGFR-induced cortactin tyrosine phosphorylation is diminished coincident with EGFR degradation, whereas ERK1/2 cortactin phosphorylation utilized in promoting activation of the Arp2/3 regulator N-WASp is sustained during EGFR downregulation. Tyrosine 89-97 epidermal growth factor receptor Homo sapiens 66-70 22952966-13 2012 Tyrosine phosphorylation of cortactin by ACK1 creates an additional means to amplify Arp2/3 dynamics through N-WASp activation, potentially contributing to the overall necessary tensile and/or propulsive forces utilized during EGFR endocytic internalization and trafficking involved in receptor degradation. Tyrosine 0-8 epidermal growth factor receptor Homo sapiens 227-231 22529914-4 2012 1) Prestimulation of CXCR4/HER1-positive 5637 or HeLa cells with CXCL12 modified the HB-EGF-dependent activation of HER1 by delaying the peak phosphorylation of tyrosine 1068 or 1173. Tyrosine 161-169 epidermal growth factor receptor Homo sapiens 116-120 21316260-5 2011 Mutations and amplifications in molecules related to receptor tyrosine signalling, such as EGFR, ErbB2, c-Met, c-Kit, VEGFR, PI3K, and PTEN are only some of the alterations known to contribute to the development of lung cancer. Tyrosine 62-70 epidermal growth factor receptor Homo sapiens 91-95 23152945-5 2012 We show that the replacement of EGFR JM domain with a (GGS)(10) unstructured linker completely abolishes the phosphorylation of all tyrosine residues, without measurable effects on receptor dimerization or ligand binding. Tyrosine 132-140 epidermal growth factor receptor Homo sapiens 32-36 21740967-8 2011 We also present the complex regulation by tyrosine phosphorylation by epidermal growth factor receptor (EGF-R), Janus Kinase 3 (JAK3) and Src and the role of phosphatases. Tyrosine 42-50 epidermal growth factor receptor Homo sapiens 70-102 21740967-8 2011 We also present the complex regulation by tyrosine phosphorylation by epidermal growth factor receptor (EGF-R), Janus Kinase 3 (JAK3) and Src and the role of phosphatases. Tyrosine 42-50 epidermal growth factor receptor Homo sapiens 104-109 21302296-4 2011 Our recent data in human breast cancer cell line MCF-7, demonstrates that EGF stimulates estradiol receptor (ER) phosphorylation on tyrosine at position 537 thereby promoting the association of a complex among EGF receptor (EGFR), androgen receptor (AR), ER, and Src that activates EGF-dependent signaling pathway. Tyrosine 132-140 epidermal growth factor receptor Homo sapiens 210-222 21302296-4 2011 Our recent data in human breast cancer cell line MCF-7, demonstrates that EGF stimulates estradiol receptor (ER) phosphorylation on tyrosine at position 537 thereby promoting the association of a complex among EGF receptor (EGFR), androgen receptor (AR), ER, and Src that activates EGF-dependent signaling pathway. Tyrosine 132-140 epidermal growth factor receptor Homo sapiens 224-228 21722395-8 2011 EGF-induced phosphorylation of EGFR at tyrosine residues was augmented when the cells were pretreated with Y27632 or were subjected to gene silencing using ROCK-siRNA. Tyrosine 39-47 epidermal growth factor receptor Homo sapiens 31-35 21896743-4 2011 Phosphorylation of Tyr-845 in the EGFR, which is mediated by Src family kinases, depended on uPAR in EGFRvIII-expressing GBM cells. Tyrosine 19-22 epidermal growth factor receptor Homo sapiens 34-38 21896743-9 2011 A human GBM in which the EGFR gene was amplified without truncation was immunonegative for both uPAR and phospho-Tyr-845. Tyrosine 113-116 epidermal growth factor receptor Homo sapiens 25-29 21642474-3 2011 Here, we established WBP2 as a tyrosine phosphorylation target of estrogen signaling via EGFR crosstalk. Tyrosine 31-39 epidermal growth factor receptor Homo sapiens 89-93 21423210-4 2011 EGFR ligands induce accumulation of activated c-Met, which begins at 8 h and continues for 48 h. This effect is accompanied by an increase in c-Met expression and phosphorylation of critical c-Met tyrosine residues without activation of mitogen-activated protein kinase (MAPK) or Akt. Tyrosine 197-205 epidermal growth factor receptor Homo sapiens 0-4 21649524-10 2011 Therefore, airway epithelial injury profoundly reduces PTPmu expression, and PTPmu depletion selectively increases phosphorylation of specific EGFR tyrosine residues, PLCgamma(1) activation, and cell migration, providing a novel mechanism through which epithelial integrity may be restored. Tyrosine 148-156 epidermal growth factor receptor Homo sapiens 143-147 20699280-6 2011 MD-2-dependent proliferation and migration appeared independent of Cox-2 activity but was reduced by endothelial growth factor receptor (EGFR) neutralizing antibodies as well as by pharmacological inhibition of EGFR tyrosine phosphorylation. Tyrosine 216-224 epidermal growth factor receptor Homo sapiens 211-215 21712056-3 2011 Also, BA1 addition to NCI-H727 or NCI-H1299-BRS-3 cells caused Tyr(1068) phosphorylation of the epidermal growth factor receptor (EGFR). Tyrosine 63-66 epidermal growth factor receptor Homo sapiens 96-128 21712056-3 2011 Also, BA1 addition to NCI-H727 or NCI-H1299-BRS-3 cells caused Tyr(1068) phosphorylation of the epidermal growth factor receptor (EGFR). Tyrosine 63-66 epidermal growth factor receptor Homo sapiens 130-134 21646361-7 2011 Moreover, pretreatment of the cells with UV-C suppressed EGF-induced phosphorylation of EGFR at tyrosine residues in addition to cell survival signal, Akt. Tyrosine 96-104 epidermal growth factor receptor Homo sapiens 88-92 21820892-3 2011 Poly(glu, tyr) (4:1) peptide, as a substrate of EGFR, was covalently immobilized on the surface of indium tin oxide (ITO) electrode by silane chemistry. Tyrosine 10-13 epidermal growth factor receptor Homo sapiens 48-52 21708247-3 2011 We observed that stimulation with WKYMVm, an FPRL1 agonist isolated by screening synthetic peptide libraries, induces EGFR tyrosine phosphorylation, p47(phox) phosphorylation, NADPH-oxidase-dependent superoxide generation, and c-Src kinase activity. Tyrosine 123-131 epidermal growth factor receptor Homo sapiens 118-122 21226813-6 2011 Nor was kinase activity required, and the fusion protein was endocytosed in the presence of an EGFR kinase inhibitor, which efficiently counteracted tyrosine phosphorylation. Tyrosine 149-157 epidermal growth factor receptor Homo sapiens 95-99 21241690-6 2011 Consistent with these results, we found that treatment of breast cancer cells with angiocidin induced a 2.3 fold increase in EGFR tyrosine 845 phosphorylation while no change in phosphorylation was observed in the remaining 16 phosphorylation sites of EGFR and those of its family members as measured by a human EGFR phosphorylation array. Tyrosine 130-138 epidermal growth factor receptor Homo sapiens 125-129 21575252-18 2011 In vitro studies revealed that tyrosine autophosphorylation is enhanced in p.R776G-mutant EGFR when compared with wild-type EGFR. Tyrosine 31-39 epidermal growth factor receptor Homo sapiens 90-94 21558399-0 2011 Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene. Tyrosine 104-112 epidermal growth factor receptor Homo sapiens 99-103 21558399-0 2011 Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene. Tyrosine 104-112 epidermal growth factor receptor Homo sapiens 221-225 21349850-11 2011 In IQGAP1-null cells, EGF-stimulated tyrosine phosphorylation of EGFR is severely attenuated. Tyrosine 37-45 epidermal growth factor receptor Homo sapiens 65-69 20446926-5 2011 EGFR phosphorylation (Tyr-992, Tyr-1045 and Tyr-1068) was higher in MCF-7Tam than in MCF-7 and it was reduced by EGCG treatment. Tyrosine 22-25 epidermal growth factor receptor Homo sapiens 0-4 20446926-5 2011 EGFR phosphorylation (Tyr-992, Tyr-1045 and Tyr-1068) was higher in MCF-7Tam than in MCF-7 and it was reduced by EGCG treatment. Tyrosine 31-34 epidermal growth factor receptor Homo sapiens 0-4 20446926-5 2011 EGFR phosphorylation (Tyr-992, Tyr-1045 and Tyr-1068) was higher in MCF-7Tam than in MCF-7 and it was reduced by EGCG treatment. Tyrosine 31-34 epidermal growth factor receptor Homo sapiens 0-4 21110957-6 2011 In this report we demonstrate that human pancreatic tumor cell lines exhibit minimal ErbB4 expression; in contrast, these cell lines exhibit varied and in some cases abundant expression and basal tyrosine phosphorylation of EGFR, ErbB2, and ErbB3. Tyrosine 196-204 epidermal growth factor receptor Homo sapiens 224-228 21262974-3 2011 We found that EGF receptor (EGFR) was a direct substrate of VHR and that overexpression of VHR down-regulated EGFR phosphorylation, particularly at Tyr-992 residue. Tyrosine 148-151 epidermal growth factor receptor Homo sapiens 14-26 21262974-3 2011 We found that EGF receptor (EGFR) was a direct substrate of VHR and that overexpression of VHR down-regulated EGFR phosphorylation, particularly at Tyr-992 residue. Tyrosine 148-151 epidermal growth factor receptor Homo sapiens 28-32 21262974-3 2011 We found that EGF receptor (EGFR) was a direct substrate of VHR and that overexpression of VHR down-regulated EGFR phosphorylation, particularly at Tyr-992 residue. Tyrosine 148-151 epidermal growth factor receptor Homo sapiens 110-114 21262974-4 2011 Expression of VHR inhibited the activation of phospholipase Cgamma and protein kinase C, both downstream effectors of Tyr-992 phosphorylation of EGFR. Tyrosine 118-121 epidermal growth factor receptor Homo sapiens 145-149 21262974-5 2011 Decreasing VHR expression by RNA interference caused higher EGFR phosphorylation at Tyr-992. Tyrosine 84-87 epidermal growth factor receptor Homo sapiens 60-64 21123182-6 2011 Ultimately a variety of in vitro and in vivo approaches were used to verify the prediction that the tyrosine phosphorylation levels of five high-ranking substrates, PLC-gamma1, Gab1, SHP2, EGFR, and SHP1, are indeed specifically modulated by PTP1B. Tyrosine 100-108 epidermal growth factor receptor Homo sapiens 189-193 21044682-6 2011 We further show that Usp8 tyrosine phosphorylation upon stimulation of EGFR-ErbB2 is (a) independent of Y1091, (b) dependent on Src- and EGFR-ErbB2-kinase activity, (c) enhanced upon coexpression of Usp8-C748A, and (d) partly dependent on the Microtubule Interacting and Transport (MIT) domain of Usp8. Tyrosine 26-34 epidermal growth factor receptor Homo sapiens 137-141 21127066-10 2011 Extracellular HSP90alpha induced EGFR phosphorylation at Tyr-1068, and this event was prevented by both the protein kinase Cdelta inhibitor, rottlerin, and the c-Src inhibitor, PP2. Tyrosine 57-60 epidermal growth factor receptor Homo sapiens 33-37 21044682-6 2011 We further show that Usp8 tyrosine phosphorylation upon stimulation of EGFR-ErbB2 is (a) independent of Y1091, (b) dependent on Src- and EGFR-ErbB2-kinase activity, (c) enhanced upon coexpression of Usp8-C748A, and (d) partly dependent on the Microtubule Interacting and Transport (MIT) domain of Usp8. Tyrosine 26-34 epidermal growth factor receptor Homo sapiens 71-75 21155880-9 2011 EGFR tyrosine phosphorylation and its association with PKCdelta was significantly higher in all histopathological types with chi2 = 7.965; P < 0.05 and 4.0830; P = 0.2530. Tyrosine 5-13 epidermal growth factor receptor Homo sapiens 0-4 21258366-0 2011 Crosstalk between Arg 1175 methylation and Tyr 1173 phosphorylation negatively modulates EGFR-mediated ERK activation. Tyrosine 43-46 epidermal growth factor receptor Homo sapiens 89-93 21258366-5 2011 Arg 1175 methylation positively modulates EGF-induced EGFR trans-autophosphorylation at Tyr 1173, which governs ERK activation. Tyrosine 88-91 epidermal growth factor receptor Homo sapiens 54-58 21258366-7 2011 Therefore, we propose a model in which the regulatory crosstalk between PRMT5-mediated Arg 1175 methylation and EGF-induced Tyr 1173 phosphorylation attenuates EGFR-mediated ERK activation. Tyrosine 124-127 epidermal growth factor receptor Homo sapiens 160-164 20850495-6 2011 Short-term stimulation with Pb2+ induced EGFR phosphorylation at the Tyr residue (position, 1173). Tyrosine 69-72 epidermal growth factor receptor Homo sapiens 41-45 21094134-4 2011 Interestingly, EGFR acetylation affects its tyrosine phosphorylation, which may contribute to cancer cell resistance to histone deacetylase inhibitors (HDACIs). Tyrosine 44-52 epidermal growth factor receptor Homo sapiens 15-19 25346782-3 2011 Although several crystal structures of the ErbB kinases have been solved, the precise mechanism of HER2 activation remains unknown, and it has been suggested that HER2 is unique in its requirement for phosphorylation of Y877, a key tyrosine residue located in the activation loop (A-loop). Tyrosine 232-240 epidermal growth factor receptor Homo sapiens 43-47 25346782-8 2011 In HER2, we also predict a role for phosphorylated Y877 in bridging a network of hydrogen bonds that fasten the A-loop in its active conformation, suggesting that HER2 may be unique among the ErbB members in requiring A-loop tyrosine phosphorylation for functionality. Tyrosine 225-233 epidermal growth factor receptor Homo sapiens 192-196 22029196-4 2011 In the ELISA assay for both cell lines investigated, as the dose of gefitinib increased, a gradual decrease in EGFR tyrosine phosphorylation was detected. Tyrosine 116-124 epidermal growth factor receptor Homo sapiens 111-115 22162641-1 2011 Epidermal growth factor receptor (EGFR) tyrosine inhibitors were first approved for the treatment of non-small cell lung cancer (NSCLC) in 2003 in the US. Tyrosine 40-48 epidermal growth factor receptor Homo sapiens 0-32 22162641-1 2011 Epidermal growth factor receptor (EGFR) tyrosine inhibitors were first approved for the treatment of non-small cell lung cancer (NSCLC) in 2003 in the US. Tyrosine 40-48 epidermal growth factor receptor Homo sapiens 34-38 21966491-2 2011 We have previously shown that EGFR, when tyrosine-phosphorylated, binds to GEP100/BRAG2 to activate Arf6, which induces cancer invasion and metastasis. Tyrosine 41-49 epidermal growth factor receptor Homo sapiens 30-34 22140559-6 2011 Conversely, epidermal growth factor receptor (EGFR)-mediated phosphorylation of the MUC1-C cytoplasmic domain on Tyr-46 conferred binding to PKM2 Lys-433 and inhibited PKM2 activity. Tyrosine 113-116 epidermal growth factor receptor Homo sapiens 12-44 22140559-6 2011 Conversely, epidermal growth factor receptor (EGFR)-mediated phosphorylation of the MUC1-C cytoplasmic domain on Tyr-46 conferred binding to PKM2 Lys-433 and inhibited PKM2 activity. Tyrosine 113-116 epidermal growth factor receptor Homo sapiens 46-50 20861192-4 2010 SFKs exert a prominent role in these cells, phosphorylating key regulators of adhesion and migration and promoting tyrosine phosphorylation of the receptor tyrosine kinases EGFR and Met. Tyrosine 115-123 epidermal growth factor receptor Homo sapiens 173-177 21123652-7 2010 At nanomolar concentrations, the EGFR (epidermal growth factor receptor) tyrosine kinase inhibitors gefitinib (Iressa) and erlotinib (Tarceva) were found to inhibit both RIP2 tyrosine phosphorylation and MDP (muramyl dipeptide)-induced cytokine release in a variety of NOD2 hyperactivation states. Tyrosine 73-81 epidermal growth factor receptor Homo sapiens 33-37 21123652-7 2010 At nanomolar concentrations, the EGFR (epidermal growth factor receptor) tyrosine kinase inhibitors gefitinib (Iressa) and erlotinib (Tarceva) were found to inhibit both RIP2 tyrosine phosphorylation and MDP (muramyl dipeptide)-induced cytokine release in a variety of NOD2 hyperactivation states. Tyrosine 73-81 epidermal growth factor receptor Homo sapiens 39-71 20049563-5 2010 In addition, among these identified proteins, ANXA3, KRT8, and KRT18 were validated to be novel tyrosine-phosphorylation targets of EGFR signaling by IP-western blotting and part of a complex EGFR phosphotyrosine signaling network. Tyrosine 96-104 epidermal growth factor receptor Homo sapiens 132-136 20049563-5 2010 In addition, among these identified proteins, ANXA3, KRT8, and KRT18 were validated to be novel tyrosine-phosphorylation targets of EGFR signaling by IP-western blotting and part of a complex EGFR phosphotyrosine signaling network. Tyrosine 96-104 epidermal growth factor receptor Homo sapiens 192-196 20797408-6 2010 This variant was also internalized by A431 cells, likely via receptor-mediated endocytosis, and it efficiently inhibited EGF-mediated tyrosine phosphorylation of the EGFR. Tyrosine 134-142 epidermal growth factor receptor Homo sapiens 166-170 20525880-3 2010 Interestingly, EGFR phosphorylation, most notably at the tyrosine 1068 residue, is dramatically upregulated, and EGFR association with the Sos1 guanine nucleotide exchange factor is concomitantly increased upon DHA supplementation. Tyrosine 57-65 epidermal growth factor receptor Homo sapiens 15-19 21085658-4 2010 METHODOLOGY/PRINCIPAL FINDINGS: Our phosphoproteomic analysis of the mutation at tyrosine 992 (Y992), one of the multifunctional docking sites of EGFR, revealed network-wide effects of the mutation on EGF signaling in a time-resolved manner. Tyrosine 81-89 epidermal growth factor receptor Homo sapiens 146-150 20650261-3 2010 We also demonstrated that EGFRvIII formed a complex with FAK, resulting in enhanced tyrosine phosphorylation levels of FAK Y397 and EGFR Y1068. Tyrosine 84-92 epidermal growth factor receptor Homo sapiens 26-30 20689057-5 2010 PTPN2 knockdown enhanced EGF-induced EGFR tyrosine phosphorylation in T(84) cells. Tyrosine 42-50 epidermal growth factor receptor Homo sapiens 37-41 20689057-6 2010 In particular, PTPN2 knockdown promoted EGF-induced phosphorylation of EGFR residues Tyr-992 and Tyr-1068 and led subsequently to increased association of the catalytic PI3K subunit, p110, with EGFR and elevated phosphorylation of the downstream marker, Akt. Tyrosine 85-88 epidermal growth factor receptor Homo sapiens 71-75 20877636-3 2010 We previously outlined the mode of binding between the TKB domain and various substrate peptide motifs, including epidermal growth factor receptor (EGFR) and Sprouty2 (Spry2), and demonstrated that an intrapetidyl hydrogen bond forms between the (pY-1) arginine or (pY-2) asparagine and the phosphorylated tyrosine, which is crucial for binding. Tyrosine 306-314 epidermal growth factor receptor Homo sapiens 148-152 20877636-6 2010 Here, we show that additional phosphorylation significantly reduces the binding affinity between the TKB domain and its target proteins, EGFR and Sprouty2, as compared to peptides bearing a single tyrosine phosphorylation. Tyrosine 197-205 epidermal growth factor receptor Homo sapiens 137-141 20628053-6 2010 Furthermore, EGFR-induced Erk activation requires Src-mediated phosphorylation of paxillin on tyrosines 31/118. Tyrosine 94-103 epidermal growth factor receptor Homo sapiens 13-17 20427760-5 2010 We further demonstrated that CsA amplified epidermal growth factor (EGF)-stimulated EGF receptor (EGFR) tyrosine phosphorylation in JEG-3 cells, and inhibition of EGFR tyrosine phosphorylation by AG1478, an EGFR tyrosine kinase inhibitor, abolished the down-regulation of E-cadherin by CsA through ERK signaling pathway. Tyrosine 104-112 epidermal growth factor receptor Homo sapiens 98-102 20427760-5 2010 We further demonstrated that CsA amplified epidermal growth factor (EGF)-stimulated EGF receptor (EGFR) tyrosine phosphorylation in JEG-3 cells, and inhibition of EGFR tyrosine phosphorylation by AG1478, an EGFR tyrosine kinase inhibitor, abolished the down-regulation of E-cadherin by CsA through ERK signaling pathway. Tyrosine 168-176 epidermal growth factor receptor Homo sapiens 163-167 20427760-5 2010 We further demonstrated that CsA amplified epidermal growth factor (EGF)-stimulated EGF receptor (EGFR) tyrosine phosphorylation in JEG-3 cells, and inhibition of EGFR tyrosine phosphorylation by AG1478, an EGFR tyrosine kinase inhibitor, abolished the down-regulation of E-cadherin by CsA through ERK signaling pathway. Tyrosine 168-176 epidermal growth factor receptor Homo sapiens 163-167 20580701-4 2010 We show here that physiological concentrations (nM) of ouabain enhance phosphorylation of EGFR on tyr-845, stimulate Ca(2+) influx and induce the acrosome reaction in sperm. Tyrosine 98-101 epidermal growth factor receptor Homo sapiens 90-94 20532621-5 2010 EGFR kinase tyrosine phosphorylation at Tyr1173, an index of activation of EGFR kinase, was determined by Western blot analysis using an anti-phospho (pTyr(1173))-EGFR kinase antibody. Tyrosine 12-20 epidermal growth factor receptor Homo sapiens 0-4 20532621-5 2010 EGFR kinase tyrosine phosphorylation at Tyr1173, an index of activation of EGFR kinase, was determined by Western blot analysis using an anti-phospho (pTyr(1173))-EGFR kinase antibody. Tyrosine 12-20 epidermal growth factor receptor Homo sapiens 75-79 20532621-5 2010 EGFR kinase tyrosine phosphorylation at Tyr1173, an index of activation of EGFR kinase, was determined by Western blot analysis using an anti-phospho (pTyr(1173))-EGFR kinase antibody. Tyrosine 12-20 epidermal growth factor receptor Homo sapiens 75-79 20388507-3 2010 By Western blot, addition of NMB or related peptides to NCI-H1299 human non-small cell lung cancer (NSCLC) cells, caused phosphorylation of Tyr(1068) of the EGF receptor. Tyrosine 140-143 epidermal growth factor receptor Homo sapiens 157-169 20572634-9 2010 Protein-protein interaction network analysis of the altered P-Tyr proteins illustrated that 11 proteins were linked to a network containing EGFR, c-Src, c-Myc, and STAT, which is known to be related to lung cancer metastasis. Tyrosine 62-65 epidermal growth factor receptor Homo sapiens 140-144 20595681-5 2010 Patch clamp analysis in TRPM6-expressing cells demonstrated that 30 muM erlotinib inhibited EGF-induced changes in TRPM6 current density and tyrosine phosphorylation of EGFR; 0.3 muM erlotinib did not have these effects. Tyrosine 141-149 epidermal growth factor receptor Homo sapiens 169-173 20388507-0 2010 Neuromedin B receptors regulate EGF receptor tyrosine phosphorylation in lung cancer cells. Tyrosine 45-53 epidermal growth factor receptor Homo sapiens 32-44 20508254-3 2010 The ArrayScan IV HCS reader was used for the measurement of tyrosine phosphorylation of the epidermal growth factor receptor (EGFR) and STAT-1 redistribution between the cytoplasm and nucleus in the human epidermoid carcinoma cell line A431. Tyrosine 60-68 epidermal growth factor receptor Homo sapiens 92-124 20508254-3 2010 The ArrayScan IV HCS reader was used for the measurement of tyrosine phosphorylation of the epidermal growth factor receptor (EGFR) and STAT-1 redistribution between the cytoplasm and nucleus in the human epidermoid carcinoma cell line A431. Tyrosine 60-68 epidermal growth factor receptor Homo sapiens 126-130 20651333-7 2010 It caused EGFR down-regulation and inhibited EGFR Tyr-845 autophosphorylation in both Du145 and PC-3 cells. Tyrosine 50-53 epidermal growth factor receptor Homo sapiens 45-49 20651333-8 2010 However, EGFR phosphorylation at Tyr-1173 and MAPK 44/42 phosphorylation were inhibited in Du145 cells, but not in PC-3 cells. Tyrosine 33-36 epidermal growth factor receptor Homo sapiens 9-13 20651357-5 2010 EGFR protein levels were not affected but EGFR-tyrosine phosphorylation in response to EGF was markedly reduced. Tyrosine 47-55 epidermal growth factor receptor Homo sapiens 42-46 20156584-9 2010 Altogether, although the involvement of other ganglioside species cannot be excluded, these findings sustain the ganglioside GM(3) as an essential molecule for EGFR/ErbB2 heterodimer stability and important regulator of EGFR tyrosine phosphorylation, but it is not crucial for tyrosine phosphorylation of the heterodimerization partner ErbB2. Tyrosine 225-233 epidermal growth factor receptor Homo sapiens 220-224 20513767-5 2010 Based on these findings, the first internalization-defective EGFR mutant with functional kinase and normal tyrosine phosphorylation was generated. Tyrosine 107-115 epidermal growth factor receptor Homo sapiens 61-65 20228838-1 2010 An adaptor protein FRS2beta inhibits epidermal growth factor-receptor (EGFR) tyrosine kinase without being phosphorylated at tyrosine residues after EGF stimulation. Tyrosine 77-85 epidermal growth factor receptor Homo sapiens 37-69 20228838-1 2010 An adaptor protein FRS2beta inhibits epidermal growth factor-receptor (EGFR) tyrosine kinase without being phosphorylated at tyrosine residues after EGF stimulation. Tyrosine 77-85 epidermal growth factor receptor Homo sapiens 71-75 20127027-5 2010 Tyrosine phosphorylation of EGFR was elevated. Tyrosine 0-8 epidermal growth factor receptor Homo sapiens 28-32 20049867-6 2010 Functional analysis suggested that genistein-regulated protein tyrosine phosphorylation mainly by inhibiting the activity of tyrosine kinase EGFR, PDGFR, insulin receptor, Abl, Fgr, Itk, Fyn and Src. Tyrosine 63-71 epidermal growth factor receptor Homo sapiens 141-145 20139904-5 2010 In addition, AG1478, 1,10-phenanthroline, and CRM197 also inhibited the tyrosine phosphorylation of EGF-R and ERK1/2 that was induced by 14,15-EET in the A549, HepG2, and MDA-MB-231 cell lines. Tyrosine 72-80 epidermal growth factor receptor Homo sapiens 100-105 19825976-5 2010 In concordance with faster EGFR clearance or desensitization, intrinsic EGFR kinase activity (phospho-Tyr-1068) and downstream protein kinase B and extracellular signal-regulated kinase/mitogen-activated protein kinase pathways were more rapidly inactivated in PR130-knockdown cells. Tyrosine 102-105 epidermal growth factor receptor Homo sapiens 72-76 19951711-3 2010 MAIN METHODS: The tyrosine phosphorylated active state of EGFR in A431 cells incubated with the test agents was evaluated by western blot with anti-phosphotyrosine antibody. Tyrosine 18-26 epidermal growth factor receptor Homo sapiens 58-62 19951711-5 2010 KEY FINDINGS: In vitro treatment of exponentially growing A431 cells with amlodipine decreased the tyrosine phosphorylation states of EGFR. Tyrosine 99-107 epidermal growth factor receptor Homo sapiens 134-138 19951711-12 2010 SIGNIFICANCE: The results indicated that amlodipine inhibits tyrosine phosphorylation of EGFR in vitro and in vivo, possibly via modulating cholesterol-rich, caveolin-1-containing membrane microdomains. Tyrosine 61-69 epidermal growth factor receptor Homo sapiens 89-93 20447077-16 2010 An immunohistochemical analysis of human normal and asthmatic airways showed a significant reduction in sLe(x) and tyrosine-phosphorylated EGFR (pY(845)-EGFR) in the epithelium of asthmatic subjects compared with that of normal subjects. Tyrosine 115-123 epidermal growth factor receptor Homo sapiens 139-143 20447077-16 2010 An immunohistochemical analysis of human normal and asthmatic airways showed a significant reduction in sLe(x) and tyrosine-phosphorylated EGFR (pY(845)-EGFR) in the epithelium of asthmatic subjects compared with that of normal subjects. Tyrosine 115-123 epidermal growth factor receptor Homo sapiens 145-157 19887107-1 2010 In our previous study, Endofin was validated to be a novel tyrosine phosphorylation target downstream of EGFR. Tyrosine 59-67 epidermal growth factor receptor Homo sapiens 105-109 20179163-2 2010 The data from immuofluorescence analyses revealed that EGFR/Tyr(1173)-pEGFR, sonic hedgehog ligand, smoothened coreceptor, and GLI-1 were colocalized with the CD133(+) stem cell-like marker in a small subpopulation of prostate cancer cells. Tyrosine 60-63 epidermal growth factor receptor Homo sapiens 55-59